background
glucos
nonfer
gram
neg
rod
known
highli
resist
hospit
set
alway
challeng
clinician
hospit
infect
control
degre
type
resist
may
due
sever
sophist
mechan
product
broad
spectrum
betalactamas
efflux
pump
alter
membran
permeabl
inactiv
class
antimicrobi
avail
treatment
cephalosporin
carbapenem
aminoglycosid
fluoruquinolon
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
speci
enterobacteriacea
select
speci
nonferment
well
gram
posit
atyp
anaerob
test
program
determin
vitro
activ
tigecyclin
compar
amikacin
ampicillin
imipenem
cefepim
ceftazidim
ceftriaxon
levofloxacin
minocyclin
piperacillintazobactam
member
acinetobact
spp
pseudomona
aeruginosa
collect
hospit
north
america
europ
asia
method
total
nonfer
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
isol
collect
throughout
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
cephalosporin
ineffect
toward
baumannii
n
tigecyclin
show
lowest
mic
baumannii
mcgml
outperform
amikacin
inhibit
imipenem
minocyclin
similar
find
found
speci
acinetobact
genu
conclus
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
strain
acinetobact
spp
includ
multidrug
resist
strain
regardless
degre
type
resist
background
resist
glycopeptid
enterococci
first
recogn
late
sinc
major
challeng
clinician
infect
control
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tigecyclin
compar
vancomycin
linezolid
ampicillin
imipenem
ceftriaxon
levofloxacin
minocyclin
penicillin
piperacillintazobactam
member
enterococcu
spp
collect
hospit
usa
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
isol
collect
throughout
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
broth
microdilut
panel
interpret
accord
nccl
guidelin
background
resist
glycopeptid
enterococci
first
recogn
late
sinc
major
challeng
clinician
infect
control
tigecyclin
member
new
class
antimicrobi
glycylcyclin
addit
biocatalyt
oxygenreduc
agent
may
requir
absenc
fresh
media
hour
old
test
tigecyclin
use
broth
microdilut
steven
b
johnson
bouchillon
j
johnson
hoban
dowzicki
p
bradford
schaumburg
pearl
river
usa
object
tigecyclin
tgc
new
glycylcyclin
antimicrobi
develop
demonstr
excel
vitro
activ
gramposit
neg
pathogen
recent
report
suggest
tgc
mic
valu
organ
may
elev
broth
use
microdilut
panel
hour
old
age
nccl
tent
recommend
test
tgc
perform
broth
hour
old
fresh
studi
look
differ
panel
use
fresh
broth
age
broth
broth
biocatalyt
oxygenreduc
agent
bora
ad
compens
potenti
broth
differ
materi
method
test
perform
approxim
organ
includ
e
coli
k
pneumonia
catarrhali
epidermidi
pneumonia
bora
use
studi
oxyras
broth
concentr
tig
microdilut
panel
evalu
studi
includ
panel
age
broth
without
oxyras
age
panel
age
broth
oxyras
ao
panel
fresh
broth
without
oxyras
fresh
panel
fresh
broth
oxyras
fo
panel
age
broth
prepar
microscan
fresh
broth
prepar
intern
organ
test
four
panel
type
qualiti
control
perform
use
nccl
approv
atcc
strain
result
combin
test
result
show
mic
correl
dilut
follow
freshao
freshag
foao
foag
qualiti
control
rang
fo
fresh
ao
complianc
age
panel
rang
time
conclus
addit
bora
age
broth
produc
result
equival
fresh
broth
without
bora
object
despit
introduct
new
antimicrobi
treat
resist
gramposit
bacteria
staphylococcu
aureu
continu
therapeut
challeng
clinician
glycylcyclin
show
promis
signific
activ
mani
gramposit
pathogen
includ
methicillinresist
aureu
tigecyclin
first
glycylcyclin
enter
clinic
trial
shown
excel
activ
staphylococcu
spp
studi
initi
evalu
vitro
activ
tigecyclin
compar
compar
agent
ampicillin
amoxicillinclavulan
acid
imipenem
ceftriaxon
levofloxacin
minocyclin
vancomycin
linezolid
piperacillintazobactam
aureu
includ
methicillinresist
staphylococcu
aureu
mrsa
methicillinsensit
staphylococcu
aureu
mssa
multin
evalu
centr
test
program
method
total
clinic
isol
identifi
speci
level
site
countri
confirm
central
laboratori
isol
collect
januari
novemb
mic
determin
particip
laboratori
use
suppli
broth
microdilut
panel
dade
microscan
test
perform
accord
nccl
guidelin
manufactur
instruct
result
mic
tigecyclin
rang
mcgml
isol
aureu
tigecyclin
mcgml
respect
mssa
similar
imipenem
minocyclin
fold
lower
remain
compar
agent
tigecyclin
mcgml
respect
mrsa
fold
lower
vancomycin
fold
lower
minocyclin
fold
lower
linezolid
isol
aureu
inhibit
tigecyclin
mic
mcgml
regardless
methicillin
phenotyp
conclus
vitro
activ
tigecyclin
compar
aureu
test
regardless
methicillin
phenotyp
tigecyclin
activ
mrsa
potent
antimicrobi
agent
test
studi
includ
imipenem
minocyclin
linezolid
vancomycin
background
rapid
increas
resist
nosocomi
pathogen
alway
challeng
clinician
hospit
infect
control
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
speci
enterobacteriacea
well
gram
posit
atyp
anaerob
test
program
determin
vitro
activ
tigecyclin
compar
amikacin
ampicillin
imipenem
cefepim
ceftazidim
ceftriaxon
levofloxacin
minocyclin
piperacillintazobactam
member
enterobacteriacea
mainli
e
coli
klebsiella
spp
enterobact
spp
serratia
spp
collect
hospit
north
america
europ
asia
method
total
clinic
isol
enterobacteriacea
identifi
speci
level
particip
site
confirm
central
laboratori
isol
collect
throughout
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
tigecyclin
activ
equival
imipenem
present
mcgml
strain
enterobacteriacea
comparison
antimicrobi
test
mcgml
tigecyclin
also
lowest
fold
lower
commonli
prescrib
broad
spectrum
antimicrobi
ceftriaxon
levofloxacin
minocyclin
fold
lower
ceftazidim
piperacillintazobactam
frequenc
esbl
product
among
k
pneumonia
e
coli
found
respect
tigecyclin
inhibit
e
coli
k
pneumonia
esbl
produc
mic
mcgml
approxim
enterobact
spp
serratia
spp
present
resist
third
gener
cephalosporin
ceftazidim
ceftriaxon
suggest
ampctyp
resist
tigecyclin
also
inhibit
major
isol
mcgml
conclus
tigecyclin
vitro
activ
compar
activ
broad
spectrum
antimicrobi
carbapenem
imipenem
greater
commonli
prescrib
broad
spectrum
agent
test
studi
present
data
suggest
tigecyclin
may
effect
therapeut
option
suscept
strain
enterobacteriacea
multidrug
resist
strain
regardless
degre
type
resist
background
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
speci
enterobacteriacea
well
gramposit
atyp
anaerob
test
program
determin
vitro
activ
tigecyclin
compar
amikacin
ampicillin
imipenem
cefepim
ceftazidim
ceftriaxon
levofloxacin
minocyclin
piperacillintazobactam
isol
enterobacteriacea
collect
hospit
across
usa
method
total
clinic
isol
collect
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
efficaci
broad
spectrum
antimicrobi
agent
still
remain
highli
activ
enterobacteriacea
unit
state
suscept
rate
amikacin
cefepim
ceftazidim
ceftriaxon
imipenem
levofloxacin
minocyclin
piperacillintazabactam
respect
tigecyclin
activ
similar
imipenem
present
mcg
ml
strain
enterobacteriacea
frequenc
esbl
product
among
k
pneumonia
e
coli
found
respect
tigecyclin
success
inhibit
e
coli
k
pneumonia
esbl
produc
mic
mcgml
also
notic
unusu
resist
imipenem
isol
still
detail
analysi
preliminari
data
shown
tigecyclin
present
mcgml
multiresist
isol
conclus
broad
spectrum
antimicrobi
agent
still
remain
activ
enterobacteriacea
us
tigecyclin
activ
compar
activ
broad
spectrum
antimicrobi
greater
activ
esbl
ampc
produc
isol
tigecyclin
also
show
vitro
activ
isol
intermedi
resist
imipenem
mani
instanc
consid
last
therapeut
option
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
suscept
strain
enterobacterieacea
multidrug
resist
strain
regardless
degre
type
resist
background
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
commonli
encount
gramposit
gramneg
speci
includ
anaerob
pathogen
respons
commun
hospit
infect
test
program
determin
vitro
activ
tigecyclin
compar
amikacin
ampicillin
imipenem
cefepim
ceftazidim
ceftriaxon
levofloxacin
minocyclin
piperacillin
tazobactam
gram
neg
rod
addit
linezolid
penicillin
vancomycin
gram
posit
speci
isol
collect
hospit
unit
state
throughout
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
shown
tabl
tigecyclin
activ
similar
imipenem
enterobacteriacea
inhibit
multiresist
esbl
ampc
produc
mic
equal
lesser
mcgml
tigecyclin
also
show
vitro
activ
mcgml
imipenem
resist
enterobacteriacea
strain
although
similar
class
broad
spectrum
antimicrobi
agent
nonferment
tigecyclin
especi
activ
acinetobact
spp
lowest
mcgml
tigecyclin
inhibit
aureu
mcgml
mssa
mrsa
isol
enterococci
tigecyclin
consist
regardless
vancomycin
suscept
conclus
tigecyclin
vitro
activ
compar
greater
commonli
prescrib
broad
spectrum
antimicrobi
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
suscept
common
gramposit
gramneg
pathogen
includ
multidrug
resist
strain
regardless
degre
type
resist
background
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tigecyclin
compar
amikacin
ampicillin
imipenem
cefepim
ceftazidim
ceftriaxon
levofloxacin
minocyclin
piperacillintazobactam
gram
neg
rod
addit
linezolid
penicillin
vancomycin
gram
posit
speci
isol
collect
hospit
locat
germani
itali
spain
unit
kingdom
throughout
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
shown
tabl
tigecyclin
activ
similar
imipenem
enterobacteriacea
inhibit
multiresist
esbl
ampc
produc
mic
equal
lesser
mcgml
although
similar
class
broad
spectrum
antimicrobi
agent
glucos
nonferment
tigecyclin
especi
activ
acinetobact
spp
present
lowest
mcgml
tigecyclin
inhibit
aureu
mcgml
regardless
sensit
resist
methicillin
result
notic
enterococci
tigecyclin
mcgml
consist
regardless
vancomycin
suscept
conclus
tigecyclin
vitro
activ
compar
greater
commonli
prescrib
antimicrobi
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
aerob
gramposit
aerob
gramneg
bacteria
includ
multidrug
resist
strain
regardless
degre
type
resist
background
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tigecyclin
compar
amikacin
ampicillin
imipenem
cefepim
ceftazidim
ceftriaxon
levofloxacin
minocyclin
piperacillin
tazobactam
gram
neg
rod
addit
linezolid
penicillin
vancomycin
gram
posit
speci
isol
collect
hospit
locat
asia
throughout
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
tigecyclin
activ
similar
imipenem
enterobacteriacea
mcgml
resist
third
gener
cephalosporin
found
e
coli
k
pneumonia
consist
esbl
phenotyp
tigecyclin
inhibit
esbl
ampc
produc
mic
equal
lesser
mcgml
although
similar
class
broad
spectrum
antimicrobi
agent
glucos
nonferment
tigecyclin
especi
activ
acinetobact
spp
present
lowest
mcgml
tigecyclin
success
inhibit
aureu
mcgml
regardless
sensit
resist
methicillin
phenomenon
notic
enterococci
tigecyclin
mcgml
consist
regardless
vancomycin
suscept
conclus
tigecyclin
vitro
activ
compar
greater
commonli
prescrib
antimicrobi
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
aerob
gramposit
aerob
gramneg
bacteria
includ
multidrug
resist
strain
regardless
degre
type
resist
background
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
speci
enterobacteriacea
well
gramposit
atyp
anaerob
test
program
determin
vitro
activ
tigecyclin
compar
amikacin
ampicillin
imipenem
cefepim
ceftazidim
ceftriaxon
levofloxacin
minocyclin
piperacillintazobactam
isol
enterobacteriacea
collect
hospit
germani
itali
spain
unit
kingdom
method
total
clinic
isol
collect
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
abstract
use
suppli
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
observ
vitro
activ
broad
spectrum
antimicrobi
agent
still
remain
highli
activ
enterobacteriacea
europ
suscept
rate
amikacin
cefepim
ceftazidim
ceftriaxon
imipenem
levofloxacin
minocyclin
respect
tigecyclin
activ
similar
effect
antimicrobi
agent
imipenem
suscept
present
mcgml
strain
enterobacteriacea
frequenc
esbl
product
among
k
pneumonia
e
coli
found
respect
tigecyclin
inhibit
esbl
produc
e
coli
mic
mcgml
mic
mcgml
esbl
produc
k
pneumonia
approxim
enterobact
spp
serratia
marcescen
present
resist
third
gener
cephalosporin
ceftazidim
ceftriaxon
suggest
ampctyp
resist
conclus
broad
spectrum
antimicrobi
agent
still
remain
activ
european
repres
enterobacteriacea
tigecyclin
vitro
activ
compar
activ
broad
spectrum
antimicrobi
greater
activ
esbl
ampc
produc
isol
mic
mcgml
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
suscept
strain
enterobacterieacea
multidrug
resist
strain
regardless
degre
type
resist
background
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tigecyclin
compar
amikacin
ampicillin
imipenem
cefepim
ceftazidim
ceftriaxon
levofloxacin
minocyclin
piperacillintazobactam
gram
neg
rod
addit
linezolid
penicillin
vancomycin
gram
posit
speci
isol
collect
hospit
north
america
europ
asia
throughout
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
shown
tabl
tigecyclin
activ
similar
imipenem
enterobacteriacea
inhibit
multiresist
esbl
ampc
produc
mic
equal
lesser
mcgml
although
similar
class
broad
spectrum
antimicrobi
agent
nonferment
tigecyclin
especi
activ
acinetobact
spp
demonstr
lowest
mcgml
tigecyclin
success
inhibit
aureu
mcgml
regardless
sensit
resist
methicillin
result
notic
enterococci
tigecyclin
consist
regardless
vancomycin
suscept
conclus
tigecyclin
vitro
activ
compar
greater
commonli
prescrib
antimicrobi
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
aerob
gramposit
aerob
gramneg
bacteria
includ
multidrug
resist
strain
regardless
degre
type
resist
background
resist
glycopeptid
enterococci
first
recogn
late
sinc
major
challeng
clinician
infect
control
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tigecyclin
compar
vancomycin
linezolid
ampicillin
imipenem
ceftriaxon
levofloxacin
minocyclin
penicillin
piperacillintazobactam
member
enterococcu
spp
collect
hospit
north
america
europ
asia
method
total
clinic
isol
enterococcu
spp
identifi
speci
level
particip
site
confirm
central
laboratori
isol
collect
throughout
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
e
faecali
evalu
resist
vancomycin
isol
observ
isol
suscept
linezolid
tigecyclin
tigecyclin
present
lowest
mcgml
among
antimicrobi
agent
evalu
among
e
faecium
resist
vancomycin
three
isol
also
resist
linezolid
tigecyclin
also
present
lowest
mcgml
five
isol
vancomycin
suscept
e
faecali
one
vancomycin
suscept
e
faecium
nonsuscept
linezolid
abnorm
resist
phenotyp
observ
enterococcu
speci
test
conclus
tigecyclin
vitro
activ
compar
greater
commonli
prescrib
antimicrobi
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
enterococcu
spp
includ
multidrug
resist
strain
regardless
degre
type
resist
tigecyclin
evalu
surveil
trial
test
global
vitro
antibacteri
activ
select
speci
glucos
nonfer
organ
object
despit
introduct
new
antimicrobi
treat
resist
gramposit
bacteria
staphylococcu
aureu
continu
therapeut
challeng
clinician
glycylcyclin
show
promis
signific
activ
mani
gramposit
pathogen
includ
methicillinresist
aureu
tigecyclin
first
glycylcyclin
enter
clinic
trial
shown
excel
activ
staphylococcu
spp
studi
initi
evalu
vitro
activ
tigecyclin
compar
compar
agent
ampicillin
amoxicillinclavulan
acid
imipenem
ceftriaxon
levofloxacin
minocyclin
vancomycin
linezolid
piperacillintazobactam
aureu
includ
methicillinresist
staphylococcu
aureu
mrsa
methicillinsensit
staphylococcu
aureu
mssa
us
centr
test
program
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
isol
collect
throughout
mic
determin
particip
laboratori
use
broth
microdilut
panel
dade
microscan
test
perform
interpret
accord
nccl
guidelin
manufactur
instruct
result
among
isol
found
resist
methicillin
mrsa
besid
cross
resist
mrsa
isol
imipenem
ceftriaxon
penicillin
ampicillin
piperacillintazobactam
observ
high
rate
nonsuscept
levofloxacin
resist
observ
vancomycin
linezolid
mic
tigecyclin
rang
mcgml
isol
aureu
tigecyclin
present
lowest
mcgml
mrsa
isol
sever
fold
lower
compar
agent
mssa
isol
show
expect
profil
high
resist
ampicillin
penicillin
unusu
pattern
nonsuscept
levofloxacin
tigecyclin
also
lowest
among
mssa
isol
conclus
vitro
activ
tigecyclin
compar
aureu
test
regardless
methicillin
phenotyp
tigecyclin
activ
mrsa
potent
antimicrobi
agent
test
studi
includ
imipenem
minocyclin
linezolid
vancomycin
tigecyclin
evalu
surveil
trial
test
unit
state
vitro
antibacteri
activ
select
speci
enterococcu
spp
result
e
faecali
evalu
observ
resist
vancomycin
isol
isol
suscept
linezolid
tigecyclin
tigecyclin
present
lowest
mcgml
among
antimicrobi
agent
evalu
typic
profil
e
faecali
fluoroquinolon
levofloxacin
tetracyclin
minocyclin
limit
activ
speci
among
e
faecium
resist
vancomycin
three
isol
also
resist
linezolid
tigecyclin
also
present
lowest
mcgml
five
isol
vancomycin
suscept
e
faecali
one
vancomycin
suscept
e
faecium
nonsuscept
linezolid
abnorm
resist
phenotyp
observ
enterococcu
speci
test
conclus
tigecyclin
vitro
activ
compar
greater
commonli
prescrib
antimicrobi
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
enterococcu
spp
includ
multidrug
resist
strain
regardless
degre
type
resist
background
glucos
nonfer
gram
neg
rod
known
highli
resist
hospit
set
alway
challeng
clinician
hospit
infect
control
degre
type
resist
may
due
sever
sophist
mechan
product
broad
spectrum
betalactamas
efflux
pump
alter
membran
permeabl
inactiv
class
antimicrobi
avail
treatment
cephalosporin
carbapenem
aminoglycosid
fluoruquinolon
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
speci
enterobacteriacea
select
speci
nonferment
well
gram
posit
atyp
anaerob
test
program
determin
vitro
activ
tigecyclin
compar
amikacin
ampicillin
imipenem
cefepim
ceftazidim
ceftriaxon
levofloxacin
minocyclin
piperacillintazobactam
member
acinetobact
spp
pseudomona
aeruginosa
collect
hospit
unit
state
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
isol
collect
throughout
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
tigecyclin
activ
p
aeruginosa
show
mcgml
toward
baumannii
n
cephalosporin
ineffect
tigecyclin
show
lowest
mcgml
outperform
amikacin
imipenem
minocyclin
similar
find
found
speci
acinetobact
genu
conclus
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
strain
acinetobact
spp
includ
multidrug
resist
strain
regardless
degre
type
resist
object
despit
introduct
new
antimicrobi
treat
resist
gramposit
bacteria
staphylococcu
aureu
continu
therapeut
challeng
clinician
glycylcyclin
show
promis
signific
activ
mani
gramposit
pathogen
includ
methicillinresist
aureu
tigecyclin
first
glycylcyclin
enter
clinic
trial
shown
excel
activ
staphylococcu
spp
studi
initi
evalu
vitro
activ
tigecyclin
compar
compar
agent
ampicillin
amoxicillinclavulan
acid
imipenem
ceftriaxon
levofloxacin
minocyclin
vancomycin
linezolid
piperacillintazobactam
aureu
includ
methicillinresist
staphylococcu
aureu
mrsa
methicillinsensit
staphylococcu
aureu
mssa
european
centr
test
program
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
isol
collect
throughout
mic
determin
particip
laboratori
use
broth
microdilut
panel
dade
microscan
test
perform
interpret
accord
nccl
guidelin
manufactur
instruct
result
among
isol
found
resist
methicillin
mrsa
besid
cross
resist
mrsa
isol
imipenem
ceftriaxon
penicillin
ampicillin
piperacillintazobactam
observ
mrsa
isol
also
nonsuscept
levofloxacin
resist
observ
vancomycin
linezolid
mic
tigecyclin
rang
mcgml
isol
aureu
tigecyclin
present
lowest
mcgml
mrsa
isol
sever
fold
lower
compar
agent
mssa
isol
show
expect
profil
high
resist
ampicillin
penicillin
opposit
mrsa
isol
mssa
present
littl
resist
levofloxacin
tigecyclin
also
lowest
among
mssa
isol
conclus
vitro
activ
tigecyclin
compar
aureu
test
regardless
methicillin
phenotyp
tigecyclin
activ
mrsa
potent
antimicrobi
agent
test
studi
includ
imipenem
minocyclin
linezolid
vancomycin
tigecyclin
evalu
surveil
trial
test
european
vitro
antibacteri
activ
select
speci
enterococcu
spp
shown
potent
expand
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tigecyclin
compar
vancomycin
linezolid
ampicillin
imipenem
ceftriaxon
levofloxacin
minocyclin
penicillin
piperacillintazobactam
member
enterococcu
spp
collect
hospit
germani
itali
spain
unit
kingdom
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
isol
collect
throughout
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
e
faecali
evalu
resist
vancomycin
isol
observ
isol
suscept
linezolid
tigecyclin
tigecyclin
present
lowest
mcgml
among
antimicrobi
agent
evalu
among
e
faecium
resist
vancomycin
tigecyclin
also
present
lowest
mcgml
abnorm
resist
phenotyp
observ
enterococci
speci
test
conclus
tigecyclin
vitro
activ
compar
greater
commonli
prescrib
antimicrobi
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
enterococcu
spp
includ
multidrug
resist
strain
regardless
degre
type
resist
tigecyclin
evalu
surveil
trial
test
european
vitro
antibacteri
activ
select
speci
glucos
nonfer
organ
background
glucos
nonfer
gram
neg
rod
known
highli
resist
hospit
set
alway
challeng
clinician
hospit
infect
control
degre
type
resist
may
due
sever
sophist
mechan
product
broad
spectrum
betalactamas
efflux
pump
alter
membran
permeabl
inactiv
class
antimicrobi
avail
treatment
cephalosporin
carbapenem
aminoglycosid
fluoruquinolon
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
speci
enterobacteriacea
select
speci
nonferment
well
gram
posit
atyp
anaerob
test
program
determin
vitro
activ
tigecyclin
compar
amikacin
ampicillin
imipenem
cefepim
ceftazidim
ceftriaxon
levofloxacin
minocyclin
piperacillintazobactam
member
acinetobact
spp
pseudomona
aeruginosa
collect
hospit
germani
itali
spain
unit
kingdom
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
isol
collect
throughout
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
tigecyclin
activ
p
aeruginosa
show
mcgml
cephalosporin
ineffect
toward
baumannii
n
tigecyclin
show
lowest
mic
baumannii
mcgml
outperform
amikacin
imipenem
minocyclin
similar
find
found
speci
acinetobact
genu
conclus
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
strain
acinetobact
spp
includ
multidrug
resist
strain
regardless
degre
type
resist
antimicrobi
activ
tigecyclin
test
bacteri
pathogen
intens
care
unit
h
sader
fritsch
r
jone
north
liberti
usa
object
evalu
antimicrobi
activ
tigecyclin
tig
select
antimicrobi
bacteri
pathogen
isol
patient
hospit
intens
care
unit
icu
worldwid
method
total
consecut
collect
medic
centr
locat
north
america
south
america
europ
asiaaustralia
region
isol
collect
isol
bloodstream
respiratori
tract
skinsoft
tissu
urinari
tract
infect
period
suscept
test
nccl
broth
microdilut
method
result
antimicrobi
activ
tig
frequenc
occurr
bacteri
pathogen
summar
tabl
gramposit
pathogen
inhibit
mgl
tig
resist
r
oxacillin
detect
sa
con
r
vancomycin
detect
enterococci
tig
activ
enterobacteriacea
ent
mgl
except
serratia
spp
e
coli
klebsiella
spp
show
esbl
phenotyp
enterobact
spp
r
ceftazidim
ent
show
r
ciprofloxacin
tig
trimethoprimsulfamethoxazol
activ
compound
maltophilia
mgl
respect
tig
also
highli
activ
asp
mgl
psa
show
decreas
tig
mgl
non
imipenem
mic
mgl
observ
asp
psa
isol
conclus
isol
icu
patient
show
high
rate
antimicrobi
r
alarm
problem
detect
vancomycin
r
among
enterococci
esbl
mediat
betalactam
r
fluoroquinolon
r
among
ent
carbapenem
r
among
psa
asp
tig
exhibit
potent
vitro
activ
vast
major
clinic
import
pathogen
bacteria
except
psa
isol
icu
patient
may
repres
excel
option
treatment
infect
clinic
environ
potenc
spectrum
tigecyclin
test
intern
collect
bacteri
pathogen
produc
skin
soft
tissu
infect
fritsch
h
sader
stilwel
r
jone
north
liberti
usa
object
tigecyclin
tig
sentinel
repres
glycylcyclin
class
develop
parenter
agent
target
bacteri
pathogen
respons
pneumonia
intraabdomin
sepsi
ssti
aim
studi
evalu
activ
potenc
tig
test
larg
collect
bacteri
pathogen
caus
ssti
method
consecut
nondupl
bacteri
isol
strain
collect
patient
document
communityacquir
nosocomi
ssti
medic
centr
particip
tig
surveil
program
north
america
europ
latin
america
asiapacif
region
isol
test
use
nccl
broth
microdilut
method
tig
repres
compar
agent
use
empir
direct
therapi
ssti
result
ssti
pathogen
rank
order
top
ten
potenc
cumul
inhibit
rate
tig
tabl
sa
streptococci
enterococci
con
ksp
ec
inhibit
mgl
tig
along
asp
ent
broadspectrum
activ
exhibit
tig
includ
tetracyclin
resist
subset
well
mrsa
vre
esblproduc
strain
pm
psa
isol
less
suscept
valu
mgl
respect
conclus
among
top
tenrank
pathogen
produc
ssti
isol
inhibit
mgl
tig
inhibit
mgl
current
nccl
breakpoint
tetracyclin
tig
may
repres
welcom
choic
among
newer
parenter
agent
common
gramposit
neg
pathogen
produc
seriou
ssti
given
vitro
test
result
thu
warrant
continu
investig
indic
object
assess
activ
tigecyclin
formerli
novel
glycylcyclin
recent
bloodstream
infect
bsi
pathogen
isol
six
contin
frequenc
clinic
occurr
pathogen
determin
antibiogram
assess
use
nccl
refer
broth
microdilut
method
method
total
strain
test
method
interpret
tigecyclin
suscept
breakpoint
defin
mgl
comparison
purpos
although
mgl
use
tetracyclin
rank
order
pathogen
aureu
sa
coagulaseneg
staphylococci
con
e
coli
ec
enterococci
ent
klebsiella
spp
ksp
p
aeruginosa
psa
enterobact
spp
eb
betahaemolyticstreptococci
bst
pneumonia
spn
viridan
group
streptococci
vg
comparison
agent
test
includ
tetracyclin
tc
ciprofloxacin
cip
result
bsi
pathogen
gramposit
enterobacteriacea
test
tigecyclin
shown
tabl
tigecyclin
consist
activ
tcresist
r
strain
versu
result
bsi
speci
p
mirabili
acinetobact
spp
serratia
spp
maltophilia
indoleposit
protea
tigecyclin
exhibit
broader
spectrum
activ
bsi
isol
compar
cip
tc
older
aminoglycosid
imipenem
tigecyclin
activ
psa
mgl
bsi
isol
conclus
tigecyclin
exhibit
wide
spectrum
antimicrobi
potenc
versu
bsi
isol
collect
worldwid
seriou
infect
nosocomi
environ
benefit
tigecyclin
among
investig
phase
agent
focus
r
strain
evalu
vitro
activ
tigecyclin
gramneg
anaerob
bacteria
object
evalu
vitro
activ
tigecyclin
comparison
tetracyclin
penicillin
piperacillin
tazobactam
cefoxitin
clindamycin
metronidazol
imipenem
recent
isol
gramneg
anaerob
bacteria
materi
method
total
gramneg
anaerob
clinic
strain
bacteroid
fragili
group
bacteroid
spp
nonfragili
prevotella
spp
miscellan
isol
period
test
use
etest
agar
dilut
method
brucella
agar
plate
supplement
hors
blood
vitamin
hemin
incub
chellab
anaerob
chamber
perform
hour
interpret
result
accord
nccl
guidelin
qualiti
control
strain
b
fragili
b
thetaiotaomicron
use
result
overal
tigecyclin
tetracyclin
penicillin
piperacillin
tazobactam
cefoxitin
clindamycin
metronidazol
imipenem
mgl
respect
wherea
mgl
respect
bacteroid
fragili
group
mgl
respect
wherea
mgl
respect
tigecyclin
concentr
mg
l
compound
inhibit
higher
percentag
isol
clindamycin
cefoxitin
tetracyclin
inhibit
isol
respect
one
strain
resist
imipenem
mic
mgl
tigecyclin
mic
mgl
addit
six
eight
strain
metronidazol
mic
mgl
tigecyclin
mic
mgl
conclus
gener
tigecyclin
show
better
vitro
activ
clindamycin
cefoxitin
tetracyclin
penicillin
gramneg
anaerob
bacteria
somewhat
lower
clinic
microbiolog
infect
volum
supplement
activ
imipenem
metronidazol
piperacillin
tazobactam
nevertheless
among
metronidazol
imipenem
resist
isol
tigecyclin
display
good
activ
result
invitro
evalu
show
tigecyclin
consid
possibl
altern
treatment
mix
aerobicanaerob
infect
object
ascertain
variat
mic
tigecyclin
determin
broth
agar
nccl
bsac
method
assess
effect
ad
tigecyclin
medium
one
day
use
use
media
age
one
week
addit
tigecyclin
inocul
method
mic
nonfastidi
bacteria
streptococci
determin
muellerhinton
broth
mhb
muellerhinton
agar
mha
isosensitest
broth
isb
isosensitest
agar
isa
fresh
antibiot
stock
solut
tigecyclin
tetracyclin
minocyclin
incorpor
bulk
media
roll
minimis
aerat
prepar
condit
otherwis
follow
freshlyprepar
media
antibiot
ad
upon
cool
inocul
b
freshlyprepar
media
antibiot
ad
upon
cool
thenstor
day
inoculationand
c
media
store
day
addit
antibiot
inocul
result
mic
fresh
mhb
nccl
refer
method
taken
standard
tetracyclin
mic
doubl
dilut
higher
mha
isa
bsac
refer
method
isb
media
tetracyclin
ad
day
use
gave
rais
mic
though
rare
one
dilut
tigecyclin
mic
increas
mhb
isb
effect
greatest
dilut
suscept
strain
mic
mgl
absent
resist
organ
mic
mgl
occur
agar
minocyclin
mic
rais
age
media
tetracyclin
mic
margin
affect
addit
blood
mhb
larg
abrog
effect
tigecyclin
mic
boil
broth
prior
ad
antibiot
conclus
rais
mic
tigecyclin
age
broth
probabl
reflect
inactiv
dissolv
oxygen
accord
lack
mic
increas
newli
boil
ie
degass
mhb
age
agar
boil
melt
use
effect
blood
may
add
reduc
capac
protect
tigecyclin
practic
level
broth
mic
method
tigecyclin
eg
nccl
refer
method
requir
freshli
prepar
steam
medium
concern
agar
dilut
method
use
bsac
sexual
transmit
diseas
preval
chlamydia
trachomati
neisseria
gonorrhoea
nativ
immigr
popul
ambit
studi
barcelona
spain
test
danish
gc
strain
isol
n
clinic
epidemiolog
data
obtain
possibl
result
pipneg
gc
isol
design
serovar
similar
mic
valu
identifi
antibiogram
isol
fingerprint
identifi
use
spei
three
use
bglii
among
isol
four
distinguish
pfge
howev
isol
differ
less
six
band
fingerprint
phylogenet
tree
analysi
sequenc
suggest
minor
differ
repres
ongo
evolut
strain
period
jan
nov
proport
pipneg
gc
per
year
denmark
respect
pipneg
gc
infect
mostli
men
women
antibiogram
danish
isol
indic
spread
least
one
pipneg
gc
strain
result
present
studi
indic
circul
least
one
n
gonorrhoea
prolyliminopeptidaseneg
strain
danish
homosexu
commun
increas
awar
pipneg
n
gonorrhoea
creat
larg
problem
diagnosi
use
eg
api
nh
rapid
nh
gonocheck
ii
neisseria
pet
essenti
new
recombin
antigen
haemagglutin
test
serolog
diagnosi
syphili
n
chepurchenko
ulanova
v
puzyrev
l
loginova
burkov
obriadina
nizhniy
novgorod
ru
introduct
passiv
treponema
pallidum
hemagglutin
ha
routin
treponem
test
equal
sensit
fluoresc
treponem
antibodi
absorpt
ftaab
test
enzym
immunoassay
eia
later
stage
syphili
studi
indic
less
sensit
primari
stage
diseas
use
recombin
pallidum
antigen
instead
poorli
defin
mixtur
antigen
wildtyp
pallidum
potenti
improv
sensit
hemagglutin
test
object
purpos
studi
evalu
diagnost
relev
recombin
protein
effici
model
antigen
epitop
treponema
pallidum
protein
method
four
fulllength
recombin
protein
tmpa
kda
express
e
coli
use
individu
develop
hemagglutin
test
ht
detect
antitreponema
pallidum
antitp
activ
serum
specimen
serum
sampl
n
patient
clinic
proven
syphili
variou
stage
diseas
primari
n
secondari
n
latent
n
normal
blood
donor
n
test
sampl
patient
primari
syphili
sampl
patient
secondari
sampl
patient
latent
stage
test
initi
commerci
avail
hemagglutin
test
base
mixtur
treponema
pallidum
antigen
http
specimen
addit
test
specif
antibodi
commerci
avail
enzym
immunoassay
eia
result
sensit
ht
detect
antitp
activ
human
serum
specimen
vari
primari
syphili
sera
secondari
latent
stage
sera
protein
tmpa
found
immunoreact
serum
sampl
patient
untreat
syphili
test
sensit
tmpa
ht
ident
http
case
untreat
secondari
latent
syphili
significantli
higher
specimen
primari
stage
diseas
overal
specif
sensit
tmpa
ht
compar
eia
respect
result
studi
indic
tmpa
ht
may
reason
altern
routin
hemagglutin
test
elisa
confirmatori
test
syphili
use
treponema
vdrl
virablot
test
use
confirmatori
assay
treponema
pallidum
antibodi
kostoula
g
vrioni
c
bobogianni
c
stergiopoul
e
papantoni
levidiot
ioannina
gr
object
detect
treponema
pallidum
subsp
pallidum
darkfield
microscopi
direct
immunofluoresc
possibl
earli
stage
diseas
serolog
becom
method
choic
syphili
diagnosi
except
convent
treponem
test
pallidum
western
immunoblot
assay
also
use
altern
confirmatori
assay
pallidum
antibodi
aim
present
studi
use
multiparamet
immunoassay
simultan
detect
treponem
specif
lipoid
antibodi
confirm
syphili
antibodi
method
total
serum
specimen
test
includ
reactiv
sera
patient
document
treponem
infect
specif
panel
sera
normal
subject
sera
rapid
plasma
reagin
rpr
reactiv
ftaab
tpha
neg
leptospira
igm
serologyposit
sera
borrelia
burgdorferi
igg
igm
serologyposit
sera
serum
sampl
test
convent
syphili
test
accord
instruct
rpr
vener
diseas
research
laboratori
vdrl
pallidum
haemagglutin
tpha
serum
dilut
fluoresc
pallidum
absorpt
ftaab
igm
captur
enzym
immunoassay
eia
subsequ
result
compar
treponema
vdrl
virablot
igg
igm
test
viram
labor
diagnostika
immunoassay
qualit
detect
specif
igg
igm
antibodi
pallidum
use
specif
treponem
protein
quantit
determin
vdrl
reaction
one
nitrocellulos
strip
result
treponema
vdrl
virablot
igg
igm
test
confirm
result
serum
specimen
posit
pallidum
antibodi
reactiv
vdrl
band
least
two
clear
band
igg
treponem
antibodi
least
one
clear
band
igm
treponem
antibodi
rpr
reactiv
sera
vdrl
virablot
reactiv
treponema
virablot
specif
antibodi
neg
none
remain
sera
react
test
treponema
vdrl
virablot
assay
conclus
treponema
vdrl
virablot
assay
combin
necessari
serolog
marker
one
test
strip
ie
specif
nonspecif
treponem
antigen
use
confirmatori
test
syphili
increas
reliabl
syphili
diagnosi
respect
current
convent
techniqu
great
imit
syphili
predomin
acut
sever
hepat
involv
ground
signific
increas
serum
transaminias
ul
gpt
respect
frank
jaundic
elev
bilirubin
mgdl
respect
evid
rise
serum
alkalin
phosphatas
gammagt
clinic
histori
show
risk
factor
viral
hepat
laboratori
examin
major
minor
hepatotrop
virus
prove
neg
well
autoimmmun
dysmetabol
druginduc
liver
damag
repeat
ultrasonographi
detect
increas
liver
spleen
dimens
absenc
abnorm
second
p
histopatholog
studi
perform
liver
biopsi
show
aspecif
cholestat
hepatopathi
moder
granulocyt
lymphomononocyt
intralobular
infiltr
appreci
necrot
foci
mild
portal
fibrosi
knodel
score
syphili
serolog
perform
despit
absenc
signific
histori
clinic
clue
allow
recogn
igm
posit
serolog
associ
tpha
titr
rang
respect
specif
chemotherapi
iv
penicillin
g
mu
daili
day
follow
muday
second
p
led
complet
resolut
hepat
involv
associ
improv
serolog
month
discuss
major
episod
syphili
liver
involv
remain
miss
subclin
earli
diagnosi
syphili
predomin
hepat
diseas
remain
unresolv
problem
differenti
diagnosi
due
rare
occurr
isol
organ
involv
compar
typic
syphili
sign
symptom
aspecif
clinic
histopatholog
imag
pictur
jozsa
l
acta
hepatogastroenterol
young
mf
j
clin
gastroenterol
recent
recrudesc
syphili
itali
diagnost
suspicion
maintain
clinician
face
appar
acut
icter
hepat
syphili
serolog
includ
among
initi
laboratori
workout
great
imit
syphili
predomin
meningoencephalit
featur
r
manfredi
sabbatani
pocaterra
f
chiodo
bologna
introduct
signific
recrudesc
syphili
observ
recent
year
contain
prophylact
measur
hiv
std
mening
meningoencephalit
involv
may
occur
also
earli
stage
syphili
thu
pose
problem
differenti
diagnosi
case
report
young
woman
hivinfect
male
develop
syphili
predomin
meningoenceph
express
first
p
base
isol
posit
borrelia
burgdorferi
serolog
later
deem
crossreact
earli
ceftriaxon
start
due
suspect
neurolog
lyme
diseas
also
diagnosi
neurosyphili
ground
posit
csf
serolog
antimicrobi
therapi
left
unchang
week
dayhospit
facil
complet
clinicalmicrobiolog
cure
second
hivinfect
p
hospit
owe
mild
fever
last
week
associ
cephalalgia
anxietyth
favor
virologicalimmunolog
statu
count
cellsll
undetect
hiv
viraemia
effect
haart
regimen
exclud
search
possibl
hivrel
disordersalthough
serum
examin
detect
potenti
latent
syphili
isol
posit
serum
treponema
pallidum
igg
tpha
iggposit
rpr
mute
histori
syphili
csf
examin
disclos
increas
cell
content
alter
brainblood
barrier
index
increas
intrathec
ig
synthesi
frank
vdrl
tpha
borderlin
pallidum
igm
serologypenicillin
g
muday
day
led
slow
resolut
neurolog
sign
symptom
tendenc
improv
specif
csfserum
syphili
serolog
subsequ
control
discuss
focus
differenti
diagnosi
luetic
etiolog
underestim
face
young
p
suffer
meningoenceph
unclear
originour
case
character
young
age
year
respect
compar
usual
mean
age
tertiari
neurosyphili
absenc
suggest
histori
syphili
sign
diagnosi
achiev
retriev
elev
syphili
serolog
posit
csf
serum
togeth
clinic
sign
seizur
alter
mentat
cognit
abnorm
anisochoria
first
p
persist
headach
anxieti
second
p
experi
ceftriaxon
start
first
p
neuroborreliosi
suspect
favor
like
highdos
iv
penicillin
g
comparison
genom
pathogen
treponem
treponema
pallidum
ssp
pallidum
ssp
pertenu
treponema
paraluiscuniculi
object
cervic
human
papillomaviru
hpv
infect
common
among
young
sexual
activ
women
cytolog
test
limit
includ
falseneg
result
molecular
techniqu
increasingli
use
identif
hpvinduc
cell
chang
cervix
polymeras
chain
reaction
pcr
hpv
diagnost
success
introduc
recent
bulgaria
howev
limit
data
specif
preval
determin
subclin
hpv
infect
avail
studi
design
multiplex
primer
pcr
system
simultan
identif
common
lowand
highrisk
hpv
women
cytolog
normal
cervic
smear
materi
method
dna
cervic
cell
sampl
women
age
year
normal
pap
smear
test
extract
standard
procedur
studi
hpv
presenc
six
typespecif
primer
set
hpv
gene
use
singletub
reaction
detect
identif
respect
control
statist
analysi
includ
result
overal
hpv
dna
preval
ten
hpv
posit
women
infect
highrisk
viru
type
eight
lowrisk
type
six
infect
highand
lowrisk
type
hpv
preval
among
women
younger
year
lowrisk
type
peak
preval
observ
women
year
besid
age
posit
associ
detect
rate
hpv
infect
number
sexual
partner
oral
contracept
use
conclus
use
techniqu
simpl
econom
rapid
reliabl
screen
studi
hpv
infect
preval
hpv
cytolog
normal
bulgarian
women
similar
report
countri
find
suggest
molecular
techniqu
hpv
detect
might
use
adjunct
pap
smear
screen
examin
mycoplasma
determin
use
commerci
avail
system
liofilchem
srl
itali
c
trachomati
antigen
dif
cellab
pti
ltd
australia
result
specimen
posit
isol
speci
age
group
summar
tabl
case
lower
genit
tract
lgt
infect
one
speci
isol
three
age
group
mycoplasma
commonli
identifi
particular
speci
isol
pathogen
group
n
mycoplasma
streptococcu
spp
candida
spp
c
trachomati
anaerob
women
group
mix
infect
three
speci
found
women
posit
cultur
symptomat
asymptomat
women
sexual
transmit
pathogen
identifi
notic
infect
women
candida
spp
c
trachomati
respect
present
symptom
conclus
rate
mix
lgt
infect
asymptomat
infect
teenag
group
symptomat
ureaplasma
mba
size
variant
woman
spontan
preterm
deliveri
j
spergser
witt
l
petricev
p
husslein
hirschl
r
rosengarten
vienna
object
despit
colon
lower
urogenit
tract
ureaplasma
reach
upper
genit
tract
subpopul
women
individu
symptom
like
preterm
deliveri
ensu
studi
indic
certain
serovar
frequent
implic
particular
diseas
other
suggest
size
variabl
multipl
band
antigen
mba
may
contribut
ureaplasm
pathogenesi
address
hypothes
vagin
placent
sampl
women
spontan
preterm
deliveri
test
ureaplasma
speci
serovar
mba
size
variant
method
placentaamnion
specimen
correspond
vagin
sampl
women
deliv
via
caesarean
section
less
week
pregnanc
collect
sampl
examin
ureaplasma
speci
serovar
cultiv
pcr
assay
determin
mba
size
variant
pcr
primer
amplifi
nonrepetit
ctermin
repeat
region
mba
gene
perform
result
case
examin
far
placentaamnion
specimen
correspond
vagin
sampl
posit
ureaplasma
cultiv
pcr
ureaplasma
posit
sampl
lower
genit
tract
carri
u
parvum
u
urealyticum
colon
placentaamnion
restrict
u
parvum
recov
women
preterm
labor
preterm
prom
contrast
ureaplasma
detect
sampl
women
hellp
syndrom
iugr
preeclampsia
oppos
previou
studi
particular
serovar
implic
advers
pregnanc
outcom
howev
signific
differ
number
length
mba
pcr
product
among
placent
vagin
ureaplasma
isol
obviou
ureaplasma
isol
placentaamnion
membran
gave
shorter
pcr
product
correspond
vagin
isol
major
vagin
ureaplasma
isol
compos
multipl
size
variant
placent
isol
predominantli
restrict
singular
mba
size
variant
conclus
u
parvum
found
frequent
present
placentaamnion
women
preterm
deliveri
certain
serovar
frequent
implic
particular
diseas
addit
mba
size
variat
repres
addit
level
phenotyp
genet
variabl
beyond
serovar
categori
may
provid
import
contribut
ureaplasm
pathogenesi
use
kanamicin
topic
therapi
aerob
vagin
g
tempera
g
bonfiglio
e
cammarata
corsello
cianci
catania
object
demonstr
efficaci
topic
therapi
kanamicin
new
patholog
call
aerob
vagin
av
method
eightyon
patient
clinic
diagnosi
av
accord
donder
criteria
includ
studi
presenc
least
four
follow
symptom
taken
diagnosi
av
object
abnorm
yellow
vagin
discharg
foul
smell
neg
koh
test
elev
vagin
ph
abund
vagin
leukocyt
lactobacillari
grade
iia
iib
iii
accord
donder
classif
characterist
vagin
dyspareunia
vulvavagin
itch
cervic
eros
well
isola
vagin
microorgan
also
document
patient
randomis
treat
kanamycin
mg
vagin
ovul
per
day
consecut
wherea
meclocyclin
mg
vagin
ovul
per
day
consecut
patient
visit
start
studi
day
day
end
studi
result
first
followup
patient
show
differ
level
symptom
reduct
particularli
reduct
presenc
leukocyt
burn
vagin
mucosa
itch
statist
signific
group
treat
kanamycin
respect
group
treat
meclocyclin
moreov
also
reduct
isola
enterobacteriaea
group
treat
kanamycin
versu
treat
meclocyclin
second
followup
vagin
homeostasi
normalis
ph
presenc
lactobacilli
demonstr
kanamycin
treat
group
conclus
data
suggest
topic
use
kanamycin
could
consid
specif
antibiot
therapi
new
patholog
object
establish
ident
lactobacillu
speci
colon
vagina
women
import
clinic
studi
demonstr
associ
presenc
h
produc
strain
lactobacillu
decreas
preval
bacteri
vaginosi
bv
recent
cultur
base
studi
use
molecular
identif
method
show
l
crispatu
l
jensenii
common
speci
vagin
lactobacilli
colon
speci
posit
associ
lower
frequenc
bv
report
l
crispatu
distinguish
lactobacilli
use
gram
stain
vagin
smear
method
sever
approach
use
character
vagin
microflora
sampl
obtain
pregnant
women
three
time
point
pregnanc
stain
smear
vagin
swab
score
accord
modifi
ison
hay
criteria
cultur
isol
obtain
anaerob
cultur
identifi
use
tdna
pcr
specif
pcr
atopobium
vagina
gardnerella
vaginali
grade
specimen
repres
normal
microflora
character
grade
ia
l
crispatu
cell
type
present
grade
ib
lactobacillu
cell
type
present
grade
iab
l
crispatu
lactobacilli
present
grade
ic
either
gramposit
rod
small
short
irregularli
shape
gramposit
rod
club
curv
edg
irregular
stain
cell
seen
result
sampl
show
normal
vagin
microflora
grade
grade
ii
grade
iii
grade
iv
base
presenc
differ
lactobacillu
speci
grade
specimen
character
grade
ia
grade
ib
grade
iab
grade
ic
classif
support
find
respect
grade
ia
iab
specimen
l
crispatu
cultur
speci
present
respect
ib
ic
specimen
addit
grade
ic
specimen
contain
bifidobacterium
spp
conclus
refin
gram
stain
base
grade
vagin
smear
possibl
distinguish
addit
class
normal
microflora
categori
gram
score
may
facilit
improv
futur
studi
regard
interpret
clinic
data
therapeut
outcom
object
import
isol
gardnerella
vaginali
bacteri
vaginosi
well
known
involv
male
urogenit
infect
uncertain
probabl
due
low
rate
isol
inadequ
specimen
process
object
studi
evalu
possibl
pathogen
rol
g
vaginali
male
urogenit
patholog
semen
recommend
specimen
diagnos
prostat
time
also
reflect
normal
genit
tract
microflora
although
composit
may
affect
sexual
activ
data
regard
chang
genit
tract
microflora
sexual
debut
object
identifi
possibl
associ
sexual
experi
reproduct
tract
inflammatori
paramet
microflora
healthi
young
men
method
total
healthi
men
age
year
includ
divid
group
base
sexual
experi
virgin
n
monogam
n
polygam
n
semen
sampl
subject
assess
basic
semen
paramet
semen
volum
sperm
concentr
sperm
motil
white
blood
cell
wbc
count
quantit
cultur
aerob
microaerob
anaerob
bacteria
possibl
correl
type
sexual
experi
wbc
count
semin
microflora
calcul
result
basic
semen
paramet
similar
group
men
high
mml
men
medium
mml
semen
wbc
count
correl
type
sexual
experi
semen
wbc
count
comparison
sexual
activ
men
virgin
subject
total
microbi
count
semen
vs
log
cfu
p
number
differ
speci
vs
p
lower
howev
differ
monoand
polygam
men
found
posit
correl
total
microbi
concentr
number
differ
speci
r
p
staphylococci
corynebacterium
seminal
coryneform
gammaand
alphahaemolyt
streptococci
peptostreptococci
preval
organ
signific
differ
microflora
observ
group
yet
gramneg
anaerob
rod
often
seen
sexual
experienc
men
virgin
subject
high
wbc
count
mml
tend
higher
number
differ
microorgan
rest
men
median
vs
p
sexual
debut
associ
enrich
semin
microflora
influx
wbc
chang
basic
semin
paramet
strong
posit
correl
observ
total
microbi
concentr
number
differ
speci
semen
sexual
transmit
infect
among
regist
femal
sex
worker
athen
investig
sexual
activ
nonpregn
women
age
year
diagnos
cervic
cytolog
examin
presenc
mucopurul
discharg
fifti
five
women
includ
studi
group
confirm
c
trachomati
cervic
women
control
group
nonchlamydialnongonococc
cervic
bv
diagnos
use
amsel
nugent
neg
intermedi
posit
criteria
use
amsel
criteria
bv
suggest
correspondingli
among
women
studi
control
group
use
nugent
criteria
bv
suggest
correspondingli
differ
statist
signific
explain
presenc
mucopurul
discharg
among
studi
women
object
helicobact
pylori
recogn
import
human
pathogen
differenti
speci
classic
phenotyp
method
realli
difficult
therefor
object
studi
develop
identif
method
helicobact
speci
base
pcrrestrict
fragment
length
polymorph
pcrrflp
analysi
rrna
gene
object
sinc
first
identif
helicobact
pylori
warren
marshal
member
genu
helicobact
increas
speci
detect
human
anim
construct
speci
specif
pcr
assay
difficult
due
close
related
differ
helicobact
speci
pcrdgge
techniqu
develop
identif
helicobact
colon
aim
studi
investig
effect
multipl
region
rrna
gene
diagnost
effici
pcrdgge
method
dna
extract
helicobact
strain
repres
helicobact
speci
amplif
kb
helicobact
rdna
contain
region
done
use
previous
publish
helicobact
genu
specif
primer
pcr
product
use
templat
two
helicobact
genu
pcr
assay
region
rdna
amplifi
use
primer
region
amplifi
use
primer
publish
http
rrnauiaacb
primer
dgge
analysi
region
perform
polyacrylamid
gel
contain
urea
formamid
gradient
respect
electrophoresi
perform
dcode
electrophoresi
unit
biorad
constant
voltag
v
hour
result
dgge
analysi
two
region
helicobact
gene
show
mobil
pattern
allow
discrimin
helicobact
speci
except
close
relat
h
pullorumh
pametensi
h
ganmanih
rodentium
h
bizozeronih
felish
salmoni
conclus
helicobact
speci
wide
distribut
gastrointestin
tract
mammal
bird
anim
pcrdgge
techniqu
proven
easi
inexpens
effici
tool
identif
helicobact
speci
detect
colonis
one
helicobact
speci
without
need
speciesspecif
pcr
assay
addit
diagnost
effici
techniqu
increas
analysi
multipl
region
rrna
gene
helicobact
spp
chronic
pancreat
pancreat
adenoma
pancrea
cancer
object
helicobact
spp
effici
colonis
variou
hostil
habitat
stomach
colon
biliari
tract
anim
man
except
h
pylori
mani
helicobact
spp
difficult
cultur
nucleic
acid
base
detect
thu
becom
method
choic
analysi
helicobact
spp
chronic
inflammatori
gastrointestin
gi
tract
diseas
cancer
pancreat
exocrin
cancer
establish
risk
factor
poor
prognosi
common
caus
cancer
death
previous
serolog
studi
found
associ
h
pylori
pancrea
cancer
pc
method
pancreat
tumour
specimen
patient
pc
n
tissu
chronic
pancreat
n
pancreat
adenoma
n
benign
pancreat
tissu
patient
cancer
choledochu
colon
duodenum
n
analys
seminest
helicobacterspecif
rdna
pcr
stomach
n
gallbladd
n
specimen
pcpatient
also
analys
character
dnasequ
analysi
result
helicobact
spp
pcr
posit
pancrea
cancer
patient
pancrea
patient
chronic
pancreat
adenoma
pancrea
tissu
gitract
cancer
well
gallbladd
specimen
neg
four
stomach
sampl
pcpatient
helicobact
posit
sequenc
homologu
h
bili
blastn
analysi
dnasequenc
pcrproduct
amplifi
pc
close
relat
h
pylori
n
h
flexispira
sp
n
h
cinaedi
n
two
pancreat
pcrproduct
match
h
pylori
conclus
helicobact
spp
common
pc
compar
benign
pancreat
tissu
helicobact
pylori
infect
low
igg
immunoglobulin
kokkin
k
pavlou
varouta
j
villiot
k
papaefstathi
moutsopoul
e
papafranga
halandri
athen
athen
gr
establish
helicobact
pylori
hp
may
caus
haematolog
disturb
iron
malabsorpt
idiopath
thrombocytopen
purpura
itp
aim
studi
show
hp
involv
human
diseas
complic
way
produc
abnorm
immunolog
profil
patient
method
work
report
presenc
signific
low
valu
igg
immunoglobulin
pt
suffer
unidentifi
iron
defici
id
iron
defici
anemia
ida
coexist
megaloblast
anemia
leukopen
pt
pt
thrombocytosi
itp
polycythemia
respect
ratio
malefemal
age
rang
year
blood
examin
titr
hpigg
type
antibodi
also
high
titr
hpiga
type
use
elisa
techniqu
histopatholog
examin
antral
biopsi
show
diffus
corpu
gastriti
atroph
gastriti
achlorydria
secondari
hp
infect
take
place
gastric
area
result
pt
unidentifi
id
ida
coexist
megaloblast
anemia
serum
iron
transferrin
satur
serum
ferritin
found
significantli
low
also
hp
infect
anemia
exist
year
unrespons
treatment
recurr
natur
twelv
pt
undefin
eukopenia
l
last
least
year
also
hp
infect
pt
significantli
low
valu
igg
immunoglobulin
mean
valu
rang
mgdl
normal
mgdl
subject
erad
therapi
one
respond
well
conclus
hp
infect
found
coincid
id
ida
leukopenia
normal
haematolog
paramet
erad
start
month
later
essenti
mechan
hp
infect
low
igg
unclear
valu
remain
low
erad
therapi
studi
larger
sampl
done
better
evalu
hp
infect
involv
human
diseas
hp
infect
act
catabol
way
human
must
consid
search
haematolog
condit
undefin
origin
helicobact
pylori
dyspept
patient
thailand
diagnosi
antimicrobi
suscept
correl
clinic
outcom
c
chomvarin
p
kulsuntiwong
p
mairiang
c
kulabkhow
khon
kaen
th
object
evalu
method
routin
clinic
diagnost
use
helicobact
pylori
infect
gastric
biopsi
studi
correl
h
pylori
infect
clinic
outcom
studi
antimicrobi
suscept
disk
agar
diffus
thailand
method
gastric
biopsi
obtain
patient
underw
endoscopi
unit
srinagarind
hospit
faculti
medicin
khon
kaen
univers
diagnos
cultur
rapid
ureas
test
rut
pronto
dri
histolog
examin
true
posit
criteria
indic
cultur
rut
histolog
test
posit
one
hundr
fifteen
isol
h
pylori
isol
test
six
antimicrobi
agent
disk
agar
diffus
method
result
h
pylori
infect
rate
sensit
vs
specif
cultur
rut
histolog
respect
preval
h
pylori
gastriti
gt
duoden
ulcer
du
gastric
ulcer
gu
gastric
cancer
gca
patient
respect
chisquar
test
show
gca
patient
significantli
often
infect
h
pylori
gt
patient
resist
h
pylori
isol
singl
antimicrobi
agent
metronidazol
mtz
clarithromycin
clr
ciprofloxacin
cip
amoxycillin
aml
tetracyclin
te
detect
percent
respect
combin
resist
mtz
clr
mtz
cip
mtz
aml
mtz
te
clr
cip
detect
percent
respect
per
cent
h
pylori
isol
resist
three
antimicrobi
agent
conclus
rut
method
highli
sensit
specif
appropri
routin
laboratori
use
correl
gca
patient
h
pylori
infect
signific
differ
compar
gt
patient
high
resist
rate
metronidazol
indic
effect
erad
h
pylori
metronidazol
consid
clinic
manag
h
pylori
infect
use
indirect
immunofluoresc
test
detect
caga
h
pylori
c
scherer
essen
object
cytotoxin
associ
gene
caga
h
pylori
frequent
discuss
virul
factor
code
cytotoxin
associ
antigen
caga
cagagen
usual
detect
pcr
method
public
phenotyp
method
detect
caga
rare
aim
investig
compar
slightli
modifi
recent
publish
indirect
immunofluoresc
test
iift
detect
caga
commonli
use
pcr
assay
method
h
pylori
atcc
cagacaga
use
posit
control
strain
atcc
cagacaga
neg
control
strain
nineteen
clinic
isol
h
pylori
examin
cagaand
cagastatu
caga
detect
iift
use
monoclon
anticagaantibodi
mice
visualis
immunofluoresc
microscopi
fitcconjug
antimouseantibodi
rabbit
dna
extract
standard
phenolchlorophorm
procedur
proteinas
k
treatment
cell
old
cultur
primer
pair
publish
protocol
use
describ
primer
pair
five
primer
pair
test
perform
duplic
result
strain
caga
posit
iift
also
caga
posit
pcr
strain
neg
iift
caganeg
pcr
show
vari
result
pcrassay
strain
could
interpret
iift
show
vari
result
pcrassay
iift
might
simpl
use
tool
determin
cagastatu
sinc
show
fals
posit
result
neither
test
pcr
differ
result
iift
pcr
suggest
genotyp
posit
strain
may
alway
express
caga
vitro
mayb
also
vivo
therefor
cagaiift
may
interest
paramet
determin
strain
virul
addit
pcrassay
evalu
elisa
serolog
primari
diagnosi
helicobact
pylori
infect
turkish
dyspept
patient
prospect
studi
develop
countri
b
kocazeybek
erzin
altun
dobrucali
aslan
erdamar
dirican
istanbul
tr
aim
hp
recogn
import
human
pathogen
virtu
associ
peptic
ulcer
diseas
gastric
cancer
gastric
lymphoma
high
preval
infect
worldwid
invas
noninvas
test
avail
diagnos
hp
infect
still
singl
gold
standard
aim
present
studi
evalu
diagnost
accuraci
commerci
avail
antihp
igg
elisa
kit
primari
diagnosi
hp
infect
materi
method
total
patient
refer
endoscopi
unit
includ
accord
gold
standard
patient
classifi
hp
cultur
andor
histolog
rapid
ureas
test
posit
hp
test
remain
neg
standard
method
use
calcul
sensit
specif
predict
valu
posit
neg
result
confid
interv
valu
result
exclud
patient
discord
patient
hp
sensit
specif
diagnost
accuraci
iggelisa
respect
conclus
due
lack
specif
conclud
quantit
antihp
elisa
test
may
suitabl
altern
primari
diagnosi
hp
countri
preval
infect
still
high
comparison
two
differ
stool
antigen
test
primari
diagnosi
helicobact
pylori
infect
turkish
dyspept
patient
b
kocazeybek
erzin
altun
dobrucali
aslan
erdamar
dirican
istanbul
tr
aim
assess
reliabl
two
differ
enzym
immunoassay
detect
helicobact
pylori
hp
statu
stool
specimen
turkish
dyspept
patient
materi
method
patient
nonulc
dyspepsia
nud
duoden
ulcer
du
gastric
cancer
admit
endoscopi
unit
istanbul
univers
cerrahpasa
medic
faculti
upper
gastrointestin
endoscopi
due
dyspepsia
enrol
studi
hp
infect
confirm
patient
histolog
rapid
ureas
test
rut
cultur
patient
classifi
hpposit
cultur
alon
histolog
rut
posit
absenc
posit
cultur
neg
test
remain
neg
stool
sampl
patient
obtain
order
assess
reliabl
monoclon
femtolab
h
pylori
connex
martinsri
germani
polyclon
premier
platinum
hpsa
meridian
diagnost
inc
cincinnati
usa
stool
antigen
test
compar
diagnost
accuraci
v
test
use
statist
comparison
valu
result
use
cutoff
femtolab
h
pylori
premier
platinum
hpsa
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
diagnost
accuraci
former
latter
test
respect
sensit
specif
npv
diagnost
accuraci
former
test
significantli
superior
latter
one
v
p
sensit
v
p
specif
v
p
npv
v
p
diagnost
accuraci
bacteri
load
affect
sensit
test
conclus
monoclon
femtolab
h
pylori
use
cutoff
sensit
specif
easi
perform
diagnost
tool
primari
diagnosi
hp
infect
turkish
dyspept
patient
evalu
two
differ
enzym
immunoassay
detect
helicobact
pylori
stool
specimen
turkish
dyspept
patient
erad
therapi
b
kocazeybek
erzin
altun
sariba
dobrucali
aslan
erdamar
dirican
istanbul
tr
aim
assess
reliabl
two
differ
enzym
immunoassay
eia
detect
hp
statu
stool
specimen
turkish
dyspept
patient
posttreat
period
materi
method
patient
nonulc
dyspepsia
nud
posit
hp
underw
one
week
regimen
tripl
therapi
stool
sampl
patient
obtain
week
breath
test
ubt
perform
week
erad
therapi
order
assess
reliabl
monoclon
femtolab
h
pylori
connex
martinsri
germani
polyclon
premier
platinum
hpsa
meridian
diagnost
inc
cincinnati
usa
stool
antigen
test
compar
diagnost
accuraci
v
fisher
exact
test
use
statist
comparison
valu
result
use
cutoff
femtolab
h
pylori
premier
platinum
hpsa
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
diagnost
accuraci
former
latter
test
versu
week
versu
week
complet
erad
therapi
respect
week
posttreat
period
diagnost
accuraci
femtolab
h
pylori
significantli
superior
premier
platinum
versu
v
p
versu
v
p
respect
conclus
monoclon
femtolab
h
pylori
use
cutoff
sensit
specif
enough
monitor
hp
infect
turkish
dyspept
patient
week
complet
erad
therapi
carrier
develop
seriou
gastroduoden
diseas
import
defin
whether
strain
specif
genotyp
associ
clinic
outcom
aim
studi
determin
distribut
caga
cage
vaca
subtyp
hp
patient
variou
gastroduoden
diseas
turkey
explor
associ
genotyp
clinic
outcom
infect
method
strain
hp
isol
cultur
patholog
archiv
patient
nonulc
dyspepsia
nud
duoden
ulcer
du
gastric
carcinoma
caga
cage
genotyp
determin
polymeras
chain
reaction
methodolog
result
statist
signific
differ
among
three
differ
clinic
outcom
accord
posit
rate
vaca
vaca
posit
rate
vaca
caga
cage
nud
du
gastric
cancer
group
respect
show
statist
signific
differ
p
p
p
respect
preval
nud
patient
higher
duoden
ulcer
group
differ
statist
signific
conclus
helicobact
pylori
caga
cage
genotyp
signific
relat
duoden
ulcer
gastric
carcinoma
turkish
popul
statist
signific
associ
vaca
vaca
strain
among
diseas
group
clinic
relev
genotyp
helicobact
pylori
turkish
patient
nonulc
dyspepsia
duoden
ulcer
gastric
cancer
b
kocazeybek
erzin
v
koksal
erdamar
altun
dobrucali
oner
istanbul
tr
object
clinic
relev
helicobact
pylori
hp
adher
factor
baba
gene
virul
determin
icea
gene
yet
determin
turkish
clinic
isol
date
therefor
aim
studi
evalu
preval
hp
genotyp
turkish
patient
nonulc
dyspepsia
nud
duoden
ulcer
du
gastric
cancer
method
strain
isol
patient
nud
isol
individu
du
isol
patient
gastric
cancer
bacteri
dna
extract
cultur
hp
posit
paraffinembed
biopsi
sampl
genotyp
icea
carri
util
polymeras
chain
reaction
molecular
techniqu
use
specif
primer
result
genotyp
detect
respect
hp
strain
studi
preval
gastric
cancer
patient
higher
nud
group
respect
p
preval
nud
group
higher
gastric
cancer
patient
respect
p
posit
rate
nud
du
gastric
cancer
group
show
statist
signific
differ
p
conclus
genotyp
distribut
evalu
differ
gastric
patholog
turkish
popul
good
marker
presenc
du
gastric
adenocarcinoma
thu
current
result
confirm
previou
experiment
studi
indic
central
role
hp
adhesin
lewi
antigen
pathogenesi
ulcer
diseas
adenocarcinoma
influenc
interleukin
interleukin
polymorph
develop
nonulc
dyspepsia
duoden
ulcer
gastric
cancer
turkish
popul
b
kocazeybek
erzin
v
koksal
erdamar
altun
dobrucali
istanbul
tr
object
gene
polymorph
encod
interleukin
receptor
antagonist
respect
associ
develop
gastric
atrophi
increas
risk
gastric
carcinoma
aim
studi
determin
influenc
host
rn
gene
polymorph
develop
variou
gastroduoden
patholog
helicobact
pylori
hp
posit
turkish
patient
nonulc
dyspepsia
nud
duoden
ulcer
du
gastric
cancer
gc
method
genom
dna
extract
hp
posit
paraffin
embed
gastric
biopsi
sampl
nud
du
gc
patient
rn
gene
polymorph
analys
polymeras
chain
reactionrestrict
fragment
length
polymorph
polymorph
site
includ
promot
region
ct
transit
tc
transit
rn
variabl
tandem
repeat
vntr
result
statist
signific
differ
among
three
clinic
outcom
frequenc
tt
tc
cc
genotyp
call
proinflamatori
genotyp
p
p
respect
preval
proinflamatori
rn
allel
gc
group
higher
nud
du
group
frequenc
rn
allel
nud
du
gc
group
show
statist
signific
differ
p
conclus
statist
signific
differ
among
three
clinic
outcom
frequenc
tt
tc
cc
genotyp
wherea
proinflamatori
rn
allel
associ
gastric
cancer
turkey
rapid
detect
clarithromycinresist
helicobact
pylori
patient
dyspept
fluoresc
situ
hybridis
fish
comparison
etest
moosavian
tajbakhsh
samarbafzadeh
ahwaz
ir
object
isol
h
pylori
patient
peptic
ulcer
demonstr
strong
relationship
bacteria
creat
ulcer
dyspept
recoveri
patient
acceler
clarithromycin
ad
therapeut
protocol
object
studi
detect
suscept
resist
strain
helicobact
pylori
clarithromycin
patient
dyspept
fish
techniqu
result
fish
epsilomet
test
etest
techniqu
method
frozen
section
gastric
biopsi
patient
dyspept
hybrid
situ
fluoresc
oligonucleotid
probe
fish
prepar
slide
examin
fluoresc
microscop
stain
dapi
also
suscept
resist
isol
strain
h
pylori
clarithromycin
determin
etest
result
etest
fish
techniqu
compar
final
result
examin
gastric
biopsi
sampl
posit
h
pylori
fish
h
pylori
strain
strain
suscept
strain
resist
strain
mixtur
suscept
resist
strain
clarithromycin
studi
show
signific
differ
fish
etest
result
view
number
suscept
resist
strain
conclus
sinc
patient
gastric
biopsi
routin
cultur
clinic
laboratori
also
isol
h
pylori
need
enrich
select
media
way
clarithromycin
expens
drug
look
like
fish
techniqu
suitabl
method
replac
cultur
antibiot
sensit
test
etest
method
diagnosi
atroph
gastriti
blood
sampl
p
douramani
mavrea
arka
adamopoulo
e
anastasak
athen
paro
gr
introduct
major
gastriti
relat
infecti
agent
h
pylori
import
common
h
pylori
gastriti
could
proceed
time
atroph
form
gastriti
seriou
diseas
increas
risk
peptic
ulcer
gastric
cancer
new
test
panel
develop
nonendoscop
diagnosi
atroph
antrum
corpu
gastriti
blood
sampl
aim
investig
whether
atroph
gastriti
diagnos
type
nonendoscop
serum
level
pepsinogen
spgi
assay
connect
h
pylori
test
materi
method
studi
popul
consist
select
dyspept
outpati
case
without
control
advanc
moder
sever
atroph
gastriti
underw
diagnost
gastroscopi
dyspept
symptom
select
case
advanc
atroph
gastriti
resect
stomach
case
advanc
antrumlimit
atroph
gastriti
resect
corpu
limit
advanc
atroph
gastriti
two
patient
advanc
atroph
gastriti
antrum
corpu
multofoc
atroph
gastriti
whole
stomach
remov
one
patient
control
compris
patient
non
atroph
h
pylori
gastriti
antrum
corpu
normal
healthi
patient
sampl
gastrin
prand
taken
min
protein
drink
spgi
igg
class
antibodi
h
pylori
determin
use
elisa
method
result
low
spgi
mgl
found
patient
patient
without
corpu
atrophi
low
prand
pmoll
found
patient
h
pylori
associ
antralatrophi
patient
resect
antrum
one
patient
h
pylorirel
nonatroph
gastriti
mean
valu
prand
spgi
decreas
increas
grade
antral
corpu
atrophi
respect
among
patient
atroph
patient
low
spgi
andor
low
prand
posit
igg
h
pylori
antibodi
low
valu
found
one
control
patient
conclus
low
serum
level
spgi
diagnost
marker
atroph
antral
corpu
gastriti
respect
low
sigh
multifoc
antrumlimit
atroph
gastriti
patient
infect
h
pylori
helicobact
pylori
gastric
mucosa
ultrastructur
studi
e
ozbek
ozbek
h
dursun
vural
erzurum
tr
object
helicobact
pylori
extraordinari
among
bacteria
abil
colon
human
gastric
mucosa
inhospit
acid
environ
stay
long
period
decad
despit
host
immun
inflammatori
respons
studi
aim
research
h
pylori
found
within
stomach
transmiss
electron
microscopi
tem
method
gastroscop
biopsi
sampl
patient
suspect
gastriti
peptic
ulcer
process
pcr
tem
presenc
h
pylori
biopsi
sampl
investig
pcr
method
use
specif
ribosom
rna
primer
sampl
electron
microscop
examin
fix
glutaraldehyd
postfix
osmic
acid
dehydr
aceton
embed
araldit
plastic
block
posit
sampl
presenc
h
pylori
confirm
pcr
cut
nova
lkb
bromma
ultratom
thin
section
stain
uranyl
acet
lead
citrat
examin
use
jeol
sx
transmiss
electron
microscop
result
observ
crossand
longitudinalsect
h
pylori
within
mucu
layer
overli
gastric
epithelium
intercellular
space
gastric
epitheli
cell
figur
two
microvilli
protrud
apic
surfac
epitheli
cell
gastric
lumen
apart
extracellular
h
pylori
found
also
intravacuolar
h
pylori
within
epitheli
cell
gastric
mucosa
observ
h
pylori
engulf
pseudopodlik
structur
apic
part
epitheli
cell
also
late
endosom
vacuol
contain
h
pylori
within
deeper
cytoplasm
part
cell
conclus
although
h
pylori
consid
gener
noninvas
pathogen
electron
microscop
observ
prove
h
pylori
abl
invad
gastric
epitheli
cell
enter
larg
cytoplasm
vacuol
h
pylori
abl
found
intracellularli
might
explain
erad
h
pylori
infect
difficult
antibiot
gentamicin
easili
cross
eukaryot
cell
membran
abbrevi
figur
h
helicobact
pylori
n
nucleu
gastric
epitheli
cell
e
crosssect
epitheli
cell
nm
nuclear
membran
intercellular
space
bar
micrometr
helicobact
pylori
associ
histolog
find
endoscop
biopsi
western
greec
c
petropoulo
e
jelastopulu
kardara
spiropoulo
erymanthia
patra
gr
object
evid
helicobact
pylori
h
pylori
infect
strongli
associ
gastric
duoden
lesion
gener
popul
studi
review
gastroscop
histolog
record
patient
underw
gastroscopi
multipl
reason
tertiari
hospit
order
evalu
frequenc
h
pylori
colon
biopsi
specimen
examin
associ
h
pylori
infect
histolog
find
method
medic
record
patient
present
gener
hospit
patra
western
greec
period
upper
gastrointestin
complaint
specifi
symptom
review
presenc
h
pylori
patient
submit
endoscopi
biopsi
mainli
gastric
mucosa
statist
analysi
perform
use
spss
result
gastroscopi
biopsi
undertaken
patient
men
women
mean
age
rang
year
patient
dyspepsia
main
indic
gastroscopi
follow
patient
anaemia
patient
black
faec
patient
reflux
usual
macroscop
find
oedema
hyperaemia
erythema
ulcer
eros
histolog
examin
reveal
chronic
gastriti
subject
mild
form
moder
sever
form
atroph
chronic
gastriti
adenocarcinoma
patient
overal
colon
h
pylori
detect
subject
case
h
pylori
posit
patient
chronic
gastriti
found
mild
form
moder
sever
form
wherea
absenc
h
pylori
infect
histolog
type
chronic
gastriti
respect
case
chronic
gastriti
sever
form
h
pylori
colon
found
p
wherea
regard
mild
form
h
pylori
presenc
observ
p
conclus
studi
reveal
h
pylori
infect
strongli
associ
sever
form
chronic
gastriti
thu
optim
manag
treatment
patient
gastriti
biopsi
mucosa
appear
necessari
object
ultim
aim
studi
explor
potenti
natur
product
altern
treatment
infect
staphylococcu
aureu
includ
methicillin
resist
staphylococcu
aureu
mrsa
specif
object
paper
assay
molecular
chang
gene
mrsa
isol
upon
inhibit
natur
product
five
gene
mrsa
isol
studi
includ
meca
meci
mecri
adab
nonmrsa
isol
adab
gene
adab
gene
encod
methyltransferas
activ
dna
repair
mechan
cell
wall
protein
gene
method
mrsa
nonmrsa
isol
obtain
patient
receiv
treatment
malaysian
hospit
isol
subject
growth
methanol
extract
marin
seawe
inhibit
assay
extract
isol
includ
sever
genera
gramneg
bacteria
determin
disc
diffus
minimum
inhibitori
mic
method
treat
untreat
isol
inhibit
extract
subject
pcr
amplif
follow
commerci
sequenc
rtpcr
assay
mrna
follow
sequenc
cdna
blastn
analysi
genbank
sequenc
result
inhibit
assay
methanol
extract
show
activ
mrsa
nonmrsa
isol
gram
neg
isol
nucleotid
sequenc
chang
seen
four
gene
treat
mrsa
isol
meca
mecri
meci
adab
nucleotid
chang
nonmrsa
mrsa
seen
adab
gene
blastn
analysi
show
variat
nucleotid
chang
gene
involv
mrsa
phenomenon
conclus
preliminari
result
util
genom
studi
nucleotid
sequenc
pathogen
aim
util
biomolecul
natur
product
target
affect
nucleotid
inhibit
growth
organ
research
activ
potenti
speed
drug
discoveri
programm
nucleotid
chang
sever
gene
treat
extract
indic
potenti
target
site
extract
inhibitori
effect
extract
nucleotid
gene
remain
unchang
pcr
rtpcr
assay
indic
select
effect
extract
gene
extract
potenti
appli
antibacteri
agent
implic
find
direct
toward
discoveri
antibacteri
drug
target
site
warrant
studi
phenotyp
genotyp
characterist
staphylococcu
aureu
strain
defect
speciesspecif
protein
luczak
j
krzysztonrussjan
k
nowak
w
hryniewicz
warsaw
pl
object
object
studi
characteris
phenotyp
clump
factor
andor
coagulas
defect
aureu
method
studi
perform
aureu
isol
identifi
clump
factor
cf
free
coagulas
fc
defect
clinic
microbiolog
laboratori
submit
nation
institut
public
health
warsaw
verif
reidentif
includ
detect
clump
factor
coagulas
thermonucleas
abil
ferment
mannitol
antimicrobi
suscept
test
perform
diskdiffus
method
accord
nccl
glycopeptid
suscept
determin
screen
method
mic
evalu
popul
analysi
pcr
reaction
perform
confirm
presenc
speci
specif
gene
cfa
cfb
coa
nuc
spa
obtain
isol
clonal
multiplelocu
variablenumb
tandem
repeat
analysi
mlva
appli
result
base
phenotyp
reidentif
method
isol
phenotyp
defect
respect
clumpingfactor
coagulas
product
one
isol
exhibit
presenc
gene
encod
cf
fc
seventyf
isol
resist
methicilin
mrsa
multiresist
twentysix
isol
show
reduc
glycopeptid
suscept
pap
hvisa
hgisa
isol
mrsa
defect
mainli
clumpingfactor
product
thirtyon
differ
mlva
group
distinguish
l
group
common
variabl
type
preval
hvisahgisa
isol
found
centr
conclus
clonal
spread
aureu
defect
speci
specif
protein
reveal
correl
decreas
suscept
glycopeptid
defect
speci
specif
protein
observ
detect
pantonvalentin
leucocidin
staphylococc
toxin
use
oligonucleotid
array
moneck
r
ehricht
dresden
jena
object
recent
outbreak
commun
acquir
mrsa
cmrsa
harbour
pantonvalentin
leucocidin
pvl
caus
seriou
concern
worldwid
order
screen
clinic
isol
design
test
oligonucleotid
array
detect
compon
virul
factor
six
staphylococc
superantigen
two
exfoli
toxin
well
sever
resist
gene
speciesspecif
control
method
twentytwo
clinic
isol
two
suspect
cmrsa
twenti
randomli
select
swab
obtain
dermatolog
clinic
saxonygermani
cultur
dna
isol
subject
linear
multiplex
amplif
incorpor
biotinlabel
dutp
amplicon
hybrid
amplicon
array
detect
use
enzymat
precipit
reaction
result
two
case
chronic
furunculosi
pvlposit
cmrsa
identifi
one
case
soldier
return
peac
mission
kosovo
appar
contract
diseas
one
spous
three
case
furunculosisabscess
pvlposit
methicillinsuscept
aureu
found
staphylococc
enterotoxin
found
four
toxic
shock
syndrom
toxin
three
isol
exfoli
toxin
one
isol
two
case
multipl
toxin
found
pvl
tst
entc
entb
entk
entq
eta
conclus
epidem
cmrsa
strain
often
presum
identifi
due
resist
profil
methicillin
tetracyclin
fusid
acid
easi
method
detect
pvlposit
methicillinsuscept
aureu
therefor
strain
carri
pvl
common
previous
suspect
high
preval
virul
factor
well
toxin
found
present
studi
warrant
investig
characteris
methicillinresist
staphylococcu
aureu
harbour
pantonvalentin
leucocidin
ander
kaas
friedrich
sg
gatermann
bochum
object
methicillinresist
staphylococcu
aureu
mrsa
known
major
problem
hospit
late
new
kind
mrsa
describ
mrsa
respons
communityacquir
infect
cmrsa
harbour
determin
pantonvalentin
leucocidin
pvl
descript
cmrsa
possess
pvl
throughout
world
differ
mlst
type
want
character
eleven
cmrsa
area
possess
gene
pantonvalentin
leucocidin
method
isol
found
summer
gene
encod
pvl
verifi
pcrwe
determin
pfge
pattern
mlst
type
sccmec
type
agr
allel
type
eleven
isol
result
far
isol
belong
st
also
describ
elsewher
germani
franc
differ
type
found
us
australia
possess
sccmec
element
type
ivb
allel
type
isol
resist
oxacillin
determin
meca
pcr
resist
fusid
acid
two
addit
resist
erythromycin
resist
could
found
fluoroquinolonesth
averag
age
patient
year
sever
communityacquir
abscess
skin
soft
tissu
caus
hospit
admiss
conclus
mrsa
longer
consid
affect
hospit
elderli
patient
also
awar
communityacquir
infect
accessori
gene
regul
agr
locu
aureu
quorumsens
gene
cluster
five
gene
hld
agrb
agrd
agrc
agra
upregul
product
secret
virul
factor
includ
alpha
beta
deltahemolysin
downregul
product
cellassoci
virul
factor
aureu
strain
divid
major
agr
group
agr
iiv
basi
polymorph
agrd
agrc
purpos
studi
know
proport
agr
ii
iii
polymorph
compar
clinic
characterist
group
ii
nongroup
ii
polymorph
methicillinresist
staphylococcu
aureu
mrsa
strain
tertiari
care
teach
hospit
korea
method
isol
identifi
aureu
convent
method
suscept
methicillin
determin
nccl
guidelin
agr
locu
identifi
use
restrict
fragment
length
polymorph
rflp
analysi
agr
bdc
amplicon
drai
digest
factor
assess
includ
patient
demograph
comorbid
diabet
mellitu
congest
heart
failur
peripher
vascular
diseas
dialysisdepend
renal
failur
cirrhosi
malign
alcohol
infect
site
central
catheterrel
bacteraemia
bacteraemia
unknown
origin
devic
endocard
intraabdomin
respiratori
skin
urin
ear
receipt
mechan
ventil
oper
presenc
nosocomi
infect
treatment
failur
creatinin
level
mortal
result
total
strain
mrsainfect
patient
male
femal
evalu
mean
age
year
old
strain
agr
group
ii
iii
polymorph
respect
nosocomi
infect
statist
signific
clinic
paramet
accord
univari
analysi
p
multivari
analysi
p
conclus
agr
group
ii
preval
studi
nosocomi
infect
correl
group
ii
polymorph
result
suggest
virul
nosocomi
spread
mrsa
strain
origin
group
ii
polymorph
recruit
strain
increas
clarifi
clinic
differ
agr
group
distribut
toxic
shock
syndrom
exfoli
toxin
enterotoxin
seg
sei
among
methicillinresist
staphylococcu
aureu
clonal
type
v
chini
g
dimitracopoulo
spiliopoul
patra
gr
object
staphylococcu
aureu
produc
varieti
exotoxin
includ
toxic
shock
syndrom
exfoli
toxin
eta
etb
enterotoxin
seg
sei
seg
sei
gene
seg
sei
coexist
operon
aim
studi
investig
presenc
gene
encod
tst
eta
eta
etb
etb
seg
seg
sei
sei
among
methicillinresist
aureu
mrsa
clinic
isol
relat
clonal
type
method
mic
oxacillin
determin
agar
dilut
method
muellerhinton
agar
supplement
nacl
accord
guidelin
nccl
product
investig
latex
agglutin
test
biomerieux
aureu
isol
mic
mgl
pcr
amplif
perform
detect
meca
gene
aforement
isol
differ
patient
result
mrsa
presenc
tst
eta
etb
seg
sei
gene
also
investig
pcr
clonal
type
determin
pfge
chromosom
dna
smai
digest
result
among
mrsa
carri
seg
sei
gene
isol
carri
tst
eta
wherea
strain
exhibit
etb
gene
precis
tst
gene
coexist
segseiposit
strain
eleven
strain
belong
pfge
type
wherea
two
type
b
mainli
associ
wound
infect
eight
mrsa
belong
pfge
type
carri
tst
seg
sei
two
strain
carri
segsei
belong
pfge
type
c
two
segseiposit
addit
mrsa
character
new
clone
f
carri
also
eta
four
mrsa
carri
tst
seg
sei
belong
clone
wherea
carri
segsei
character
pfge
type
c
isol
associ
wound
infect
abscess
conclus
studi
period
incid
tst
gene
carriag
among
mrsa
reduc
segsei
gene
almost
constantli
present
distribut
gene
mainli
associ
strain
clonal
type
exhibit
drift
toward
clone
type
c
predomin
last
two
year
detect
decreas
suscept
glycopeptid
staphylococcu
aureu
use
tablet
disc
prediffus
sv
nielsen
jb
casal
taastrup
dk
object
aim
studi
develop
screen
confirmatori
method
detect
staphylococcu
aureu
decreas
suscept
glycopeptid
hvisavisa
gisa
method
glycopeptid
resist
staphylococcu
aureu
strain
strain
collect
includ
wellknown
resist
strain
atcc
atcc
atcc
atcc
examin
compar
zone
size
vancomycin
lg
teicoplanin
lg
neosensitab
rosco
diagnostica
prediffus
h
disc
h
without
disc
muellerhinton
bhi
media
supplement
hors
blood
ii
agar
dilut
mic
iii
zone
size
around
cefoxitin
lg
neosensitab
inoculum
use
mcfarland
plate
incub
h
result
regress
line
prepar
good
correl
mic
vancomycin
teicoplanin
correspond
zone
size
hvisavisagisa
strain
test
show
zone
less
mm
cefoxitin
lg
zone
mm
teicoplanin
andor
mm
vancomycin
mh
blood
agar
correspond
mic
lgml
antimicrobi
bhi
agar
zone
mm
teicoplanin
andor
mm
vancomycin
hvisavisagisa
strain
correspond
mic
lgml
antimicrobi
conclus
zone
obtain
agar
diffus
method
use
prediffus
vancomycin
teicoplanin
neosensitab
correl
mic
predict
hvisavisagisa
strain
screen
high
resist
cefoxitin
zone
mm
may
use
select
strain
test
daili
routin
laboratori
system
evalu
routin
diagnost
laboratori
high
rate
vancomycin
intermedi
staphylococcu
aureu
among
methicillinresist
isol
taiwan
patient
triservic
gener
hospit
taiwan
screen
vancomycin
resist
isol
reduc
suscept
vancomycin
studi
characterist
method
brain
heart
infus
agar
plate
contain
vancomycin
lgml
use
vancomycin
resist
screen
minimum
inhibitori
concentr
mic
vancomycin
determin
bhia
standard
muellerhinton
agar
mha
screenedposit
isol
strain
mic
equal
lgml
characterist
includ
popul
analysi
suscept
triton
induc
autolysi
van
gene
puls
field
gel
electrophoresi
pfge
type
perform
previous
describ
background
mrsa
isol
decreas
suscept
glycopeptid
gisa
report
worldwid
sinc
strain
isol
cathet
foreign
bodi
patient
treat
glycopeptid
aim
determin
preval
gisa
isol
belgian
hospit
mrsa
endem
mani
year
method
mrsa
isol
collect
screen
reduc
suscept
glycopeptid
muellerhinton
agar
mgl
teicoplanin
mhteico
recommend
casfm
macromethod
etest
bhi
agar
mcfarland
mf
inoculum
h
incub
perform
secondari
screen
isol
grew
coloni
mhteico
gisahgisa
phenotyp
confirm
etest
mic
determin
mh
agar
mf
h
incub
well
vancomycin
v
teicoplanin
popul
analysi
profil
pap
confirm
gisahgisa
isol
identifi
compar
pfge
strain
identifi
belgium
order
delin
clonal
result
among
mrsa
strain
patient
isol
show
growth
mhteico
patient
yield
posit
macromethod
etest
mic
lgml
v
seven
confirm
pap
hgisa
one
gisa
mic
lgml
v
mic
lgml
origin
isol
lower
respiratori
tract
urin
wound
hgisa
strain
similar
antibiot
resist
phenotyp
disk
diffus
gentamicin
rifampin
erythromycin
clindamycin
ofloxacin
molecular
analysi
hgisa
gisa
isol
cluster
two
differ
pfge
group
n
g
n
pfge
group
previous
describ
hgisa
isol
belgium
studi
subdivid
type
includ
strain
one
pfge
type
result
small
outbreak
patient
stay
icu
isol
sporad
appar
geograph
tempor
relationship
case
conclus
gisahgisa
found
mrsaposit
patient
none
present
sever
infect
previou
known
exposur
glycopeptid
view
low
preval
gisahgisa
hospit
screen
perform
systemat
rather
individu
basi
take
account
clinic
data
risk
factor
whenev
occurr
gisa
consid
teicomh
agar
appear
suitabl
first
screen
approach
casecontrol
studi
evalu
econom
outcom
earli
po
linezolid
patient
methicillinresist
staphylococcu
aureu
infect
oral
therapi
linezolid
lzd
potenti
decreas
hospit
cost
shorten
length
stay
patient
gramposit
infect
would
otherwis
continu
receiv
iv
therapi
object
evalu
impact
earli
po
convers
lzd
patient
receiv
tradit
iv
therapi
methicillinresist
aureu
mrsa
infect
method
patient
document
mrsa
infect
evalu
match
casecontrol
studi
case
includ
patient
convert
po
lzd
iv
tabl
includ
comparison
cost
durat
therapi
lo
predict
patient
receiv
lzd
hospit
higher
drug
cost
howev
decreas
lo
contribut
lower
cost
hospit
lzd
iv
vancomycin
vanc
control
patient
receiv
iv
vanc
patient
pair
ratio
case
control
match
base
infect
type
age
comorbid
demograph
antimicrobi
agent
concomit
infect
clinic
statu
assess
daili
onset
infect
end
treatment
hospit
antibiot
cost
length
stay
lo
clinic
success
rate
compar
group
result
patient
assess
demograph
characterist
similar
group
averag
age
mean
sd
apach
ii
median
rang
charlson
comorbid
score
male
patient
treat
skinsoft
tissu
infect
pneumonia
bonejoint
infect
bacteraemia
infect
clinic
microbiolog
outcom
similar
group
clinic
success
end
therapi
object
compar
efficaci
safeti
linezolid
lzd
vancomycin
van
treatment
infect
caus
methicillinresist
staphylococcu
aureu
mrsa
japan
method
random
openlabel
studi
conduct
japan
patient
nosocomi
pneumonia
complic
skin
soft
tissu
infect
sepsi
syndrom
caus
mrsa
random
lzd
van
receiv
lzd
mg
h
van
g
h
outcom
evalu
end
therapi
eot
followup
fu
evalu
day
complet
therapi
result
patient
receiv
studi
drug
lzd
van
treatment
group
similar
regard
demograph
risk
factor
eot
clinic
success
rate
mrsamicrobiolog
evalu
popul
lzd
van
group
respect
microbiolog
erad
rate
two
group
respect
p
fu
clinic
success
rate
group
microbiolog
erad
rate
respect
clinic
success
rate
group
reflect
automat
outcom
failur
patient
receiv
prohibit
antimicrobi
prior
fu
revers
anemia
thrombocyotopenia
report
advers
event
frequent
lzd
patient
analysi
laboratori
data
show
platelet
count
decreas
frequent
lzd
patient
recoveri
fu
mean
platelet
count
lzd
patient
advers
event
thrombocytopenia
significantli
low
platelet
count
frequent
observ
van
patient
vs
differ
observ
mean
chang
hemoglobin
level
treatment
group
conclus
lzd
effect
van
treatment
mrsa
infect
serious
ill
patient
may
effect
achiev
microbiolog
erad
although
hematolog
advers
event
report
frequent
lzdtreat
patient
analysi
laboratori
data
show
mild
revers
trend
toward
lower
platelet
count
costeffect
linezolid
versu
vancomycin
complic
skin
softtissu
infect
due
suspect
methicillinresist
staphylococcu
aureu
infect
germani
san
diego
calif
object
present
analysi
evalu
costeffect
linezolid
compar
vancomycin
treatment
cssti
due
suspect
mrsa
infect
german
perspect
method
decisionanalyt
model
develop
examin
cost
outcom
use
linezolid
versu
vancomycin
hospit
patient
cssti
germani
expert
panel
german
physician
experienc
treat
cssti
provid
resourceutil
data
structur
interview
cost
publish
sourc
rote
list
dkgnt
ebm
appli
clinic
laboratori
test
advers
event
isol
procedur
intraven
iv
oral
linezolid
drug
treatment
hospit
ward
type
medic
intens
care
outpati
physician
consult
appropri
patient
could
discharg
hospit
treat
ambul
set
model
assum
suspect
mrsa
patient
proven
mrsa
outcom
includ
total
cost
per
patient
cost
per
death
avoid
cost
per
lifeyear
gain
cost
per
cure
result
addit
patient
treat
linezolid
versu
vancomycin
cure
averag
total
cost
per
episod
versu
linezolidversu
vancomycintr
patient
give
save
per
episod
model
sensit
lo
hospit
day
isol
durat
oral
versu
iv
treatment
percentag
mrsa
patient
price
linezolid
conclus
decis
analyt
model
patient
cssti
due
suspect
mrsa
achiev
clinic
cure
linezolid
group
compar
vancomycin
group
linezolid
cost
save
versu
vancomycin
treatment
cssti
linezolid
result
shorter
treatment
durat
shorter
lo
offset
higher
acquisit
cost
linezolid
versu
vancomycin
cssti
germani
clinic
microbiolog
infect
volum
supplement
train
scientif
output
infecti
diseas
bibliometr
analysi
worldwid
trend
research
product
microbiolog
p
vergidi
karavasi
k
paraschaki
blizioti
p
papastamataki
falaga
athen
gr
background
microbiolog
contribut
significantli
understand
control
infecti
diseas
alway
field
extens
research
howev
literatur
lack
studi
estim
quantiti
qualiti
worldwid
research
product
evalu
contribut
differ
world
region
research
product
field
microbiolog
method
use
medlin
databas
retriev
articl
journal
includ
categori
citat
databas
institut
scientif
inform
period
world
divid
region
base
geograph
econom
scientif
criteria
use
elabor
retriev
system
obtain
data
publish
articl
differ
world
region
evalu
introduc
estim
quantiti
qualiti
research
produc
world
region
per
year
use
total
number
public
mean
impact
factor
public
product
two
paramet
result
data
countri
origin
research
avail
retriev
articl
western
europ
exce
world
region
research
product
period
studi
usa
rank
second
tabl
differ
product
two
region
increas
gradual
howev
mean
impact
factor
articl
publish
microbiolog
journal
highest
usa
western
europ
rest
world
region
combin
conclus
usa
western
europ
make
strike
world
research
product
term
quantiti
qualiti
world
region
increas
research
product
period
studi
highest
increas
achiev
asia
exclud
japan
latin
america
eastern
europ
confer
abstract
full
paper
differ
data
present
confer
journal
e
rosmaraki
p
vergidi
kapask
k
paraschaki
falaga
athen
gr
background
occas
note
differ
data
present
confer
abstract
subsequ
publish
paper
studi
frequenc
type
differ
field
infecti
diseas
microbiolog
method
review
abstract
first
session
major
research
categori
present
icaac
select
pair
icaac
abstract
relat
full
paper
publish
journal
index
index
medicu
two
independ
investig
perform
comparison
data
abstract
correspond
inform
publish
paper
use
cox
logist
regress
model
analys
variabl
associ
differ
data
result
abstract
review
subsequ
publish
paper
march
refer
studi
period
popul
abstract
paper
differ
data
present
confer
abstract
publish
paper
found
pair
analys
ci
identifi
differ
relat
number
andor
rate
studi
patient
number
rate
isol
mic
valu
ki
valu
chemic
properti
antibiot
odd
ratio
durat
observ
differ
substanti
sever
pair
time
public
full
paper
found
independ
associ
presenc
differ
p
per
year
research
categori
type
present
oral
poster
number
public
present
last
author
impact
factor
journal
countri
origin
conclus
sever
explan
note
differ
data
present
confer
abstract
full
paper
like
research
commun
may
improv
accuraci
present
data
worldwid
trend
quantiti
qualiti
publish
articl
field
infecti
diseas
blizioti
k
paraschaki
p
vergidi
karavasi
kapask
falaga
athen
gr
background
tri
confront
widespread
burden
infecti
diseas
societi
worldwid
invest
consider
research
howev
literatur
lack
studi
estim
quantiti
qualiti
worldwid
research
product
evalu
contribut
differ
world
region
research
product
infecti
diseas
divid
region
base
geograph
econom
scientif
criteria
use
elabor
retriev
system
obtain
data
publish
articl
differ
world
region
evalu
introduc
estim
quantiti
qualiti
research
produc
world
region
per
year
use
total
number
public
mean
impact
factor
public
product
two
paramet
result
data
countri
origin
research
avail
retriev
articl
usa
western
europ
far
product
region
concern
public
research
articl
display
tabl
howev
rate
increas
product
articl
higher
develop
world
region
studi
period
mean
impact
factor
highest
articl
origin
usa
western
europ
rest
world
region
combin
conclus
usa
western
europ
make
strike
world
research
product
infecti
diseas
term
quantiti
qualiti
howev
world
region
present
steadi
increas
product
infecti
diseas
articl
develop
countri
display
highest
rate
increas
financi
support
obtain
pharmaceut
compani
howev
sponsor
role
organ
scientif
content
programm
result
physician
includ
id
specialist
select
sever
univers
hospit
tertiari
care
govern
hospit
run
clinic
trial
common
practic
pretrain
queri
reveal
among
traine
popul
never
obtain
inform
consent
patient
random
patient
trial
run
phase
iiv
trial
use
placebo
trial
purpos
report
seriou
advers
event
local
intern
author
preand
postcours
test
basic
principl
gcp
local
eu
regul
run
clinic
trial
appli
determin
compar
knowledg
traine
subject
prior
cours
percentag
correct
answer
rang
cours
complet
p
conclus
train
gcp
regul
run
clinic
trial
may
increas
awar
knowledg
physician
educ
activ
also
help
rais
qualiti
clinic
trial
learn
appropri
use
antibiot
pkpd
guidelin
cdrom
cours
healthcar
profession
student
e
amp
glupczynski
pm
tulken
f
van
bambek
brussel
montgodinn
b
object
context
grow
resist
limit
suppli
new
molecul
ration
use
antibiot
high
prioriti
object
train
healthcar
profession
student
pkpd
correct
implement
guidelin
sinc
could
help
improv
antibiot
use
short
midterm
method
develop
pkpd
guidelin
cours
cdrom
target
physician
pharmacist
also
usabl
student
cours
prepar
team
pharmacist
clinic
microbiologist
pharmacologist
sourc
inform
textbook
review
paper
primari
paper
intern
recogn
expert
ii
materi
present
train
workshop
intern
societi
antiinfect
pharmacolog
isap
wwwisaporg
last
year
iii
nation
avail
intern
guidelin
manag
respiratori
tract
urinari
tract
infect
result
cours
organ
seri
power
point
present
cover
progress
fashion
follow
topic
base
microbiolog
vitro
properti
antibiot
pharmacokinet
definit
main
paramet
pharmacodynam
concept
b
method
pertin
model
c
data
includ
paramet
take
account
optim
dosag
main
antibiot
class
resist
includ
main
mechan
b
use
pharmacodynam
avoid
select
resist
appropri
use
includ
appropri
dosag
antibiot
respiratori
tract
b
urinari
tract
infect
conclus
cours
promot
continu
educ
pharmacolog
pharmacotherapi
antibiot
format
easili
usabl
cours
seminar
student
profession
background
although
macrolid
intrins
antipseudomon
activ
drug
appear
effect
control
infect
p
aeruginosa
mechan
disrupt
quorum
sens
antiinflammatori
effect
object
aim
prospect
studi
evalu
efficaci
macrolid
patient
bronchiectasi
infect
colonis
p
aeruginosa
method
studi
includ
hospitalis
patient
ct
evid
bronchiectasi
present
acut
exacerb
p
aeruginosa
isol
sputum
microbiolog
find
clinic
data
treatment
recommend
record
admiss
end
therapi
patient
complet
daili
diari
card
symptom
pef
valu
patient
follow
year
result
twentytwo
patient
men
mean
age
bronchiectasi
p
aeruginosa
infect
includ
hospit
stay
patient
treat
least
two
suscept
antipseudomon
drug
accord
antibiogram
usual
betalactam
plu
aminoglycosid
period
day
oral
macrolid
azithromycin
mg
x
daysweek
patient
clarithromycin
mg
daili
patient
administr
month
end
longterm
therapi
patient
show
evid
p
aeruginosa
sputum
patient
still
present
p
aeruginosa
sputum
discontinu
treatment
less
month
advers
event
patient
signific
reduct
sputum
volum
mlday
therapi
vs
mlday
end
therapi
p
mean
number
exacerb
followup
previou
year
vs
followup
year
p
increas
mean
pef
valu
also
note
although
statist
signific
lmin
therapi
vs
l
min
end
therapi
p
conclus
observ
find
suggest
macrolid
may
role
modul
p
aeruginosa
colonis
patient
bronchiectasi
object
littl
inform
cap
requir
hospit
young
adult
year
analys
clinic
featur
caus
organ
outcom
cap
patient
popul
method
prospect
observ
studi
nonimmunocompromis
adult
patient
cap
cap
patient
hiv
infect
transplant
neutropenia
includ
purpos
studi
patient
divid
agegroup
year
year
result
document
consecut
patient
cap
patient
year
year
mean
patient
age
year
former
group
year
latter
group
main
reason
hospit
young
adult
hypoxia
patient
port
high
sever
risk
class
ivv
patient
empyema
patient
shock
patient
young
patient
frequent
current
smoker
vs
p
comorbid
condit
common
older
patient
vs
p
mainli
diabet
mellitu
copd
chronic
heart
diseas
multilobar
pneumonia
frequent
young
patient
vs
p
common
caus
organ
streptococcu
pneumonia
vs
ns
legionella
pneumophila
vs
ns
atyp
agent
frequent
young
adult
vs
p
haemophilu
influenza
vs
p
gramneg
bacilli
vs
ns
rare
identifi
group
frequenc
bacteraemia
similar
group
vs
ns
icu
admiss
frequent
young
adult
vs
p
differ
found
regard
need
mechan
ventil
vs
median
lo
shorter
young
patient
vs
day
p
five
young
patient
die
shock
patient
multiorgan
failur
earli
mortal
hour
similar
group
vs
overal
mortal
day
higher
older
patient
vs
p
conclus
cap
requir
hospit
young
adult
mainli
smoker
uncommon
respiratori
failur
frequent
reason
admiss
pneumonia
atyp
agent
frequent
caus
organ
group
although
overal
mortal
rel
low
number
young
patient
requir
icu
admiss
complic
cours
corticosteroid
patient
sever
communityacquir
pneumonia
impact
mortal
c
garcia
vidal
e
calbo
c
ferrer
v
pascual
quintana
j
garau
terrassa
e
background
mortal
patient
sever
cap
tradit
relat
microorgan
virul
host
characterist
recent
increas
interest
hostpathogen
interact
inadequ
immunolog
respons
shown
associ
higher
mortal
immun
modul
concomit
antibiot
therapi
postul
improv
outcom
aim
studi
determin
risk
factor
increas
mortal
patient
sever
cap
evalu
impact
administr
corticosteroid
outcom
method
review
chart
hospit
cap
patient
centr
octob
decemb
sever
cap
defin
pneumonia
sever
index
psi
categori
includ
data
demograph
comorbid
measur
charlson
score
bacteri
aetiolog
presenc
immunosuppress
copd
icu
admiss
antibiot
therapi
use
corticosteroid
mortal
record
result
sever
cap
patient
includ
categori
respect
patient
treat
standard
antimicrobi
therapi
receiv
also
corticosteroid
mean
age
vs
charlson
score
vs
neoplasm
vs
hiv
vs
chronic
liver
diseas
diabet
mellitu
icu
admiss
vs
monotherapi
vs
aetiolog
pneumonia
vs
l
pneumophila
other
unknown
similar
patient
receiv
corticotherapi
expos
anoth
immunosuppress
treatment
frequent
vs
p
copd
common
vs
p
mortal
higher
vs
p
group
treat
corticosteroid
multivari
analysi
sever
diseas
p
use
corticosteroid
ic
p
found
relat
mortal
conclus
experi
corticosteroid
treatment
patient
sever
cap
appear
associ
higher
mortal
use
levofloxacin
communityacquir
pneumonia
j
olalla
escot
jj
marbella
e
introduct
object
commun
acquir
pneumonia
cap
preval
import
diseas
import
consum
resourc
hospit
aim
studi
profil
incom
patient
cap
diagnosi
year
introduct
levofloxacin
centr
compar
length
stay
order
differ
antibiot
treatment
adjust
result
fine
scale
method
hospit
second
level
hospit
marbella
spain
diagnosi
discharg
codifi
includ
hospit
databas
diagnosi
cap
septemb
march
collect
clinic
report
examin
demograph
data
regist
paramet
affect
fine
classif
antibiot
treatment
intens
care
unit
icu
incom
death
length
stay
result
case
cap
found
male
femal
mean
age
year
ys
ci
differ
gender
patient
pt
live
resid
pt
previou
diagnosi
heart
failur
hf
mean
age
vs
p
pt
cerebrovascular
diseas
cvd
mean
age
vs
p
pt
chronic
hepatopathi
form
cancer
pt
chronic
renal
failur
mean
age
vs
p
pt
chronic
obstruct
pulmonari
diseas
copd
pt
admit
icu
death
regist
blood
cultur
collect
case
cultur
sputum
legionella
antigen
urin
accord
fine
classif
patient
stratifi
group
ii
iii
iv
v
case
correspond
fine
ii
levofloxacin
use
alon
vs
fine
iii
iv
v
length
stay
analys
patient
fine
ii
use
levofloxacin
associ
non
signific
reduct
mean
se
day
vs
day
peopl
group
iii
iv
v
use
levofloxacin
show
reduct
length
stay
day
peopl
use
levofloxacin
vs
day
readmiss
relationship
recurr
cap
regist
conclus
experi
use
levofloxacin
associ
less
sever
cap
non
signific
reduct
length
stay
observ
telithromycin
versu
firstlin
singleag
antibiot
treatment
communityacquir
pneumonia
randomis
superior
trial
mouton
v
thamlikitkul
rb
nieman
c
janu
tourco
f
bangkok
th
bridgewat
usa
pari
f
object
macrolid
betalactam
commonli
recommend
treatment
outpati
communityacquir
pneumonia
cap
aim
studi
demonstr
superior
ketolid
telithromycin
tel
firstlin
oral
singleag
antibiot
compar
comp
achiev
clinic
cure
outpati
mild
moder
cap
geograph
area
high
pneumococc
resist
erythromycin
resist
rate
method
patient
clinic
radiolog
evid
cap
randomis
central
receiv
either
tel
mg
daili
day
comp
chosen
investig
accord
local
treatment
guidelinespractic
efficaci
assess
posttherapi
day
clinic
outcom
openlabel
trial
valid
three
independ
expert
fulli
blind
treatment
assign
result
patient
enrol
includ
modifi
intent
treat
mitt
per
protocol
pp
efficaci
analys
comp
group
patient
receiv
macrolid
betalactam
fluoroquinolon
resist
penicillin
erythromycin
among
streptococcu
pneumonia
isol
respect
clinic
cure
rate
tel
group
significantli
higher
comp
group
shown
follow
tabl
tel
comp
similarli
well
toler
conclus
outpati
cap
studi
posttherapi
clinic
cure
rate
achiev
tel
shown
statist
superior
achiev
usual
care
firstlin
antibiot
mitt
pp
popul
accord
evalu
investig
blind
expert
chang
epidemiolog
clinic
featur
outcom
acut
communityacquir
pneumonia
among
adult
india
background
acut
cap
third
lead
caus
mortal
india
two
prospect
studi
centr
identifi
common
caus
cap
india
mycoplasma
pneumonia
mp
legionella
pneumophila
lp
serolog
spn
cultur
respiratori
secretionsblood
conclus
although
spn
common
isol
rise
number
gram
neg
organ
atyp
pathogen
associ
increas
mortal
stress
need
review
initi
antibiot
choic
adult
higher
port
class
view
endur
suscept
spn
pcn
minim
resist
narrow
spectrum
activ
drug
choic
spn
india
fqr
wide
coverag
respiratori
pathogen
includ
atyp
consid
initi
choic
hospit
ambulatori
set
continu
surveil
respiratori
pathogen
need
fluoroquinolon
treatment
commun
hospitalacquir
legionella
pneumonia
object
communityacquir
pneumonia
cap
major
caus
morbid
mortal
worldwid
inabl
failur
compli
standard
antibiot
regimen
may
last
day
may
result
patient
receiv
suboptim
antibiot
treatment
treatment
singledos
antibiot
regimen
maxim
complianc
prescrib
therapi
novel
microspher
formul
azithromycin
make
possibl
administ
drug
singl
dose
maintain
toler
object
studi
test
hypothesi
singl
g
oral
dose
azithromycin
microspher
effect
regimen
oral
levofloxacin
mgday
use
treat
adult
patient
mild
moder
cap
fine
class
ii
iii
object
mani
guidelin
issu
treatment
cap
want
assess
frequent
nation
guidelin
treatment
cap
follow
spanish
acut
care
hospit
patient
admit
cap
method
retrospect
review
chart
patient
admit
hospit
diagnosi
cap
period
geograph
scatter
hospit
spain
data
avail
patient
result
amoxicillinclavulan
common
antibiot
choic
given
monotherapi
associ
clarithromycin
levofloxacin
given
monotherapi
follow
close
follow
third
gener
cephalosporin
ceftriaxon
cefotaxim
given
associ
clarithromycin
clarithromycin
use
mainli
complement
amoxicillinclavulan
cephalosporin
sinc
given
monotherapi
antibiot
uncommonli
prescrib
cefepim
ciprofloxacin
conclus
monotherapi
levofloxacin
follow
amoxicillinclavulan
acid
common
first
line
antibiot
choic
spanish
hospit
howev
amoxicillinclav
alon
combin
clarithromycin
common
antibiot
prescrib
monotherapi
clarithromycin
rel
uncommon
choic
reflect
quit
well
recommend
differ
nation
guidelin
issu
countri
environ
high
preval
resist
penicillin
macrolid
pneumonia
spain
concomit
coverag
legionella
atyp
pathogen
microbiolog
abecb
potenti
predict
valu
clinic
criteria
j
kahn
raritan
usa
object
explor
relationship
specif
pulmonari
diseas
sever
criteria
microbiolog
acut
bacteri
exacerb
chronic
bronchiti
abecb
method
doubleblind
random
clinic
trial
evalu
levofloxacin
mg
qd
day
abecb
potenti
subject
meet
at
definit
chronic
bronchiti
patient
anthonisen
type
exacerb
n
enrol
stratif
diseas
sever
determin
use
paramet
suggest
grossman
predict
valu
defin
comorbid
number
exacerb
previou
month
differ
spectra
etiolog
organ
expect
basi
stratif
differ
compar
agent
use
uncompl
patient
azithromycin
five
day
consid
complic
amoxicillinclavulan
ten
day
result
initi
microbiolog
intenttotreat
patient
reveal
notabl
differ
two
strata
among
isol
uncompl
case
triad
pneumonia
h
influenza
catarrhali
inclus
h
parainfluenza
rais
figur
complic
arm
figur
respect
gramneg
bacilli
primarili
enterobacteriacea
spp
sever
pseudomonad
repres
uncompl
complic
isol
microbiolog
erad
rate
percentag
organ
persist
therapi
uncompl
stratum
compat
unexpectedli
larg
number
macrolideresist
organ
isol
complic
arm
levofloxacin
amoxicillinclavulan
lower
compar
erad
persist
rate
clinic
efficaci
microbiologcallyevalu
patient
consist
figur
conclus
clearli
overlap
among
flora
isol
two
strata
defin
applic
grossman
criteria
separ
popul
predict
approach
seem
valu
identifi
optim
antimicrobi
regimen
especi
uncompl
exacerb
work
defin
valid
predict
clinic
paramet
may
help
optim
choic
durat
antimicrobi
agent
abecb
object
nosocomi
pneumonia
second
common
nosocomi
infect
along
primari
bacteraemia
lead
caus
death
infect
acquir
hospit
despit
frequenc
ventilatorassoci
pneumonia
vap
threat
pose
patient
surviv
consensu
appropri
antibiot
treatment
vap
yet
establish
uncertainti
compound
lack
wellcontrol
comparison
specif
treatment
regimen
impact
relev
outcom
morbid
mortal
cost
compar
analysi
clinic
microbiolog
efficaci
cefepim
combin
ceftazidim
amikacin
treatment
vap
sever
trauma
patient
aim
present
studi
method
prospect
random
studi
approv
institut
review
board
human
research
thirti
adult
patient
admit
icu
emerg
municip
hospit
sever
trauma
complic
vap
includ
cpi
use
diagnost
vap
combin
ceftazidim
g
tid
iv
amikacin
g
daili
iv
use
initi
empir
therapi
vap
patient
monotherapi
cefepim
g
bid
iv
patient
regim
empir
therapi
chosen
accord
local
microbiolog
monitor
p
aeruginosa
preval
pathogen
vap
costeffect
analysi
perform
compar
cost
outcom
compet
regim
result
differ
group
mean
age
averag
time
mechan
ventil
onset
vap
cpi
mean
apach
ii
score
group
combin
therapi
group
monotherapi
posit
clinic
outcom
regist
patient
cefepim
patient
ceftazidim
plu
amikacin
rate
erad
respect
durat
effect
treatment
cefepim
day
mean
day
combin
therapi
day
mean
day
mean
cost
vap
treatment
cefepim
euro
comparison
euro
empir
therapi
initi
ceftazidim
amikacin
conclus
cefepim
monotherapi
regimen
clinic
bacteriolog
efficaci
comparison
combin
ceftazidim
amikacin
vap
patient
sever
trauma
use
cefepim
result
lower
cost
influenc
antibacteri
protocol
multipl
trauma
patient
incid
mortal
vap
protsenko
yaroshetskiy
yakovlev
b
gelfand
moscow
ru
object
aim
present
studi
evalu
antibacteri
protocol
multipl
trauma
patient
incid
mortal
vap
method
compar
analysi
incid
attribut
mortal
chisquar
test
pathogen
vap
multipl
trauma
patient
perform
two
period
introduct
protocol
introduct
protocol
year
develop
protocol
includ
abandon
antibiot
prophylaxi
vap
intrus
criteria
earli
diagnost
vap
exclus
gener
cephalosporin
aminoglycosid
fluoroquinolon
empir
therapi
vap
cefepim
apach
ii
carbapenem
apach
ii
use
initi
empir
therapi
vap
efficaci
antibiot
treatment
evalu
within
hour
carbapenem
andor
vancomycin
ad
initi
therapi
ineffici
case
suspect
diagnosi
vap
microbiolog
analysi
broncoalveolar
lavag
fluid
bal
perform
widespread
use
broad
spectrum
antibiot
shift
structur
nosocomi
pathogen
observ
decreas
mrsa
rate
signific
increas
time
rate
klebsiella
pneumonia
strain
resist
gener
cephalosporin
rate
acinetobact
baumanii
strain
resist
ceftazidim
conclus
introduct
strict
antibacteri
protocol
patient
multipl
trauma
vap
result
signific
decreas
attribut
mortal
without
chang
incid
vap
antimicrobi
prophylaxi
cardiac
surgeri
postop
pneumonia
rate
object
purpos
studi
assess
postop
pneumonia
rate
accord
antimicrobi
prophylaxi
regimen
patient
cardiac
surgeri
cardiopulmonari
bypass
patient
method
cardiac
surgeri
patient
includ
n
retrospect
studi
observ
patient
postop
pneumonia
pneumonia
group
patient
without
infecti
complic
postop
period
group
compar
age
sex
volum
transact
sever
diseas
studi
period
two
main
regimen
antimicrobi
prophylaxi
use
ceftriaxon
g
iv
oper
cefuroxim
g
iv
oper
addit
dosag
mg
hour
surgeri
begin
prophylaxi
conduct
oper
hour
data
compar
fisher
exact
determin
significantli
differ
group
p
result
preoper
prophylaxi
cefrtiaxon
administ
often
pneumonia
group
patient
without
infect
complic
vs
ns
ceftriaxon
use
significantli
often
comparison
cefuroxim
subgroup
patient
cardiopulmonari
bypass
less
min
develop
postop
pneumonia
vs
p
cardiopulmonari
bypass
longer
min
reveal
differ
antimicrobi
prophylaxi
regimen
conclus
cefuroxim
prefer
ceftriaxon
antimicrobi
prophylaxi
postop
pneumonia
patient
cardiac
surgeri
cardiopulmonari
bypass
less
min
durat
close
versu
open
tracheal
suction
system
prevent
ventilatorassoci
pneumonia
object
aim
studi
analyz
incid
ventilatorassoci
pneumonia
vap
use
close
tracheal
suction
system
object
dalbavancin
novel
second
gener
lipoglycopeptid
shown
clinic
efficaci
onceweekli
treatment
complic
skin
skin
structur
infect
csssi
dosag
use
clinic
studi
mg
day
mg
day
vitro
studi
determin
dalbavancin
less
equal
mgl
target
bacteria
princip
staphylococci
streptococci
includ
isol
resist
antibiot
plasma
protein
bind
dalbavancin
skin
infect
occur
extravascular
space
antibiot
concentr
assess
blister
fluid
measur
skin
penetr
obtain
pharmacokinet
observ
may
correl
efficaci
method
phase
open
label
singledos
studi
conduct
healthi
subject
subject
administ
mg
iv
dose
dalbavancin
blister
induc
appli
cantharidin
ointment
skin
blister
fluid
collect
prior
dose
hour
day
day
day
blood
sampl
collect
throughout
studi
blister
fluid
plasma
assay
dalbavancin
use
valid
lcmsm
method
pharmacokinet
paramet
determin
area
concentrationtim
curv
auc
determin
blister
fluid
aucbf
plasma
aucp
first
week
degre
penetr
skin
determin
aucbfaucp
result
dalbavancin
well
toler
seriou
advers
event
advers
event
mild
selflimit
maximum
observ
dalbavancin
blister
fluid
concentr
achiev
first
collect
hour
concentr
maintain
mgl
day
mean
sd
aucbf
aucp
mg
hl
respect
skin
penetr
approxim
dalbavancin
blister
fluid
concentr
maintain
well
mic
throughout
treatment
interv
even
consid
possibl
effect
protein
bind
conclus
blister
fluid
concentr
maintain
well
mic
csssi
target
organ
week
follow
singl
dose
dalbavancin
data
support
onceweekli
regimen
consist
efficaci
observ
clinic
studi
safeti
pharmacokinet
dalbavancin
subject
renal
impair
endstag
renal
diseas
ja
dowel
e
seltzer
kraus
henkel
king
prussia
usa
object
dalbavancin
novel
second
gener
lipoglycopeptid
antibiot
late
stage
clinic
develop
complic
skin
skin
structur
infect
csssi
weekli
dosag
use
clinic
studi
mg
day
mg
day
sinc
dalbavancin
like
use
patient
variou
degre
renal
impair
import
determin
safeti
pharmacokinet
popul
well
evalu
dosag
adjust
necessari
method
singl
intraven
dose
mg
dalbavancin
examin
subject
mild
clcr
mlmin
moder
clcr
mlmin
renal
impair
dose
mg
dalbavancin
studi
subject
endstag
renal
diseas
esrd
dialysisdepend
singl
dose
mg
mg
dalbavancin
studi
subject
sever
renal
impair
clcr
mlmin
subject
normal
renal
function
studi
use
control
pharmacokinet
data
analys
use
noncompartment
method
paramet
includ
maximum
concentr
cmax
area
plasma
concentr
time
curv
auc
result
total
subject
receiv
dalbavancin
includ
pharmacokinet
analysi
mild
moder
sever
esrd
normal
dalbavancin
well
toler
renal
impair
group
major
advers
event
mild
moder
sever
unrel
studi
drug
relat
seriou
advers
event
dalbavancin
pharmacokinet
similar
subject
mild
moder
renal
impair
subject
normal
renal
function
concentr
subject
esrd
similar
subject
normal
renal
function
indic
compens
renal
insuffici
due
regular
dialysi
timesweek
subject
sever
renal
impair
increas
concentr
exposur
concentr
increas
first
week
post
dose
differ
continu
increas
rest
profil
auc
increas
almost
background
tlv
novel
lipoglycopeptid
antibiot
multipl
mechan
action
exert
rapid
concentrationdepend
bactericid
activ
clinic
import
gramposit
bacteria
includ
methicillinresist
aureu
kidney
primari
rout
elimin
tlv
man
phase
studi
ongo
skin
skin
structur
infect
hospit
acquir
pneumonia
line
repres
modelbas
predictedprob
first
occurr
naus
box
repres
percentil
auc
dose
group
wisker
extend
minimum
maximum
valu
object
compar
singl
dose
pk
tlv
subject
maintain
hemodialysi
age
sexmatch
group
healthi
subject
without
renal
dysfunct
method
six
hemodialysi
subject
male
femal
receiv
singl
dose
tlv
intraven
hour
approxim
hour
prior
hemodialysi
session
six
subject
male
femal
normal
renal
function
mean
creatinin
clearanc
mlmin
also
receiv
dose
tlv
hour
blood
dialys
sampl
obtain
specifi
interv
post
dose
assay
tlv
valid
lcmsm
assay
pk
paramet
determin
use
noncompartment
method
result
averag
valu
plasma
pk
paramet
tlv
group
subject
shown
belowth
averag
rang
clearanc
tlv
via
dialysi
mlmin
per
cent
dose
remov
dialysi
subject
toler
tlv
well
conclus
dose
reduct
tlv
recommend
patient
maintain
hemodialysi
supplement
tlv
dose
post
dialysi
need
pharmacokinet
tissu
penetr
telavancin
healthi
subject
background
tlv
novel
lipoglycopeptid
antibiot
multipl
mechan
action
exert
rapid
concentrationdepend
bactericid
activ
clinic
import
gramposit
bacteria
includ
methicillinresist
aureu
aureu
includ
mrsa
gisa
pool
studi
lgml
phase
studi
ongo
skin
skin
structur
infect
hospit
acquir
pneumonia
object
determin
steadyst
pk
profil
tlv
plasma
skin
blister
fluid
healthi
subject
method
subject
male
femal
receiv
three
daili
dose
tlv
mgkg
intraven
hour
cantharidin
ointment
appli
forearm
produc
blisterssubject
begin
hour
prior
third
dose
tlv
blood
blister
fluid
sampl
obtain
specifi
interv
day
assay
tlv
valid
lcmsm
assay
pk
paramet
matric
determin
use
noncompartment
method
averag
valu
pk
paramet
tlv
plasma
blister
fluid
shown
result
singl
intraven
infus
mg
equival
eq
ceftobiprol
minut
mg
eq
ceftobiprol
minut
mean
cmaxvalu
infus
endpoint
lg
ml
lgml
respect
correspond
mean
lg
hml
lg
hml
intersubject
variabl
paramet
auc
cmax
ceftobiprol
mean
system
clearanc
lh
mean
steadyst
volum
distribut
l
mg
mg
dose
regimen
respect
infus
mg
minut
mg
minut
target
mic
lgml
methicillin
resist
staphylococcu
aureu
hour
total
plasma
concentr
hour
correct
unbound
plasma
concentr
respect
twicedaili
administr
mg
minut
mg
minut
proport
dose
interv
mic
lgml
would
total
plasma
concentr
unbound
plasma
concentr
respect
conclus
ceftobiprol
infus
mg
eq
minut
mg
eq
minut
result
similar
time
target
concentr
lgml
well
minimum
efficaci
requir
requir
mrsa
method
studi
random
threeway
crossov
studi
hour
washout
period
healthi
volunt
subject
receiv
imipenem
three
regimen
h
infus
g
everi
h
dose
ii
h
infus
g
everi
h
dose
iii
h
infus
g
everi
h
dose
conclus
h
infus
g
imipenem
give
greater
valu
mic
h
infus
h
infus
may
use
mode
administr
tropic
countri
drug
instabl
may
prevent
use
continu
infus
pharmacodynam
characteris
haemophilu
influenza
vitro
hollowfibr
system
meagher
p
smith
forrest
odundel
p
ambros
buffalo
albani
usa
object
peptid
deformylas
inhibitor
vitro
activ
pathogen
commonli
associ
communityacquir
respiratori
tract
infect
purpos
studi
determin
pharmacokineticpharmacodynam
pkpd
measur
strongli
associ
drug
respons
examin
relationship
drug
exposur
respons
haemophilu
influenza
hi
method
two
wildtyp
hi
strain
mic
mgl
studi
hollowfib
system
hf
inocul
approxim
cfuml
logphas
growth
simul
human
pharmacokinet
hour
bacteria
expos
escal
free
drug
exposur
auc
rang
mg
hl
use
dose
fraction
studi
design
deliv
drug
hour
hour
continu
infus
ci
serial
sampl
collect
determin
bacteri
count
cfuml
drug
concentr
drug
effect
quantifi
log
ratio
lr
hour
area
bacteri
growthkil
curv
drug
growth
control
lr
log
aucdrugaucgrowth
control
result
overal
greatest
activ
seen
ci
regimen
ci
due
short
halflif
dose
hour
yield
net
kill
compar
baselin
neither
per
cent
time
mic
auc
mic
ratio
peak
mic
ratio
could
comodel
hour
regimen
ci
result
separ
dataset
vs
ci
auc
mic
ratio
could
adequ
describ
ci
result
emax
lr
auc
mic
ratio
dataset
reason
fit
auc
mic
ratio
per
cent
time
mic
emax
lr
auc
mic
ratio
per
cent
time
mic
respect
peak
mic
ratio
inform
conclus
intermitt
dose
regimen
per
cent
time
mic
auc
mic
ratio
adequ
describ
drug
respons
percent
time
mic
auc
mic
ratio
associ
maxim
declin
respect
ci
regimen
could
comodel
intermitt
regimen
suggest
neither
per
cent
time
mic
auc
mic
ratio
complet
describ
drug
effect
drug
effect
continu
increas
beyond
time
mic
hour
dose
effect
hour
dose
would
probabl
effect
regimen
human
hi
pharmacodynam
antimicrobi
empir
treatment
nosocomi
pneumonia
report
optama
program
object
appropri
empir
antibiot
therapi
vital
maxim
patient
outcom
treatment
nosocomi
pneumonia
depend
drug
exposur
achiev
patient
caus
pathogen
mic
purpos
studi
compar
probabl
achiev
bactericid
exposur
commonli
use
intraven
antibiot
bacteria
commonli
implic
nosocomi
pneumonia
high
target
attain
fep
caz
tzp
decreas
carbapenem
target
attain
remain
regardless
pathogen
preval
conclus
target
attain
greatest
ipm
mem
follow
higher
dose
fep
caz
tzp
antibiot
regimen
provid
optim
bactericid
exposur
would
suitabl
empir
treatment
nosocomi
pneumonia
along
antimrsa
antibiot
pathogen
identif
suscept
result
avail
minim
inhibitori
concentr
effect
sme
antibacteri
agent
two
strain
b
anthraci
method
pasub
mic
sme
determin
expos
bacteria
antibiot
concentr
time
mic
h
follow
repeat
wash
centrifug
remov
antibiot
cultur
divid
four
tube
three
tube
test
antibiot
ad
make
final
concentr
mic
mic
mic
fourth
tube
antibiot
ad
optic
densiti
determin
exposur
immedi
wash
hourli
h
determin
sme
procedur
perform
except
organ
preexpos
antibiot
od
convert
cfu
use
standard
curv
pasub
mic
defin
pasub
mic
tpa
c
tpa
time
cultur
previous
expos
antibiot
reexpos
differ
submic
increas
log
count
determin
immedi
wash
c
correspond
time
antibiot
unexpos
control
sme
defin
sme
ts
c
ts
time
cultur
expos
submic
increas
log
count
determin
immedi
wash
c
correspond
time
unexpos
control
method
serum
csf
cefepim
pk
data
obtain
hospit
patient
pneumonia
extern
ventricular
drain
concentrationtim
profil
serum
csf
model
use
threecompart
model
zeroord
infus
first
order
elimin
transfer
appar
volum
central
compart
vc
appar
volum
csf
vcsf
intercompartment
transfer
rate
constant
plasma
clearanc
cl
identifi
popul
pk
analysi
npag
tabl
cefepim
g
iv
h
h
infus
mont
carlo
simul
subject
adapt
ii
perform
estim
probabl
attain
target
free
cefepim
serum
concentr
assum
protein
bind
total
cefepim
csf
concentr
mic
mic
mgl
tabl
csfserum
median
penetr
ratio
calcul
post
mapbayesian
observedpredict
regress
r
serum
csf
follow
serum
observ
predict
r
csf
observ
predict
r
penetr
cefepim
measur
median
auccsfauc
serum
percentil
result
serum
csf
target
attain
analysi
cefepim
g
iv
conclus
set
noninflam
mening
cefepim
g
iv
h
provid
adequ
mic
csf
patient
mic
mgl
influenc
inflamm
calcul
csf
target
attain
rate
unknown
definit
pharmacodynam
target
csf
elucid
research
need
applic
microbiolog
capillari
electrophoresi
method
phenoxymethylpenicillin
dissolut
assay
w
grzybowska
g
pajchel
zapasnik
tyski
warsaw
pl
object
drug
absorpt
solid
dosag
form
oral
administr
depend
releas
activ
substanc
medicin
product
case
drug
analysi
especi
result
test
specif
necessari
use
anoth
assay
simultan
refer
method
case
phenoxymethylpenicillin
tablet
refer
method
dissolut
assay
spectrophotometr
method
aim
studi
appli
parallel
microbiolog
capillari
electrophoresi
method
compar
result
obtain
use
uv
assay
method
two
prepar
tablet
contain
iumg
penicillin
v
taropen
ospen
examin
dissolut
test
perform
temperatur
phosphat
buffer
ph
ml
ospen
ml
taropen
use
basket
rotat
speed
rpm
sampl
taken
minut
minut
case
profil
dissolut
analysi
amount
penicillin
v
dissolv
assay
spectrophotometr
nm
hanson
research
dissolut
system
ce
apparatu
quanta
water
use
pharmacopo
microbiolog
agar
diffus
method
staphylococcu
aureu
atcc
p
strain
appli
result
dissolut
penicillin
v
taropen
prepar
minut
independ
method
appli
case
ospen
tablet
valu
differ
depend
analyt
assay
statist
fishersnedecor
test
comparison
dissolut
data
obtain
use
three
method
perform
fisher
fcalc
valu
lower
theoret
taropen
case
dissolut
profil
two
examin
prepar
also
compar
statist
evalu
accord
fda
method
result
calcul
show
dissolut
profil
phenoxymethylpenicillin
taropen
ospen
tablet
differ
significantli
conclus
perform
analysi
prove
capillari
electrophoresi
microbiolog
method
use
altern
determin
taropen
dissolut
penetr
penicillin
g
combin
sulbactam
nasal
tissu
u
frank
ttele
w
maier
f
knapp
r
trittler
h
egl
k
kuemmer
freiburg
object
penetr
antimicrobi
agent
target
tissu
essenti
treatment
site
infect
investig
distribut
penicillin
g
combin
sulbactam
human
nasal
tissu
method
determin
pharmacokinet
penicillin
g
sulbactam
inform
written
consent
obtain
patient
age
year
schedul
endonas
oper
septoplasti
conchotomi
infus
iu
penicillin
g
g
sulbactam
concentr
agent
determin
serum
variou
nasal
tissu
septal
mucosa
septal
cartilag
bone
serum
nasal
tissu
concentr
determin
liquid
chromatographymass
spectrometri
lcm
result
hour
infus
mean
serum
concentr
penicillin
g
lgml
sd
lgml
sd
sd
lgml
sd
lgml
sd
lgml
mean
serum
concentr
lgml
sd
lgml
sd
lgml
sd
lgml
sd
lgml
sd
mean
penicillin
g
sulbactam
concentr
septal
mucosa
decreas
lgg
hour
lgg
hour
respect
septal
cartilag
highest
tissu
concentr
observ
hour
infus
mean
penicillin
g
sulbactam
concentr
lgg
respect
mean
penicillin
g
sulbactam
concentr
bone
decreas
lgg
hour
lgg
hour
respect
regress
analysi
data
show
h
administr
drug
combin
level
still
exceed
methicillinsuscept
staphylococcu
aureu
streptococcu
pyogen
moraxella
catarrhali
haemophilu
influenza
conclus
data
support
use
drug
combin
periop
prophylaxi
treatment
ent
nasal
paranas
infect
due
common
bacteri
pathogen
mic
vs
killcurv
base
pharmacokinet
pharmacodynam
model
activ
cefpodoxim
cefixim
h
derendorf
p
liu
k
rand
b
obermann
gainesvil
usa
munich
object
pharmacokinet
pk
pharmacodynam
pd
model
antibiot
usual
consist
comparison
plasma
pk
mic
mic
cmax
mic
aucmic
indic
limit
due
innat
inaccuraci
mic
fact
reflect
vivo
scenario
concentr
static
fluctuat
dose
altern
use
timekil
curv
follow
bacteri
kill
growth
function
time
concentr
studi
provid
systemat
comparison
mic
killcurv
approach
show
potenti
method
antibiot
evalu
exampl
develop
mathemat
pharmacokineticpharmacodynam
pkpd
cefepim
popul
pk
mean
sd
paramet
estim
obtain
npag
analysi
model
integr
vitro
antimicrobi
activ
pk
profil
two
oral
cephalosporin
tissu
site
method
kill
curv
could
describ
differ
combin
maximum
kill
rate
kmax
drug
concentr
halfmaximum
effect
bacteri
growth
rate
result
mic
scenario
experiment
part
bacteri
timekil
curv
cefpodoxim
cefixim
four
bacteri
strain
compar
vitro
kinet
model
previous
measur
human
pharmacokinet
profil
unbound
antibiot
integr
result
differ
combin
kmax
yield
mic
consequ
micbas
index
howev
depend
combin
pd
paramet
kill
curv
may
predict
quit
opposit
outcom
scenario
valu
cefpodoxim
cefixim
consist
respect
mic
valu
antibiot
similar
high
potenc
h
influenza
mgl
catarrhali
mgl
potenc
cefpodoxim
pneumonia
strain
higher
cefixim
sensit
vs
mgl
vs
mg
l
simul
show
cefpodoxim
higher
bacteriolog
success
pneumonia
cefixim
conclus
simpl
comparison
exposur
mic
may
suffici
evalu
antiinfect
efficaci
kill
curv
provid
detail
approach
predict
antimicrobi
effect
develop
emax
model
effect
describ
pharmacodynam
cefpodoxim
cefixim
cefpodoxim
mg
bid
higher
tissu
penetr
antimicrobi
efficaci
cefixim
mg
qd
pneumonia
bacteriolog
efficaci
intraven
piperacillin
tazobactam
ampicillinsulbactam
infect
diabet
foot
ulcer
object
test
efficaci
singleag
empir
treatment
either
intraven
administ
piperacillintazobactam
tzp
g
h
ampicillinsulbactam
sam
g
h
moder
sever
infect
foot
ulcer
patient
diabet
openlabel
trial
adult
random
receiv
tzp
sam
day
patient
polymicrobi
infect
involv
methicillinresist
staphylococcu
aureu
also
receiv
vancomycin
g
h
sampl
bacteriolog
evalu
taken
baselin
infect
ulcer
blood
document
caus
pathogen
test
antimicrobi
suscept
sampl
taken
clinic
indic
endoftreat
testofcur
visit
day
posttreat
minim
risk
contamin
sampl
obtain
aspir
curettag
biopsi
rather
swab
result
total
patient
studi
bacteriolog
evalu
common
caus
pathogen
monomicrobi
infect
aureu
streptococcu
agalactia
enterococcu
faecali
pseudomona
aeruginosa
patient
treatment
arm
polymicrob
infect
combin
aureu
plu
agalactia
common
median
durat
treatment
day
group
bypathogen
bacteriolog
success
rate
similar
treatment
group
aureu
agalactia
e
faecali
tzp
erad
rate
p
aeruginosa
sam
activ
p
aeruginosa
patient
p
aeruginosa
sam
group
n
discontinu
studi
conclus
previou
studi
shown
tzp
dose
g
h
effect
treatment
diabet
foot
infect
studi
confirm
less
frequent
administr
tzp
g
h
suffici
attain
bacteriolog
success
rate
aureu
agalactia
e
faecali
p
aeruginosa
bacteriolog
evalu
popul
studi
differ
previou
studi
infect
diabet
foot
ulcer
found
gramneg
enter
common
p
aeruginosa
caus
pathogen
howev
consist
data
show
p
aeruginosa
recent
becom
gramneg
pathogen
frequent
isol
soft
tissu
infect
europ
north
american
latin
america
penetr
betalactamas
inhibitor
tazobactam
sulbactam
sever
acut
pancreat
object
despit
high
standard
intens
care
surgic
manag
acut
necrotis
pancreat
still
relat
extrem
high
mortal
rate
determin
local
infecti
complic
especi
necrotis
area
limit
penetr
antimicrobi
drug
area
consid
major
caus
failur
therapi
sever
infect
combin
betalactamas
inhibitor
bli
betalactam
antibiot
like
broadspectrum
penicillin
bsp
antibacteri
activ
common
pathogen
sever
necrotis
pancreat
coadministr
lead
increas
antibacteri
activ
due
inhibit
betalactamas
compar
betalactam
antibiot
alon
bsp
shown
penetr
rapidli
effici
pancreat
tissu
penetr
bli
inflam
pancreat
tissu
investig
yet
method
address
penetr
capabl
bli
clinic
trial
design
investig
penetr
tazobactam
taz
n
sulbactam
sul
n
patient
sever
necrotis
pancreat
undergo
pancrea
surgeri
sampl
taken
blood
necrot
area
pancreat
tissu
pn
peripancreat
fatti
tissu
pft
bursa
secret
bs
follow
intraven
administr
g
taz
g
sul
concentr
bli
determin
hplc
uv
aim
concentr
full
enzymat
effect
bli
lgmg
taz
lgmg
sul
respect
result
mean
plasma
concentr
h
applic
lgml
taz
lgml
sul
background
uti
one
common
infecti
condit
treat
gener
practic
repres
major
part
abstract
antibiot
use
commun
major
import
know
treat
infect
correctli
ie
maximum
efficaci
least
amount
drug
order
reduc
risk
develop
resist
materi
method
uti
induc
anesthet
femal
nmri
mice
via
intraurethr
inocul
cfu
e
coli
one
day
later
treatment
start
hour
dose
schedul
differ
dose
drug
secur
wide
variat
time
mic
aucmic
h
last
dose
mice
sacrif
urin
collect
bladder
kidney
remov
bladder
kidney
homogen
cfu
determin
drug
use
cephalosporin
cefuroxim
cef
mic
mgl
ceftriaxon
cro
mic
mgl
penicillin
mecillinam
mic
mgl
pk
drug
serum
determin
similar
mice
well
two
cephalosporin
studi
togeth
cef
min
cro
min
respect
mice
pd
paramet
calcul
serum
total
antibiot
concentr
sinc
proteinbind
minor
issu
urin
relat
estim
hillequ
result
drug
reduc
urin
kidney
tissu
log
littl
effect
found
bladder
tissu
two
cephalosporin
combin
time
mic
dose
interv
best
describ
correl
urin
r
p
kidney
tissu
r
p
respect
correl
found
bladder
tissu
neither
aucmic
reveal
correl
urin
organ
found
mecillinam
ie
correl
aucmic
vs
urin
organ
time
mic
significantli
p
correl
urin
r
kidney
tissu
r
respect
time
mic
maximum
efficaci
around
three
antibiot
conclus
optim
pkpd
paramet
efficaci
betalactam
antibiot
uti
time
mic
maximum
effect
seen
time
mic
dose
interv
serum
total
drug
concentr
use
surrog
paramet
human
would
call
tid
dose
mecillinam
cefuroxim
od
dose
ceftriaxon
compar
perform
differ
method
simul
drug
exposur
variabl
popul
vh
tam
gl
rosner
houston
usa
object
stochast
pharmacokinet
pk
forecast
mont
carlo
simul
mc
increasingli
use
predict
pk
variabl
antimicrobi
popul
base
data
rel
subject
howev
variou
mc
approach
may
significantli
differ
accuraci
precis
predict
compar
perform
differ
mc
approach
use
dataset
known
paramet
valu
dispers
method
concentrationtim
profil
subject
intraven
bolu
mg
randomli
gener
use
elimin
rate
constant
k
h
mean
sd
volum
distribut
v
l
normal
distribut
paramet
valu
correl
k
v
assum
system
nois
incorpor
linear
function
drug
concentr
use
concentrationtim
profil
bestfit
paramet
estim
determin
standard
twostag
method
four
method
subsequ
use
simul
popul
mc
use
central
tendenc
dispers
follow
subject
sampl
k
v
clearanc
v
doseclear
scenario
subject
simul
perform
adapt
ii
use
normal
distribut
input
paramet
mean
varianc
set
fit
valu
result
reason
good
paramet
estim
obtain
k
h
v
l
compar
true
popul
mg
hl
simul
variou
method
mg
hl
respect
conclus
result
suggest
variou
mc
approach
may
predict
pk
variabl
popul
differ
realist
approach
appear
base
variabl
subject
sampl
observ
consist
statist
principl
concern
estim
method
amplifi
variabl
model
paramet
least
like
associ
model
misspecif
object
fluoroquinolon
treatment
human
anim
rapidli
select
organ
increas
resist
antibiot
anim
model
key
investig
vivo
antibiot
concentr
prevent
select
resist
eg
mutant
prevent
concentr
mpc
concept
use
model
requir
valid
procedur
extract
analysi
fluoroquinolon
relev
tissu
report
valid
method
quantifi
concentr
enrofloxacin
metabolit
ciprofloxacin
extract
chicken
liver
caecal
content
serum
follow
treatment
baytril
tm
enrofloxacin
method
extract
procedur
describ
wiuff
et
al
valid
fluoroquinolon
analysi
pig
tissu
fortif
target
matric
enrofloxacin
ciprofloxacin
norfloxacin
ad
intern
standard
sampl
sampl
homogenis
extract
acetonitril
ml
centrifug
supernat
retain
analysi
extract
dilut
distil
water
analys
hplc
equip
fluoresc
detect
analyt
chromatograph
revers
phase
column
elut
isocrat
potassium
phosphat
buffer
acetonitril
system
result
liver
sampl
fortifi
lgg
enrofloxacin
provid
recoveri
respect
quantif
ciprofloxacin
lgg
level
possibl
due
interfer
sampl
coextract
recoveri
caecal
content
sampl
enrofloxacin
recoveri
respect
ciprofloxacin
recoveri
serum
much
higher
sampl
fortifi
enrofloxacin
ciprofloxacin
yield
recoveri
respect
select
sampl
also
analys
zonal
microbi
growth
inhibit
bioassay
hplc
equip
msm
detect
data
broadli
similar
method
conclus
valid
method
analysi
fluoroquinolon
chicken
liver
caecal
content
serum
establish
appli
vivo
mpc
studi
sampl
matric
interfer
eg
liver
caeca
bioassay
lcm
ms
must
use
provid
valid
result
ecolog
effect
norfloxacin
pivmecillinam
piv
periurethr
vagin
flora
women
recurr
urinari
tract
infect
object
compar
ecolog
effect
periurethr
vagin
microflora
time
normalis
oral
administ
norfloxacin
nflx
pivmecillinam
piv
women
recurr
lower
uti
method
women
recurr
lower
uti
particip
random
singl
blind
parallel
multicentr
studi
twentyf
women
age
year
posit
nitrit
test
symptom
urgenc
frequenc
dysuria
andor
suprapub
pain
lower
uti
includ
patient
uti
caus
e
coli
klebsiella
spp
evalu
key
exclus
criteria
menopaus
pregnanc
breast
feed
known
hypersensit
studi
drug
antibiot
within
preced
month
impair
liver
kidney
function
known
clinic
suspect
pyelonephr
complic
uti
andor
gastrointestin
infect
studi
drug
seven
day
treatment
either
nflx
mg
bid
piv
mg
tid
sampl
midstream
urin
periurethra
vagina
obtain
start
treatment
day
two
followup
day
inform
consent
obtain
ethic
review
committe
medic
product
agenc
approv
studi
protocol
result
nineteen
patient
nflx
piv
fulfil
inclus
exclus
criteria
differ
patient
characterist
seen
two
group
initi
visit
nflx
patient
colon
aerob
bacteria
although
differ
seen
anaerob
bacteria
e
coli
strain
suppress
markedli
nflx
piv
locat
epidermidi
increas
markedli
follow
piv
treatment
compar
nflx
periurethr
locat
piv
group
e
faecali
less
frequent
initi
increas
visit
return
pretreat
number
visit
nflx
group
patient
colon
initi
e
faecali
decreas
visit
lactobacilli
decreas
slightli
periurethra
nflx
group
whilst
chang
seen
piv
bacteroid
spp
decreas
markedli
nflx
restor
pretreat
colon
level
occur
gradual
except
e
coli
markedli
suppress
nflx
throughout
studi
period
bacteriolog
outcom
urinari
tract
infect
shortterm
longterm
follow
success
conclus
limit
ecolog
effect
microflora
seen
follow
treatment
nflx
piv
benefit
antibiot
use
treatment
patient
uti
antibiot
influenc
releas
kb
cell
gingiv
fibroblast
eick
lauss
schwarz
p
wachter
w
pfister
e
straub
jena
object
gener
antibiot
use
defens
pathogen
bacteria
nevertheless
side
effect
immunomodulatori
activ
consid
purpos
studi
determin
effect
antibiot
normal
use
periodont
treatment
releas
kb
cell
gingiv
fibroblast
method
kb
cell
primari
gingiv
fibroblast
infect
actinobacillu
actinomycetemcomitan
aa
porphyromona
gingivali
atcc
pg
antibiot
doxycyclin
tetracyclin
minocyclin
metronidazol
moxifloxacin
ad
concentr
rang
mic
lgml
h
supernat
obtain
level
measur
elisa
techniqu
addit
h
number
surviv
bacteria
enumer
result
minocyclin
moxifloxacin
concentr
predict
serum
well
lgml
effect
kill
plancton
aa
pg
well
adher
intracellular
bacteria
low
level
interleukin
releas
kb
cell
fibroblast
infect
pg
found
addit
tetracyclin
lgml
metronidazol
moxifloxacin
tetracyclin
subinhibitori
concentr
enhanc
releas
noninfect
aainfect
fibroblast
pgml
h
contradictori
lgml
tetracyclin
minocylin
reduc
releas
supernat
kbcell
detect
addit
lgml
moxifloxacin
lgml
tetracyclin
minocyclin
suppress
total
releas
non
infect
infect
fibroblast
kb
cell
metronidazol
moxifloxaxin
high
concentr
promot
releas
conclus
antibiot
influenc
releas
besid
good
antibacteri
effect
especi
minocyclin
might
suppress
inflamm
nevertheless
kill
bacteria
well
possibl
inhibit
virul
factor
bacteri
proteas
pg
tetracyclin
might
influenc
enhanc
reduc
releas
cytokin
exceedingli
infrequ
infecti
complic
orthotop
liver
transplant
tubercular
periton
introduct
tuberculosi
infrequ
complic
patient
p
undergo
solid
organ
transplant
liver
transplant
recipi
rate
retriev
literatur
updat
p
occur
within
month
less
case
observ
repeat
transplant
pulmonari
local
predomin
p
follow
dissemin
extrapulmonari
exceedingli
rare
event
report
nu
anectdot
p
descript
pathogenet
periton
follow
dissemin
infect
primari
enter
local
born
mortal
rate
case
report
femal
p
mute
person
famili
histori
normal
chest
xray
underw
liver
transplant
year
ago
hcvrelat
decompens
cirrhosia
four
year
later
novel
graft
need
develop
endstag
hepat
insuffici
due
massiv
hcv
reinfect
one
year
later
cyclosporin
treatment
abdomin
pain
ascit
format
prompt
admiss
tuberculosi
sensibl
test
drug
repeatedli
isol
abdomin
fluid
elev
lymphocytemonocyt
count
associ
ethambutol
isoniazid
streptomycin
levofloxacin
one
replac
cycloserin
month
led
complet
clinic
bacteriolog
cure
alreadi
achiev
month
although
antit
treatment
continu
year
conclusiona
rare
case
report
select
antit
chemotherapi
show
success
efficaci
toler
profil
contain
untoward
event
despit
critic
clinic
context
due
sever
complic
broad
spectrum
problem
relat
graft
associ
issu
order
obtain
earli
diagnosi
elev
clinic
suspicion
maintain
rare
complic
recommend
microscopi
cultur
search
mycobacteria
ascit
fluid
method
januari
decemb
prospect
cohort
studi
conduct
determin
rate
bacteri
nosocomi
infect
renal
transplant
recipi
patient
divid
two
group
accord
origin
allograft
cadav
live
donor
enterobact
cloaca
strain
preval
multidrugresist
bacteri
organ
isol
uti
determin
use
genom
analysi
pulsedfield
gel
electrophoresi
pfge
result
one
hundr
sixtythre
patient
receiv
renal
transplant
review
hospit
one
hundr
ten
renal
transplant
cadav
live
donor
median
length
stay
hospit
day
rang
day
transplant
live
donor
day
rang
day
transplant
cadav
p
twentyon
live
donor
recipi
cadav
donor
recipi
bacteri
infect
episod
p
posttranspl
nosocomi
infect
diagnos
hospit
uti
ssi
pneumonia
bloodstream
catheterrel
infect
other
risk
factor
uti
multivari
analysi
includ
cadav
donor
recipi
substitut
initi
immunosuppress
regimen
day
urinari
bladder
catheter
length
stay
hospit
infect
substitut
initi
protocol
posttranspl
immunosuppress
regimen
surgeon
also
associ
ssi
six
differ
e
cloaca
multidrugresist
antibiot
dna
profil
detect
uti
recipi
hospit
dissemin
document
conclus
uti
singl
import
type
hospit
infect
renal
transplant
recipi
signific
differ
incid
uti
found
compar
live
donor
cadav
donor
recipi
high
incid
uti
earli
period
posttranspl
suggest
oper
manipul
urinari
tract
may
import
caus
factor
develop
uti
use
cmv
antigenaemia
assay
liver
transplant
recurr
rate
higher
p
symptomat
infect
underli
liver
diseas
recipi
infecti
complic
cmv
reject
rate
surviv
rate
differ
symptomat
asymptomat
cmv
infect
p
conclus
half
recipi
experienc
cmv
reactiv
mostli
within
day
posttransplant
thirti
percent
reactiv
symptomat
peak
valu
durat
cmv
antigenaemia
significantli
higher
symptomat
infect
asymptomat
infect
toxoplasma
gondii
infect
bone
marrow
transplant
recipi
polymeras
chain
reactionblood
sampl
combin
diagnosi
earli
detect
sensini
r
castronari
c
ferranti
aloisi
f
aversa
f
bistoni
perugia
object
toxoplasmosi
rare
frequent
fatal
complic
bone
marrow
transplant
recipi
present
local
brain
lesion
dissemin
infect
usual
diagnosi
base
histolog
confirm
observ
typic
lesion
radiolog
imag
resolv
appropri
therapi
aim
studi
stress
pivot
role
polymeras
chain
reaction
pcr
diagnosi
earli
detect
toxoplasma
infect
clinic
microbiolog
infect
volum
supplement
method
januari
juli
two
hundr
thirteen
patient
underw
allogen
peripher
blood
stem
cell
transplant
pbsct
presenc
symptom
suggest
cerebr
pulmonari
dissemin
toxoplasma
infect
biolog
sampl
blood
serum
csf
pleural
fluid
bal
collect
examin
nest
pcr
result
fourteen
case
toxoplasmosi
identifi
incid
ten
patient
manifest
cerebr
toxoplasmosi
two
pulmonari
infect
two
dissemin
overal
mortal
group
necessarili
due
toxoplasmosi
pretranspl
recipi
serostatu
known
patient
seroposit
note
seroneg
wherea
unknown
mri
studi
perform
patient
typic
lesion
observ
patient
sensit
pulmonari
toxoplasmosi
occur
earli
day
cerebr
toxoplasmosi
day
day
mean
pbsct
one
case
dissemin
infect
cn
local
day
pulmonari
day
wherea
second
case
first
pulmonari
involv
day
immedi
follow
cn
blood
sampl
demonstr
higher
sensit
csf
identif
etiolog
agent
patient
toxoplasmosi
treat
pyrimethamin
sulfadiazin
studi
confirm
pivot
role
pcr
earli
diagnosi
toxoplasmosi
pbsct
experi
posit
pcr
signal
blood
earli
sign
toxoplasma
infect
therefor
blood
appear
suitabl
reliabl
biolog
sampl
diagnosi
moreov
sampl
pcrneg
start
therapi
therefor
pcr
use
monitor
effect
treatment
final
studi
indic
toxoplasmosi
potenti
patholog
even
pretranspl
seroneg
subject
suggest
primari
infect
cryptosporidium
associ
cholang
livertranspl
patient
c
denking
p
harigop
p
ruiz
tzaki
l
dowdi
rzburg
miami
usa
cryptosporidium
parvum
parasit
group
coccidia
c
parvum
caus
selflimit
diarrhoeal
ill
immunocompet
host
sever
long
stand
diarrhoea
immunocompromis
patient
scleros
cholang
sc
caus
c
parvum
frequent
found
hivinfect
patient
transplant
recipi
two
case
report
exist
describ
sc
due
c
parvum
one
adult
renal
transplant
patient
other
three
children
underw
liver
transplant
report
herein
first
case
c
parvum
associ
cholang
adult
liver
transplant
patient
male
patient
underw
liver
transplant
three
year
prior
present
initi
transplant
fail
due
acut
reject
requir
retranspl
within
one
year
second
transplant
complic
sepsi
tacrolimu
induc
hemolyt
urem
syndrom
leav
patient
hemodialysi
depend
present
pruritu
hypotens
sever
dehydr
threeweek
histori
sever
diarrhoea
endoscop
biopsi
reveal
numer
organ
stomach
chang
colon
consist
cryptosporidiosi
stool
cultur
neg
addit
gamma
gluytamyl
transferas
alkalin
phosphatas
elev
bilirubin
ast
normal
patient
diagnos
coliti
due
cryptosporidium
treat
azithromycin
immunosuppress
tacrolimu
continu
patient
continu
diarrhoea
lowgrad
fever
fatigu
two
week
later
cholangiogram
liver
biopsi
perform
liver
biopsi
reveal
c
parvum
line
ductal
epithelium
sc
diagnos
cholangiogram
show
scleros
chang
biliari
tree
suggest
earli
phase
diseas
paromomycin
ad
regimen
patient
improv
discharg
home
believ
first
case
sc
associ
c
parvum
adult
liver
transplant
recipi
object
human
herpesviru
infect
usual
occur
first
year
life
preval
higher
adult
popul
neg
serostatu
solid
organ
transplant
recipi
risk
factor
fungal
infect
incid
sever
infect
seroneg
patient
evalu
object
evalu
prospect
seroneg
solid
organ
transplant
patient
infect
mean
quantit
pcr
method
februari
august
prospectli
evalu
solid
organ
transplant
patient
patient
must
minimum
followup
month
patient
underw
basal
determin
igg
seroneg
patient
includ
followup
blood
sampl
obtain
day
posttranspl
viral
dna
analysi
follow
dna
amplif
determin
hibrid
microplaqu
affigen
result
studi
period
patient
evalu
kidney
liver
heart
kidney
pancrea
liver
kidney
pancrea
heart
kidney
nine
patient
seroneg
kidney
liver
heart
analys
plasma
sampl
patient
one
neg
pcr
patient
primari
infect
maximum
dna
copiesml
clinic
patient
suffer
slight
abdomin
pain
discret
cholestasi
blood
analys
fever
seriou
complic
detect
receiv
preemptiv
treatment
ganciclovir
fungal
infect
detect
conclus
primari
infect
seroneg
solid
organ
transplant
patient
frequent
patient
appear
slight
symptom
howev
larger
studi
seroneg
patient
need
develop
valid
new
realtim
pcr
assay
detect
differenti
becker
ziegelmai
wach
laue
grew
hamburg
object
human
herpesviru
identifi
etiolog
agent
roseola
infantum
infant
adult
caus
complic
immunocompromis
patient
aid
patient
transplant
recipi
two
viru
variant
distinguish
sever
studi
shown
variant
specif
clinic
outcom
object
work
develop
reliabl
sensit
specif
detect
assay
base
realtim
pcr
technolog
enabl
discrimin
b
assay
ought
run
temperatur
profil
realart
lc
pcr
assay
ebv
cmv
vzv
artu
gmbh
method
sequenc
align
region
genom
defin
allow
specif
amplif
realtim
pcr
discrimin
b
melt
curv
analysi
assay
specif
test
analys
ab
refer
materi
abi
cell
cultur
supernat
clinic
isol
cross
reactiv
exclud
test
dna
relat
virus
bacteria
analyt
sensit
determin
probit
analysi
heterolog
pcr
system
incorpor
serv
intern
control
set
quantit
standard
establish
exact
quantit
viral
load
result
realart
ab
lc
pcr
assay
artu
gmbh
develop
readytous
assay
detect
distinct
differenti
b
quantit
viral
load
within
broad
linear
rang
possibl
variant
simultan
amplif
parallel
detect
intern
control
specif
sampl
one
reaction
tube
exclud
fals
neg
result
realart
ab
lc
pcr
assay
temperatur
profil
realart
lc
pcr
assay
ebv
cmv
vzv
conclus
realart
ab
lc
pcr
assay
allow
sensit
specif
detect
well
subtyp
lead
reliabl
diagnosi
also
better
understand
role
variant
pathogenesi
due
temperatur
profil
realart
ab
pcr
assay
complet
realart
lc
pcr
assay
detect
differ
herp
virus
parallel
detect
ebv
cmv
vzv
ab
possibl
singl
realtim
pcr
run
thu
clinician
receiv
reliabl
diagnost
tool
rapid
detect
herp
virus
especi
transplant
recipi
quantit
cmv
pcr
allogen
stemcel
transplant
patient
l
oso
c
blazquez
r
rodriguez
j
e
loma
p
sanchez
r
madrid
e
object
assess
clinic
valu
commerci
quantit
plasma
cmvpcr
assay
coba
amplicor
cmv
monitor
test
roch
molecular
system
allogen
sct
patient
compar
result
obtain
pcr
obtain
antigenaemia
evalu
impact
automatis
dna
extract
method
lower
cutoff
pcr
sensibl
method
patient
monitor
day
postsct
weekli
antigenaemia
pcr
total
blood
sampl
patient
mieloabl
nonmieloabl
hla
ident
sibl
unrel
donor
test
prospect
twentyseven
cmv
seroposit
patient
neg
seroposit
donor
receiv
high
dose
acyclovir
prophylaxi
pcr
consid
posit
equal
dna
copiesml
detect
antigenemia
consid
posit
one
posit
cell
detect
pmn
posit
sampl
antigenaemia
andor
pcr
n
sampl
test
retrospect
automatis
extract
method
magnapur
result
cmv
seroneg
patient
seroneg
donor
n
antigenaemia
pcr
neg
seroposit
patient
n
posit
antigenaemia
andor
pcr
total
cmv
infect
episod
none
develop
cmv
diseas
pcr
detect
cmv
episod
overal
posit
antigenemia
belong
patient
pcr
pcr
neg
pcr
inhibit
patient
posit
pcr
neg
antigenaemia
automatis
magnapur
extract
increas
sensibl
pcr
method
pcr
detect
episod
contrast
manual
extract
sampl
less
dna
copiesml
manual
calcul
number
copi
retrospect
done
use
new
cutoff
copiesml
lower
cutoff
pcr
detect
cmv
episod
none
neg
patient
antigenaemia
pcr
gave
posit
result
automatis
extract
method
lower
cutoff
pcr
conclus
quantit
cmv
pcr
assay
show
lower
sensibl
detect
cmv
infect
allogen
sct
compar
antigenaemia
two
technic
modif
increas
sensibl
without
decreas
specif
automatis
magnapur
extract
lower
cutoff
trichosporon
beigelii
lifethreaten
pathogen
bone
marrow
transplant
recipi
first
case
report
iran
patient
undergo
bone
marrow
transplant
bmt
profoundli
immunosuppress
result
intens
chemotherapi
high
risk
opportunist
fungal
infect
mainli
caus
candida
spp
aspergillu
spp
trichosporon
beigelii
beigelii
emerg
lifethreaten
opportunist
pathogen
immunocompromis
host
respons
antifung
agent
poor
mortal
high
immunolog
recoveri
import
factor
favor
outcom
patient
trichosporonosi
present
first
case
beigelii
infect
patient
undergo
allogen
bmt
iran
femal
present
aplast
anemia
cough
fever
receiv
cytotox
drug
therapi
broad
spectrum
antibiot
neutropen
beigelii
repeatedli
demonstr
appropri
morpholog
physiolog
characterist
sputum
nose
mouth
ulcer
direct
microscopi
cultur
also
isol
histopatholog
recogn
postmortem
lung
liver
trichosporonosi
like
recogn
frequent
appar
avail
report
object
trichinellosi
wellknown
problem
greenland
west
greenland
number
larg
outbreak
took
place
sinc
sporad
case
regist
unknown
whether
decreas
trichinellosi
case
reflect
gener
transit
greenland
toward
western
lifestyl
less
consumpt
meat
wildlif
whether
reflect
insuffici
case
registr
object
present
studi
determin
preval
human
trichinellosi
present
time
nuuk
capit
greenland
ammassalik
district
east
coast
greenland
tradit
food
still
eaten
evalu
chang
lifestyl
effect
preval
method
blood
sampl
person
collect
person
collect
nuuk
ammassalik
district
test
trichinellaspecif
igg
antibodi
use
elisa
western
blot
analys
background
inform
obtain
questionnair
studi
result
trichinellosi
preval
nuuk
ammassalik
district
preval
nuuk
ammassalik
district
person
live
settlement
ammassalik
district
higher
trichinellaspecif
antibodi
preval
person
live
town
tasiilaq
follow
risk
factor
signific
univari
analysi
ethnic
age
place
live
dietari
habit
intak
seal
meat
hunt
multivari
model
construct
consist
variabl
ethnic
age
place
live
diet
group
intak
seal
meat
hunt
variabl
remov
stepwis
follow
order
seal
meat
p
hunt
p
age
p
ethnic
p
final
multivari
model
consist
diet
group
place
live
signific
thu
live
greenland
diet
live
settlement
ammassalik
district
impli
higher
rel
risk
trichinella
seroposit
live
diet
domin
import
food
item
live
nuuk
conclus
lifestyl
settlement
tradit
compar
tasiilaq
nuuk
result
indic
declin
human
trichinellosi
case
centuri
like
reflect
transit
tradit
greenland
lifestyl
western
dietari
habit
studi
preval
toxocara
cati
vagrant
cat
sari
township
iran
sharif
p
ziapoor
h
ziaee
kholami
sari
ir
object
toxocara
cati
one
import
preval
parasit
cat
common
human
anim
ingest
larva
parasit
lack
matur
human
bodi
infect
person
develop
viscer
larva
migran
known
toxocariasi
consid
signific
transmiss
parasit
human
due
increas
vagrant
cat
sari
township
studi
perform
order
determin
sever
preval
toxocara
cati
cat
sari
township
method
cross
section
descript
studi
done
vagrant
cat
male
femal
april
octob
sampl
done
randomli
differ
region
net
specif
vagant
cat
record
hunt
deepli
anaesthet
chloroform
annihil
intestin
content
examin
presenc
parasit
count
number
done
final
fixat
stain
recommend
kit
refer
book
genu
speci
identif
result
cat
infect
toxocara
cati
male
femal
rang
infect
mean
sever
infect
cat
rate
infect
west
region
site
femal
male
also
immatur
matur
cat
conclus
consid
mere
high
preval
zoonot
parasit
hygien
signific
caus
toxocariasi
human
particularli
children
contact
soil
also
lack
control
vagrant
cat
popul
potenti
risk
factor
recommend
control
person
dietari
hygien
avoid
store
garbag
unprotect
wire
box
street
order
prevent
gather
vagrant
street
cat
imag
patient
pulmonari
hydatid
diseas
review
unusu
imag
appear
zahirifard
bakhshayeshkaram
tahbaz
k
kaynama
tehran
ir
object
evalu
chest
radiographi
ct
scan
characterist
pulmonari
hydatid
diseas
materi
method
patient
surgic
proven
pulmonari
hydatid
cyst
enrol
studi
review
clinic
find
imag
patient
radiolog
featur
local
diamet
architectur
densiti
radiolog
sign
appear
determin
result
cxr
cyst
determin
avail
ct
scan
total
cyst
detect
discret
cyst
detect
cxr
avail
ct
total
cyst
detect
ct
scan
cyst
detect
cyst
ruptur
patient
ruptur
cyst
hemoptysi
singl
cyst
patient
multipl
cyst
median
ct
densiti
respect
seen
ct
cxr
waterlili
sign
patient
airfluid
level
patient
cresent
sign
patient
invers
cresent
sign
calcif
observ
cxr
one
record
ct
scan
ct
scan
cyst
smooth
unilocul
cyst
infect
conclus
ct
scan
done
elucid
cystic
natur
lung
mass
accur
local
preoper
period
endem
region
like
iran
atyp
imag
present
complic
pulmonari
hydatid
diseas
solid
mass
consid
differenti
diagnosi
pulmonari
lesion
abstract
truncat
word
seropreval
coxiellosi
farmer
cattl
northeastern
turkey
seyitoglu
z
ozkurt
u
dinler
b
okumu
erzurum
tr
object
coxiellosi
worldwid
zoonosi
caus
coxiella
burnetii
aim
studi
determin
abstract
preval
coxiellosi
cattl
farmer
north
eastern
turkey
method
total
cattl
human
sera
collect
test
antibodi
cburnetii
commerci
elisa
test
result
antibodi
c
burnetii
detect
cattl
healthi
farmer
seroposit
found
cattl
abort
histori
cattl
without
abort
histori
p
correl
anim
human
seropreval
district
thirteen
farmer
antibodi
posit
seroposit
anim
seroposit
anim
villag
remain
case
observ
seropreval
coxiellosi
higher
north
district
anim
human
drier
warmer
climat
district
anim
human
human
anim
p
conclus
studi
show
coxiellosi
import
health
problem
human
anim
region
unusu
case
graminea
sublingu
salivari
gland
l
doganc
calgurel
gungen
g
kiran
ankara
tr
foreign
bodi
organ
natur
parasit
element
rare
oral
caviti
salivari
gland
human
structur
function
featur
report
interest
case
sublingu
salivari
gland
involv
graminea
brachiaria
spp
thought
parasit
life
cycl
gland
case
yo
femal
teacher
recent
histori
travel
mountain
drunk
exposur
unsaf
spring
water
strong
sting
pain
right
drunk
water
mouth
radiat
neck
develop
fever
pain
lymph
node
swell
difficulti
eat
weight
lost
remark
eosinophilia
also
note
self
move
small
taillik
object
orific
sublingu
salivari
gland
remov
object
reveal
interest
unusu
live
object
definit
diagnosi
graminea
brachiaria
spp
parasitolog
patholog
consult
comment
best
knowledg
unusu
case
first
present
patient
relat
travel
region
differenti
diagnosi
sever
entiti
includ
squid
sperm
bag
sting
marin
anim
larva
nematod
trematod
life
stage
evalu
echinococcu
granulosu
preval
use
elisa
abdomin
ultrasonographi
group
student
stay
state
hostel
turkey
object
cystic
echinococcosi
caus
larval
form
echinococcu
granulosu
one
import
wide
distribut
parasit
zoonot
diseas
world
echinococcosi
major
problem
region
turkey
particularli
preval
rural
area
domest
livestock
rais
common
report
epidemiolog
find
usual
base
retrospect
evalu
pf
surgic
find
hospit
chart
well
plan
epidemiolog
studi
limit
studi
aim
analys
seropreval
cystic
echinococosi
preval
lesion
abdomin
ultrasonographi
group
young
adult
univers
student
stay
state
hostel
bornovaizmirturkey
method
studi
group
consist
student
woman
men
age
min
max
inform
written
consent
receiv
student
request
fill
questionnair
form
blood
sampl
perform
iv
punctur
sera
obtain
centrifug
anti
echinococcu
granulosu
antibodi
detect
use
elisa
tecniqu
particip
gven
appoint
abdomin
ultrasonographi
result
student
seroposit
anti
echinococcu
granulosu
ig
g
tabl
total
student
seroneg
perform
abdomin
ultrasonographi
mhz
transduc
sonolin
elegrasiemen
two
student
liver
kidney
seroposit
cystic
lesion
refer
surgeri
well
design
epidemiolog
studi
cystic
echinococcosi
lack
turkey
previou
studi
show
seroposit
rate
echinococcu
granulosu
find
suggest
cystic
echinococcosi
preval
turkey
epidemiolog
studi
combin
elisa
abdomin
ultrasonograpi
warrant
object
anthrax
epidem
zoonosi
eastern
part
turkey
studi
aim
investig
epizootiolog
epidemiolog
anthrax
region
method
anim
human
anthrax
case
period
includ
studi
data
obtain
formal
record
health
director
institut
veterinari
control
investig
diagnosi
anthrax
base
clinic
find
andor
microbiolog
procedur
includ
gram
strain
cultur
materi
obtain
lesion
result
period
anim
case
human
case
anthrax
detect
anim
case
sheep
other
cattl
case
occur
juli
septemb
anim
human
anthrax
seen
frequent
erzurum
import
centr
anim
commenc
first
year
period
compar
last
year
period
number
anim
case
vs
human
case
vs
analysi
yearli
case
distribut
show
incid
anthrax
region
chang
conclus
anthrax
import
health
problem
anim
human
region
prevent
measur
taken
decreas
incid
anthrax
object
anthrax
endem
kazakhstan
occur
among
human
incid
rate
per
popul
per
year
late
sever
epidem
occur
associ
home
slaughter
infect
anim
gener
increas
incid
seen
among
anim
human
histor
kazakhstan
account
anthrax
case
report
soviet
union
plain
central
asia
may
serv
histor
sourc
b
anthraci
rest
world
kazakhstan
geograph
distribut
anthrax
among
anim
human
focal
gener
associ
area
consid
determin
focal
distribut
poorli
understood
addit
strain
b
anthraci
isol
outbreak
within
foci
compar
molecular
pathogen
basi
method
work
initi
studi
geograph
distribut
potenti
environment
prefer
b
anthraci
use
geograph
inform
system
gi
technolog
result
gi
use
map
set
b
anthraci
strain
sever
outbreak
evalu
geograph
pattern
gi
also
use
deriv
histor
databas
spatial
explicit
human
livestock
outbreak
spatial
analys
nationwid
distribut
b
anthraci
databas
contain
inform
locat
anthrax
incid
year
month
occurr
whether
incid
involv
livestock
human
outcom
diseas
biolog
inform
strain
conclus
although
preliminari
stage
applic
arcgi
softwar
use
map
loci
anthrax
occurr
futur
map
use
identifi
factor
influenc
occurr
spread
pathogen
prevent
infect
livestock
human
research
describ
abstract
made
possibl
part
support
provid
us
defens
threat
reduct
agenc
dtra
project
administ
us
civilian
research
develop
foundat
crdf
object
anthrax
situat
countri
unfavor
anthrax
kazakhstan
occup
diseas
anim
husbandri
practic
rais
livestock
privat
use
increas
report
show
time
incid
anthrax
person
involv
practic
increas
significantli
method
order
character
epidem
process
use
method
descript
epidemiolog
use
epidemiolog
variabl
becam
ill
trend
diseas
time
sourc
transmiss
factor
b
anthraci
age
gender
occup
person
becom
ill
anthrax
result
anthrax
occur
rural
area
among
privat
owner
livestock
famili
person
hire
assist
slaughter
last
decad
case
anthrax
ill
human
caus
slaughter
domest
livestock
case
unemploy
rural
resid
shepherd
work
cooper
bluecollar
worker
whitecollar
worker
student
singl
sourc
path
factor
transmiss
b
anthraci
typic
type
diseas
recent
year
major
case
involv
infect
sever
person
slaughter
singl
diseas
anim
sourc
infect
cattl
case
sheep
goat
case
hors
case
soil
case
factor
transmiss
b
anthraci
human
contact
meat
livestock
slaughter
butcher
case
vectorborn
transmiss
case
soil
case
larg
number
human
case
occur
juli
septemb
conclus
kazakhstan
today
preval
subtyp
anthrax
diseas
human
involv
nonprofession
activ
home
requir
chang
tactic
prevent
diseas
research
describ
abstract
object
sever
acut
respiratori
syndrom
sar
emerg
infect
caus
novel
coronaviru
known
sarscov
earli
phase
diseas
presenc
replic
intermedi
sarscov
shown
pbmc
patient
inform
avail
abil
sarscov
stimul
ifn
induct
although
ifngamma
may
activ
sar
patient
investig
capabl
sarscov
give
rise
product
infect
normal
pbmc
parallel
abil
activ
ifnalpha
andgamma
gene
express
method
normal
pbmc
infect
moi
viru
progeni
format
measur
subsequ
time
point
backtitr
cell
lysat
vero
cell
cell
mortal
apoptosi
detect
trypan
blue
propidium
iodid
stain
order
detect
virusspecif
plusand
minusrna
strand
total
rna
extract
sarscovinfect
pbmc
retrotranscrib
presenc
sens
antisens
primer
respect
target
replicas
gene
measur
sarscov
genom
rna
perform
quantit
real
time
rtpcr
ifn
induct
perform
expos
pbmc
sarscov
differ
moi
rang
induct
ifnalpha
gamma
analys
measur
mrna
level
limit
dilut
rtpcr
sensit
sarscov
replic
exogen
ifnalpha
gamma
test
vero
cell
preexpos
individu
cytokin
combin
result
unstimul
pbmc
infecti
viral
progeni
format
detect
day
postinfect
nevertheless
minusstrand
genom
sarscov
rna
peak
hour
postinfect
dose
depend
induct
ifnalpha
ifngamma
mrna
observ
evid
moi
combin
two
cytokin
shown
strongli
inhibit
sarscov
replic
vero
cell
result
show
sarscov
abl
infect
normal
pbmc
howev
appear
transient
phenomenon
follow
progress
disappear
virusspecif
rna
strand
infecti
viru
progeni
product
moreov
sarscov
appear
intrins
abil
activ
dosedepend
ifnalpha
andgamma
gene
express
pbmc
cultur
result
pathogen
relev
inflammatori
event
occur
diseas
tissu
mediat
endogen
activ
inf
system
object
trichoderma
speci
potenti
candid
biocontrol
plant
pathogen
fungi
cellulas
produc
biotechnolog
import
hand
emerg
opportunist
pathogen
immunocompromis
dializ
patient
studi
design
examin
abil
clinic
trichoderma
isol
produc
extracellular
proteas
screen
toxic
mammalian
cell
method
supernat
induc
liquid
cultur
examin
strain
screen
proteolyt
enzym
activ
differ
chromogen
pnitroanilin
substrat
trypsinand
chymotrypsinlik
activ
separ
sephadex
column
chromatographi
phdepend
studi
sperm
toxic
bioassay
perform
expos
boar
sperm
suspens
trichodermamethanol
extract
motil
spermatozoa
estim
phasecontrast
microscopi
mitochondri
membran
damag
spermatozoa
studi
epifluresc
microscopi
use
iodid
stain
result
product
trypsinlik
chymotrypsinlik
chymoelastaselik
proteas
activ
common
among
examin
strain
separ
trypsinand
chymotrypsinlik
activ
column
chromatographi
reveal
system
complex
consist
sever
isoenzym
rel
high
activ
level
detect
ph
suggest
differ
isoenzym
differ
ph
characterist
spermatozoa
motil
nonexpos
control
sampl
sampl
expos
microlit
methanol
spermatozoa
immotil
sampl
expos
longibrachiatum
uamh
atcc
harzianum
cb
concentr
mg
biomass
indic
strain
produc
heatstabl
substanc
toxic
sperm
cell
four
strain
found
inhibit
motil
boar
spermatozoa
even
low
concentr
reduct
motil
case
microgramm
ml
extend
boar
sperm
induc
dissip
mitochondri
membran
potenti
studi
strain
toxic
effect
conclus
product
extracellular
proteolyt
enzym
toxic
metabolit
among
potenti
virul
factor
trichoderma
strain
emerg
fungal
pathogen
work
support
grant
hungarian
scientif
research
fund
academi
finland
occurr
scabi
patient
staff
healthcar
facil
object
scabi
itch
dermatosi
continu
frequent
health
problem
longterm
followup
epidemiolog
situat
confirm
thirtyyear
cycl
satisfactori
explan
method
standard
methodolog
diagnost
base
subject
sensat
patient
b
object
dermatolog
find
c
posit
epidemiolog
histori
laboratori
demonstr
caus
agent
e
remiss
symptom
upon
specif
therapi
case
scabi
diagnos
report
dermatologist
nationwid
includ
public
health
servic
central
system
epidat
niph
pragu
result
last
two
document
epidem
wave
scabi
affect
czech
republ
peak
specif
morbid
highest
among
person
year
age
close
connect
sexual
activityth
sourc
infest
adult
sexual
partner
confirm
almost
ident
trend
report
scabi
morbid
fresh
case
syphili
year
morbid
trend
fall
sharpli
year
howev
morbid
person
year
age
gradual
rise
recent
year
group
epidem
repeatedli
report
facil
depart
geriopsychiatri
institut
longterm
chronic
patient
old
folk
home
social
care
institut
chariti
facil
occur
bedridden
subject
hospit
longterm
basi
mental
retard
superannu
scabi
nosocomi
charact
affect
staff
healthcar
institut
often
sourc
transmiss
other
name
immobil
patient
well
especi
vulner
individu
higher
risk
infect
analysi
report
case
reveal
share
healthcar
worker
infect
greater
risk
senior
nurs
junior
nurs
auxiliari
paramed
staff
last
physician
scabi
occup
diseas
occur
almost
exclus
healthcar
sector
conclus
scabi
pose
increas
risk
younger
popul
activ
scabi
elderli
popul
passiv
scabi
pose
great
occup
risk
paramed
healthcar
staff
carri
nurs
manag
servic
necessari
consist
observ
prevent
repress
epidemiolog
measur
popul
fire
ant
new
public
health
problem
iran
k
akbarzadeh
nateghpour
tirgari
tehran
ir
ant
probabl
success
insect
present
almost
countri
place
bite
sting
squirt
formic
acid
formica
rufibarbi
other
secondari
host
dicrocoelium
dentriticum
iran
newest
public
health
problem
depend
ant
countri
bite
sting
fire
ant
pachycondyla
sennaarensi
formicida
hymenoptera
south
southeastern
iran
ecolog
biolog
morpholog
p
sennaarensi
consid
iranshahr
counti
southeast
iran
much
infect
ant
accord
survey
question
individu
bitten
least
ant
usual
effect
sting
mild
ant
capabl
multipl
sting
induc
annoy
peopl
especi
children
object
tick
play
import
role
diseas
transmiss
human
differ
tickborn
diseasea
includ
borreliasi
cchf
report
iran
method
attempt
made
determin
fauna
geograph
distribut
soft
hard
tick
area
octob
april
villag
select
randomli
tick
collect
carri
use
standard
method
tick
collect
indoor
rest
hide
place
villag
well
insid
stabl
rodent
borrow
sheep
lamp
goat
cattel
monthli
season
result
tick
collect
identifi
use
nation
systemat
key
copmosit
frequenc
follow
ornithodoro
lahorensi
arga
persicu
rhipicephalu
bursa
rhipicephalu
sanguin
haemaphysiali
concinna
haemaphysiali
sulcata
haemaphysiali
punctata
hyaloma
schulzei
hyaloma
marginatum
hyaloma
dentriticum
hyaloma
asiaticum
conclus
distribut
ferquenc
tlck
differ
variou
season
locat
evalu
use
saliva
sooth
bloodsuck
arthropod
bite
dedicoat
et
al
j
infect
di
condit
transmiss
met
child
skin
respond
bite
bloodsuck
arthropod
ii
mother
caregiv
attempt
reliev
child
itch
reduc
scratch
appli
infect
saliva
bite
site
use
saliva
tradit
behaviour
practic
subsaharan
africa
heal
herbal
leav
crush
mix
saliva
medic
practic
premast
food
wojcicki
jm
br
j
cancer
human
behaviour
associ
transfer
saliva
parent
infant
use
herbal
leav
treat
saliva
relat
arthropod
bite
could
risk
factor
infect
perhap
infect
hepat
b
viru
method
evalu
extent
saliva
use
heal
insect
bite
children
skin
draw
questionnair
direct
student
elementari
intermedi
school
two
group
test
one
itali
school
near
rome
latium
school
veneto
one
subsaharan
african
countri
known
high
transmiss
level
uganda
kampala
entebb
lake
victoria
result
frequenc
use
saliva
significantli
differ
latium
veneto
averag
frequenc
compar
frequenc
uganda
p
frequenc
two
group
relat
also
differ
cultur
econom
develop
improv
hygien
conclus
suggest
bloodsuck
promot
arthropod
play
role
spread
infect
particularli
africa
therefor
behaviour
chang
limit
use
saliva
skin
prepar
herbal
leav
could
attempt
control
spread
infect
aim
studi
find
csf
baselin
marker
inflamm
redox
statu
estim
develop
tendenc
clinic
cours
patholog
process
tbe
patient
method
patient
mening
meningoencephalit
form
tbe
treat
infectolog
center
latvia
includ
studi
diagnosi
tbe
confirm
elisa
enzygnost
antitb
igm
blood
andor
csf
tradit
clinic
criteria
use
character
tbe
sever
degre
nontradit
lab
method
use
creactiv
protein
crp
immunoturbidimetr
reduc
glutathion
gsh
concentr
colorimetr
detect
csf
result
concentr
crp
csf
significantli
higher
tbe
patient
acut
phase
mgl
n
reconvalesc
mgl
n
p
crp
gsh
tbe
case
csf
detect
valu
second
part
tbe
patient
demonstr
tendenc
increas
gsh
acut
stage
diseas
mg
n
compar
reconvalesc
mg
n
p
statist
signific
differ
crp
gsh
concentr
csf
found
case
moder
mening
form
tbe
compar
sever
meningoencephalit
form
tbe
conclus
analysi
data
obtain
patient
tbe
give
evid
substanti
crp
gsh
chang
csf
depend
diseas
stage
sever
degre
object
biochem
data
csf
investig
give
proof
separ
moder
sever
tbe
case
clinic
interpret
alway
equal
sever
origin
crp
gsh
csf
unknown
product
cn
andor
blood
due
bloodbrain
barrier
permeabl
increas
background
cholera
sever
diseas
caus
vibrio
cholera
natur
reservoir
aquat
pathogen
bacterium
refer
group
show
egg
mass
nonbit
midg
chironomida
spp
diptera
harbour
v
cholera
provid
nutrient
sourc
multipl
therebi
offer
new
natur
reservoir
cholera
bacterium
object
presenc
viabl
v
cholera
fli
adult
chironomid
suggest
v
cholera
carri
air
water
bodi
adult
fli
insect
henc
new
rout
infest
water
sourc
bacteria
suggest
method
field
studi
chironomid
egg
mass
adult
simultan
collect
environ
addit
fresh
drink
qualiti
water
left
expos
net
vicin
adult
chironomid
hatch
foci
expos
water
monitor
chironomid
egg
mass
v
cholera
presenc
laboratori
experi
repeat
v
cholera
tag
green
fluoresc
protein
result
date
v
cholera
serogroup
isol
chironomid
egg
mass
adult
field
experi
clearcut
connect
net
v
cholera
absenc
note
impli
relationship
exist
entranc
larg
invertebr
water
bodi
presenc
v
cholera
water
laboratori
experi
gfp
tag
bacteria
found
outer
surfac
adult
chironomid
locat
prone
microbi
attach
conclus
evid
shown
suggest
aerial
transport
v
cholera
chironomid
fli
adult
feasibl
lead
v
cholera
contamin
unprotect
water
bodi
object
cholera
sever
potenti
lifethreaten
diarrheal
diseas
caus
certain
spice
gramneg
bacterium
vibrio
cholera
mani
million
case
cholera
occur
annual
epidem
pandem
form
due
v
cholera
also
sporad
due
v
cholera
strain
context
surviv
v
cholera
natur
interest
epidemiolog
perspect
although
natur
reservoir
surviv
multipl
v
cholera
far
compeletli
disclos
previou
studi
shown
freeliv
amoeba
reservoir
seventhpandem
v
cholera
el
torinaba
strain
surviv
grow
intracellularli
acanthamoeba
castellaniith
aim
studi
examin
abil
differ
strain
v
cholera
el
tor
grow
surviv
acanthamoeba
castellanii
examin
whether
intraamoeb
surviv
bacteria
alter
pattern
resist
sensit
differ
antibiot
method
v
cholera
el
tor
strain
cocultur
castellanii
two
week
interact
microorgan
follow
viabl
count
aloneand
cocultiv
microorgan
intraamoeb
growth
local
bacteri
strain
estim
gentamicin
assay
viabl
count
microscopi
pcr
detect
cholera
toxin
gene
amoeb
rna
gene
disclos
symbionthost
associ
result
result
show
examin
v
cholera
el
tor
strain
multipli
surviv
insid
trophozoit
cyst
castellanii
bacteri
intern
cytoplasm
compart
amoeba
cell
relat
microorgan
cocultur
could
classifi
symbiosi
sinc
presenc
amoeba
enhanc
growth
bacteri
strain
presenc
bacteria
affect
amoeb
growth
intraamoeb
surviv
bacteria
alter
pattern
resist
sensit
differ
antibiot
ampicillin
gentamicin
tetracyclin
conclus
studi
show
facult
intracellular
behaviour
examin
v
cholera
el
tor
strain
contrast
gener
held
view
consid
bacterium
extracellular
microorgan
clinic
import
freeliv
amoeba
possibl
role
genet
variat
antigen
protein
studi
strain
recov
palermo
sequenc
analysi
show
strain
recov
though
crossreact
mab
belong
fact
genotyp
ident
strain
recov
palermo
sequenc
comparison
strain
group
three
sublineag
ia
ic
contain
respect
viral
strain
collect
amino
acid
sequenc
well
conserv
within
sublineag
peculiar
singl
amino
acid
insert
observ
variabl
region
sublineag
ic
strain
italian
strain
exhibit
p
genotyp
sequenc
cluster
previous
defin
lineag
follow
tempor
distribut
strain
collect
fell
within
lineag
p
recov
cluster
lineag
p
varieti
deduc
amino
acid
sequenc
enabl
us
describ
respect
two
six
differ
pattern
substitut
regard
lineag
p
p
refer
strain
comparison
gene
sequenc
italian
european
strain
indic
differ
popul
circul
europ
year
latest
italian
strain
close
relat
recent
isol
countri
refer
vaccin
strain
result
help
increas
knowledg
rotaviru
epidemiolog
evolut
might
use
futur
rotaviru
vaccin
formul
detect
rotaviru
adenovirus
astroviru
gastroenter
case
among
young
children
first
experi
adenoviru
identif
pcr
micropl
hybridis
assay
adeno
human
serotyp
astrovirus
antigen
seven
human
serotyp
perform
enzym
immunoassay
method
dako
ideia
rotaviru
adenoviru
astroviru
test
respect
specimen
posit
adenovirus
confirm
identifi
pcrmicropl
hybrid
assay
pcr
adenoviru
consensu
argen
biosoft
use
adenoviru
genusspecif
primer
one
gener
six
speciesspecif
probe
defin
va
rna
gene
accord
result
rotaviru
detect
case
adenoviru
case
astroviru
case
pcr
adenoviru
consensu
assay
identifi
adenoviru
speci
case
adenoviru
speci
f
enter
adenoviru
serotyp
case
adenoviru
speci
c
case
adenoviru
speci
case
rotaviru
gastroenter
present
season
distribut
spring
adenoviru
astroviru
gastroenter
present
season
conclus
rotaviru
gastroenter
significantli
common
adenoviru
astroviru
infect
young
children
territori
pcr
adenoviru
consensu
techniqu
use
method
identif
adenoviru
stool
specimen
eventhought
enter
adenovirus
speci
f
caus
major
acut
gastroenter
due
adenoviru
nonenter
serotyp
speci
c
occasion
involv
aetiolog
acut
diarrhoea
studi
continu
examin
great
number
specimen
patient
investig
use
specif
result
immigr
inpati
today
pressur
exert
infecti
diseas
ward
r
manfredi
bologna
object
foreign
individu
offici
live
bologna
provinc
predomin
origin
northern
africa
eastern
europ
far
east
tempor
trend
admiss
patient
come
outsid
european
union
examin
accord
broad
seri
variabl
method
electron
databas
hospit
locat
metropolitan
area
northern
itali
inform
relat
foreign
patient
p
hospit
follow
dayhospit
centr
collect
januari
march
record
discharg
diagnosisrel
group
drg
code
focus
attent
regard
infecti
diseas
result
overal
discharg
regard
foreign
p
preval
femal
sex
notic
foreign
p
mean
age
rang
year
rate
foreign
compar
overal
admit
p
vari
year
maximum
year
major
involv
born
obstetricsgynecolog
intern
medicin
specialist
surgeri
specialist
medicin
pediatr
emerg
medicin
consid
infecti
diseaserel
drg
tuberculosi
case
hivaid
chronic
viral
hepat
relat
complic
septicemia
central
nervou
system
infect
acut
viral
hepat
episod
frequent
discharg
code
follow
infecti
diseas
drg
case
durat
admiss
foreign
p
short
day
case
reach
day
p
day
case
mean
hospit
time
infecti
diseas
ward
day
p
even
hospit
end
voluntari
discharg
occur
first
day
admiss
p
discuss
pilot
studi
demostr
need
health
care
express
foreign
p
increasingli
frequent
cover
broad
spectrum
disord
infecti
diseasesassoci
ill
gain
increas
role
time
signific
problem
repres
tendenc
short
durat
hospit
foreign
p
often
end
voluntari
discharg
admiss
carri
special
infecti
diseas
ward
significantli
prolong
although
expect
give
increas
benefit
term
effect
manag
chang
characterist
natur
focus
plagu
microbiolog
properti
plagu
microb
result
consequ
natur
calam
aral
sea
enzoot
plagu
transmiss
feral
herd
feral
nidal
infect
determin
interact
diseas
caus
agent
warmblood
carrier
specif
ecolog
environ
introduct
object
chang
characterist
natur
focus
plagu
microbiolog
properti
plagu
microb
result
consequ
natur
calam
aral
sea
method
convent
microbiolog
research
method
use
studi
microbiolog
properti
strain
plagu
microb
kyzylkum
natur
focus
plagu
isol
rodent
tick
flea
result
strain
kyzylkum
natur
focus
plagu
determin
virul
show
characterist
allow
attribut
continent
varieti
ie
glycerin
digest
ferment
rhamnos
decompos
arabinos
nutrient
need
typic
strain
central
asian
desert
focu
differ
need
amino
acid
leucin
wherea
strain
ustyurt
gissar
focus
depend
strain
kyzylkum
natur
focu
turn
depend
luecin
identifi
stain
kyzylkum
natur
focu
essenti
differ
properti
compar
major
isol
cultur
particular
synthes
fraction
plagu
agent
growth
factor
differ
natur
ie
lower
depend
phenylalanin
plagu
bacteria
strain
circul
rodent
popul
kyzylkum
natur
focu
character
low
virul
white
mice
guineapig
although
determin
virul
studi
resist
antibiot
identifi
strain
nonsuscept
streptomycin
conclus
thu
studi
properti
caus
agent
plagu
great
import
solv
problem
natur
focus
understand
pattern
fluctuat
epizoot
situat
certain
territori
understand
integr
part
determin
epidem
potenti
natur
focus
use
organ
epidemiolog
surveil
infect
object
tolllik
receptor
tlr
play
key
role
recognit
product
virtual
class
pathogen
organ
amyloid
peptid
also
stimul
innat
immun
system
reason
hypothet
bacteri
compound
amyloid
peptid
may
jointli
stimul
innat
immun
system
method
interact
endogen
exogen
stimul
innat
immun
examin
primari
cultur
mous
microgli
cell
applic
defin
tolllik
receptor
tlr
agonist
lipopolysaccharid
lp
synthet
lipopeptid
tripalmytoylcysteinylseryl
lysyl
singlestrand
unmethyl
cytosineguanosin
cpg
oligodesoxynucleotid
alon
combin
amyloid
beta
peptid
abeta
supernat
stimul
glial
cultur
unstimul
control
analys
nitric
oxid
tumor
necrosi
factoralpha
tnfalpha
product
result
coadministr
lp
led
addit
releas
tnfalpha
contrast
coapplic
cpg
led
substanti
decreas
tnfalpha
releas
compar
stimul
cpg
alon
cpg
compound
investig
induc
releas
antiinflammatori
cytokin
conclus
addit
effect
lp
abeta
may
one
reason
clinic
deterior
frequent
observ
patient
alzheim
diseas
infect
substanti
decreas
tnfalpha
releas
cpg
abeta
applic
compar
stimul
cpg
alon
suggest
microbi
product
enhanc
stimulatori
effect
abeta
innat
immun
caus
diverg
behaviour
activ
versu
stimul
probabl
lie
differ
signal
cascad
marker
suscept
sever
reactiv
arthriti
salmonella
shigella
yersinia
infect
campylobact
e
coli
enter
p
schiellerup
h
locht
ka
krogfelt
copenhagen
dk
object
reactiv
arthriti
rea
wellknown
complic
infect
salmonella
yersinia
shigella
campylobact
presenc
tissueantigen
associ
rea
may
marker
prolong
diseas
cours
design
casecas
comparison
studi
rea
gastrointestin
infect
caus
salmonella
yersinia
campylobact
shigella
e
coli
evalu
impact
attack
rate
sever
rea
bacteria
method
januari
novemb
consecut
patient
includ
danish
registri
gastrointestin
infect
cultur
posit
salmonella
yersinia
campylobact
shigella
e
coli
patient
address
questionnair
studi
rea
includ
reactiv
arthriti
arthralgia
debut
pain
previous
healthi
joint
regist
patient
ask
mark
swollen
tender
joint
draw
vasscal
use
assess
pain
caus
rea
patient
encourag
donat
blood
sampl
serolog
type
pcr
result
total
patient
return
questionnair
respons
rate
subject
monoinfect
includ
malefemal
ratio
blood
sampl
obtain
campylobact
n
salmonella
n
e
coli
n
shigella
n
yersinia
n
overal
preval
correspond
rate
within
danish
popul
odd
ratio
contract
rea
individu
posit
campylobact
ci
salmonella
ci
e
coli
ci
shigella
ci
yersinia
ci
thu
significantli
frequent
among
reapati
salmonella
yersinia
shigella
compar
campylobact
e
coli
vasscor
rea
significantli
higher
group
yersinia
salmonella
signific
posit
correl
vasscor
fraction
patient
conclus
larg
compar
studi
show
signific
impact
suscept
contract
rea
salmonella
shigella
yersinia
campylobact
e
coli
furthermor
sever
rea
measur
va
differ
among
bacteri
speci
strongli
correl
presenc
antigen
object
normal
gut
microbiota
trigger
experiment
coliti
larg
intestin
manifest
human
inflammatori
bowel
diseas
ibd
howev
avail
anim
model
studi
ileiti
limit
thu
littl
known
hitherto
small
intestin
ibd
recent
parasiteinduc
ileiti
mous
mimick
characterist
ileiti
human
ibd
propos
model
crohn
diseas
cd
oral
infect
suscept
mice
toxoplasma
gondii
induc
sever
immunopatholog
restrict
termin
ileum
order
unravel
mechan
underli
ileiti
use
model
monitor
microflora
chang
ileal
inflamm
determin
contribut
gut
microbiota
ileal
diseas
method
mice
infect
peror
cyst
gondii
strain
ciprofloxacin
metronidazol
ciprofloxacin
plu
metronidazol
mg
kg
bodi
weight
po
piperacillin
plu
tazobactam
mgkg
bodi
weightd
ip
appli
day
day
gondiiinfect
ileal
bacteri
flora
analys
day
pi
microbiolog
molecular
method
rdnatarget
denatur
gel
electrophoresi
dgge
sequenc
clone
librari
result
microbiolog
molecular
approach
reveal
ileal
inflamm
lead
increas
total
bacteri
load
drastic
chang
flora
composit
acut
stage
diseas
gramposit
cocci
rod
predomin
ilea
healthi
mice
displac
gramneg
identifi
escherichia
coli
bacteroid
sp
respect
antibacteri
treatment
ciprofloxacin
metronidazol
combin
piperacillin
plu
tazobactam
amelior
diseas
symptom
reduc
ileal
inflamm
also
seen
spfmice
colon
one
gramposit
bacteri
speci
conclus
fact
gramneg
bacteria
accumul
acut
ileiti
contribut
profoundli
intestin
inflamm
well
line
similar
observ
experiment
coliti
human
ibd
provid
evid
gut
flora
modul
valuabl
therapeut
strategi
ibd
treatment
final
contribut
gut
microbiota
ileal
diseas
support
use
parasiteinduc
small
intestin
inflamm
model
ibd
research
object
pathophysiolog
mechan
contribut
brain
injuri
neuroinflammatori
disord
includ
breakdown
bloodbrainbarri
extravas
leukocyt
cerebr
hypoperfus
vascul
matrixmetalloproteinas
mmp
includ
collagenas
crucial
involv
step
studi
aim
assess
extent
invivo
collagenolyt
activ
cerebrospin
fluid
csf
determin
amino
acid
hydroxyprolin
major
exclus
degrad
product
collagen
method
pair
serum
csf
sampl
patient
bacteri
mening
n
asept
meningitisenceph
n
multipl
sclerosi
n
normal
csf
n
assess
degrad
collagen
hydrolys
dissolv
major
compon
hydroxyprolin
subsequ
determin
spectrophotometr
csf
level
studi
gel
zymographi
rat
model
pneumococc
mening
local
collagenolyt
activ
perform
insitu
zymographi
intramolecularli
quench
gelatin
result
hydroxyprolin
csf
patient
bacteri
mening
significantli
increas
compar
studi
group
p
serum
hydroxyprolin
differ
significantli
group
amount
hydroxyprolin
csf
correl
significantli
amount
r
p
rat
model
insitu
zymographi
local
gelatinolyt
activ
subarachnoid
ventricular
space
inflamm
associ
cortic
lesion
studi
document
signific
increas
collagen
degrad
product
hydroxyprolin
csf
patient
bacteri
mening
close
correl
hydroxyprolin
csf
valid
assess
hydroxyprolin
index
csf
collagenolyt
activ
neuroinflammatori
diseas
support
role
collagenas
pathogenesi
bacteri
mening
introduct
toxic
shock
syndrom
tss
acut
noncontagi
system
ill
caus
toxin
produc
strain
aureu
bhaemolyt
streptococci
occur
nonimmun
person
expos
tss
toxin
tss
commonli
associ
menstruat
tampon
use
howev
also
relat
skin
soft
tissu
infect
particularli
post
surgic
skelet
infect
respiratori
tract
infect
tss
often
nonimmunis
recurr
menstrualassoci
tss
welldescrib
literatur
suggest
tss
extrem
rare
diagnost
difficulti
lead
misdiagnosi
tss
fatal
left
undiagnos
report
seri
three
case
tss
present
within
short
period
time
case
report
case
year
old
femal
present
sudden
onset
collaps
diarrhoea
vomit
abdomin
pain
gave
histori
menstruat
initi
diagnosi
sever
gastroenter
made
fail
respond
conserv
manag
requir
itu
support
discharg
firm
diagnosi
repres
one
month
later
similar
symptom
diagnosi
staphylococc
tss
confirm
case
year
old
femal
present
mens
sudden
onset
rash
rigor
sever
diarhhoea
vomit
abdomin
pain
diagnos
staphylococc
tss
admiss
case
year
old
femal
present
sudden
onset
sever
diarrhoea
vomit
pyrexia
rash
gave
histori
menstruat
respond
poorli
treatment
requir
itu
support
high
dose
steroid
eventu
diagnos
streptococc
tss
discuss
diagnost
criteria
tss
includ
high
fever
hypotens
erythemat
rash
complic
multisystem
disfunct
patient
often
requir
aggress
manag
public
health
laboratori
servic
report
averag
case
diagnos
tss
uk
per
year
howev
uncommon
difficult
natur
diagnosi
mani
case
misdiagnos
therefor
go
unreport
essenti
maintain
high
level
suspicion
patient
epidemiolog
high
risk
importantli
also
less
ill
patient
suggest
symptom
fail
meet
diagnost
criteria
atrisk
group
high
morbid
mortal
report
undiagnos
untreat
case
object
staphylococcu
aureu
colon
infect
burn
wound
increas
morbid
delay
wound
heal
patient
suffer
burn
wound
vulner
moment
rout
transmiss
aureu
expos
burn
wound
dress
chang
aim
studi
evalu
effect
dress
chang
laminar
flow
condit
burn
wound
patient
regard
aureu
colon
method
first
februari
first
june
patient
includ
studi
burn
centr
patient
dress
chang
laminar
flow
condit
patient
frequent
screen
aureu
nose
throat
burn
wound
aureu
isol
genotyp
puls
field
gel
electrophoresi
result
admiss
patient
aureu
colon
nose
throat
burn
wound
dress
chang
laminar
flow
condit
carri
patient
group
howev
patient
acquir
burn
wound
colon
aureu
stay
centr
six
patient
whose
dress
chang
carri
laminar
flow
condit
acquir
burn
wound
colon
aureu
total
patient
acquir
burn
wound
colon
patient
also
acquir
carriag
aureu
nose
throat
type
aureu
carri
nose
throat
well
burn
wound
patient
result
studi
suggest
firstli
dress
chang
laminar
flow
condit
prevent
colon
burn
wound
aureu
secondli
exogen
rout
play
import
role
transmiss
dynam
pathogen
burn
wound
centr
futur
research
focus
mode
transmiss
aureu
special
circumst
mupirocin
prophylaxi
prevent
staphylococcu
aureu
wound
colonis
patient
admit
burn
centr
object
staphylococcu
aureu
aureu
colonis
burn
wound
increas
morbid
delay
wound
heal
mani
burn
wound
colonis
aureu
endogen
natur
aim
studi
evalu
effect
erad
nasal
aureu
mupirocin
patient
regard
aureu
colonis
burn
wound
method
septemb
march
patient
admit
burn
centr
screen
aureu
nose
burn
wound
isol
genotyp
pfge
patient
receiv
nasal
mupirocin
time
admiss
burn
centr
fiftyf
patient
unit
follow
septemb
till
may
receiv
mupirocin
prophylaxi
serv
histor
control
group
result
admiss
patient
mupirocin
trial
aureu
colonis
burn
wound
group
patient
noncarri
patient
nasal
carrier
aureu
seven
noncarri
nasal
carrier
acquir
burn
wound
colonis
aureu
stay
centr
histor
control
group
patient
aureu
colonis
burn
wound
time
admiss
group
patient
noncarri
patient
nasal
carrier
noncarri
nasal
carrier
acquir
aureu
wound
colonis
stay
overal
probabl
wound
colonis
patient
treat
mupirocin
significantli
lower
histor
nontreat
group
p
chisquar
test
yate
correct
conclus
result
studi
suggest
applic
nasal
mupirocin
patient
upon
admiss
burn
centr
may
reduc
elimin
risk
subsequ
aureu
colonis
burn
wound
measur
includ
improv
infect
control
practic
erad
exogen
aureu
reservoir
includ
aureu
carriag
among
healthcar
worker
may
necessari
reduc
incid
aureu
burn
wound
colonis
control
outbreak
staphylococcu
aureu
surgic
ward
result
characteris
aureu
februari
show
cluster
ident
strain
three
patient
hcw
strain
two
patient
similar
strain
hcw
b
three
patient
uniqu
strain
surveil
period
total
eighteen
isol
sixteen
patient
found
surveil
period
epidemicstrain
found
patient
patient
ward
epidem
period
two
patient
ident
new
isol
indic
exchang
patient
aureu
may
occur
without
notion
anoth
remark
observ
patient
lost
origin
strain
acquir
new
isol
aureu
hospitalis
conclus
small
outbreak
aureu
could
trace
hcw
prove
carrier
reliev
patient
contact
stop
outbreak
molecular
surveil
appropri
way
evalu
success
measur
taken
underscor
import
hygien
measur
risk
factor
aureu
carriag
health
care
worker
widmer
lang
r
frei
basel
ch
introduct
aureu
mssa
carriag
common
among
health
care
worker
hcw
might
associ
type
care
provid
potenti
risk
factor
transmiss
mssa
observ
cloud
adult
object
determin
risk
factor
mssa
carriag
hcw
percentag
methicillinresist
aureu
mrsa
tertiari
care
centr
method
retrospect
review
data
staff
health
depart
microbiolog
laboratori
hcw
work
high
mrsa
preval
countri
routin
screen
time
hire
institut
addit
data
gener
mrsa
screen
hcw
evid
nosocomi
transmiss
mrsa
patient
mrsa
defin
aureu
oxacillinresist
express
andor
posit
meca
gene
pcr
data
hcw
collect
chart
review
casereport
form
includ
demograph
data
work
place
skin
diseas
variabl
data
compar
univari
multipl
logist
regress
analys
result
total
swab
taken
hcw
jan
data
avail
origin
switzerland
germani
franc
countri
overal
preval
mssa
mrsa
respect
one
sampl
avail
individu
repeat
sampl
neg
neg
one
singl
posit
cultur
consist
posit
sex
profess
work
place
number
year
institut
associ
aureu
carriag
p
signific
risk
factor
aureu
carriag
young
age
defin
p
preval
mssa
increas
eight
hcw
carrier
mrsa
young
half
report
skin
diseas
conclus
aureu
carriag
among
hcw
common
young
age
remain
risk
factor
even
adjust
variabl
mrsa
rare
among
hcw
preval
nasal
carriag
methicillinsuscept
methicillinresist
staphylococcu
aureu
among
hospit
personnel
outpati
st
foka
sp
foka
c
tsamolia
skoutari
eghio
gr
object
assess
nasal
colon
staphylococcu
aureu
among
hospit
staff
absenc
epidem
compar
nasal
carrier
statu
among
outpati
focus
mrsa
rate
method
studi
includ
hospit
personnel
adult
admit
outpati
clinic
hospit
given
histori
hospit
import
facilit
factor
colon
staphylococcu
aureu
exclud
individu
histori
hospit
preced
year
studi
specimen
obtain
swab
anterior
naresecolog
nich
aureusand
cultur
accord
nccl
guidelin
id
staph
strip
use
identif
confirm
slidex
staph
plu
kit
biomerieux
mrsa
strain
detect
achiev
slidex
mrsa
detect
kit
compani
antibiot
suscept
mrsa
strain
determin
atb
staph
method
version
accord
recommend
produc
biomerieux
result
among
hospit
staff
carriag
rate
mrsa
methicillin
suscept
aureu
respect
none
outpati
found
nasal
carrier
mrsa
addit
mssa
carriag
group
preval
mrsa
nasal
carriag
rate
among
personnel
work
differ
medic
ward
also
examin
differ
rate
among
personnel
work
surgic
ward
oper
theater
rest
staff
statist
signific
p
mrsa
strain
suscept
oral
antibiot
conclus
although
preval
mrsa
low
among
hospit
personnel
educ
need
one
import
reservoir
nosocomi
mrsa
infect
low
incid
mrsa
infect
around
time
studi
suggest
usual
infect
control
practic
mrsa
spread
avoid
mrsa
carrier
treat
intranas
muripocin
elimin
nasal
carrier
statu
continu
monitor
mrsa
carriag
need
avoid
nosocomi
spread
aid
patient
special
popul
relat
high
risk
infect
due
staphylococcu
aureu
previou
colon
recogn
predispos
factor
develop
infect
due
organ
howev
nasal
carriag
aureu
hivpati
still
complet
character
object
describ
epidemiolog
featur
communityacquir
aureu
nasal
colon
care
hivpati
base
molecular
genotyp
method
hivoutpati
without
previou
hospit
within
last
two
year
screen
aureu
nasal
colon
three
sampl
patient
collect
variabl
associ
colon
assess
nasal
carriag
classifi
absent
transient
colon
persist
colon
persist
colon
assess
accord
molecular
profil
perform
pulsedfield
gel
electrophoresi
simpl
profil
multipl
differ
profil
combin
two
e
one
differ
profil
result
patient
enrol
studi
seventi
patient
least
one
cultur
posit
aureu
patient
conclud
three
sampl
collect
one
isol
commun
acquir
mrsa
rate
colon
higher
two
sampl
taken
rang
first
sampl
sampl
collect
hivpati
aid
like
colon
nonaid
patient
among
patient
aureu
nasal
carriag
transient
persist
carrier
whose
genom
subtyp
simpl
combin
multipl
persist
colon
previou
use
antibiot
associ
absenc
aureu
colon
p
conclus
hiv
care
patient
high
rate
oxacillinsuscept
aureu
nasal
colon
regardless
recent
literatur
one
isol
communityacquir
mrsa
common
characterist
colon
simpl
persist
colon
show
genom
profil
object
aureu
bacteraemia
sab
continu
major
problem
relat
communityacquir
nosocomi
infect
undertook
evalu
larg
cohort
patient
sab
assess
featur
infect
predictor
mortal
patient
method
case
sab
admit
hospit
prospect
studi
patient
least
one
posit
blood
cultur
aureu
clinic
symptom
bacteraemia
sab
consid
nosocomi
first
posit
blood
cultur
specimen
obtain
h
admiss
clinic
evid
infect
admiss
microbiolog
studi
carri
standard
protocol
epidemiolog
clinic
characterist
antimicrobi
treatment
outcom
relaps
mortal
analys
result
case
sab
identifi
prospect
includ
studi
protocol
incid
highest
year
per
case
male
mean
age
year
sd
yet
implement
similar
guidelin
studi
evalu
detect
report
mlsb
result
staphylococcu
use
bd
phoenix
tm
autom
microbiolog
system
bdxpert
system
nccl
sfm
din
interpret
standard
method
comment
regard
mlsb
resist
list
nccl
convert
expert
rule
special
bdxpert
rule
also
construct
detect
report
mlsb
resist
appli
sfm
din
guidelin
total
strain
staphylococcu
aureu
epidermidi
coagulaseneg
staphylococci
test
phoenix
panel
contain
erythromycin
e
clindamycin
cc
nccl
sfm
din
breakpoint
use
interpret
phoenix
mic
result
doubl
disk
diffus
dtest
e
cc
use
refer
method
determin
mlsb
resist
phenotyp
result
phoenix
e
cc
mic
valu
interpret
base
standard
select
bdxpert
rule
execut
applic
expert
messag
display
phoenix
correctli
detect
constitut
mlsb
cmlsb
phenotyp
compar
dtest
result
remain
cmlsb
strain
interpret
bdxpert
potenti
induc
mlsb
imlsb
efflux
phenotyp
total
imlsb
efflux
phenotyp
isol
report
bdxpert
imlsbefflux
phenotyp
user
alert
perform
dtest
report
cc
result
cc
interpret
suppress
isol
nccl
sfm
din
show
ident
detect
interpret
mlsb
resist
phenotyp
phoenix
bdxpert
system
conclus
phoenix
bdxpert
system
assist
laboratori
rapid
detect
accur
interpret
mlsb
result
staphylococcu
special
messag
use
commun
time
accur
inform
clinician
proper
therapi
staphylococc
infect
mlsb
resist
phenotyp
vitro
activ
new
compound
test
multidrug
resist
aureu
isol
latin
american
medic
centr
background
oxacillinresist
aureu
orsa
isol
lamc
show
high
rate
coresist
r
antimicrobi
class
use
clinic
set
evalu
mdr
pattern
orsa
strain
collect
lamc
sentri
antimicrobi
surveil
program
also
evalu
suscept
new
investig
compound
import
endem
pathogen
method
among
aureu
collect
r
oxacillin
strain
isol
lamc
countri
test
antimicrobi
nccl
broth
microdilut
method
orsa
strain
group
mdr
pattern
primari
drug
conclus
newer
compound
lzd
qd
dap
dal
tei
van
activ
endem
epidem
orsa
lamc
aureu
mdr
pattern
ave
r
agent
requir
greater
use
newer
compound
particularli
brazil
object
coagulas
neg
staphylococci
con
repres
part
physiolog
microflora
howev
recent
year
also
emerg
nosocomi
pathogen
infect
associ
indwel
medic
devic
e
g
pleural
drain
mainli
immunocompromis
patient
aim
studi
determin
dynam
nasopharyng
colon
con
patient
resect
lung
cancer
shortterm
hospit
especi
receiv
routin
preoper
antimicrobi
prophylaxi
method
present
studi
con
speci
select
patient
divid
two
group
patient
undergo
pulmonari
resect
receiv
preoper
prophylaxi
piperacillin
cefuroxim
alon
combin
amikacin
group
ii
control
group
throat
nasal
specimen
taken
patient
twice
fourday
interv
isol
identifi
biochem
microtest
api
staph
biomerieux
test
drug
suscept
accord
nccl
reccomend
result
strain
con
strain
select
clinic
specimen
strain
group
strain
control
group
often
isol
speci
staphylococcu
epidermidi
predomin
api
numer
profil
detail
analys
api
numer
profil
resist
antimicrobi
agent
indic
fourday
interv
hospit
chang
phenotyp
among
con
colon
nasopharynx
observ
group
patient
chang
drug
resist
pattern
found
often
group
compar
control
group
respect
differ
statist
signific
p
test
yate
correct
conclus
data
suggest
preoper
antimicrobi
prophylaxi
routin
use
patient
resect
lung
cancer
may
regard
import
factor
predispos
chang
drug
resist
pattern
among
con
isol
colon
nasopharynx
suscept
coagulaseneg
staphylococci
teach
hospit
compar
secondari
care
hospit
result
total
six
differ
speci
identifi
isol
staphylococcu
epidermidi
lumc
speci
divers
greater
mca
five
isol
staphylococcu
haemolyticu
found
first
differ
two
hospit
found
activ
antibiot
test
except
li
follow
v
mg
l
mg
l
c
mg
l
mg
l
l
mg
l
li
mg
l
lumc
mg
l
mca
accord
dutch
guidelin
total
isol
found
resist
intermedi
resist
isol
suscept
v
conclus
first
choic
glycopeptid
seriou
con
infect
v
influenc
suscept
con
antibiot
accord
dutch
guidelin
activ
c
l
con
rel
low
wherea
activ
le
suscept
rang
object
staphylococcu
epidermidi
one
bacteri
speci
mainli
implic
foreign
bodi
associ
infect
character
sever
sepidermidi
clinic
isol
abil
form
biofilm
resist
antibiot
method
sepidermidi
strain
isol
implant
medic
devic
collect
hospit
central
itali
suscept
penicillin
methicillin
erythromycin
tetracyclin
determin
vitro
etest
accord
nccl
guidelin
specif
antibiot
resist
determin
check
pcr
blaz
meca
erma
ermb
ermc
msra
tetk
tetm
abil
form
biofilm
determin
pcr
detect
gene
specif
attach
biofilm
develop
icaadbc
operon
aap
atl
ii
congo
red
agar
cra
plate
test
assay
product
polisaccarid
intercellular
adhesin
pia
iii
crystal
violet
cv
stain
determin
biofilm
biomass
develop
polystyren
microtit
plate
iv
cslm
microscopi
observ
investig
biofilm
structur
result
strain
studi
resist
penicillin
methicillin
erythromycin
tetracyclin
side
biofilmspecif
gene
detect
strain
posit
ica
operon
gene
possess
atl
gene
aap
determin
popul
cra
test
confirm
correl
presenc
ica
gene
slime
express
cv
assay
classifi
quasitot
strain
biofilm
produc
plastic
surfac
addit
distribut
optic
densiti
valu
obtain
cv
stain
show
signific
statist
differ
biofilm
biomass
develop
icaadbcposit
strain
icaadbcneg
one
final
correl
although
alway
present
observ
abil
strain
develop
highstructuret
biofilm
specif
biofilmform
determin
conclus
analys
origin
colon
infect
patient
con
isol
oper
site
bacteria
could
trace
one
patient
develop
infect
transmiss
probabl
occur
direct
contact
low
level
bacteri
contamin
uca
togeth
lack
correl
genotyp
isol
found
uca
wound
suggest
airborn
transmiss
play
major
role
develop
swi
staphylococci
found
air
sampl
traceabl
investig
sourc
probabl
origin
non
swab
part
hcw
bodi
sinc
traceabl
isol
uca
origin
non
scrub
team
member
protect
oper
site
lfv
appear
suboptim
clonal
endem
methicillinresist
staphylococcu
epidermidi
strain
isol
neonat
intens
care
unit
n
ben
saida
ferjani
n
sfar
j
boukadida
souss
tn
object
methicillinresist
staphylococcu
epidermi
mrse
one
import
pathogen
respons
nosocomi
infect
particularli
newborn
aim
studi
establish
infect
caus
endem
clone
incident
occur
bacteri
strain
ubiquit
speci
evalu
perform
pcr
novel
method
type
mrse
strain
use
pulsedfield
gel
electrophoresi
pfge
refer
method
method
twenti
strain
mrse
meca
collect
period
survey
decemb
septemb
differ
patholog
product
newborn
hospit
neonat
intens
care
unit
public
matern
hospit
souss
tunisia
identif
strain
done
convent
procedur
api
staph
apibiomerieux
sa
suscept
test
antibiot
determin
accord
casfm
recommend
strain
character
genotypag
pulsedfield
gel
electrophoresi
pfge
varieti
chef
smai
macrorestrict
genom
profil
interpret
accord
criteria
tenov
j
clin
microbiol
strain
also
character
electrophoret
profil
obtain
pcrbase
analysi
spacer
polymorph
result
mrse
repres
total
strain
sepidermidi
collect
neonatolog
ward
period
survey
major
strain
come
blood
sampl
strain
vascular
cathet
pu
sound
antibiotyp
genotyp
profil
accord
tenov
criteria
individu
type
subtyp
type
b
type
c
subtyp
type
subtyp
type
e
subtyp
type
f
total
four
pcr
pattern
obtain
base
interpret
criteria
pcr
pattern
exhibit
one
band
differ
consid
repres
distinct
type
type
conclus
mrse
appear
endem
multiclon
domin
clone
neonat
intens
care
unit
studi
demonstr
signific
proport
mrse
infect
may
attribut
transmiss
among
newborn
certain
strain
becom
endem
long
period
set
clonal
staphylococcu
haemolyticu
strain
isol
neonat
intens
care
unit
n
ben
saida
ferjani
j
boukadida
souss
tn
object
methicilllinresist
staphylococcu
haemolyticu
mrsh
increasingli
import
nosocomi
pathogen
particularli
critic
ill
neonat
aim
studi
establish
infect
caus
endem
clone
incident
occur
bacteri
strain
speci
method
thirteen
strain
mrsh
accord
casfm
recommend
meca
murakami
k
jclinmicrobiol
collect
period
survey
april
octob
eleven
strain
come
differ
patholog
product
newborn
hospit
neonat
intens
care
unit
public
matern
hospit
tow
strain
come
paediatr
intern
medicin
ward
use
control
ensur
endem
strain
differenti
outbreak
strain
strain
identifi
apistaph
method
api
biomerieux
strain
character
genotypag
pulsedfield
gel
electrophoresi
pfge
varieti
chef
smai
macrorestrict
genom
profil
interpret
accord
tenov
criteria
j
result
haemolyticu
quantit
second
staphylococci
epidermidi
isol
neonatolog
ward
mrsh
repres
total
strain
haemolyticu
collect
neonatolog
ward
period
studi
major
strain
come
blood
sampl
pu
csf
eight
resist
antibiotyp
profil
genotyp
pattern
accord
tenov
criteria
individu
type
type
b
subtyp
type
c
strain
come
paediatr
ward
present
pattern
type
strain
come
intern
medicin
ward
present
distinct
pattern
conclus
mrsh
major
bacterium
nosocomi
infect
neonat
intens
care
unit
bacterium
respons
shown
studi
endem
multiclon
nosocomi
infect
predomin
clone
result
haemolyticu
isol
posit
blood
cultur
repres
coagulas
neg
staphylococci
twentynin
case
shb
occur
studi
period
episod
per
patientsday
case
hospitalacquir
occur
mean
hospitalis
day
mean
age
year
rang
patient
male
twentyeight
patient
central
venou
cathet
cvc
patient
receiv
previous
antimicrobi
therapi
thirteen
patient
polymicrobi
bacteraemia
case
sourc
bacteraemia
cvc
isol
resist
oxacillin
gentamicin
resist
ciprofloxacin
teicoplanin
respect
strain
suscept
vancomycin
sixteen
patient
sepsi
sever
sepsi
polymicrobi
septic
shock
patient
shb
clinic
signific
twenti
patient
die
death
directli
relat
shb
patient
partial
relat
nine
patient
survivedth
patient
die
shb
develop
persist
cvcrelat
bacteraemia
cours
therapi
streptococc
endocard
haemolyticu
becom
resist
teicoplanin
teicoplaninbas
therapi
patient
die
day
onset
bacteraemia
patient
death
partial
relat
shb
polimicrobi
bacteraemia
due
c
tropicali
enterococcu
spp
respect
die
day
respect
septic
shock
adequ
therapi
among
patient
death
relat
shb
receiv
adequ
therapi
clear
blood
cultur
patient
improv
remov
cvc
without
antimicrobi
therapi
conclus
haemolyticu
emerg
pathogen
respons
sepsi
frequent
cvcrelat
strain
resist
mani
antistaphylococc
agent
current
use
empir
therapi
thu
constitut
clinic
concern
nevertheless
pathogen
show
low
virul
associ
low
relat
mortal
probabl
repres
marker
sever
underli
diseas
staphylococci
skin
patient
chang
associ
treatment
isotretinoin
thoma
r
william
n
hepburn
watt
r
dixon
lincoln
uk
object
isotretinoin
retinoid
use
treat
patient
moder
sever
acn
despit
advers
effect
mucos
surfac
dri
contraind
use
pregnanc
clinic
practic
patient
frequent
prescrib
system
isotretinoin
respond
previou
treatment
oral
topic
antibiot
broadspectrum
antibacteri
therapi
nevertheless
promot
chang
divers
antibiot
resist
statu
skin
microbiota
studi
effect
isotretinoin
chang
method
present
studi
investig
recoveri
analysi
skin
organ
patient
mean
age
rang
treatment
cours
isotretinoin
mg
kg
bodi
weight
number
aerob
bacteri
isol
presumpt
staphylococci
recov
bairdpark
agar
three
specif
site
per
patient
compar
agematch
control
healthi
volunt
result
patient
control
gener
similar
number
organ
nare
cheek
toe
web
treatment
wherea
patient
show
signific
reduct
staphylococci
recov
one
site
week
isotretinoin
treatment
major
patient
greater
reduct
log
cheek
site
either
nare
toe
web
show
minim
reduct
conclus
preliminari
result
studi
show
pronounc
reduct
number
presumpt
staphylococci
recov
treat
group
immedi
follow
isotretinoin
compar
untreat
control
sinc
isotretinoin
littl
known
antibacteri
activ
staphylococci
observ
reduct
would
suggest
effect
mediat
chang
skin
nutrit
microenviron
object
emerg
mutat
resist
linezolid
lin
staphylococcu
aureu
associ
loss
erythromycin
resist
methylas
erm
gene
vivo
vitro
test
gener
valid
claim
examin
whether
emerg
lin
resist
delay
presenc
eri
method
six
linsuscept
aureu
strain
use
geneticallyrel
eryresist
ermc
suscept
pair
also
isogen
pair
hypermut
mutant
harbour
ermb
replic
experi
erysuscept
eryresist
isol
grown
agar
contain
increas
concentr
lin
addit
eryresist
isol
grown
mg
l
eri
increas
concentr
lin
number
day
isol
develop
abil
grow
presenc
mg
l
lin
record
absenc
erm
gene
check
pcr
mic
lin
eri
determin
agar
dilut
pfge
profil
mutant
verifi
result
thirtythre
mutant
obtain
experi
clinic
isol
linresist
emerg
slowli
eryresist
clinic
isol
grown
lin
eri
isol
grown
lin
alon
mean
day
sd
emerg
mg
l
lin
versu
day
sd
presenc
lin
eri
grow
hypermut
strain
presenc
lin
eri
delay
emerg
linresist
day
sd
either
case
absenc
eri
select
loss
erm
emerg
linresist
note
one
isol
experi
isol
grown
presenc
eri
retain
erm
determin
eri
mg
l
supress
growth
eryresist
strain
linezolid
stabl
within
ambit
longselect
experi
conclus
grow
clinic
isol
presenc
eri
lin
slow
emerg
linresist
merit
studi
lower
clinicallyrelev
concentr
eri
vitro
select
linezolid
resist
hypermut
wildtyp
staphylococcu
aureu
object
resist
linezolid
lin
rare
aris
via
mutat
rrna
gene
hypothesis
resist
would
emerg
preferenti
staphylococci
hypermut
phenotyp
engin
mutat
mut
gene
b
hypermut
might
coselect
linezolid
resist
mut
part
dna
mismatch
repair
mmr
system
identifi
correct
genom
alter
postrepl
therebi
influenc
net
mutat
rate
method
linezolidresist
linr
mutant
staphylococcu
aureu
hypermut
mut
delet
mutant
harbour
erythromycin
resist
marker
gene
ermb
geneticallyrel
pair
clinic
isol
select
repeat
passag
increas
concentr
lin
mutant
parentag
confirm
pfge
suscept
test
agar
dilut
amplifi
fragment
rrna
gene
studi
sequenc
rflp
analysi
frequenc
linr
mutant
yield
variant
resist
fusid
acid
rifampin
calcul
triplic
experi
result
seventeen
linr
mutant
mic
lgml
rais
ten
mutant
mutat
rrna
gene
typic
seen
linr
gramposit
cocci
clinic
identifi
mutat
curious
mutant
lost
ermb
cours
experi
revert
macrolid
suscept
linr
mutant
mutat
frequenc
rifampicin
fusid
acid
resist
compar
parent
impli
coselect
stabl
hypermut
conclus
linr
mutant
obtain
hypermut
strain
wild
type
strain
mutant
obtain
hypermut
organ
data
suggest
hypermut
facilit
emerg
linr
nevertheless
linr
mutant
deriv
wildtyp
parent
elev
mutat
frequenc
object
mechan
resist
glycopeptid
intermedi
staphylococcu
aureu
gisa
hgisa
isol
unknown
howev
inactiv
certain
gene
shown
confer
increas
glycopeptid
resist
two
gene
tcaa
mprf
inactiv
gisa
strain
caus
reduct
glycopeptid
mic
overexpress
tcaa
caus
increas
teicoplanin
suscept
gene
may
play
role
develop
glycopeptid
resist
studi
aim
investig
express
level
tcaa
mprf
set
gisa
hgisa
glycopeptidesuscept
aureu
gssa
method
rna
extract
follow
set
clinic
relat
cr
gssa
hgisa
lla
lle
set
cr
hgisa
gisa
harvest
exponenti
phase
growth
ex
exponenti
phase
growth
presenc
submic
level
vancomycin
exv
rna
extract
hgisa
gisa
well
clinic
gssa
strain
rtpcr
perform
customis
primer
product
visualis
electrophoresi
band
intens
taken
indic
mrna
quantiti
henc
express
level
time
cell
harvest
result
express
tcaa
similar
strain
test
strain
within
relat
strain
set
show
similar
band
intens
despit
differ
glycopeptid
resist
phenotyp
also
exhibit
similar
express
level
found
gisa
hgisa
gssa
strain
level
express
affect
presenc
submic
level
vancomycin
strain
test
sequenc
analysi
tcaa
strain
show
mutat
present
previous
thought
express
level
mprf
found
strain
specif
differ
gene
express
found
cr
relat
strain
set
conclus
reduct
express
level
tcaa
mprf
found
correl
clinic
strain
exhibit
higher
glycopeptid
resist
thu
uncertain
role
tcaa
ot
mprf
play
mediat
glycopeptid
resist
staphylococcu
aureu
object
gisa
hgisa
strain
characterist
thicken
cell
wall
reportedli
fewer
crosslink
fewer
peptidoglycan
crosslink
creat
increas
daladala
pentapeptid
termini
henc
vancomycin
target
shown
transpeptidas
dcarboxypeptidas
activ
cleav
termin
dalanin
residu
uncrosslink
muropeptid
reduc
level
report
laboratorygener
gisa
mutant
clinic
gisa
strain
studi
aim
investig
express
level
set
gisa
hgisa
glycopeptidesuscept
aureu
gssa
method
rna
extract
follow
set
clinic
relat
cr
vssa
hgisa
lla
lle
set
cr
hgisa
gisa
harvest
exponenti
phase
growth
ex
overnight
growth
exponenti
phase
growth
presenc
submic
level
vancomycin
exv
rna
extract
clinic
unrel
cu
gisa
includ
cu
hgisa
includ
gssa
ex
rtpcr
perform
customis
primer
product
visualis
electrophoresi
band
intens
taken
indic
mrna
quantiti
time
harvest
henc
gene
express
result
express
vari
accord
strain
band
intens
relat
strain
set
lla
gssa
lle
hgisa
reduc
slightli
increas
intermedi
vancomycin
resist
howev
two
cr
hgisa
gisa
strain
set
variat
express
observ
exhibit
lower
express
strain
presenc
submic
level
vancomycin
reduc
express
express
found
reduc
gisa
hgisa
show
lower
band
intens
gssa
conclus
reduc
level
suspect
associ
reduc
suscept
vancomycin
aureu
exclus
express
reduc
clinic
gisa
report
previous
howev
gisa
strain
exhibit
express
level
similar
gssa
isol
therefor
express
level
appear
strain
specif
lower
express
level
essenti
requir
develop
gisa
phenotyp
object
prolong
use
vancomycin
known
import
factor
induc
vancomycin
resist
aureu
methicillinresist
aureu
mrsa
colon
respiratori
tract
might
chronic
expos
subtherapeut
concentr
vancomycin
level
vancomycin
within
pulmonari
line
fluid
much
lower
concentr
serum
despit
continu
use
vancomycin
mrsa
still
found
present
respiratori
specimen
patient
method
mrsa
continu
isol
respiratori
specimen
vancomycin
therapi
collect
jul
seoul
paik
hospit
mrsa
screen
brain
heart
infus
plate
contain
vancomycin
lg
ml
lg
ml
vancomycin
resist
minim
inhibitori
concentr
mic
determin
etest
agar
dilut
method
broth
dilut
method
pattern
puls
field
gel
electrophoresi
analys
result
nine
patient
isol
assess
five
patient
pneumonia
four
patient
mrsa
infect
twelv
mrsa
isol
tracheal
aspir
expector
sputum
specimen
durat
vancomycin
use
rang
day
five
isol
one
isol
cultur
respect
vancomycin
mic
isol
reveal
lg
ml
etest
mic
agar
dilut
method
broth
dilut
method
show
lg
ml
conclus
vancomycin
resist
treatment
patient
develop
object
fusid
acid
resist
fusr
staphylococcu
aureu
usual
result
acquisit
fusb
resist
determin
mutat
fusa
gene
encod
drug
target
elong
factor
g
follow
recent
report
fusr
intermediu
detect
studi
fusr
lugdunensi
unpublish
examin
whether
resist
strain
result
fusa
fusbtyp
mechan
method
standard
methodolog
employ
strain
identif
suscept
test
southern
hybrid
sh
pcr
amplif
dna
sequenc
primer
pcr
amplif
previouslyunsequenc
intermediu
fusa
gene
base
portion
flank
gene
rpsg
tufa
conserv
b
subtili
aureu
result
three
fusr
lugdunensi
fu
mic
ug
ml
two
fusr
intermediu
fu
mic
ug
ml
probe
presenc
fusb
sh
alongsid
wildtyp
fuss
counterpart
fu
mic
ug
ml
respect
fusr
lugdunensi
carri
fusb
gene
detect
intermediu
fuss
strain
furthermor
fusb
appear
chromosomallyloc
sinc
hybrid
observ
purifi
plasmid
dna
pcr
analysi
map
fusb
chromosom
region
upstream
groel
gene
locu
gene
carri
epidem
fusr
european
aureu
clone
examin
whether
mutat
fusa
respons
fusr
intermediu
pcr
amplif
sequenc
fusa
resist
sensit
strain
perform
rel
fuss
intermediu
nctc
resist
strain
carri
six
code
polymorph
fusa
although
none
correspond
report
fusr
mutat
fusa
gene
aureu
conclus
fu
resist
recent
strain
lugdunensi
result
carriag
fusb
determin
chromosom
probabl
acquir
horizont
fusr
aureu
strain
fusb
gene
detect
intermediu
strain
although
multipl
fusa
polymorph
identifi
may
respons
observ
fusr
phenotyp
object
methicillinresist
aureu
mrsa
methicillinresist
coagulaseneg
staphylococci
mrcn
import
pathogen
caus
nosocomi
infect
worldwid
one
antibiot
still
effect
mrsa
mupirocin
mupirocinresist
aureu
increas
sinc
first
report
aureu
isol
tertiari
hospit
korea
report
high
level
mupirocin
resist
studi
investig
restrict
fragment
length
polymorph
rflp
type
mupa
gene
loci
plasmid
dna
sequenc
mupr
plasmid
contain
mupa
gene
high
level
mupirocin
resist
muh
staphylococci
tertiari
hospit
method
suscept
antimicrobi
agent
includ
mupirocin
test
disk
diffus
mic
mupirocin
determin
agar
dilut
method
plasmidencod
mupa
gene
detect
pcr
mupa
polymorph
plasmid
dna
digest
hind
iii
ecor
cla
restrict
enzym
investig
southern
hybrid
use
mupa
probe
aureu
isol
show
preval
rflp
type
conjug
filter
mate
method
select
transconjug
show
mupirocin
resist
phenotyp
mupr
plasmid
select
transconjug
purifi
analys
plasmid
dna
sequenc
result
muhstaphylococci
isol
among
staphylococci
tertiari
hospit
korea
muhmrsa
isol
haemolyticu
isol
homini
isol
epidermidi
isol
isol
mupa
pcr
product
detect
plasmid
muh
isol
isol
contain
two
plasmid
molecul
repeatedli
purifi
differ
effici
three
differ
polymorph
mupa
loci
investig
preval
mupa
polymorph
clai
hybrid
fragment
mupirocin
resist
plasmid
dna
sequenc
locat
conclus
highlevel
mupirocin
resist
staphylococci
multipl
plasmid
variou
size
divers
rflp
type
suggest
variat
mupa
gene
loci
mupr
plasmid
contain
transfer
element
mupa
gene
genet
basi
macrolid
lincosamid
streptogramin
resist
coagulaseneg
staphylococci
gatermann
koschinski
friedrich
bochum
object
aureu
erythromycin
resist
almost
exclus
caus
erma
ermc
gene
wherea
export
macrolid
antibiot
msra
inactiv
lincosamid
lina
rare
resist
may
induc
clindamycin
appear
suscept
constitut
clindamycin
appear
resist
express
therapi
induc
resist
strain
clindamycin
mutat
may
occur
render
object
lysostaphin
antibacteri
enzym
specif
capabl
cleav
crosslink
pentaglycin
bridg
cell
wall
staphylococci
aureu
cell
wall
contain
high
proport
pentaglycin
make
lysostaphin
highli
effect
agent
activ
grow
quiescent
bacteria
relationship
lysostaphin
suscept
vancomycin
suscept
cell
wall
thick
passageselect
vancomycin
resist
staphylococcu
aureu
isol
vrsa
parent
strain
studi
order
investig
character
isol
decreas
suscept
vancomycin
method
suscept
lysostaphin
six
vrsa
parent
strain
determin
use
spectrophotometr
macrodilut
method
spectrophotometr
determin
turbid
measur
decreas
incub
isol
sampl
mic
determin
broth
macrodilut
method
cationadjust
muellerhinton
broth
accord
standard
nation
committe
clinic
laboratori
standard
cell
wall
measur
determin
use
transmiss
electron
microscopi
result
determin
lysostaphin
activ
reveal
signific
decreas
per
cent
reduct
turbid
activ
lysostaphin
vrsa
vrsa
shown
resist
lysostaphin
parent
strain
mic
lysostaphin
vrsa
strain
also
increas
either
fold
increas
mic
lysostaphin
electron
microscopi
vrsa
show
enhanc
cell
wall
thick
uneven
surfac
irregular
shape
contrast
thin
regular
cell
wall
morpholog
parent
strain
strain
acquir
highest
thick
cell
wall
demonstr
highest
resist
lysostaphin
conclus
mechan
lysostaphin
resist
relationship
vancomycin
resist
remain
unclear
possibl
increas
cell
wall
thick
observ
prevent
lysostaphin
access
pentaglycin
target
increas
number
crosslink
requir
cleavag
strain
could
lyse
type
epidemiolog
mrsa
method
creation
distribut
consensu
document
detail
need
harmon
sequenc
technolog
diagnost
microbiolog
follow
certif
program
sequenc
base
type
use
methicillinresist
aureu
mrsa
prototyp
organ
type
method
spatyp
use
five
strain
dna
forward
revers
chromatogram
file
well
character
mrsa
strain
distribut
particip
laboratori
annual
profici
test
sequenc
base
type
mrsa
plan
staphylococcu
aureu
import
human
pathogen
relat
abil
develop
resist
mani
antimicrobi
agent
methicillin
resist
aureu
mrsa
becom
major
public
health
problem
especi
nosocomi
infecti
commun
acquir
mrsa
grow
concern
rate
mrsa
vari
importantli
within
countri
highest
rate
report
especi
southern
european
countri
multicentr
studi
done
establish
antimicrobi
resist
aureu
isol
clinic
specimen
hospit
patient
five
year
period
aureu
identifi
convent
method
antibiot
suscept
test
perform
disk
diffus
method
accord
nccl
standard
total
strain
aureu
collect
recov
mainli
pu
blood
cultur
respiratori
sampl
urin
strain
medicin
surgeri
orthopaed
paediatr
intens
care
unit
rate
resist
differ
antibiot
gentamicin
ofloxacin
erythromycin
clindamycin
isol
suscept
vancomycin
accord
data
rate
mrsa
remain
rel
low
signific
chang
time
period
howev
mrsa
present
high
rate
associ
resist
gentamicin
amikacin
erythromycin
clindamycin
ofloxacin
trimethoprimsulfamethoxazol
mrsa
great
concern
countri
meticillin
remain
effect
antibiot
treatment
aureu
infect
characteris
gentamicinsuscept
strain
methicillinresist
staphylococcu
aureu
two
spanish
hospit
c
potel
alvarez
c
lopezmelendez
otero
vigo
e
object
character
gentamicinsuscept
methicillinresist
staphylococcu
aureu
gsmrsa
two
molecular
type
method
find
whether
gsmrsa
clone
relat
grmrsa
describ
spread
clone
method
one
hundr
twelv
samr
isol
two
hospit
epidemiolog
related
studi
repetit
element
sequencebas
pcr
coa
gene
restrict
fragment
length
polymorph
gene
ant
aac
aph
codifi
two
aminoglycosid
modifi
enzym
detect
pcrwe
analys
gentamicin
consumpt
relat
emerg
gsmrsa
result
thirti
nine
strain
gsmrsa
gsmrsa
belong
two
epidem
clone
clone
tobramycin
sensit
clone
b
tobramycin
resist
clone
isol
hospitali
replac
epidem
grsamr
clone
clone
c
clone
b
isol
hospitalii
displac
clone
c
object
longterm
care
facil
ltcf
patient
seriou
underli
diseas
poor
function
statu
wound
pressur
sore
invas
devic
urinari
cathet
increas
concern
emerg
resist
antimicrobi
agent
includ
methicillin
resist
aureu
ltcf
mupirocin
use
ltcf
prevent
occurr
spread
mrsa
induc
mlsresist
nitrocefin
disc
use
betalaktamas
detect
induct
cefoxitin
andor
oxacillin
oxacillin
mg
l
agar
method
use
mrsa
screen
mrsa
confirm
meca
nuc
pcr
analys
smaipulsedfield
gel
electrophoresi
pfge
result
total
strain
betalactamas
posit
resist
preval
rate
tc
em
cm
ci
gm
ts
fu
thirteen
strain
mrsascreen
posit
oxacillinagar
test
cefoxitin
disc
confirm
mrsa
meca
nuc
pcr
mrsa
strain
isol
hospit
patient
express
multipl
resist
pfgeanalysi
reveal
mrsastrain
belong
three
differ
pfgetyp
type
consist
strain
depart
gener
surgeri
icu
type
group
consist
strain
gener
surgeri
depart
final
one
strain
patient
depart
pulmonari
medicin
belong
type
group
abl
type
one
strain
mlsttype
mrsastrain
perform
result
total
infant
includ
studi
mrsa
colon
detect
infant
nicu
stay
detect
first
sampl
nari
umbilicu
common
site
colon
clinic
mrsa
isol
identifi
infant
among
infant
mrsa
colon
either
preced
later
acquir
note
infant
clinic
isol
infant
episod
possibl
mrsa
infect
avail
genotyp
analysi
prior
colon
detect
episod
among
colon
clinic
isol
indistinguish
episod
highli
relat
episod
distinct
episod
among
episod
without
prior
colon
colon
acquir
follow
infect
episod
among
indistinguish
highli
relat
colon
strain
acquir
episod
conclus
surveil
mrsa
strain
basi
activ
antibiot
polici
becom
increas
concern
health
care
provid
hospit
commun
gener
practition
need
better
awar
mrsa
infect
among
health
care
profession
public
incid
mrsa
infect
last
year
czech
republ
show
slightli
increas
trend
interest
local
distribut
mrsa
strain
develop
incid
mrsa
infect
spread
subject
studi
comparison
phenotyp
type
method
pfge
methicillin
resist
aureu
isol
two
univers
hospit
thailand
c
chomvarin
k
chaicumpar
srigulbutr
khon
kaen
th
object
comparison
phenotyp
type
method
genotyp
type
method
differenti
mrsa
isol
obtain
two
univers
hospit
thailand
method
seventyfour
mrsa
isol
randomli
collect
two
univers
hospit
central
northeastern
thailand
confirm
presenc
meca
gene
antibiogram
phage
type
enterotoxin
product
use
phenotyp
type
analysi
pulsedfield
gel
electrophoresi
pfge
smai
digest
chromosom
dna
use
genotyp
type
analysi
result
found
distinct
profil
phenotyp
type
method
pfge
type
design
major
type
e
subtyp
frequent
type
relat
subtyp
found
hospit
c
repres
respect
isol
resist
penicillin
cephalosporin
erythromycin
gentamicin
kanamycin
tetracyclin
oxacillin
variabl
resist
cotrimoxazol
lincomycin
chloramphenicol
ciprofloxacin
isol
suscept
vancomycin
fosfomycin
ten
mrsa
isol
produc
enterotoxin
fortyf
isol
nontyp
phage
type
method
signific
correl
phenotyp
type
method
genotyp
type
method
found
conclus
phenotyp
type
method
significantli
correl
genotyp
type
pfge
result
demonstr
pfge
type
c
common
endem
mrsa
clone
hospit
thailand
object
investig
molecular
characterist
methicillinresist
staphylococcu
aureu
mrsa
strain
isol
neonat
transfer
primari
care
obstetr
clinic
method
twelv
mrsa
strain
isol
neonat
ten
mrsa
strain
also
isol
nurs
facil
correspond
primari
care
obstetr
clinic
molecular
featur
mrsa
strain
analys
use
multilocu
sequenc
type
mlst
arccaroeglpfgmkptatpiyqil
spa
type
sccmec
type
presenc
pantonvalentin
leukocidin
pvl
gene
investig
pcr
method
result
mrsa
strain
analys
studi
contain
sccmec
type
iva
six
isol
neonat
clinic
five
show
resist
gentamicin
tetracyclin
remain
one
show
novel
st
share
one
isol
nurs
clinic
four
mrsa
strain
neonat
clinic
b
show
resist
erythromycin
gentamicin
characterist
three
isol
nurs
environ
clinic
b
two
mrsa
strain
neonat
clinic
b
show
share
six
strain
nurs
environ
clinic
b
spa
type
mrsa
strain
ident
ujebkbp
strain
neg
pvl
gene
object
last
year
dramat
increas
preval
methicillinand
multiresist
staphylococcu
aureu
mrsa
lead
major
health
problem
especi
nosocomi
set
support
infect
control
measur
type
mrsa
essenti
present
strain
type
puls
field
gel
electrophoresi
pfge
sever
sequenc
base
method
includ
spa
type
recent
introduc
therefor
studi
initi
compar
type
result
obtain
pfge
spa
type
method
well
character
aureu
strain
differ
evolutionari
origin
includ
methicillin
sensit
resist
isol
includ
strain
select
varieti
clonal
group
preval
germani
middl
europ
last
ten
year
collect
compris
hospit
deriv
strain
well
isol
commun
includ
recent
emerg
commun
acquir
mrsa
isol
subject
pfge
subsequ
cluster
analysi
addit
polymorph
xregion
protein
gene
sequenc
spa
type
assign
use
ridom
staphtyp
softwar
newli
develop
algorithm
burp
base
upon
repeat
pattern
appli
spa
sequenc
cluster
result
spa
type
differ
group
cluster
result
compar
obtain
pfge
mlst
result
overal
result
obtain
differ
type
approach
agreement
case
pfge
result
inconsist
despit
uniform
epidemiolog
background
spa
type
abl
group
correspond
strain
togeth
two
strongli
relat
epidem
clone
could
separ
spa
type
conclus
spa
type
combin
burp
analysi
easi
rapid
reliabl
method
epidemiolog
analys
aureu
superior
pfge
case
pfge
might
rare
case
second
discriminatori
locu
exampl
singl
mlst
locu
might
help
ultim
classif
antibiot
suscept
methicillinresist
staphylococcu
aureu
methicillinresist
staphylococci
mrsa
often
multidrug
resist
repres
major
problem
antimicrobi
therapi
glicopeptid
golden
standard
infect
resist
toxic
concern
limit
usag
mrsa
antibiot
resist
may
divid
two
distinct
profil
multidrug
resist
probabl
nosocomi
infect
variabl
resist
usual
nonbetalactam
antibiot
often
correl
communityrel
mrsa
infect
result
total
pn
resist
erythromycin
invas
noninvas
pyo
resist
erythromycin
none
isol
resist
clindamycin
among
eryr
pn
frequent
gene
mef
erm
b
found
two
isol
resist
gene
identifi
mef
carri
isol
serotyp
mef
present
invas
eryr
pyo
isol
none
isol
posit
erm
b
noninvas
eryr
pyo
isol
pcrposit
erm
erm
b
mef
respect
conclus
contrast
pyo
eryr
pn
domin
one
serotyp
carri
mef
overal
resist
profil
pn
pyo
still
favour
resist
macrolid
grow
concern
denmark
resist
streptococcu
pneumonia
auc
mic
breakpoint
differ
gatifloxacin
gemifloxacin
levofloxacin
moxifloxacin
k
laplant
rybak
b
tsuji
g
kaatz
detroit
usa
object
potenti
resist
develop
streptococcu
pneumonia
sp
secondari
vari
exposur
gatifloxacin
gemifloxacin
levofloxacin
moxifloxacin
examin
high
inoculum
log
cfuml
hour
vitro
pharmacodynam
model
result
molecular
analysi
one
hundr
forti
serotyp
dspn
isol
reveal
six
clonal
type
howev
vast
major
belong
singl
clone
preval
domin
clone
studi
rang
dissemin
daycar
centr
conclus
serotyp
capsular
type
import
represent
drugresist
collect
commonli
studi
worldwid
howev
seem
common
among
dspn
strain
serotyp
collect
show
littl
genet
variabl
fact
one
genotyp
found
domin
dissemin
success
daycar
centr
studi
find
suggest
serotyp
clone
frequent
colon
thu
monitor
import
particularli
introduct
sevenval
pneumococc
conjug
vaccin
diseas
abrupt
antimicrobi
resist
increas
clonal
spread
resist
pneumococc
strain
result
seriou
therapeut
problem
recent
year
aim
studi
analyz
resist
pattern
genet
divers
pneumonia
resist
strain
isol
region
three
year
method
use
etest
method
nccl
criteria
benzylpenicillin
p
erythromycin
e
clindamycin
l
tetracyclin
cotrimoxazol
ceftriaxon
c
chloramphenicol
h
vankomycin
w
imipenem
fifti
nine
resist
intermedi
least
one
drug
strain
obtain
strain
submit
molecular
characterist
pfge
smai
restrict
enzym
comput
analysi
use
molecular
analyst
softwar
applic
strain
resist
pattern
pfge
profil
determin
result
resist
determin
antibiot
except
vancomycin
describ
strain
show
differ
resist
pattern
tsh
strain
psi
elt
often
resist
degre
reach
drug
strain
strain
mdr
found
pfge
profil
u
uniqu
singl
isol
cluster
ak
repres
strain
similar
numer
cluster
ak
consist
strain
isol
three
year
studi
show
similar
resist
pattern
atsh
strain
th
bpsi
cpelshi
ptshi
ptschi
delt
el
esh
ts
strain
tsh
psi
resist
pattern
found
one
cluster
respect
strain
elt
pelshi
pattern
belong
differ
cluster
uniqu
pfge
profil
anoth
cluster
fk
repres
two
strain
differ
resist
pattern
conclus
popul
pneumonia
resist
strain
region
present
high
genet
divers
numer
differ
resist
pattern
major
strain
resist
pattern
show
differ
pfge
profil
observ
strain
resist
pattern
belong
one
cluster
isol
three
year
studi
hlpr
strain
show
profil
ident
relat
two
epidem
clone
remain
hlpr
pneumococci
belong
uniqu
rare
clone
llpr
isol
characteris
variabl
background
term
pfge
pattern
serotyp
hlpr
strain
fact
show
ident
relat
profil
arbitrarili
call
serotyp
previous
describ
itali
exhibit
pfge
pattern
typic
relat
clone
remain
llpr
isol
belong
differ
profil
distinct
serotyp
studi
circul
found
conclus
recent
increas
total
penicillinresist
itali
ascrib
emerg
new
clone
diffus
two
well
known
intern
clone
whose
abil
spread
higher
autochthon
italian
clone
describ
chang
antibiot
prescrib
habit
includ
recent
strict
limit
consumpt
parenter
drug
may
also
explain
variat
describ
result
studi
period
strain
pneumonia
isol
csf
blood
total
incid
inhabitantsyear
maximum
incid
winter
spring
largest
number
case
children
detect
total
number
strain
whose
sensit
penicillin
fell
mic
mgml
penicillinresist
strain
also
resist
erythromycin
reduc
sensit
cefotaxim
intermedi
sensit
resist
erythromycin
detect
studi
period
resist
antibiot
decreas
gradual
way
resist
percentag
year
penicillin
cefotaxim
erythromycin
differ
observ
resist
percentag
differ
age
group
conclus
preval
csf
blood
strain
pneumonia
reduc
sensit
penicillin
studi
treatment
choic
pneumonia
invas
diseas
thirdgener
cephalosporin
due
low
level
resist
resist
main
antimicrobi
type
strain
fallen
studi
period
resist
penicillin
fell
cefotaxim
erythromycin
fall
resist
among
invas
pneumonia
could
due
vaccin
children
elderli
onward
sinc
vaccin
includ
common
resist
serotyp
low
number
isol
children
could
due
low
number
sampl
process
chang
distribut
macrolideresist
streptococcu
pneumonia
genotyp
year
data
protekt
object
analysi
data
countri
first
year
protekt
global
surveil
studi
undertaken
investig
longitudin
region
trend
distribut
macrolid
resist
mechan
among
streptococcu
pneumonia
suscept
isol
antibacteri
includ
ketolid
telithromycin
object
formul
pneumococc
conjug
vaccin
introduc
usa
februari
gener
recommend
use
children
year
age
vaccin
licens
children
year
age
europ
vaccin
licens
children
year
age
countri
gener
recommend
use
protekt
global
longitudin
studi
antimicrobi
suscept
bacteri
respiratori
tract
pathogen
complet
fourth
year
comparison
made
serotyp
distribut
coverag
method
analysi
perform
streptococcu
pneumonia
isol
obtain
paediatr
patient
centr
common
year
n
n
serotyp
perform
neufeld
quellung
reaction
use
staten
serum
institut
antisera
ssi
denmark
result
coverag
decreas
usa
latin
america
respect
chisquar
p
respect
serotyp
show
greatest
increas
usa
brazil
similar
pattern
seen
although
chang
proport
isol
serotyp
contrast
chang
serotyp
distribut
observ
canada
western
europ
far
east
vaccin
routin
use
paediatr
vaccin
conclus
result
analysi
protekt
data
indic
proport
pneumonia
isol
paediatr
patient
cover
vaccin
decreas
significantli
year
region
vaccin
routin
use
serotyp
known
highli
resist
antimicrobi
cover
increas
region
studi
demonstr
import
serotyp
antimicrobi
surveil
studi
isol
order
monitor
chang
potenti
futur
implic
therapi
vaccin
formul
background
sequenti
alter
pbp
sequenc
constitut
classic
mechan
acquir
penicillin
resist
pneumonia
reflect
chang
cell
wall
peptidoglycan
structur
murm
gene
control
addit
first
amino
acid
dipeptid
bridg
pneumococc
muropeptid
mutat
gene
appar
requir
high
penicillin
cefotaxim
resist
aim
studi
compar
murm
gene
sequenc
within
earlier
latest
highli
penicillin
resist
pneumococc
popul
recov
spain
materi
method
total
pneumonia
isol
resist
penicillin
mic
lgml
includ
suscept
differ
blactam
macrolid
tetracyclin
levofloxacin
chloramphenicol
trimethoprimsulfamethoxazol
sxt
determin
agar
dilut
method
isol
group
accord
serotyp
pulsotyp
pfgesmai
pattern
murm
gene
sequenc
result
high
percentag
resist
intermedi
plu
resist
observ
cefotaxim
sxt
isol
remain
suscept
telithromycin
levofloxacin
suscept
isol
recov
genet
unrel
mainli
belong
serotyp
contrast
frequent
serotyp
period
predomin
detect
isol
serotyp
isol
serotyp
capsular
switch
isol
serotyp
belong
singl
clone
analysi
murm
sequenc
isol
period
reveal
exist
differ
allel
homolog
sequenc
murma
ident
describ
penicillin
suscept
strain
replac
part
differ
variant
allel
detect
collect
conclus
earli
high
penicillin
resist
pneumonia
isol
spain
genet
unrel
correspond
serotyp
contrari
recent
isol
show
dissemin
select
clone
particularli
mani
pneumonia
isol
highlevel
resist
penicillin
retain
reacquir
murm
gene
suscept
strain
differ
allel
variant
also
detect
object
determin
among
pneumonia
clinic
isol
recov
differ
spanish
hospit
three
differ
period
preval
erythromycin
resist
phenotyp
resist
gene
associ
resist
method
suscept
test
perform
standard
microdilut
techniqu
nccl
pcr
assay
carri
identifi
erythromycin
resist
gene
erm
mef
multiplexpcr
design
distinguish
mef
mef
e
gene
within
mef
posit
isol
clonal
studi
use
smaipfg
techniqu
studi
period
rang
first
studi
period
third
studi
period
penicillin
first
studi
period
third
studi
period
erythromycin
first
studi
period
third
studi
period
clindamycin
levofloxacin
resist
found
isol
recov
third
studi
period
phenotyp
observ
test
isol
consid
nonsuscept
erythromycin
isol
ermb
mef
gene
found
isol
respect
sole
erythromycin
resist
gene
concomit
presenc
determin
found
isol
interestingli
among
isol
mef
pcr
posit
result
one
carri
mef
gene
wherea
mef
e
gene
detect
other
increas
mef
preval
observ
first
second
studi
period
slightli
decreas
third
period
pfge
analysi
reveal
polyclon
structur
mef
posit
isol
conclus
preval
mef
posit
isol
among
erythromycinresist
strain
remain
low
countri
mef
e
gene
preval
mef
determin
among
isol
result
among
young
children
singl
eri
resist
promin
countri
sweden
belgium
except
spain
proport
dual
resist
highest
countri
dual
resist
among
young
children
rang
denmark
belgium
except
ireland
spain
singl
pen
resist
remain
conclus
countri
larg
differ
pattern
pneumonia
resist
found
among
young
children
eri
resist
common
among
young
children
may
indic
greater
use
macrolid
age
group
order
assess
effect
intervent
like
vaccin
resist
serotyp
data
monitor
care
evolut
pattern
sensit
penicillin
cefotaxim
streptococcu
pneumonia
background
increas
resist
penicillin
recent
cefotaxim
mean
necessari
studi
preval
resist
antibiot
give
huge
clinic
import
studi
compar
sensit
pneumonia
penicillin
cefotaxim
method
total
strain
spneumonia
signific
respiratori
tract
isol
studi
correspond
year
conclus
isol
erythromycinresist
clindamycinand
miocamycin
suscept
phenotyp
smaller
percentag
previou
studi
signific
increas
isol
mlsb
constitut
phenotyp
high
preval
resist
telithromycin
strain
mlsb
constitut
phenotyp
pattern
macrolid
resist
determin
among
pyogen
pneumonia
isol
saudi
arabia
object
character
macrolid
sensit
recent
isol
pyogen
pneumonia
collect
differ
hospit
around
saudi
arabia
investig
resist
determin
carri
macrolideresist
isol
method
suscept
test
perform
use
standard
nccl
methodolog
pyogen
pneumonia
isol
macrolid
resist
mechan
phenotyp
identifi
use
doubl
disk
diffus
result
pyogen
penicillin
sensit
macrolid
resist
main
mechan
mphenotyp
approxim
pneumonia
penicillin
nonsuscept
macrolid
resist
pneumonia
account
major
phenotyp
lowlevel
resist
mediat
mefbear
strain
predomin
conclus
effort
focu
antibiot
resist
surveil
develop
guidelin
also
appropri
use
antibiot
strategi
propos
includ
restrict
access
complianc
promot
reduct
prescript
inappropri
use
antibiot
newer
macrolid
includ
azithromycin
still
consid
drug
choic
empir
treatment
respiratori
infect
circumst
object
mlsb
phenotyp
erythromycin
resist
eryr
often
associ
tetracyclin
resist
tetr
streptococci
mediat
methylas
gene
erm
b
erm
tr
streptococcu
pneumonia
erm
b
carri
transposon
also
carri
tetr
gene
tet
phenotyp
eryr
associ
efflux
gene
mef
mef
e
gene
carri
genet
element
commonli
includ
tetr
gene
mef
e
element
pneumonia
insert
transposon
carri
tet
object
investig
tetr
eryr
betahaemolyt
streptococci
group
b
c
g
method
eryr
betahaemolyt
streptococci
group
b
c
g
collect
two
year
tetr
determin
disc
diffus
mic
etest
pcr
perform
tet
tet
tet
l
eryr
gene
characteris
previous
result
preval
tetr
amongst
eryr
mlsb
isol
high
group
b
c
lower
group
g
rang
mic
tetr
isol
mgl
tet
gene
respons
tetr
group
b
c
g
tet
l
tet
found
isol
group
b
g
least
erm
b
isol
erm
tr
isol
group
b
c
carri
tet
contrast
erm
tr
isol
group
g
carri
tet
amongst
phenotyp
isol
preval
tetr
high
group
b
g
lower
group
c
tetr
detect
phenotyp
group
phenotyp
tet
respons
tetr
group
b
group
g
isol
group
c
carri
tet
tet
tet
found
mef
e
isol
mef
isol
tetr
isol
group
b
g
tetr
gene
identifi
conclus
preval
tetr
eryr
betahaemolyt
streptococci
high
mlsb
isol
group
b
c
isol
group
b
g
tet
predomin
tetr
gene
tet
strongli
associ
erm
b
lesser
extent
erm
tr
tet
found
associ
mef
e
mef
result
reduc
suscept
mic
mgl
detect
pyogen
isol
total
pyogen
isol
demonstr
mlsb
phenotyp
resist
domin
gene
erm
n
encod
resist
strain
wherea
erm
b
detect
five
strain
isol
one
cmlsb
strain
carri
erm
mef
gene
anoth
cmlsb
strain
reproduc
neg
erm
mef
pcr
analys
investig
remain
isol
carri
mef
gene
show
consist
phenotyp
resist
thirti
strain
resist
tetracyclin
carri
ermposit
strain
n
gene
mtype
strain
suscept
tetracyclin
type
analys
reveal
ttype
domin
nine
mtype
phenotyp
wherea
ttype
associ
erm
posit
tetracyclin
resist
strain
result
emm
type
support
clonal
observ
conclus
preval
macrolid
resist
among
pyogen
norway
low
ii
mlsb
resist
erm
erm
b
preval
resist
type
coresist
tetracyclin
frequent
observ
rate
resist
macrolid
vari
region
region
rate
import
defin
role
macrolid
empir
therapi
macrolid
lincosamid
resist
mediat
distinct
mechan
mefa
encod
resist
erythromycin
clindamycin
ermb
encod
resist
erythromycin
clindamycin
erma
encod
resist
erythromycin
induc
resist
clindamycin
method
consecut
pharyng
isol
streptococcu
pyogen
isol
collect
januari
april
isol
confirm
pyogen
lancefield
group
use
pastorex
strep
rapid
agglutin
kit
erythromycin
suscept
test
perform
nccl
disc
diffus
erythromycin
resist
isol
test
suscept
erythromycin
azithromycin
etest
mechan
resist
assess
use
erythromycin
clindamycin
disc
approxim
test
pcr
primer
specif
erma
ermb
mefa
gene
posit
control
kindli
provid
ralf
r
reinert
result
four
consecut
isol
resist
erythromycin
erythromycin
resist
confirm
etest
isol
also
resist
azithromycin
erythromycinresist
studi
isol
previous
collect
erythromycinresist
isol
confirm
erma
posit
pcr
exhibit
induc
resist
disc
approxim
one
previous
collect
isol
suscept
clindamycin
mefa
posit
pcr
conclus
data
show
macrolid
resist
pyogen
uncommon
area
encod
primarili
erma
object
aim
studi
evalu
antimicrobi
prophylaxi
ap
practic
cost
intens
care
unit
heart
surgeri
depert
hospit
method
studi
perform
prospect
januarydecemb
ap
last
day
consid
inappropri
unless
patient
high
risk
group
heart
transplant
repeat
bypass
addit
ap
two
beta
lactam
agent
beta
lactamaminoglycosid
beta
lactamgentamicin
allow
gener
cephalosporin
quinolon
glycopeptid
consid
inappropri
high
risk
patient
ap
last
day
ap
glycopeptid
consid
appropri
cost
inappropri
ap
calcul
use
price
euro
cost
inappropri
ap
patient
receiv
cefazolin
beta
lactambeta
lactamas
inhibitor
ampicillinsulbactam
amoxycillinclavulan
calcul
substract
cost
day
last
ap
total
ap
cost
case
inappropri
glycopeptid
quinolon
aminoglycosid
usag
one
day
last
cefazolin
cost
substract
total
ap
cost
high
risk
patient
cost
inappropri
glycopeptid
usag
calcul
substract
day
last
ap
cost
total
cost
infect
diagnos
accord
criteria
center
diseas
control
prevent
cdc
data
analys
chi
squar
student
ttest
object
aim
present
studi
investig
frequenc
type
wound
infect
well
bacteria
involv
posterior
spinal
fusion
children
especi
spinal
deform
period
materi
method
total
spinal
fusion
perform
children
without
instrument
spinal
scoliosi
spondylolisthesi
fractur
reason
object
therapi
chronic
wound
lucilia
sericata
present
promis
altern
classic
approach
antibiot
larva
place
wound
freeroam
biobag
therapi
often
stimul
process
wound
heal
effect
base
differ
mechan
saliva
contain
collagenas
trypsin
chymotrypsinlik
enzym
dilut
necrot
tissu
furthermor
antibacteri
effect
describ
studi
focus
question
whether
effect
could
explain
ingest
bacteria
larva
method
free
roam
maggot
place
agar
plate
escherichia
coli
bacteria
transform
green
fluoresc
protein
gfp
contain
plasmid
gfpfree
escherichia
coli
blue
serv
control
two
day
old
maggot
put
agar
plate
group
ten
room
temperatur
everi
thirti
second
maggot
displac
agar
plate
wash
steril
salin
dead
larva
could
taken
bacteria
serv
control
maggot
test
flouresc
fluoresc
microscop
zeiss
axioskop
axiocam
mrmzeiss
larva
examin
independ
observ
well
result
maggot
place
gfplabel
escherichia
coli
show
intens
green
fluoresc
especi
back
head
intestin
control
show
fluoresc
three
four
minut
gfplabel
escherichia
coli
could
detect
insid
maggot
bodi
earli
stage
digest
gfpfluoresc
could
mainli
examin
area
head
fluoresc
result
ingest
gfplabel
escherichia
coli
larva
proven
uptak
bacteria
repres
mechan
antibacteri
activ
larva
dilut
necrot
tissu
also
minim
rate
infect
maggot
therapi
also
wellknown
biosurgeri
could
benefici
altern
use
antibiot
mechan
uptak
nonspecif
process
might
risk
resist
antibiot
resist
nosocomi
pathogen
antimicrobi
resist
pattern
bacteri
pathogen
blood
cultur
cancer
patient
singl
cancer
institut
faiz
h
aziz
bashir
asghar
lahor
pak
object
widespread
emerg
resist
antimicrobi
agent
among
bacteri
pathogen
well
known
impact
abil
treat
patient
effect
blood
stream
infect
bacteraemia
among
cancer
patient
develop
cours
diseas
potenti
life
threaten
suppress
immun
system
chang
spectrum
incid
epidemiolog
microbi
pathogen
result
increas
resist
mani
antibiot
compound
emphas
need
monitor
preval
resist
strain
method
suscept
resist
pattern
clinic
signific
bacteri
isol
posit
blood
cultur
collect
studi
isol
strain
test
wide
rang
antibiot
belong
cephalosporin
aminoglycosid
carbapenem
quinolon
deriv
group
disc
diffus
method
result
interpret
accord
british
standard
antimicrobi
chemotherapi
result
total
bacteri
pathogen
isol
gram
posit
gram
neg
bacteria
domin
pathogen
staphylococcu
aureu
streptococci
pseudomona
enterobact
klebsiella
among
gram
neg
strain
highest
level
resist
third
gener
cephalosporin
observ
follow
carbapenem
penicillin
respect
similarli
high
resist
aminoglycosid
found
ampicillin
tobramycin
resist
quinolon
deriv
group
antibiot
howev
resist
ciprofloxacin
gram
posit
bacteria
high
resist
ciprofloxacin
observ
compar
gram
neg
bacteria
still
higher
resist
level
observ
aminoglycosid
third
gener
cephalosporin
respect
conclus
spectrum
isol
among
patient
shift
toward
gram
posit
bacteria
high
resist
differ
group
antimicrobi
agent
limit
choic
altern
therapi
infect
control
antimicrobi
resist
continu
increas
ongo
surveil
microbi
pathogen
essenti
studi
also
warrant
need
infect
control
measur
ration
antibiot
polici
rapid
laboratori
detect
resist
prevent
spread
resist
among
strain
epidemiolog
swab
throat
rectum
found
two
suscept
group
group
patient
resist
amox
clavulacid
piptazobactam
aztreonam
cefuroxim
group
patient
suscept
antibiot
rapd
profil
correspond
suscept
test
result
drug
resist
profil
group
could
attribut
overproduct
chromosom
encod
betalactamas
group
ru
group
nicu
pu
su
analysi
sociodemograph
variabl
potenti
risk
factor
show
differ
analys
group
mean
birth
weight
length
hospit
stay
antimicrobi
treatment
invas
therapeut
procedur
usag
outbreak
analysi
reveal
concurr
isol
two
k
oxytoca
clone
normal
overproduc
rapd
result
support
antibiotyp
result
result
total
isol
analys
isol
nonsuscept
least
one
agent
highest
proport
due
monodrug
resist
piperacillin
strain
classifi
multiresist
frequent
pattern
pipcazctxgen
pipcazctxgencip
two
strain
resist
six
antibiot
signific
differ
multidrug
resist
rate
associ
ward
type
highest
rate
icupati
furthermor
multiresist
rate
vari
significantli
centr
involv
rang
centr
differ
respect
multidrug
resist
rate
also
respect
domin
phenotyp
conclus
relev
multiresist
k
pneumonia
major
clinic
problem
prove
overal
rate
almost
five
per
cent
german
univers
hospit
even
higher
proport
icupati
among
agent
test
piperacillin
play
emin
role
regard
monoresist
rate
well
compon
frequent
resist
pattern
resist
combin
pip
tazobactam
howev
rare
develop
antimicrobi
resist
german
hospit
object
quinolon
q
among
frequent
use
agent
treat
ltcfacquir
infect
consequ
bacteria
exhibit
increas
resist
q
multicentr
survey
conduct
order
determin
preval
risk
factor
colon
qrgn
greek
ltcf
ii
correspond
antimicrobi
resist
rate
r
method
total
ltcf
randomli
select
public
sanit
list
attica
provinc
urin
nasopharyng
wound
sampl
collect
elderli
resid
chose
randomli
exist
popul
ltcf
minimum
sum
resid
age
year
gram
neg
bacteria
identifi
api
strip
underw
antimicrobi
disk
suscept
test
follow
nccl
guidelin
data
also
collect
resid
factor
institut
variabl
univari
multivari
analys
perform
odd
ratio
p
valu
calcul
result
gram
neg
gn
strain
isol
sampl
preval
rate
major
recov
urin
sampl
resid
take
system
antibiot
preced
month
q
lead
class
r
gn
ciprofloxacin
cip
estim
tabl
multidrug
qrgn
account
isol
strain
preval
phenotyp
resist
ampicillin
cip
trimethoprimsulfamethoxazol
multivari
analysi
prior
exposur
antimicrobi
agent
p
specif
q
p
presenc
urinari
cathet
p
significantli
associ
colon
qrgn
object
colon
resist
dynam
gramneg
bacteria
intestin
oropharyng
microflora
patient
admit
intens
care
unit
icu
gener
ward
gw
investig
hospit
method
specimen
obtain
admiss
weekli
hospit
discharg
icu
discharg
hospit
one
three
month
discharg
hospit
five
coloni
per
specimen
select
identif
suscept
test
vitek
system
result
total
specimen
patient
collect
patient
popul
gramneg
colon
rate
oropharyng
specimen
increas
hospit
decreas
three
month
discharg
rectal
specimen
colon
rate
decreas
hospit
increas
discharg
chang
speci
distribut
among
domin
microflora
hospit
klebsiella
spp
enterobact
spp
serratia
marcescen
pseudomona
aeruginosa
often
isol
wherea
frequenc
e
coli
declin
percentag
icu
patient
colon
ampicillin
andor
cephalothin
resist
faecal
e
coli
significantli
increas
discharg
hospit
chang
three
month
discharg
emerg
multidrug
resist
observ
mani
gramneg
speci
stay
icu
resist
frequenc
e
coli
significantli
increas
length
stay
icu
gw
popul
signific
chang
resist
frequenc
found
hospit
conclus
popul
perspect
risk
dissemin
resist
gramneg
bacteria
commun
hospit
patient
appear
low
gw
patient
notic
higher
among
icu
patient
associ
antibiot
resist
phenotyp
presenc
class
integron
sampl
bacteri
isol
us
hospit
object
assess
associ
class
integron
pattern
resist
aminoglycosid
betalactam
quinolon
chloramphenicol
escherichia
coli
klebsiella
speci
isol
us
hospit
particip
project
icar
method
conveni
sampl
e
coli
klebsiella
speci
isol
collect
octob
decemb
us
hospit
part
phase
iv
project
icar
test
suscept
varieti
antimicrobi
agent
organ
submit
respons
request
organ
resist
gener
cephalosporin
ceftazidim
ceftriaxon
cefotaxim
andor
fluoroquinolon
isol
screen
presenc
class
integron
use
set
primer
specif
conserv
segment
integras
gene
obtain
measur
associ
presenc
absenc
integron
resist
phenotyp
result
e
coli
klebsiella
speci
isol
screen
contain
class
integron
signific
associ
seen
presenc
class
integron
resist
amikacin
gentamycin
tobramycin
ampillicin
chloramphenicol
aztreonam
ceftazidim
cefotaxim
cefpodoxim
resist
ciprofloxacin
cefepim
significantli
associ
presenc
integron
presenc
class
integron
conveni
sampl
e
coli
klebsiella
speci
isol
along
differenti
associ
integron
resist
drug
other
suggest
integron
may
play
import
role
determin
epidemiolog
bacteri
resist
result
antimicrobi
agent
select
pressur
object
main
purpos
studi
investig
mechan
resist
fluoroquinolon
two
isogen
citrobact
freundii
clinic
isol
led
us
character
acra
acrb
gene
microorgan
method
two
c
freundii
strain
sequenti
isol
patient
character
relationship
determin
reppcr
pfge
suscept
ciprofloxacin
chloramphenicol
determin
etest
mutat
quinolon
resist
determin
region
gyra
parc
gene
outer
membran
protein
profil
accumul
ciprofloxacin
also
investig
express
gene
strain
analys
use
dna
microarray
e
coli
express
acra
acrb
gene
verifi
rtpcr
use
gapa
gene
control
acra
gene
clone
dna
sequenc
result
c
freundii
belong
clone
reppcr
pfge
mic
ciprofloxacin
strain
mgl
strain
mic
chloramphenicol
mgl
respect
two
strain
show
substitut
gyra
parc
gyra
parc
major
differ
found
outer
membran
protein
profil
howev
differ
observ
amount
ciprofloxacin
accumul
strain
show
less
accumul
eleven
gene
overexpress
strain
compar
strain
among
gene
acra
overexpress
result
corrobor
rtpcr
nucleotid
similar
partial
sequenc
acra
bp
acrb
bp
gene
c
freundii
e
coli
respect
conclus
acra
acrb
gene
c
freundii
similar
describ
e
coli
collabor
mutat
gyra
parc
gene
overexpress
may
play
import
role
modul
final
mic
fluoroquinolon
high
preval
aac
object
multidrug
resist
gram
neg
bacilli
gnb
becom
major
public
health
problem
tunisia
surveil
antimicrobi
resist
antimicrobi
consumpt
recognis
essenti
plan
futur
strategi
control
resist
aim
studi
examin
whole
hospit
ward
risk
correl
resist
gnb
consumpt
third
gener
cephalosporin
gc
imipenem
period
januari
septemb
method
surveil
antibiot
resist
antibiot
consumpt
establish
respect
laboratori
depart
pharmaci
data
antimicrobi
resist
antibiot
consumpt
collect
quarterli
antibiot
consumpt
calcul
defin
daili
dose
ddd
use
abc
calc
result
express
per
bedday
bd
statist
analysi
done
use
spss
softwar
calcul
spearman
rank
correl
rs
alpha
risk
result
whole
hospit
resist
gc
rang
bd
highest
rate
observ
intens
care
unit
icu
bd
lowest
rate
orthopaed
ward
bd
mrsa
isol
resist
multipl
class
antimicrobi
wherea
mssa
sensit
p
esbl
bacteria
resist
multipl
class
sensit
meropenem
colistin
amikacin
cotrimoxazol
chloramphenicol
resist
nonesbl
bacteria
detect
ampicillin
cefalexin
gener
cephalosporin
chloramphenicol
cotrimoxazol
ciprofloxacin
trimethoprim
gentamicin
netilmicin
tobramycin
potenti
commun
acquir
isol
show
lower
rate
resist
trimethoprim
ciprofloxacin
gentamicin
amikacin
tobramycin
gener
cephalosporin
durat
hospit
stay
risk
acquir
either
esbl
bacteria
mrsa
wherea
surgeri
associ
exposur
quinolon
risk
factor
mrsa
esbl
bacteria
aminoglycosid
cephalosporin
risk
esbl
bacteria
acquir
mrsa
esbl
enterobacteriaca
togeth
correl
durat
hospit
stay
addit
exposur
aminoglycosid
cephalosporin
conclus
major
patient
remain
free
resist
bacteria
impli
crosstransmiss
alon
suffici
absenc
risk
factor
particularli
exposur
antimicrobi
good
handhygien
prudent
use
antimicrobi
realist
option
resourc
poor
countri
reduc
burden
resist
bacteria
uniqu
opportun
sequenti
introduc
specif
infect
control
measur
evalu
effect
antimicrobi
resist
intens
care
unit
adopt
antibiot
rotat
programm
empir
therapi
ventilatorassoci
pneumonia
result
among
gramneg
aerob
bacilli
found
p
aeruginosa
strain
meropenem
piperacillintazobactamresist
case
respect
p
aeruginosa
e
coli
k
pneumonia
resist
ceftazidim
case
respect
resist
ciprofloxacin
case
respect
neither
e
coli
k
pneumonia
resist
either
meropenem
piperacillintazobactam
among
gramposit
aerob
cocci
oxacillinresist
aureu
cn
respect
aureu
isol
suscept
cotrimoxazol
resist
rifampin
wherea
resist
exceed
clindamycin
gentamicin
norfloxacin
ampicillinand
penicillinresist
e
faecali
respect
neither
aureu
e
faecali
resist
vancomycin
wherea
one
cn
strain
resist
teicoplanin
conclus
icu
care
polici
antibiot
use
predetermin
restrict
appli
year
ar
among
gramneg
gramposit
microorgan
gener
lower
icu
itali
mediterranean
countri
expect
institut
arp
empir
therapi
vap
minim
ar
icu
background
although
newer
antibiot
introduc
market
last
year
solv
problem
aris
manag
infect
due
multiresist
gramneg
bacteria
colistin
antibiot
almost
forgotten
decad
prove
help
use
parenter
patient
lot
classic
newer
antibiot
fail
method
report
experi
manag
case
young
patient
head
trauma
five
episod
mening
due
multidrugresist
gramneg
microorgan
result
patient
admit
hospit
coma
three
month
prior
admiss
sustain
acut
brain
injuri
due
fall
hospit
elsewher
entir
period
computer
tomographi
scan
brain
admiss
first
hospit
show
multipl
cerebr
contus
intracerebr
hematoma
caus
deviat
midlin
underw
decompress
craniotomi
remov
hematoma
longstand
hospit
develop
episod
mening
ie
day
head
trauma
pathogen
isol
episod
mening
multiresist
strain
pseudomona
aeruginosa
episod
acinetobact
baumannii
episod
enterobact
cloaca
episod
acinetobact
baumannii
episod
two
episod
acinetobact
baumannii
mening
manag
colistin
amikacin
given
intraventricular
addit
intraven
rout
long
period
time
six
week
last
episod
high
dose
iu
colistin
mg
amikacin
result
eight
patient
receiv
aerosol
colistin
admit
icu
mean
acut
physiolog
chronic
health
evalu
ii
apach
ii
score
day
icu
admiss
day
aerosol
colistin
administr
respect
six
patient
ventilatorassoci
pneumonia
respons
pathogen
acinetobact
baumannii
case
pseudomona
aeruginosa
case
strain
half
isol
pathogen
sensit
colistin
daili
dosag
aerosol
colistin
rang
million
iu
divid
dose
mean
durat
administr
day
seven
patient
receiv
concomit
intraven
treatment
colistin
antimicrobi
agent
clinic
respons
pneumonia
observ
patient
cure
improv
transfer
anoth
facil
one
patient
deterior
die
due
septic
shock
multipl
organ
failur
aerosol
colistin
well
toler
patient
bronchoconstrict
chest
tight
report
conclus
aerosol
colistin
may
benefici
adjunct
treatment
manag
nosocomi
pneumonia
vap
due
multidrugresist
gramneg
bacteria
date
suscept
rate
imipenem
colistin
nosocomi
strain
report
high
respect
particular
resist
colistin
rare
describ
mechan
resist
poorli
understood
report
case
colistin
resist
baumannii
infect
patient
without
previou
administr
colistin
case
report
method
colistin
resist
mic
mcgml
baumannii
isol
set
blood
cultur
patient
admit
burn
unit
without
previou
colistin
exposur
patient
treat
ampicillinsulbactam
colistin
despit
document
resist
antibiot
mdr
baumannii
repeatedli
isol
differ
site
patient
die
day
hospit
strain
identif
suscept
test
perform
use
phoenix
autom
microbiolog
system
resist
ampicillin
ampicillinsulbactam
ceftazidim
imipenem
meropenem
cotrimoxazol
amikacin
ciprofloxacin
colistin
confirm
disk
diffus
test
broth
microdilut
accord
nccl
guidelin
suscept
result
confirm
refer
laboratori
conclus
colistin
one
effect
drug
avail
mdr
acinetobact
infect
acquir
resist
except
report
point
colistin
resist
baumannii
may
found
hospit
patient
without
previou
exposur
colistin
nosocomi
infect
colistinresist
baumannii
could
repres
new
therapeut
challeng
programm
activ
surveil
cultur
contact
precaut
implement
control
spread
mdr
microorgan
intrathec
colistin
treatment
central
nervou
system
infect
due
multiresist
acinetobact
baumannii
c
p
f
tubau
l
corral
mateu
j
ariza
barcelona
e
object
optim
therapi
cn
infect
due
multiresist
acinetobact
baumannii
mrab
establish
publish
first
two
case
ventricul
due
mrab
treat
intrathec
colistin
one
patient
receiv
mg
colistin
hour
delay
csf
steril
document
initi
dosag
hour
describ
extend
experi
kind
treatment
method
retrospect
review
document
cn
infect
due
mrab
diagnos
terciari
hospit
mrab
defin
strain
suscept
colistin
mic
mgl
cn
infect
defin
case
suggest
clinic
featur
plu
ventricular
lumbar
csf
characterist
cytochem
alter
posit
cultur
result
case
document
nosocomi
cn
infect
due
mrab
six
acquir
neurosurg
procedur
surgic
wound
infect
local
cathet
infect
one
case
caus
hematogen
spread
urolog
manipul
intrathec
therapi
administ
ventricular
cathet
five
case
lumbar
cathet
one
case
ventricular
lumbar
cathet
one
case
usual
dose
administ
colistin
base
mg
equival
colistimeth
sodium
mg
everi
hour
csf
continu
drainag
interrupt
hour
length
treatment
day
appar
advers
effect
six
patient
receiv
simultan
intraven
colistin
therapi
cultur
steril
document
patient
two
patient
die
one
unclear
caus
initi
favor
evolut
one
receiv
two
dose
colistin
rest
cure
sequela
attribut
previou
neurolog
diseas
conclus
experi
combin
treatment
intrathec
intraven
colimicin
seem
safe
effect
administ
local
rout
patient
continu
csf
drainag
suggest
dosag
colistin
base
mg
everi
hour
temporari
interrupt
drainag
bacillu
cereu
forgotten
pathogen
unusu
infect
orthopaed
patient
thoma
pillai
j
arora
ac
ogden
dumfri
uk
background
infect
bacillu
cereu
well
document
literatur
centuri
infect
gener
associ
gastrointestin
effect
food
poison
link
consumpt
infect
rice
dish
howev
bacillu
genu
extrem
heterogen
occupi
wide
varieti
ecolog
nich
bacillu
spore
found
ubiquit
environ
even
bacillu
cereu
isol
hospit
clinic
set
materi
vomitu
faec
commonli
dismiss
sinc
known
contamin
blood
cultur
bacillu
bactereamia
transient
usual
insignific
case
report
report
case
bacillu
cereu
wound
infect
previous
healthi
male
admit
orthopaed
ward
comminut
fractur
right
distal
tibia
develop
compart
syndrom
one
day
later
taken
theatr
fasciotomi
within
hour
develop
chest
complic
admit
high
depend
unit
three
day
taken
back
theatr
wound
inspect
chang
dress
seven
day
later
extern
fixat
appli
subsequ
wound
site
becam
red
inflam
tender
associ
acut
rise
inflammatori
marker
microbiolog
report
show
bacillu
cereu
growth
sutur
site
sensit
ciprofloxacin
sourc
identifi
discuss
report
merit
concern
highlight
risk
wound
cross
infect
unlik
pathogen
speci
bacillu
cereu
known
contamin
dress
intraven
cathet
theatr
scrub
suit
linen
point
array
possibl
infect
sourc
within
hospit
emphas
need
theatr
hospit
steril
stress
import
vigil
infrequ
caus
potenti
seriou
nongastrointestin
bacillu
infect
particular
import
alcoholbas
clean
solut
known
ineffect
bacillu
spore
infect
dismiss
contamin
may
lead
rapid
clinic
deterior
antibacteri
effect
phenytoin
wound
heal
object
phenytoin
antiseizur
medic
sinc
report
promot
wound
heal
appli
topic
agent
effect
due
rapid
infiltr
fibroblast
collagen
deposit
new
vessel
format
well
antibacteri
activ
studi
undertaken
evalu
effect
chronic
skin
ulcer
differ
caus
compar
normal
salin
method
fifti
inpati
chronic
skin
ulcer
includ
casecontrol
studi
diabet
foot
fractur
surgeri
wound
decubitu
ulcer
result
warrel
patient
match
age
sex
sever
size
wound
randomli
assign
two
group
phenytoin
treat
pht
control
ctl
group
includ
men
women
age
rang
surfac
area
ulcer
cm
ulcer
debrad
necrot
tissu
requir
cultur
ulcer
taken
begin
treatment
day
pht
thin
dust
phenytoin
powder
dri
gauz
dress
appli
daili
wash
normal
salin
ctl
group
receiv
daili
wash
normal
salin
plain
dress
result
bacteriolog
cultur
group
confirm
strain
staphylococcu
aureu
kelebsiella
proteu
psudomona
begin
treatment
cultur
posit
pht
case
becam
neg
day
case
becam
neg
day
ctl
cultur
posit
nt
becom
neg
day
seventysix
per
cent
pht
neg
cultur
day
compar
ctl
mean
time
appear
granul
tissu
day
pht
compar
ctl
p
averag
time
complet
heal
pht
day
compar
ctl
p
pht
patient
requir
analges
mean
compar
ctl
patient
requir
analges
p
age
sex
kind
wound
nt
effect
heal
time
group
conclus
studi
statist
analysi
demonstr
good
improv
efficaci
phenytoin
treatment
chronic
ulcer
compar
normal
salin
prompt
pain
relief
reduct
ulcer
size
chang
bacteri
cultur
neg
rapid
granul
heal
time
character
pht
group
recommend
wider
use
safe
inexpens
readili
avail
easi
use
agent
posit
effect
wound
heal
especi
countri
lot
patient
suffer
decubitu
ulcer
result
warrel
wound
limit
access
expens
wound
care
therapi
recurr
osteomyel
secondari
differ
bacteria
uckay
assal
l
legout
p
rohner
r
stern
lew
p
hoffmey
l
bernard
behalf
osteomyel
group
studi
object
recurr
osteomyel
due
bacteria
prior
site
infect
without
evid
trauma
bacteraemia
entiti
wellknown
literatur
clinic
practic
object
studi
tri
determin
reactiv
actual
due
bacteria
assum
previou
case
report
case
report
report
three
case
osteomyel
recur
bone
otherwis
healthi
patient
three
patient
histori
ill
trauma
assum
anoth
origin
surprisingli
strain
differ
two
infecti
episod
conclus
reactiv
osteomyel
caus
differ
strain
bacteria
mani
year
initi
episod
without
trauma
evid
bacteraemia
former
infect
therefor
alter
bone
surfac
might
region
diminish
resist
new
infect
silent
transient
bacteraemia
reminisc
clinic
entiti
recurr
infecti
endocard
alter
valv
surfac
object
vascular
graft
infect
prove
danger
complic
vascular
surgeri
patient
aim
studi
identif
microorgan
caus
vascular
graft
infect
evalu
antimicrobi
suscept
patient
infect
vascular
graft
treat
vascular
surgeri
depart
took
part
research
patient
late
type
infect
recogn
patient
infect
qualifi
earli
method
purul
discharg
obtain
fistula
inocul
bacteriolog
media
antimicrobi
suscept
assess
discdiffus
method
result
staphylococcu
aureu
pseudomona
aeruginosa
present
patient
prove
frequent
isol
microorgan
staphylococcu
epidermidi
e
coli
isol
patient
respect
mix
infect
caus
two
distinct
bacteria
occur
patient
case
one
speci
belong
gramposit
second
one
gramneg
bacteria
patient
earli
type
infect
differ
speci
gramneg
rod
present
patient
staph
aureu
staph
epidermidi
isol
enterococcu
faecali
occur
patient
late
type
infect
gramneg
rod
isol
patient
gramposit
bacteria
patient
frequent
isol
speci
appear
pseudomona
aeruginosa
one
patient
candida
crusei
isol
isol
speci
bacteria
vari
depend
degre
infect
accord
shilagi
samson
iiia
degre
infect
staph
epidermidi
e
coli
present
patient
respect
pseudomona
aeruginosa
staph
aureu
isol
patient
iiib
degre
infect
variou
speci
gramneg
rod
isol
patient
iiic
degre
graft
infect
conclus
isol
bacteria
appear
possess
resist
pattern
typic
hospit
flora
among
methicillinresist
staph
aureu
mrsa
methicillinresist
coagulaseneg
saphylococci
mrcn
strain
gramneg
rod
produc
extend
spectrum
betalactamas
esbl
ampc
betalactamas
enterococcu
faecali
high
level
aminoglicosid
resist
hlar
treatment
failur
due
emerg
resist
imipenem
therapi
shewanella
alga
bacteraemia
object
describ
case
bacteraemia
caus
alga
initi
suscept
imipenem
bacteria
later
becam
resist
treatment
addit
investig
propens
alga
develop
resist
imipenem
use
serial
passag
techniqu
method
vitro
test
resist
induct
bacteri
strain
resist
variant
select
singl
step
resist
variant
obtain
clinic
isol
muellerhinton
agar
contain
increas
amount
imipenem
b
serial
passag
experi
alga
strain
p
aeruginosa
atcc
grown
overnight
muellerhinton
agar
grown
overnight
muellerhinton
agar
swab
onto
muellerhinton
agar
plate
contain
onehalf
mic
imipenem
surfac
growth
h
swab
muellerhinton
agar
contain
twice
prior
concentr
imipenem
result
singl
step
resist
variant
select
isol
time
mic
wherea
resist
variant
p
aeruginosa
atcc
could
select
time
mic
resist
variant
alga
select
either
singl
step
sequenti
stepwis
passag
exhibit
lgml
mic
wherea
p
aeruginosa
atcc
show
lgml
mic
conclus
document
alga
initi
suscept
imipenem
subsequ
becam
resist
imipenem
treatment
also
demonstr
vitro
initi
isol
alga
could
easili
develop
resist
imipenem
organ
expos
imipenem
suggest
alga
organ
propens
toward
resist
imipenem
object
periton
remain
common
seriou
complic
periton
dialysi
studi
evalu
frequenc
microorgan
isol
periton
fluid
patient
continu
ambulatori
periton
dialysi
capd
method
year
period
periton
fluid
sampl
collect
capd
patient
periton
symptom
specimen
inocul
appropri
media
centrifug
gram
stain
smear
aerob
anaerob
broth
cultur
perform
isol
identifi
commerci
id
panel
mic
determin
microdilut
method
accord
nccl
guidelin
result
fifti
two
sampl
posit
six
posit
polymicrobi
follow
microorgan
obtain
pseudomona
aeruginosa
staphylococcu
epidermidi
escherichia
coli
staphylococcu
aureu
streptococcu
viridan
klebsiella
pneumonia
enterococcu
faecali
stenotrophomona
maltophilia
enterobact
aerogen
acinetobact
baumannii
enterococcu
faecium
proteu
mirabili
pseudomona
fluorescensputida
acinetobact
lwoffii
salmonella
group
bacteroid
spp
fungi
isol
three
patient
candida
tropicali
candida
krusei
candida
parapsilosi
three
aureu
strain
three
epidermidi
isol
found
resist
methicillin
saphylococci
enterococci
suscept
vancomycin
linezolid
gramneg
pathogen
sensit
use
antibiot
conclus
thirti
five
patient
develop
periton
preval
etiolog
agent
periton
capd
patient
pseudomona
aeruginosa
staphylococcu
epidermidi
escherichia
coli
staphylococcu
aureu
streptococcu
viridan
sinc
capd
patient
commonli
outpati
antimicrobi
resist
gramneg
strain
low
compar
nosocomi
isol
appropri
antibiot
therapi
base
microbiolog
result
need
manag
periton
capd
patient
object
cefepim
fourth
gener
cephalosporin
broader
spectrum
activ
gramneg
gramposit
pathogen
comparison
cephalosporin
due
excel
antibacteri
activ
includ
pseudomona
aeruginosa
enterobact
spp
togeth
low
rate
resist
favour
pharmacokinet
clinic
properti
cefepim
drug
choic
initi
empir
treatment
sever
nosocomi
infect
nevertheless
addit
recommend
guidelin
surveil
local
resist
data
import
empir
treatment
decis
hospit
method
studi
vitro
activ
cefepim
cep
imipenem
imi
piperacillin
tazobactam
pt
ceftazidim
caz
cefotaxim
cft
investig
bacteri
strain
isol
year
mic
determin
microdilut
method
accord
din
refer
test
strain
ecoli
atcc
aureu
atcc
paeruginosa
atcc
spneumonia
atcc
result
highest
vitro
activ
gram
neg
enterobacteriacea
determin
cep
imi
suscept
rate
enterobact
spp
mmorganii
proteu
spp
citrobact
spp
wherea
suscept
rate
pt
caz
cft
much
lower
espp
mm
pspp
cspp
pseudomona
aeruginosa
n
suscept
rate
cep
caz
imi
pt
lowest
resist
rate
cep
follow
caz
pt
imi
studi
confirm
excel
cefepim
activ
gram
posit
isol
pneumococci
streptococcu
viridan
bhemolyt
streptococci
high
cefepim
suscept
rate
staphylococci
mssa
msse
contrari
ceftazidim
mssa
msse
conclus
regard
vitro
data
cep
reliabl
treatment
option
empir
therapi
patient
sever
nosocomi
infect
demonstr
high
activ
gram
posit
isol
compar
activ
gram
neg
enterobacteriacea
carbapenem
imi
lowest
resist
rate
pseudomona
aeruginosa
antimicrobi
activ
spectrum
cefepim
test
clinic
strain
north
american
medic
centr
report
sentri
antimicrobi
surveil
program
program
h
sader
biedenbach
fritsch
r
jone
north
liberti
usa
object
evalu
antimicrobi
spectrum
potenc
cefepim
cpm
select
compar
clinic
bacteri
strain
collect
north
america
na
period
method
isol
consecut
collect
bloodstream
respiratori
tract
urinari
tract
skinsoft
tissu
infect
medic
centr
isol
hospit
patient
isol
suscept
test
refer
nccl
broth
microdilut
method
central
laboratori
oxacillinresist
r
staphylococci
or
enterococci
exclud
result
activ
cpm
key
organ
test
summar
tabl
overal
gramposit
cocci
gp
test
cpm
imipenem
imp
mgl
activ
compound
test
ent
follow
cpm
mgl
amikacin
amk
ceftriaxon
aztreonam
lowest
rate
ent
observ
ciprofloxacin
cipro
imp
also
activ
compound
esblproduc
ksp
e
coli
respect
follow
amk
cpm
cpm
activ
psa
similar
imp
ossa
cpm
potent
ceftazidim
caz
mgl
show
higher
activ
cipro
cpm
activ
compound
spn
gatifloxacin
levofloxacin
vg
cpm
potent
caz
potent
piperacillintazobactam
region
mdr
rang
lo
angel
south
florida
r
pen
eri
sxt
common
mdr
phenotyp
region
except
baltimoredc
r
eri
sxt
common
specimen
sourc
blood
lr
ur
isol
mdr
r
pen
eri
sxt
common
phenotyp
regardless
specimen
sourc
strain
test
fluoroquinolon
mic
rang
mgl
gem
mgl
gat
mgl
mxf
mgl
lfx
conclus
mdr
among
sp
phenotyp
wide
dispers
geograph
like
encount
regardless
site
infect
fluoroquinolon
show
activ
mdr
isol
use
fluoroquinolon
compound
increas
surveil
monitor
preval
mdr
track
vitro
activ
agent
gem
use
resist
strain
must
continu
background
multidrug
resist
mdr
pneumonia
strain
increas
alarm
rate
worldwid
therapi
respiratori
tract
infect
due
strain
challeng
urgent
need
antimicrobi
reliabl
activ
mdr
strain
compar
activ
oral
cephalosporin
parenter
cephalosporin
variou
pneumococc
mdr
phenotyp
analys
larg
multiyear
intern
collect
clinic
strain
pneumonia
method
pneumonia
strain
collect
worldwid
particip
sentri
program
test
interpret
use
nccl
guidelin
antimicrobi
agent
analys
includ
penicillin
pen
erythromycin
er
clindamycin
cm
tetracyclin
tet
trimethoprimsulfamethoxazol
ts
cephalosporin
monitor
includ
oral
cefpodoxim
cefuroxim
parenter
ceftriaxon
cefepim
agent
result
rank
order
occurr
rate
variou
resist
phenotyp
pen
pen
er
pen
er
cm
pen
er
cm
tet
pen
er
cm
ts
five
drug
suscept
rate
strain
oral
administ
cephalosporin
cefpodoxim
cefuroxim
drop
respect
fivedrug
mdr
phenotyp
parenter
cephalosporin
retain
excel
activ
mdr
phenotyp
resist
rate
lower
cefepim
ceftriaxon
cefepim
ceftriaxon
oral
cephalosporin
cefpodoxim
cefuroxim
use
respiratori
infect
breakpoint
nccl
conclus
vitro
find
confirm
parenter
cephalosporin
cefepim
ceftriaxon
retain
excel
activ
mdr
phenotyp
analys
remain
use
drug
armamentarium
treat
mdr
pneumococc
respiratori
tract
infect
antibiot
resist
surveil
period
spain
result
mystic
programm
result
three
icu
two
neutropenia
unit
two
gener
ward
provid
total
gramneg
gramposit
isol
period
common
speci
test
escherichia
coli
methicillinsuscept
staphylococcu
aureu
coagulaseneg
staphylococci
pseudomona
aeruginosa
enterobact
cloaca
klebsiella
pneumonia
abaumannii
gener
carbapenem
mem
ipm
activ
antimicrobi
agent
test
common
organ
rang
respect
among
enterobacteriacea
enterobact
spp
citrobact
spp
serratia
spp
suscept
carbapenem
e
coli
k
pneumonia
suscept
carbapenem
respect
mem
higher
ipm
everi
organ
test
cip
resist
e
coli
around
caz
taz
least
activ
antimicrobi
agent
enterobact
sp
respect
citrobact
spp
respect
mem
taz
activ
agent
p
aeruginosa
respect
baumannii
suscept
carbapenem
suscept
cip
period
around
methicillinsuscept
staphylococci
suscept
mem
conclus
signific
decreas
suscept
carbapenem
throughout
fiveyear
period
mem
imp
appear
remain
reliabl
option
treatment
seriou
nosocomi
infect
clinic
use
mem
increas
bacteri
resist
agent
spanish
centr
evalu
surveil
antimicrobi
suscept
anaerob
belgian
univers
hospit
glupczynski
h
nizet
c
berhin
yvoir
b
background
antimicrobi
resist
becom
grow
concern
among
anaerob
involv
human
infect
sinc
scarc
data
vitro
suscept
anaerob
countri
aim
determin
suscept
resist
profil
anaerob
bacteria
isol
hospit
tabl
conclus
blactamsblactamas
inhibitor
carbapenem
met
remain
highli
activ
anaerob
includ
resist
bfg
organ
resist
cli
actual
almost
reach
observ
among
almost
differ
speci
anaerob
mox
repres
newer
fluoroquinolon
exhibit
broad
spectrum
potent
activ
vitro
anaerob
test
look
promis
treatment
mix
infect
involv
anaerob
pharmacokineticspharmacodynam
quinolon
object
garenoxacin
grn
novel
desf
quinolon
effect
broad
spectrum
pathogen
includ
anaerob
fluoroquinolon
potenti
prolong
qtc
determin
effect
grn
qtc
retrospect
analysi
perform
manual
read
ecg
five
phase
studi
method
serial
ecg
collect
random
doubleblind
placebocontrol
studi
healthi
adult
subject
administ
oral
po
intraven
iv
grn
dose
therapeut
dose
mg
dose
durat
day
therapeut
durat
day
qt
interv
correct
heart
rate
use
bazett
qtcb
fridericia
qtcf
formula
effect
grn
assess
count
outlier
linear
regress
singleand
multipledos
pharmacokinet
po
iv
grn
deriv
plasma
concentr
versu
time
data
result
total
subject
receiv
grn
receiv
placebo
grn
plasma
exposur
auc
cmax
increas
increas
dose
subject
experienc
prolong
qtcb
interv
msec
male
msec
femal
one
subject
experienc
prolong
msec
qtcb
chang
baselin
occur
day
subsequ
day
despit
continu
dose
incid
borderlin
qtcb
chang
msec
compar
placebo
grn
mean
qtcb
max
qtcb
avg
qtcb
tmax
chang
baselin
grn
similar
placebo
except
qtcb
max
qtcb
tmax
chang
mg
iv
grn
day
although
mg
po
mg
iv
grn
produc
higher
plasma
exposur
mg
iv
day
mean
deriv
qtcb
valu
compar
placebo
confid
interv
linear
regress
slope
deriv
delta
qtcb
cavg
h
equal
less
except
delta
qtcb
tmax
day
indic
grn
effect
qtcb
result
obtain
qtcf
similar
qtcb
conclus
grn
appear
dose
rout
administrationor
concentrationdepend
effect
qtc
interv
healthi
subject
object
garenoxacin
grn
novel
desf
quinolon
develop
varieti
indic
efficaci
broad
spectrum
pathogen
includ
anaerob
object
studi
assess
tissu
fluid
plasma
ratio
grn
follow
singl
oral
dose
method
openlabel
studi
conduct
subject
year
age
bodi
mass
index
undergo
abdomin
surgic
procedur
would
permit
remov
tissu
fluid
without
increas
risk
subject
singl
mg
oral
dose
grn
administ
base
schedul
oper
time
tissu
fluid
correspond
plasma
sampl
collect
hour
postdos
concentr
grn
biolog
fluid
tissu
determin
use
valid
lcmsm
assay
safeti
assess
measur
vital
sign
physic
examin
electrocardiograph
clinic
laboratori
evalu
advers
event
ae
monitor
perform
time
consent
discharg
studi
result
thirtyon
subject
enrol
complet
studi
mean
fluid
tissu
grn
concentr
greater
found
plasma
mean
fluid
tissu
plasma
ratio
occur
larg
small
bowel
tissu
gallbladd
liver
mean
fluid
tissu
grn
concentr
less
found
plasma
occur
adipos
tissu
bone
sinu
mucosa
striat
muscl
incision
skin
subcutan
tissu
mean
grn
concentr
bile
lymph
node
tissu
roughli
similar
found
plasma
tissu
fluid
concentr
grn
exceed
target
organ
involv
skin
soft
tissu
bone
intraabdomin
infect
sinus
treatmentemerg
ae
seriou
ae
consid
relat
grn
conclus
mg
oral
dose
grn
penetr
well
tissu
fluid
studi
concentr
exceed
pathogen
caus
sinus
skin
soft
tissu
infect
bone
infect
intraabdomin
infect
result
suggest
adequ
concentr
grn
achiev
treat
infect
site
penetr
garenoxacin
lung
tissu
patient
undergo
lung
biopsi
resect
object
garenoxacin
grn
novel
desf
quinolon
effect
broad
spectrum
pathogen
includ
commonli
found
respiratori
tract
rt
studi
conduct
determin
penetr
grn
lung
parenchyma
lp
bronchial
mucosa
bm
follow
singl
mg
oral
dose
penetr
grn
bone
also
assess
openlabel
nonrandom
studi
subject
undergo
invas
procedur
lung
percutan
lung
biopsi
facilit
remov
macroscop
normal
healthi
lung
tissu
without
expos
subject
undu
risk
penetr
grn
bone
determin
remov
rib
bone
part
normal
surgic
procedur
singl
mg
oral
grn
dose
administ
base
schedul
oper
time
lp
possibl
bm
andor
bone
sampl
correspond
plasma
sampl
remov
h
postdos
concentr
grn
sampl
determin
use
valid
lcmsm
assay
safeti
assess
base
occurr
advers
event
ae
chang
physic
examin
vital
sign
clinic
laboratori
result
electrocardiograph
result
result
twentyseven
subject
enrol
sampl
taken
minimum
patient
time
interv
mean
grn
concentr
lp
increas
h
postdos
suggest
rapid
penetr
lp
declin
similar
decreas
seen
plasma
concentr
concentr
grn
lp
exceed
organ
associ
rt
infect
h
period
grn
concentr
bm
h
period
exceed
respiratori
pathogen
concentr
grn
bone
exceed
organ
associ
bone
infect
except
pseudomona
aeruginosa
mrsa
fusobacterium
speci
enterobact
speci
h
period
across
time
interv
mean
ratio
tissu
plasma
grn
concentr
lp
bm
bone
reach
respect
suggest
adequ
penetr
grnrelat
ae
report
indic
singl
mg
oral
grn
dose
well
toler
subject
undergo
invas
procedur
conclus
grn
penetr
rapidli
lp
bm
bone
tissu
produc
sustain
concentr
predict
adequ
coverag
grnsuscept
pathogen
site
bioavail
safeti
healthi
volunt
unalt
crush
garenoxacin
tablet
administ
via
nasogastr
tube
without
enter
feed
r
noveck
r
varga
g
krishna
grasela
new
orlean
kenilworth
princeton
usa
object
purpos
trial
assess
healthi
volunt
bioavail
safeti
singl
dose
novel
desf
quinolon
garenoxacin
grn
administ
crush
tablet
without
concomit
enter
feed
compar
intact
tablet
method
random
crossov
singledos
studi
healthi
adult
volunt
age
receiv
grn
mg
one
mg
one
mg
tablet
oral
regimen
intact
tablet
b
crush
tablet
suspend
water
deliv
via
nasogastr
ng
tube
c
regimen
b
plu
concomit
enter
feed
osmolit
ml
mlhr
subject
random
receiv
regimen
crossov
sequenc
abc
acb
bac
bca
cab
cba
separ
washout
interv
treatment
subject
enter
facil
day
confin
hour
drug
administr
subject
discharg
studi
final
assess
day
third
treatment
postscreen
assess
includ
vital
sign
plasma
drug
level
pk
analysi
physic
laboratori
ecg
examin
drug
safeti
result
male
subject
enrol
white
black
mean
age
pk
analysi
grn
administ
crush
tablet
without
concomit
enter
feed
vs
intact
tablet
show
differ
adjust
geometr
mean
cmax
lgml
vs
lgml
auc
inf
lg
hrml
vs
lg
hrml
ci
logtransform
cmax
auc
inf
b
c
compar
contain
within
protocolspecifi
limit
mean
grn
halflif
similar
among
group
mean
rang
h
tmax
hour
follow
administr
intact
tablet
compar
hour
group
singl
oral
mg
dose
grn
well
toler
whether
administ
crush
tablet
suspend
water
deliv
via
ng
tube
without
enter
feed
intact
tablet
three
advers
event
ae
report
nausea
deem
probabl
relat
studi
drug
seriou
ae
meaning
chang
safeti
examin
discontinu
due
ae
conclus
bioavail
grn
similar
crush
versu
intact
tablet
regardless
whether
enter
feed
given
crush
tablet
result
show
grn
may
administ
crush
tablet
without
concomit
feed
garenoxacin
pharmacokinet
subject
sever
renal
impair
object
garenoxacin
grn
novel
desf
quinolon
effect
broad
spectrum
pathogen
absolut
bioavail
grn
oral
intak
approxim
grn
excret
unchang
urin
object
studi
evalu
pharmacokinet
grn
subject
sever
renal
impair
method
nonrandom
openlabel
studi
enrol
patient
group
healthi
control
subject
hc
normal
renal
function
clcr
mlmin
subject
sever
renal
impair
sri
clcr
mlmin
requir
dialysi
subject
sri
receiv
hemodialysi
hd
subject
sri
receiv
continu
ambulatori
periton
dialysi
capd
singl
mg
oral
dose
grn
administ
day
group
except
hd
patient
hd
patient
receiv
singl
mg
oral
grn
dose
hd
dose
separ
washout
blood
urin
dialys
sampl
collect
h
postdos
concentr
grn
determin
use
valid
lcmsm
assay
safeti
assess
physic
examin
vital
sign
electrocardiograph
laboratori
evalu
result
twentyf
subject
receiv
grn
hc
n
sri
n
n
capd
n
six
subject
receiv
grn
mean
grn
exposur
auc
similar
hc
higher
sri
capd
respect
hc
howev
mani
individu
valu
within
rang
observ
hc
averag
increas
auc
exceed
valu
previous
shown
well
toler
decreas
cmax
observ
sri
capd
consid
clinic
relev
approxim
grn
dose
remov
dialys
capd
respect
total
treatmentemerg
advers
event
ae
report
mild
moder
sever
consid
probabl
possibl
relat
grn
one
treatmentemerg
treatmentrel
seriou
ae
report
conclus
singl
dose
mg
grn
well
toler
patient
sri
includ
requir
hd
capd
clinic
signific
increas
grn
exposur
patient
sri
base
broad
therapeut
index
grn
therefor
grn
dosag
adjust
recommend
subject
sri
effect
omeprazol
bioavail
safeti
garenoxacin
healthi
volunt
j
kisicki
g
krishna
olsen
grasela
lincoln
kenilworth
princeton
usa
object
novel
desf
quinolon
garenoxacin
grn
solubl
acid
condit
neutral
ph
therefor
studi
design
determin
omeprazol
affect
bioavail
grn
method
nonrandom
openlabel
pharmacokinet
studi
conduct
healthi
adult
subject
day
singledos
pharmacokinet
mg
oral
grn
one
one
mg
tablet
determin
fast
subject
serial
blood
sampl
obtain
hour
postdos
omeprazol
mg
administ
daili
day
achiev
steadyst
inhibit
gastric
acid
secret
day
singl
dose
grn
omeprazol
administ
concomitantli
omeprazol
treatment
continu
day
throughout
period
pharmacokinet
blood
sampl
studi
assess
includ
vital
sign
physic
laboratori
electrocardiograph
examin
safeti
gm
cmax
valu
grn
grnomeprazol
coadministr
mcgml
respect
ci
halflif
mean
rang
h
tmax
median
rang
h
similar
administr
grn
either
alon
concomitantli
omeprazol
concomit
administr
garenoxacin
omeprazol
well
toler
nine
subject
experienc
total
advers
event
ae
major
ae
mild
deem
possibl
probabl
relat
studi
drug
frequent
cite
ae
headach
nausea
abdomin
pain
mild
moder
sever
two
subject
withdrew
studi
neither
discontinu
due
ae
conclus
concomit
administr
omeprazol
effect
garenoxacin
bioavail
find
indic
garenoxacin
administ
omeprazol
agent
affect
gastric
ph
similar
lesser
extent
effect
maalox
bioavail
safeti
garenoxacin
healthi
volunt
j
kisicki
g
krishna
olsen
grasela
lincoln
kenilworth
princeton
usa
object
garenoxacin
grn
novel
broadspectrum
desf
quinolon
antibiot
quinolon
known
chelat
cation
aluminum
impair
antibiot
absorpt
studi
therefor
design
assess
effect
dose
contain
mg
aluminum
hydroxid
mg
magnesium
hydroxid
pharmacokinet
grn
administ
concomitantli
hour
hour
maalox
method
random
openlabel
controlbalanc
residu
effect
design
pharmacokinet
studi
oral
treatment
consist
mg
grn
one
one
mg
grn
tablet
given
alon
concomit
maalox
h
maalox
h
maalox
h
maalox
h
maalox
healthi
adult
subject
receiv
treatment
washout
period
treatment
treatment
serial
blood
sampl
pharmacokinet
analysi
collect
h
grn
dose
studi
assess
includ
vital
sign
physic
laboratori
electrocardiograph
examin
drug
safeti
result
twenti
subject
male
femal
mean
age
year
enrol
exposur
grn
auc
inf
reduc
coadminist
maalox
exposur
grn
also
reduc
administ
hour
maalox
respect
contrast
administ
hour
maalox
grn
exposur
affect
grn
administ
hour
maalox
small
reduct
grn
exposur
observ
unlik
clinic
relev
halflif
mean
rang
hour
tmax
median
rang
hour
similar
across
treatment
group
singl
oral
mg
dose
grn
well
toler
mild
advers
event
report
subject
subject
discontinu
due
mild
abdomin
pain
blood
stool
conclus
maalox
affect
grn
bioavail
grn
administ
least
h
prior
maalox
howev
reduct
grn
exposur
observ
grn
administ
concomitantli
h
maalox
therefor
grn
administ
h
h
administr
maalox
product
contain
high
content
cation
particularli
aluminum
object
demonstr
fluoroquinolon
treatment
human
anim
rapidli
select
bacteria
reduc
suscept
fluoroquinolon
antibiot
recent
year
consider
interest
concept
mutant
prevent
concentr
mpc
mpc
defin
concentr
antibiot
mutant
select
organ
previou
studi
mpc
ciprofloxacin
enrofloxacin
determin
vitro
salmonella
enterica
serovar
typhimurium
dt
use
chick
model
investig
mpc
enrofloxacin
vivo
report
method
chick
experiment
infect
typhimurium
treat
baytril
enrofloxacin
mgkg
day
recommend
therapeut
dose
day
mgkg
day
mgkg
day
chick
receiv
dose
drink
water
ppm
oral
gavag
mgkg
hour
dose
bird
kill
tissu
sampl
caecal
content
liver
sera
taken
level
enrofloxacin
ciprofloxacin
determin
tissu
hplc
bioassay
caecal
content
also
monitor
presenc
salmonella
dose
week
dose
select
resist
monitor
replica
plate
coloni
media
clinic
microbiolog
infect
volum
supplement
contain
ciprofloxacin
nalidix
acid
mic
strain
treatmentresult
condit
antibiot
treatment
select
reduc
suscept
eg
mic
parent
strain
bird
receiv
antibiot
dose
day
oral
gavag
dose
day
water
oral
gavag
treatment
also
significantli
reduc
count
salmonella
compar
oral
gavag
treatment
oral
gavag
studi
concentr
fluoroquinolon
caecal
content
mpc
least
hour
dose
treatment
regim
conclus
interest
note
whilst
fluoroquinlon
antibiot
regard
concentr
rather
time
depend
antibiot
day
dose
effect
reduc
count
salmonella
experi
day
dose
result
would
suggest
length
treatment
well
dose
rout
administr
critic
minimis
select
fluoroquinolon
resist
vivo
effect
levofloxacin
coadministr
intern
normalis
ratio
acenocumarol
therapi
j
de
otero
payera
c
carratala
artigu
sanz
p
nadal
manacor
e
levofloxacin
l
show
effect
warfarin
pharmacokinet
healthi
volunt
sever
recent
descript
reveal
elev
intern
normalis
ratio
inr
patient
receiv
concurr
l
warfarin
knowledg
case
lacenocumarol
interact
report
object
report
case
hypoprothrombot
respons
result
addit
l
therapi
chronic
therapi
method
retrospect
analysi
adult
patient
receiv
admit
ward
l
prescript
basi
clinic
diagnosi
judgement
descript
statist
measur
perform
result
six
patient
year
old
median
includ
four
men
suffer
median
rang
concurr
chronic
medic
problem
includ
coronari
heart
diseas
atrial
fibril
hypertens
obstruct
pulmonari
diseas
renal
insuffici
cardiomyopathi
heart
failur
took
median
rang
differ
kind
drug
includ
digoxin
furosemid
antihypertens
inhal
bronchodil
type
infect
patient
treat
l
includ
acut
bronchiti
case
pneumonia
case
object
cip
substrat
mrp
efflux
pump
mous
macrophag
michot
et
al
aac
reduc
cellular
accumul
recent
shown
macrophag
select
upon
chronic
exposur
cell
cip
cip
accumul
becom
neglig
increas
activ
andor
express
efflux
transport
icaac
icaac
abstract
examin
whether
reduc
accumul
affect
cip
intracellular
activ
use
model
intracellular
infect
l
monocytogen
lm
compar
resist
cell
wild
type
parent
cell
line
method
infect
carri
use
bacteria
macrophag
ratio
accord
procedur
describ
seral
et
al
jac
cfumg
cell
protein
determin
h
exposur
increas
concentr
cip
mm
probenecid
inhibitor
mrp
transport
cip
cellular
concentr
measur
fluorimetri
aac
result
wild
cell
extracellular
concentr
correspond
x
mic
suffici
obtain
static
effect
valu
rose
x
cipresist
cell
valu
decreas
x
x
mic
wild
cipresist
cell
respect
presenc
probenecid
cell
incub
mgl
cip
x
mic
cip
accumul
wild
cip
resist
cell
increas
presenc
probenecid
conclus
increas
express
andor
activ
cip
efflux
transport
caus
reduct
antibiot
efficaci
intracellular
infect
revers
upon
inhibit
efflux
transport
object
quinolon
caus
tendin
tendon
ruptur
retrospect
studi
case
report
reveal
addit
therapi
glucocorticoid
increas
risk
quinoloneinduc
tendon
disord
method
investig
possibl
combin
effect
quinolon
glucocorticoid
vitro
model
human
tendon
cell
tenocyt
cultur
day
monolay
incub
ciprofloxacin
levofloxacin
mgl
b
nm
dexamethason
c
ciprofloxacin
levofloxacin
mgl
plu
nm
dexamethason
immunoblot
use
quantifi
chang
amount
activ
src
homolog
collagen
shc
activ
furthermor
ultrastructur
alter
analys
electron
microscopi
result
mgl
ciprofloxacin
caus
signific
decreas
amount
day
onward
effect
seen
mg
levofloxacinl
medium
nm
dexamethason
compar
untreat
control
combin
quinolon
mgl
nm
dexamethason
result
earlier
onset
reduct
ciprofloxacin
dexamethason
first
day
incub
levofloxacin
dexamethason
day
onward
quinoloneinduc
chang
signal
protein
activ
shc
fortifi
dexamethason
concentr
test
interestingli
time
concentr
depend
increas
apoptosi
marker
activ
intensifi
dexamethason
result
immunoblot
respect
induct
apoptosi
confirm
electron
microscopi
conclus
result
show
quinoloneinduc
chang
amount
well
apoptosi
marker
activ
enhanc
dexamethason
vitro
addit
glucocorticoid
caus
earlier
onset
quinoloneinduc
chang
result
support
clinic
observ
glucocorticoid
addit
risk
factor
quinoloneinduc
tendopathi
pharmacokinet
pharmacodynam
novel
extend
releas
formul
ciprofloxacin
compar
levofloxacin
extend
spectrum
betalactamas
produc
enterobacteriacea
schubert
h
stass
u
ullmann
dalhoff
kiel
wuppert
background
extend
releas
formul
ciprofloxacin
cip
xr
mg
qd
po
develop
deliv
peak
concentr
higher
follow
administr
convent
formul
cip
ir
mg
bid
po
area
curv
auc
compar
object
first
cip
use
treatment
infect
due
enterobacteriacea
frequent
esbl
produc
thu
pkpd
characterist
cip
xr
vs
ir
esbl
strain
examin
second
cip
use
urinari
tract
infect
uti
thu
pkpd
profil
cip
xr
vs
ir
serum
urin
studi
third
pkpd
characterist
either
bhi
artifici
urin
compar
method
genotyp
characteris
esbl
produc
e
coli
ec
k
pneumonia
kpn
wild
type
counterpart
expos
geometr
mean
plasma
urin
concentr
profil
follow
cip
mg
xr
qd
mg
ir
bid
lev
mg
qd
cip
lev
urin
concentr
fit
phase
studi
data
compartment
model
use
topfit
bacteria
cultiv
modifi
grasso
model
brainheart
infus
broth
well
artifici
urin
acc
griffith
et
al
viabl
count
quantit
h
area
bacteri
kill
curv
normalis
inoculum
calcul
result
first
irrespect
pk
profil
simul
wt
elimin
rapidli
esbl
produc
ec
kpn
moder
neglig
affect
upon
simul
serum
pk
profil
cip
lev
second
simul
urin
concentr
use
artifici
urin
ir
xr
result
elimin
esbl
produc
test
system
lev
elimin
esbl
produc
k
pneumonia
ecoli
strain
regrew
cip
xr
kill
esbl
kpn
strain
rapidli
cip
ir
lev
third
pkpd
surrog
deriv
studi
convent
media
artifici
urin
significantli
differ
conclus
model
use
artifici
urin
predict
rapid
pronounc
effect
cip
xr
compar
cip
ir
lev
object
antibacteri
spectrum
moxifloxacin
includ
major
respiratori
pathogen
pharmacokinet
demonstr
high
peak
concentr
plasma
well
respiratori
site
nevertheless
tonsillar
tissu
concentr
never
investig
present
studi
determin
moxifloxacin
concentr
plasma
tonsil
administr
three
dose
mg
adult
patient
chronic
recurr
tonsil
undergo
tonsillectomi
method
uncontrol
openlabel
randomis
parallel
group
studi
includ
patient
randomli
assign
group
patient
depend
time
last
dose
moxifloxacin
plasma
tissu
sampl
h
moxifloxacin
given
oral
od
day
moxifloxacin
concentr
measur
valid
hplc
assay
fluoresc
detect
sampl
analys
twice
mean
valu
obtain
use
statist
analysi
pharmacokinet
data
analys
present
descript
statist
moxifloxacin
level
plasma
tonsillar
tissu
result
cmax
occur
plasma
mean
valu
mg
l
tonsillar
tissu
mean
mgl
tonsillar
tissu
plasma
ratio
mean
valu
constantli
mgl
collect
time
rang
mgl
h
mgl
h
indic
prolong
mainten
moxifloxacin
level
tonsillar
tissu
compar
plasma
variabl
among
pt
present
h
tonsillar
tissu
plasma
ratio
rang
mgl
conclus
moxifloxacin
achiev
good
penetr
tonsillar
tissu
favour
compar
report
fluoroquinolon
moxifloxacin
concentr
observ
exceed
mic
usual
respiratori
tract
pathogen
object
acut
necrot
pancreat
still
relat
high
mortal
rate
base
local
infecti
complic
particularli
due
bacteri
infect
necrot
pancreat
parapancreat
area
limit
penetr
antimicrobi
drug
areascompart
consid
major
caus
failur
therapi
sever
local
pancreat
infect
howev
fluoroquinolon
eg
ciprofloxacin
levofloxacin
shown
penetr
suffici
pancreat
tissu
score
valu
new
quinolon
moxifloxacin
mxf
investig
yet
use
rat
model
acut
necrot
pancreat
mxf
demonstr
penetr
rapidli
effici
pancreat
tissu
also
inflam
necrot
pancrea
method
address
penetr
capabl
mxf
follow
intraven
iv
oral
po
administr
respect
human
pancrea
prospect
clinic
trial
design
use
singl
iv
patient
po
dose
patient
mg
mxf
antimicrobi
prophylaxi
patient
undergo
pancrea
resect
sampl
taken
blood
resect
area
pancreat
tissu
two
time
point
applic
sampl
begin
sampl
end
resect
concentr
mxf
determin
hplcuv
use
ofloxacin
intern
standard
result
mean
plasma
concentr
mxf
iv
po
first
sampl
time
h
lgml
respect
end
resect
h
lgml
measur
correspond
mean
concentr
mxf
pancreat
tissu
higher
lgg
sampl
lgg
sampl
mxf
concentr
pancreat
tissu
exceed
relev
pathogen
encompass
mxf
eg
e
coli
lgml
klebsiella
spp
lgml
aureu
lgml
least
five
hour
dose
interv
conclus
mxf
demonstr
penetr
effici
human
pancreat
tissu
follow
iv
well
po
administr
studi
mxf
concentr
po
administr
found
slightli
lower
observ
healthi
subject
probabl
due
diminish
delay
intestin
absorpt
prior
surgeri
object
clinic
practic
icu
ward
moxifloxacin
mfx
may
occasion
administ
nasogastr
ng
feed
tube
absenc
oral
liquid
formul
sinc
dival
cation
contain
enter
feed
may
potenti
impair
absorpt
mfx
given
via
way
want
studi
effect
concomit
enter
feed
pharmacokinet
toler
mfx
pass
crush
tablet
ng
tube
firstli
healthi
volunt
method
random
crossov
studi
oral
bioavail
mfx
investig
healthi
volunt
f
subject
receiv
separ
intact
mg
mfx
tablet
crush
tablet
suspens
ng
tube
water
b
receiv
enter
feed
c
concentr
mfx
serum
measur
valid
hplc
auc
cmax
analys
statist
assum
log
normal
distribut
data
use
anova
result
mfx
treatment
well
toler
auc
slightli
significantli
decreas
treatment
b
c
geo
mean
thu
rate
absorpt
affect
ng
tube
administr
rout
ingest
seem
associ
slight
loss
bioavailabilityindepend
carrier
medium
use
water
vs
enter
feed
clinic
relev
interact
multival
cation
contain
enter
feed
observ
indic
mfx
enter
nutrit
administ
concomitantli
conclus
clinic
relev
effect
enter
feed
pharmacokinet
oral
mfx
healthi
volunt
result
evalu
patient
especi
icu
characteris
sever
infecti
andor
concomit
diseas
might
influenc
absorpt
mfx
healthi
volunt
studi
complianc
dose
regimen
strictli
enforc
particip
signific
underli
diseas
concomit
medic
could
confound
interpret
safeti
data
therefor
purpos
analysi
healthi
volunt
serv
control
group
patient
popul
group
subject
receiv
po
mgd
divid
dose
result
treatmentrel
ae
trae
occur
healthi
volunt
common
headach
dri
mouth
dizzi
patient
mani
ae
consist
underli
diseas
trae
occur
patient
common
nausea
vomit
headach
abdomin
pain
diarrhoea
notabl
gastrointestin
gi
trae
occur
healthi
volunt
patient
treatmentrel
abnorm
liver
function
test
result
observ
healthi
volunt
patient
clinic
signific
differ
mean
qtc
interv
chang
baselin
either
popul
seriou
ae
sae
consid
possibl
probabl
relat
po
occur
patient
healthi
volunt
common
sae
patient
alter
drug
level
increas
hepat
enzym
nausea
rash
vomit
signific
trend
relat
age
sex
race
observ
either
group
addit
uniqu
trae
identifi
patient
longterm
exposur
month
compar
identifi
shorterdur
therapi
conclus
safeti
profil
po
patient
similar
observ
control
popul
healthi
volunt
like
indic
observ
clinic
set
headach
gi
event
nausea
vomit
abdomin
pain
diarrhoea
common
trae
observ
patient
given
favor
safeti
profil
po
provid
addit
treatment
option
sever
ill
patient
ifi
object
evalu
drug
interact
di
potenti
posaconazol
po
extendedspectrum
triazol
antifung
agent
phase
studi
po
inhibitor
cytochrom
cyp
activ
affect
activ
cyp
enzym
studi
conduct
evalu
potenti
chang
pharmacokinet
po
coadminist
medic
given
combin
method
seven
openlabel
di
studi
conduct
subject
receiv
po
mg
consecut
day
alon
combin
singl
multipl
dose
cimetidin
cyclosporin
glipizid
phenytoin
rifabutin
tacrolimu
antiretrovir
medic
zidovudin
lamivudin
ritonavir
indinavir
cyclosporin
antiretrovir
studi
patient
receiv
establish
dose
ed
drug
plasma
concentr
presum
steadi
state
ss
po
administr
bioavail
base
logtransform
auc
valu
express
ratio
combin
treatment
po
concomit
drug
given
alon
effect
coadministr
auc
valu
po
concomit
medic
summar
tabl
conclus
dose
adjust
requir
glipizid
zidovudin
lamivudin
indinavir
ritonavir
coadminist
po
small
differ
exposur
consid
clinic
signific
howev
po
given
glipizid
glucos
concentr
decreas
healthi
volunt
glipizid
administ
alon
monitor
cyclosporin
tacrolimu
blood
level
warrant
po
coadministr
dose
adjust
cyclosporin
tacrolimu
made
accordingli
concomit
use
po
rifabutin
phenytoin
cimetidin
avoid
unless
benefit
outweigh
risk
due
decreas
po
concentr
object
pharmacokinet
pk
mani
medic
may
alter
elderli
popul
alter
pk
potenti
affect
clinic
outcom
pk
paramet
posaconazol
po
extendedspectrum
investig
triazol
antifung
agent
examin
healthi
elderli
person
year
clinic
implic
agerel
pk
differ
evalu
method
conduct
metaanalysi
po
steadyst
pk
data
clinic
studi
healthi
volunt
pk
data
elderli
healthi
volunt
compar
elderli
patient
invas
fungal
infect
object
develop
bioassay
measur
csp
blood
level
use
hypersuscept
c
albican
cell
wall
sensor
mutant
method
c
albican
mutant
mic
csp
mgl
construct
target
delet
gene
encod
cell
wall
sensor
put
involv
mainten
cell
wall
integr
bioassay
valid
accord
intern
guidelin
shah
et
al
fda
standard
curv
includ
csp
concentr
rang
mgl
four
qualiti
control
use
mgl
studi
stabil
csp
concentr
time
differ
preanalyt
storag
condit
ii
accuraci
measurednomin
valu
x
valid
rang
iii
precis
coeffici
variat
sdmean
measur
valu
x
valid
rang
valid
procedur
includ
intrarun
interrun
measur
result
limit
detect
quantif
mgl
correspond
ng
csp
sampl
volum
ml
respect
reproduc
standard
curv
obtain
clinic
relev
concentr
rang
mgl
r
analyt
time
h
csp
concentr
deviat
nomin
valu
measur
day
plasma
day
whole
blood
c
ii
day
respect
c
iii
month
plasma
c
iv
freezethaw
cycl
intraand
interrun
valid
four
qualiti
control
mean
valu
sd
shown
object
identifi
pharmacokinet
pharmacodynam
pkpd
paramet
antifung
therapi
predict
intraand
interrun
bioassay
valid
intra
n
inter
n
accuraci
precis
invas
fungal
infect
patient
admit
intens
care
unit
icu
medic
record
ptt
admit
tertiari
hospit
icu
month
period
retrospect
review
antifung
therapi
record
correl
find
fungi
ptt
pkpdparamet
pt
estim
treatment
given
mic
isol
candida
ie
aucmicratio
h
azol
peakmic
ratio
free
fraction
amphotericinb
candida
isol
variou
infecti
foci
surveil
sampl
taken
routin
three
time
week
suscept
test
use
etest
fluconazol
itraconazol
amphotericinb
result
total
ptt
includedamong
ptt
invas
fungal
infect
ptt
bloodstream
infect
admiss
one
remain
receiv
system
prophylact
therapi
get
colon
ptt
prophylact
treat
colon
ptt
fluconazol
aucmic
one
pt
liposom
amphotericinb
peakmic
object
predict
pharmacokinet
properti
new
azol
antifung
humansmethod
watersolubl
prodrug
incub
lgml
pool
heparin
rat
cynomolgu
monkey
human
plasma
minut
incub
lgml
equival
rat
cynomolgu
monkey
human
liver
microsom
min
presenc
mgml
protein
extent
plasma
protein
bind
rat
cynomolgu
human
plasma
measur
use
red
blood
cell
partit
method
rat
receiv
singl
oral
dose
mgkg
equival
singl
intraven
dose
mgkg
equival
cynomolgu
monkey
receiv
singl
oral
intraven
dose
mgkg
serial
blood
sampl
obtain
plasma
concentr
quantifi
use
hplcfluoresc
method
lcmsm
assay
result
plasma
convert
within
minut
speci
investig
presenc
rat
cynomolgu
monkey
human
liver
microsom
less
metabol
min
period
bound
plasma
protein
free
fraction
rat
cynomolgu
monkey
human
respect
intraven
administr
prodrug
convert
within
minut
larg
volum
distribut
valu
greater
total
bodi
water
lkg
lkg
rat
cynomolgu
monkey
respect
slowli
elimin
halfliv
h
rat
h
cynomolgu
monkey
oral
administr
prodrug
reach
cmaxvalu
hour
observ
high
bioavail
rat
cynomolgu
monkey
conclus
base
vitro
result
anim
data
predict
prodrug
rapidli
convert
man
due
protein
bind
vitro
metabol
stabil
expect
behav
low
intrins
clearanc
drug
human
clearanc
liver
blood
flow
combin
larg
volum
distribut
explain
long
halflif
hour
observ
man
anim
data
suggest
good
oral
bioavail
confirm
human
pharmacokinet
fungicid
activ
aminocandin
novel
echinocandin
healthi
volunt
b
sandag
g
cooper
n
najarian
j
lowther
lexington
usa
romainvil
f
object
aminocandin
ac
echinocandin
develop
treatment
system
fungal
infect
studi
carri
determin
pharmacokinet
pk
fungicid
activ
ac
plasma
sampl
strain
c
albican
strain
fumigatu
follow
singl
iv
dose
method
singl
iv
dose
mg
ac
administ
healthi
male
volunt
singleblind
random
placebocontrol
trial
individu
plasma
sampl
collect
activ
placebo
pbo
treat
volunt
serial
dilut
control
growth
medium
fungicid
titr
determin
c
albican
strain
inhibitori
titr
fumigatu
strain
titr
pk
result
mean
valu
n
due
dilut
factor
test
medium
limit
detect
titr
germicid
effect
ceilingand
wall
mount
ultraviolet
c
uvc
light
nm
isol
unit
neg
pressur
pascal
examin
compar
disinfect
chloramin
enddisinfect
patient
stay
microbi
sampl
taken
surfac
disinfect
uvc
min
chloramin
h
exposur
use
standard
contact
plate
uvcdistribut
isol
unit
monitor
posit
output
floor
vari
wm
averag
sd
wm
patient
room
wm
sluic
wm
bath
decontamin
room
place
valu
vari
w
unit
uvcdisinfect
min
correspond
dose
rang
jm
shadow
area
jm
highest
expos
site
accord
publish
uvcdosimetri
surviv
bacteria
bacteri
spore
reduc
dose
rang
jm
jm
respect
thu
uvc
dose
use
studi
high
enough
inactiv
bacteri
organ
includ
spore
even
surfac
directli
expos
uvc
uvcdisinfect
significantli
reduc
bacteria
surfac
directli
indirectli
expos
uvc
low
number
ca
cfuplat
chloramin
disinfect
fom
ca
cfu
per
plate
alon
p
p
respect
sinc
clean
disinfect
may
risk
staff
isol
unit
disinfect
uvcor
chemic
alway
perform
first
presenc
complet
shadow
area
isol
unit
bed
rail
locker
matress
etc
still
need
disinfect
chemic
clean
therefor
uvc
may
use
alon
good
addit
chemic
disinfect
lower
biolog
burden
infecti
agent
isol
unit
high
risk
infecti
patient
disinfect
medic
equip
use
dri
mist
hydrogen
peroxid
object
compar
antimicrobi
efficaci
disinfect
pine
core
wood
surfac
surfac
made
polyethylen
synthet
lamin
organ
typic
caus
hospitalacquir
infect
method
aureu
mrsa
e
faecium
e
coli
p
aeruginosa
calbican
terra
p
camembertii
use
test
organ
inocul
test
organ
surfac
made
pine
core
wood
polypropylen
synthet
lamin
sampl
collect
rodac
plate
disinfect
commonli
use
hospit
germicid
alcohol
aldehyd
glucoprotamin
quaternari
ammonium
compound
bacteri
coloni
count
min
h
result
substanti
lower
coloni
count
measur
pine
core
wood
surfac
applic
disinfect
compar
count
polypropylen
synthet
lamin
surfac
bacteri
contamin
surfac
signific
coloni
count
observ
surfac
disinfect
alcohol
aldehyd
glucoprotamin
howev
disinfect
quaternari
ammonium
compound
signific
elev
coloni
count
found
pine
core
wood
surfac
comparison
polypropylen
synthet
lamin
surfac
discuss
poor
efficaci
quaternari
ammonium
compound
wooden
materi
might
explain
interact
wood
anion
polyphenol
cation
surfact
contain
disinfect
studi
find
corrobor
antimicrobi
effect
pine
core
wood
organ
typic
caus
nosocomi
infect
except
quaternari
compound
germicid
display
good
disinfect
properti
hygien
point
view
pine
core
wood
suitabl
use
hospit
survey
microbiolog
qualiti
drink
water
suppli
hospit
drink
water
cooler
vs
tap
water
fed
dispens
vs
bottl
water
object
hygien
econom
ecolog
comparison
drink
water
cooler
versu
tap
main
waterf
dispens
versu
bottl
drink
water
method
sampl
taken
system
without
preflow
clean
nozzl
compris
sampl
drink
water
cooler
month
sampl
per
week
tap
water
dispens
month
sampl
differ
bottl
drink
water
total
coloni
count
analys
respect
total
p
aeruginosa
e
coli
coliform
well
sulphitereduc
clostridia
examin
accord
european
norm
en
iso
complianc
german
drink
water
ordin
limit
valu
total
coloni
count
cfuml
cfuml
cfuml
bottl
water
cost
per
litr
calcul
compar
base
econom
data
suppli
manufactur
ecolog
impact
differ
system
evalu
base
expert
opinion
result
sampl
water
cooler
system
exceed
german
drink
water
ordin
threshold
valu
sampl
taken
tap
water
dispens
one
except
sampl
bottl
water
compli
german
drink
water
ordin
l
water
consum
per
month
tap
water
dispens
system
bottl
water
econom
water
cooler
system
per
l
water
cooler
month
tap
water
dispens
per
l
bottl
water
econom
term
water
cooler
system
recommend
consumpt
level
l
per
month
ecolog
point
view
tap
water
dispens
favour
express
per
year
l
freiburg
univers
hospit
follow
water
cooler
system
final
bottl
water
conclus
reason
hygien
use
water
cooler
system
recommend
hospit
furthermor
drink
water
cool
system
econom
low
consumpt
rate
tap
main
waterf
dispens
featur
best
hygien
econom
ecolog
properti
object
applic
antimicrobi
finish
textil
prevent
bacteri
growth
might
reduc
risk
infect
result
fabric
contamin
pathogen
microorgan
hospit
main
aim
studi
determin
antibacteri
activ
chemic
treatment
appli
textil
comparison
test
method
assess
antibacteri
effici
conduct
studi
perform
order
select
right
method
evalu
antibacteri
bacteriostat
activ
finish
method
fiber
fabric
made
cotton
appli
quaternari
ammonium
salt
test
finish
treat
bactericid
agent
compar
sampl
treat
disinfect
european
standard
iso
di
aatcc
suitabl
assess
antibacteri
activ
appli
bacteri
strain
recommend
standard
klebsiella
pneumonia
atcc
staphylococcu
aureu
atcc
escherichia
coli
atcc
test
due
high
resist
quaternari
ammonium
salt
addit
p
aeruginosa
atcc
examin
bacteri
suspens
x
cfuml
prepar
accord
requir
sampl
impregn
biocid
product
examin
agar
diffus
plate
test
specimen
locat
transvers
across
bacteri
inoculum
nutrient
agar
level
antibacteri
activ
assess
examin
extent
bacteri
growth
contact
zone
agar
specimen
addit
extent
zone
inhibit
minim
mm
around
specimen
consider
result
test
fiber
show
antibacteri
activ
fabric
show
antibacteri
activ
k
pneumonia
aureu
inhibit
zone
mm
examin
specimen
show
bacteriocid
activ
escherichia
coli
pseudomona
aeruginosa
result
obtain
two
appli
method
compar
assess
antibacteri
activ
finish
antymicrobi
finish
fulfil
requir
standard
conclus
base
obtain
result
test
antimicrobi
finish
may
consid
effect
prevent
bacteri
transfer
contamin
area
hospit
new
interact
approch
improv
hand
hygien
complianc
j
holt
e
tvenstrup
jensen
buhl
copenhagen
dk
introduct
complianc
guidelin
hand
hygien
well
despit
sever
attempt
improv
plan
educ
outlin
promot
behaviour
chang
hand
hygien
practic
aim
lower
incid
nosocomi
infect
map
critic
factor
implic
affect
practic
utmost
import
object
studi
empir
investig
aspect
hand
hygien
practic
take
place
danish
health
care
system
today
studi
attempt
answer
question
health
staff
lack
complianc
hand
hygien
explain
understood
basi
plan
educ
materi
support
behaviour
chang
method
literatur
studi
hand
hygien
questionnair
base
done
survey
respond
qualit
interview
n
perform
order
uncov
explan
low
rate
complianceth
data
analys
discuss
basi
theori
action
experi
reflect
think
control
ritual
order
aim
broader
view
understand
field
result
questionnair
interview
show
hygien
still
field
great
implic
interact
individu
furthermor
seem
difficult
staff
draw
profession
privat
line
clean
unclean
therebi
perform
hand
hygien
without
compromis
interview
show
difficult
staff
react
someth
see
give
immedi
result
staff
act
prescrib
introduct
leishmaniasi
increas
import
recent
year
hivinfect
patient
emerg
risk
group
diseas
howev
real
preval
gener
popul
unknown
objet
object
know
antibodi
seropreval
infect
leishmania
infantum
gener
popul
castillaleon
spain
method
random
sampl
gener
popul
sera
hivinfect
patient
autonom
commun
castillaleon
collect
seropreval
antibodi
l
infantum
determin
indirect
enzymoimmunoanalysi
eia
test
design
laboratori
result
antileishmania
infantum
antibodi
seropreval
gener
popul
signific
increas
seropreval
age
p
year
group
year
old
signific
differ
women
men
versu
p
seropreval
significantli
higher
peopl
rural
area
citi
versu
p
hivinfect
patient
seropreval
l
infantum
differ
observ
women
men
preval
increas
age
efficaci
intralesion
pentaval
antimoni
combin
oral
azol
treatment
oldworld
cutan
leishmaniasi
result
man
present
histori
slowli
grow
round
lesion
right
arm
leg
histori
travel
mediterranean
area
includ
north
african
middl
east
countri
month
prior
present
examin
show
one
nodular
lesion
cm
margin
indur
depress
central
ulcer
right
arm
second
nodular
lesion
cm
right
leg
red
papul
cm
left
arm
man
histori
stay
iraq
month
prior
present
show
lesion
grown
last
three
month
two
nodular
lesion
cm
cm
erythemat
margin
thick
crust
left
arm
round
lesion
cm
depress
central
ulcer
left
arm
right
arm
right
leg
second
finger
right
hand
man
stay
iraq
month
prior
present
show
two
painless
confluent
nodular
lesion
cm
depress
central
ulcer
right
elbow
grown
month
two
round
lesion
cm
thick
crust
left
poplitea
fossa
one
nodular
lesion
cm
right
leg
patient
receiv
alternateday
intralesion
inject
meglumin
antimoni
week
oral
fluconazol
lesion
heal
complet
end
therapi
followup
none
patient
complain
advers
event
treatment
follow
conclus
treatment
intralesion
pentaval
antimoni
combin
azol
effect
absolut
safe
reduc
total
amount
antimoni
exposur
entomolog
studi
sandfli
dipthera
psychodidea
three
foci
endem
cutan
leishmaniasi
iran
human
leishmaniasi
global
widespread
parasit
diseas
caus
member
genu
leishmania
current
leishmaniasi
consid
endem
countri
includ
iran
phlebotomin
sandfli
vector
leishmaniasi
receiv
consider
attent
recent
year
due
resurg
leishmaniasi
endem
area
iran
extens
studi
conduct
ecolog
sandfli
differ
part
countri
recent
year
total
sandfli
collect
use
funnel
trap
rodent
burrow
rural
district
provinc
iran
shiraz
yazd
khozestan
sandfli
identifi
main
croup
phlebotomu
papatasi
p
sergenti
p
sergentomya
find
indic
p
papatasi
could
vector
human
gerbil
merion
libycu
close
contact
vector
resevoir
creat
effici
cycl
transmiss
diseas
area
villag
around
provinc
erysipela
like
cutan
leishmaniasi
case
report
erdogan
balaban
e
dervi
g
sengoz
g
barut
karaoglu
istanbul
tr
cutan
leishmaniasi
infecti
disord
skin
caus
leishmania
major
tropica
aethiopica
infantum
transmit
phlebotomin
sandfli
present
patient
demonstr
morpholog
rare
form
erysipela
like
cutan
leishmaniasi
woman
fourmonth
histori
erythema
edema
nasal
left
malar
area
refer
clinic
evalu
dermatolog
examin
reveal
erythemat
edemat
fine
desquam
plaqu
nose
left
malar
region
resembl
erysipela
physic
laboratori
find
normal
punch
biopsi
taken
lesion
dy
reveal
dens
lymphocyt
infiltr
layer
beneath
epidermi
deep
dermi
addit
huge
number
amastigot
found
macrophag
histiocyt
form
granuloma
light
find
patient
diagnos
cutan
leishmaniasi
commenc
regimen
meglumin
antimonat
mg
bid
two
week
therapi
lesion
gradual
disappear
without
scar
format
conclus
case
cutan
leishmaniasi
still
observ
countri
alway
usual
clinic
appear
also
like
present
case
may
clinic
resembl
erysipela
provid
difficulti
differenti
diagnosi
studi
human
infect
cutan
leishmaniasi
focu
diseas
southern
iran
scar
case
ulcer
mean
acut
lesion
scar
per
infect
case
respect
total
case
observ
sore
scar
infect
area
highest
rate
acut
lesion
observ
year
old
age
group
meanwhil
highest
rate
scar
year
old
age
group
sore
locat
hand
foot
face
part
bodi
studi
school
student
boy
girl
visit
infect
rate
acut
lesion
student
scar
signific
differ
male
femal
base
acut
infect
p
differ
signific
base
scar
x
p
highest
infect
rate
observ
tashkooieh
villag
two
inject
mice
develop
acut
lesion
agent
diseas
identifi
leishmania
major
pcr
test
conclus
infect
rate
sore
scar
show
diseas
locat
studi
area
recent
year
diseas
one
peak
increas
first
time
parasit
isol
human
area
therefor
focu
must
ad
zoonot
cutan
leishmaniasi
foci
iran
diseas
endem
area
case
infect
local
giardia
cryptosporidium
netherland
object
studi
design
get
insight
incid
protozo
bacteri
viral
infect
patient
diarrheal
complaint
differ
group
patient
consult
gener
praction
dutch
popul
focu
giardia
cryptosporidium
decreas
diagnost
deficit
studi
risk
factor
method
three
studi
design
conduct
gener
practition
haarlem
region
nivel
casecontrol
studi
sentinel
gener
practition
practic
gener
practition
practic
sensor
prospect
popul
base
cohort
studi
nest
casecontrol
studi
dutch
popul
studi
differ
inclus
criteria
diagnost
laboratori
techniqu
use
esp
virolog
stool
examin
result
incid
gastroenter
nivel
gp
studi
correct
per
personyear
mean
person
consult
gp
annual
gastroenter
incid
gastroenter
populationbas
studi
per
personyear
giardia
detect
case
haarlem
case
nivel
studi
control
cryptosporidium
resp
diagnost
deficit
decreas
substantiali
test
viral
pathogen
like
nlv
detect
pathogen
influenc
age
season
durat
symptom
abl
construct
algoritm
diagnost
workup
gi
patient
statist
survey
made
effect
climat
epidem
diseas
tropic
area
much
clarifi
relat
variat
meteorolog
element
number
patient
paper
appli
eof
analysi
method
time
seri
diarrhoea
patient
meteorolog
element
bangladesh
understand
effect
meteorolog
variat
preval
diarrhoea
diseas
eof
analysi
time
seri
patient
meteorolog
element
averag
everi
two
week
year
show
domin
compon
anomali
number
diarrhoea
patient
differ
sign
period
june
correspond
two
season
peak
number
patient
higher
maximum
temperatur
humid
premonsoon
period
found
tendenc
enhanc
first
peak
diarrheal
occurr
also
report
result
differ
type
diarrhoea
v
cholera
rota
etec
serolog
evid
babesiosi
northern
eastern
tyrol
austria
southern
tyrol
itali
method
leptospirosi
diagnos
leptospir
igm
enzym
link
immunosorb
assay
elisa
serovar
confirm
microscop
agglutin
test
mat
use
batteri
live
leptospir
strain
antigen
result
outdoor
manual
worker
housew
indoor
nonmanu
worker
unknown
mean
durat
symptom
day
major
patient
present
fever
jaundic
chill
rigor
vomit
cough
abdomin
pain
diarrhoea
alter
sensorium
purpurableed
salient
laboratori
abnorm
includ
anaemia
leucocytosi
thrombocytopaenia
elev
erythrocyt
sediment
rate
esr
hyponatremia
hypokalemia
acut
renal
failur
occur
hepat
function
derang
occur
three
patient
pulmonari
infiltr
sputum
reveal
haemosiderin
laden
macropahg
two
other
manifest
exud
pleural
effus
bilater
sequenti
one
common
serovar
encount
includ
l
autumnali
l
hebdomadi
l
grippotyphosa
l
icterohaemorrhagia
l
javanica
l
australi
patient
treat
parenter
crystallin
penicillin
oral
doxycyclin
manag
conserv
haemodialysi
requir
four
patient
two
patient
die
develop
multiorgan
system
failur
conclus
leptospirosi
import
caus
acut
febril
ill
renal
hepat
dysfunct
bleed
abnorm
high
index
clinic
suspicion
requir
confirm
diagnosi
earli
condit
respond
well
conserv
manag
determin
promis
antimalari
agent
human
serum
capillari
electrophoresi
pharmacokinet
studi
acetyl
deriv
fosmidomycin
demonstr
twice
activ
plasmodium
falciparum
vitro
plasmodium
vinckei
mous
model
fosmidomycin
inhibitor
doxp
reductoisomeras
essenti
enzym
nonmevalon
pathway
isoprenoid
biosynthesi
biosynthesi
isoprenoid
plasmodium
depend
doxp
pathway
found
eubacteria
alga
plant
human
plasmodium
doxp
pathway
localis
insid
plastid
like
organel
socal
apicoplast
report
develop
highperform
capillari
electrophoresi
hpce
techniqu
determin
serum
variou
instrument
set
migrat
voltag
capillari
temperatur
test
buffer
properti
ph
valu
compon
molar
optim
assay
submit
standard
qualiti
control
procedur
within
betweenday
reproduc
accuraci
limit
detect
lod
quantif
loq
linear
short
long
term
stabil
final
work
buffer
use
mm
mm
methanol
mm
hexadecyltrimethylammonium
bromid
htab
ph
adjust
electroosmot
flow
modifi
cation
ion
pair
reagent
htab
assay
linear
larg
concentr
rang
test
lgml
recoveri
sampl
pretreat
higher
good
precis
obtain
betweenday
reproduc
result
coeffici
variat
cv
withinday
reproduc
cv
lgml
respect
lod
lgml
loq
lgml
studi
short
longterm
stabil
serum
show
good
stabil
molecul
room
temperatur
moreov
resist
numer
cycl
freez
thaw
inde
four
freezethaw
cycl
day
recov
lgml
sampl
respect
conclus
develop
conveni
ce
techniqu
determin
serum
offer
advantag
speed
sensit
accuraci
present
procedur
appli
pharmacokinet
studi
anim
model
ttingen
minipig
present
futur
malaria
kahnouj
endem
area
southern
iran
object
kahnouj
district
associ
one
malaria
region
southeast
iran
anophelein
fauna
appear
chang
much
sever
decad
method
entomolog
studi
mosquito
collect
perform
everi
day
indoor
door
shelter
malaria
surveil
carri
health
center
ministri
health
microscopi
perform
patient
fever
suspect
malaria
malaria
case
detect
mostli
perform
passiv
rare
activ
posit
case
treat
chorolquienprimaquen
result
present
studi
five
vector
speci
malaria
found
studi
previous
record
decad
ago
district
like
malaria
endem
area
iran
pressur
anti
malaria
programm
includ
case
find
residu
spray
insecticid
well
larvicid
vector
sinc
annual
incid
malaria
declin
ten
year
transmiss
occur
octob
decemb
temperatur
suitabl
vector
activ
kahnouj
area
electr
recent
suppli
rural
area
malaria
case
found
therefor
hous
equip
air
condition
resid
keep
window
close
secur
mosquito
bite
hot
season
begin
spring
autumn
temperatur
mild
enough
order
save
electr
cost
resid
use
air
condition
wherea
leav
window
open
protect
mosquito
bite
provid
residu
spray
insecticid
indoor
shelter
stop
five
year
activ
antimalaria
programm
set
base
case
find
conclus
order
control
malaria
indoor
residu
spray
insecticid
would
assist
effect
given
knowledg
peopl
use
bed
net
particularli
season
peopl
expos
mosquito
bite
may
consid
effect
measur
control
malaria
khanouj
district
also
develop
area
effect
push
back
malaria
near
futur
entomolog
studi
mosquito
collect
perform
everi
day
indoor
outdoor
shelter
well
breed
place
aid
suction
tube
dipper
result
entomolog
research
found
five
vector
speci
malaria
studi
previous
record
decad
ago
anophel
stephensi
recogn
main
vector
malaria
area
two
peak
one
may
decemb
malaria
transmiss
occur
june
decemb
larval
habitat
includ
dray
river
bed
pool
rocki
river
pool
stagnant
stream
slow
foothil
stream
temporari
pool
slow
move
water
without
veget
conclus
oper
insecticid
adult
larval
control
well
surveil
malaria
case
would
assist
effect
control
malaria
given
anoth
malaria
control
method
impregn
bed
net
well
repel
particularli
season
peopl
expos
mosquito
bite
may
consid
effect
measur
control
malaria
area
case
report
year
old
boy
present
fever
gener
exanthema
local
dermatolog
clinic
mix
appear
pustul
umbil
non
purul
vesicl
led
suspicion
orthopoxviru
infect
patient
report
littl
red
dot
occur
week
earlier
extrem
contact
sick
pet
rat
week
later
gener
pustular
exanthema
appear
associ
high
fever
pronounc
feel
sick
histolog
viral
inclus
bodi
found
pustul
materi
poxviru
particl
detect
elmi
swab
pustul
ground
follow
anamnest
suspicion
transmiss
infect
rat
unfortun
perish
soon
afterward
experi
made
recent
monkeypox
outbreak
usa
initi
import
rat
one
major
aim
exclus
monkeypoxviru
accomplish
pcr
type
like
elmi
establish
occas
implement
austrian
plan
poxviru
prepared
despit
diagnost
mean
detect
variola
vera
also
includ
abil
discrimin
anim
orthopoxvirus
addit
serolog
diagnosi
perform
presum
due
protract
cours
infect
cowpox
specif
igg
antibodi
alreadi
present
admiss
titr
interestingli
humor
immun
respons
initi
seem
rather
cowpox
specif
antibodi
crossreact
vaccinia
viru
detect
indirect
immunofluoresc
exclus
immun
reaction
one
speci
alon
would
rare
situat
observ
orthopoxvirus
extens
test
western
blot
analysi
although
exclus
direct
cowpoxviru
antigen
restrict
reactiv
patient
serum
observ
earli
cours
infect
use
differ
recombin
virusderiv
orthopoxviru
antigen
would
suggest
also
serolog
method
might
abl
give
hint
toward
rapid
determin
orthopoxviru
speci
certainli
also
case
immunolog
antigen
detect
method
crimeancongo
haemorrhag
fever
result
forti
veterinerian
endem
region
tokat
nonendem
region
aydin
includ
demograph
characterist
two
group
similar
wherea
profession
activ
veterinarian
nonendem
region
intens
p
cchf
igg
posit
vs
brucella
agglutin
titr
vs
common
endem
region
nonendem
region
three
veterinarian
tokat
malais
myalgia
fever
multivari
analysi
detect
risk
factor
serum
tube
agglutin
veterinarian
live
endem
area
found
time
higher
risk
brucella
infect
one
live
nonendem
area
confid
interv
p
preval
coxiella
burnetii
serolog
equal
region
none
seroposit
complaint
histori
tick
bite
significantli
common
endem
region
nonendem
region
versu
p
conclus
cchf
brucellosi
compos
infect
risk
veterinarian
endem
region
despit
veterinarian
endem
region
perform
less
riskful
profession
activ
veterinarian
cchf
endem
region
warn
protect
tick
bite
accord
univers
precaut
use
mask
employ
prevent
inhal
transmiss
brucellosi
endem
region
chang
temperatur
crimean
congo
haemorrhag
fever
outbreak
turkey
ergonul
akgunduz
kocaman
z
vatansev
v
korten
ankara
istanbul
tr
object
investig
role
climat
factor
could
effect
activ
hyalomma
marginatum
marginatum
popul
consequ
emerg
crimeancongo
hemorrhag
fever
cchf
epidem
method
meteorolog
data
obtain
three
meteorolog
station
tokat
siva
yozgat
major
cchf
case
report
last
year
provinc
locat
northern
part
eastern
anatolia
southern
part
black
sea
region
temperatur
data
observ
record
turkish
state
meteorolog
servic
tsm
avail
year
siva
year
tokat
year
yozgat
meteorolog
station
locat
citi
centr
airport
temperatur
variat
trend
turkey
analys
use
data
set
includ
monthli
averag
daili
mean
minimum
temperatur
annual
rainfal
number
day
april
temperatur
also
includ
analysi
order
detect
homogen
mean
annual
seri
first
homogen
analysi
perform
use
nonparametr
kruskalw
kw
test
nonparametr
mannkendal
mk
rank
correl
test
interest
coordin
properti
acryl
acid
homologu
gener
facil
synthesi
mcm
materi
compound
polymeris
lot
organ
monom
lead
variou
metalcontain
polym
polymer
transform
mcm
led
new
research
field
current
interest
due
practic
import
obtain
product
exhibit
number
uniqu
featur
high
catalyt
activ
unusu
magnet
electrophys
biolog
propertiesthes
polym
especi
appropri
biolog
applic
tissu
engin
implant
medic
devic
dentistri
bone
repair
etc
molecular
weight
composit
architectur
regul
control
reaction
report
antibacteri
antifung
activ
new
complex
type
phen
mn
ni
cu
zn
phen
phenantrolin
acryl
anion
repres
first
step
product
synthesi
polymer
materi
vitro
antimicrobi
test
perform
broth
microdilut
method
order
establish
minim
inhibitori
concentr
mic
gramposit
bacillu
subtili
listeria
monocytogen
staphylococcu
aureu
gramneg
psedomona
aeruginosa
escherichia
coli
klebsiella
pneumonia
salmonella
enteritidi
well
candida
sp
use
refer
clinic
multidrug
resist
strain
result
show
test
compound
exhibit
specif
antimicrobi
activ
concern
microbi
spectrum
mic
valu
mic
valu
wide
rang
mgml
mcgml
test
compund
highli
activ
salmonella
listeria
mic
mcgml
object
c
glabrata
innat
less
suscept
azol
speci
candida
acquir
azol
resist
shortterm
exposur
fluconazol
recent
note
oropharyng
isol
sinc
c
glabrata
emerg
signific
caus
candidemia
examin
chang
azol
mic
karyotyp
sequenti
isol
c
glabrata
cours
fungaemia
relationship
antifung
therapi
method
serial
bloodstream
isol
c
glabrata
obtain
patient
fungaemia
period
day
fortyseven
c
glabrata
isol
patient
patient
receiv
antifung
therapi
patient
receiv
antifung
therapi
analys
use
electrophoret
karyotyp
ek
test
antifung
suscept
fluconazol
voriconazol
itraconazol
result
overal
rate
resist
fluconazol
mic
lgml
itraconazol
mic
lgml
isol
respect
patient
sequenti
strain
patient
exhibit
similar
azol
suscept
howev
sequenti
isol
two
patient
show
threeor
fourfold
increas
mic
three
azol
antifung
retain
karyotyp
azoleresist
strain
isol
patient
fluconazol
therapi
discontinu
interv
first
blood
isol
day
respect
isol
one
patient
exhibit
increas
express
efflux
pump
sequenti
strain
patient
ident
karyotyp
patient
two
four
differ
karyotyp
patient
sequenti
isol
five
patient
exhibit
similar
antifung
suscept
show
one
two
chromosom
band
differ
associ
previou
antifung
therapi
conclus
studi
show
sequenti
bloodstream
isol
c
glabrata
abl
acquir
azol
resist
associ
fluconazol
therapi
develop
two
four
differ
karyotyp
patient
cours
fungaemia
result
next
tabl
show
mic
obtain
test
drug
three
isol
voriconazol
mic
mgl
two
fluconazol
mic
mgl
six
isol
voriconazol
mic
mgl
found
fluconazol
mic
one
mgl
anoth
four
mgl
last
one
mgl
conclus
nt
found
fluconazol
voriconazol
isol
haart
era
b
percentag
isol
voriconazol
mic
mgl
higher
describ
work
c
voriconazol
isol
fluconazol
cross
resist
mechan
could
implic
vitro
susceptibiil
test
micafungina
anidulafungin
candida
spp
object
despit
antifung
therapi
mortal
dissemin
zygomycosi
still
high
analys
vitro
activ
posaconazol
po
voriconazol
vrc
caspofungin
ca
strain
genera
rhizopu
mucor
absidia
cunninghamella
differ
media
composit
method
follow
five
media
composit
compar
rpmi
glucos
glucos
hrmedium
mic
determin
microdilut
method
follow
nccl
guidelin
minor
modif
well
read
visual
growth
well
compar
growth
control
two
endpoint
evalu
drug
inhibit
growth
war
record
inhibit
growth
record
mic
final
concentr
antifung
agent
mgl
po
vrc
mgl
ca
result
po
significantli
activ
ca
vor
r
g
hr
media
p
compar
po
hr
medium
vrc
p
comparison
growth
rpmi
media
supplement
glucos
robust
correspond
media
lack
glucos
glucos
littl
influenc
mic
valu
agreement
compar
evalu
glucos
use
endpoint
yield
agreement
genera
compar
data
obtain
rpmi
glucos
hr
agreement
good
percentag
agreement
use
endpoint
contrast
agreement
glucos
media
gener
poor
moreov
averag
mic
obtain
medium
lower
obtain
either
hr
rpmi
due
differ
among
genera
conclus
result
suggest
follow
po
activ
vitro
zygomycet
clinic
relev
concentr
b
within
zygomycet
differ
genera
term
antifung
susceptibili
c
growth
medium
import
variabl
mic
determin
zygomycet
relev
medium
appear
rpmi
supplement
glucos
object
describ
first
clinic
case
caspofungin
resist
c
glabrata
infect
patient
year
old
male
aml
receiv
match
unrel
hsct
month
prior
death
complic
hospit
cours
includ
c
glabrata
sepsi
c
glabrata
cultur
stool
time
transplant
death
initi
blood
cultur
isol
azol
resist
amphotericin
b
start
stop
due
renal
insuffici
caspofungin
start
mic
lgml
prolong
durat
therapi
compris
altern
cours
iv
voriconazol
caspofungin
four
month
initi
fungaemia
c
glabrata
cultur
caspofungin
resist
mic
azol
resist
despit
addit
amphotericin
b
patient
die
week
later
c
glabrata
isol
bone
marrow
autopsi
method
seri
patient
isol
time
transplant
death
suscept
perform
per
nccl
document
isol
type
use
probe
mlst
result
suscept
demonstr
caspofungin
resist
blood
isol
lgml
azol
resist
initi
stool
isol
isol
shown
ident
determin
mlst
group
previous
shown
preval
clade
c
glabrata
worldwid
discuss
describ
first
caspofungin
resist
clinic
isol
c
glabrata
recent
report
c
albican
data
detail
isol
develop
resist
presenc
therapi
resist
caspofungin
common
thought
due
mutat
synthas
fk
gene
fk
gene
c
glabrata
preliminari
sequenc
data
one
gene
far
reveal
nonconserv
mutat
remain
gene
yet
sequenc
presenc
mechan
rule
object
aim
studi
investig
product
slime
factor
among
candida
speci
isol
hospit
patient
anoth
aim
studi
see
vitro
activ
antifung
agent
compar
result
slime
product
method
total
candida
spp
c
albican
nonalbican
candida
spp
isol
variou
specimen
includ
studi
fluconazol
itraconazol
amphotericin
b
caspofungin
suscept
strain
determin
broth
microdilut
method
accord
nccl
standard
biofilm
product
candida
spp
determin
micropl
method
polystyren
microtit
plate
use
brain
heart
infus
broth
supplement
glucos
growth
medium
result
caspofungin
amphotericin
b
activ
agent
valu
mgml
respect
fluconazol
resist
mic
obtain
isol
biofilm
format
detect
total
strain
statist
import
differ
p
determin
biofilm
product
c
albican
nonalbican
speci
signific
correl
biofilm
product
amphotericin
b
mic
valu
establish
p
conclus
candida
speci
one
import
etiolog
agent
cathet
relat
infect
especi
biolfilm
produc
strain
studi
show
us
biofilm
product
rate
high
particularli
nonalbican
strain
explain
rise
incid
non
albican
strain
especi
c
parapsilosi
seriou
infect
studi
also
implic
mic
valu
amphotericin
b
one
activ
agent
candida
infect
signific
correl
slime
product
problem
treatment
slime
produc
candida
infect
drug
conclus
scedosporium
spp
carri
high
mic
antifung
agent
even
new
antifung
agent
po
ii
prolifican
multiresist
organ
iii
apiospermum
resist
itc
tbf
strain
suscept
vitro
amb
mic
mgl
vrc
mic
mgl
po
mic
mgl
iv
find
reinforc
need
continu
surveil
programm
analyz
antifung
suscept
profil
medic
import
fungal
isol
assess
suscept
fungi
isol
hospit
environ
disinfect
object
past
decad
wit
worldwid
increas
serv
invas
ga
infect
rapidli
progress
infect
associ
high
mortal
rate
despit
prompt
antimicrobi
therapi
aim
studi
character
ga
isol
caus
sever
invas
diseas
differ
region
poland
emmtyp
multilocu
sequenc
type
mlst
pfge
virul
gene
distribut
suscept
antimicrobi
agent
method
total
ga
isol
blood
pu
sputum
peritoneum
fluid
sourc
examin
suscept
penicillin
erythromycin
clindamycin
telithromycin
tetracyclin
levofloxacin
chloramphenicol
quinupristindalfopristin
linezolid
determin
microdilut
method
accord
nccl
guidelin
clonal
isol
studi
emm
type
pfge
sma
irestrict
bacteri
dna
well
mlst
strain
also
test
presenc
spea
speb
spec
spef
ssa
gene
pcr
result
resist
erythromycin
found
four
isol
two
exhibit
imlsb
two
cmlsb
phenotyp
twentyon
five
resist
tetracyclin
chloramphenicol
respect
test
isol
fulli
suscept
penicillin
levofloxacin
quinupristin
dalfopristin
linezolid
twenti
differ
emm
type
detect
common
follow
type
type
correspond
respect
altogeth
differ
pfge
pattern
design
ay
discern
among
isol
two
predomin
profil
n
b
n
studi
show
isol
possess
speb
spef
gene
frequenc
spec
spea
respect
conclus
two
clone
predomin
among
ga
strain
caus
sever
invas
diseas
poland
clone
emm
type
present
actinomyc
spp
isol
identif
speci
level
clinic
sourc
addit
perform
suscept
test
strain
drug
identif
actinomyc
spp
done
take
account
cultur
featur
atmospher
biochem
enzimat
test
accord
scheme
propos
sarkonen
n
funk
g
moncla
b
hillier
bernard
k
studi
clinic
sourc
actinomyc
spp
isol
lone
associ
mucosa
normal
flora
suscept
test
perform
agar
dilut
method
mueller
hinton
agar
supplement
sheep
blood
read
minimum
inhibitori
concentr
mic
done
hour
incub
atmospher
enrich
co
strain
grown
sheep
blood
agar
plate
co
ad
radinga
europaeu
odontolyticu
frequent
isol
speci
one
follow
israelii
graevenitzii
turicensi
viscosu
isol
actinomyc
spp
recov
sole
microorgan
remaind
associ
mucosa
normal
flora
relat
actinomyc
speci
clinic
sourc
sampl
mic
penicilin
ampicilin
cefotaxim
lgml
bimod
behaviour
macrolid
erythromycin
azithromycin
clarithromycin
mic
lgml
observ
quinolon
levofloxacin
ciprofloxacin
moxifloxacin
mic
lgml
isol
present
mic
vancomycin
lgml
identif
actinomyc
genu
present
diagnost
difficulti
due
growth
requir
speci
infrequ
sourc
recov
suggest
may
clinic
relev
often
isol
sole
pathogen
isotretinoin
versu
tetracyclin
compar
studi
regard
effici
treatment
acn
vulgari
c
oprica
l
emtestam
ce
nord
stockholm
tetracyclin
commonli
use
treatment
moder
sever
inflammatori
acn
system
administ
isotretinoin
prove
effici
treatment
use
patient
moder
sever
acn
fail
respond
therapi
object
random
clinic
trial
conduct
compar
clinic
efficaci
antimicrobi
suscept
propionibacterium
acn
strain
isol
treatment
either
tetracyclin
isotretinoin
patient
acn
vulgari
method
male
femal
patient
year
age
moder
sever
acn
random
two
group
patient
receiv
oral
tetracyclin
hydrochlorid
gramday
togeth
topic
retinoid
differin
gel
isotretinoin
roaccutan
mgkgday
therapi
given
period
clinic
evalu
leed
acn
grade
system
lesion
count
bacteri
sampl
taken
treatment
start
treatment
month
treatment
stop
dermatolog
life
qualiti
index
questionnair
complet
patient
treatment
order
determin
impair
life
qualiti
result
acn
sever
significantli
reduc
regimen
therapi
patient
isotretinoin
group
continu
improv
acn
score
treatment
stop
month
treatment
isotretinoin
produc
greater
lesion
reduct
tetracyclin
mean
per
cent
reduct
differ
lesion
count
follow
versu
noninflammatori
lesion
p
versu
inflammatori
lesion
p
isotretinoin
tetracyclin
group
respect
drugfre
period
group
patient
treat
isotretinoin
present
significantli
less
inflammatori
lesion
compar
group
treat
tetracyclin
p
treatment
improv
life
qualiti
p
independ
acn
sever
resist
p
acn
strain
isol
treatment
tetracyclin
group
isotretinoin
group
conclus
treatment
effect
treatment
period
resist
strain
recov
tetracyclin
group
psoa
abscess
differ
pyogen
tubercul
abscess
object
compar
demograph
characterist
clinic
featur
laboratori
microbiolog
imag
data
therapeut
option
outcom
pyogen
tubercul
psoa
abscess
patient
method
retrospect
descript
studi
medic
record
patient
diagnos
psoa
abscess
institut
period
result
period
patient
diagnos
psoa
abscess
secondari
adjac
sourc
infect
nine
patient
pyogen
abscess
tuberculosi
causal
microorgan
patient
patient
bilater
involv
three
tubercul
abscess
underli
diseas
present
patient
pyogen
abscess
tubercul
abscess
one
malign
intraven
drug
use
cirrhosi
use
steroid
inflammatori
bowel
diseas
patient
tubercul
abscess
younger
vs
year
present
longer
durat
symptom
present
diagnosi
vs
day
patient
pyogen
abscess
abdomin
pain
frequent
symptom
diagnosi
pyogen
abscess
wherea
lumbar
pain
tubercul
abscess
clinic
manifest
similar
group
sourc
infect
pyogen
abscess
gastrointestin
patient
polymicrobi
patient
infect
aortobifemor
bypass
sacroil
caus
aureu
tubercul
abscess
secondari
spondil
differ
group
analysi
imag
alter
cultur
abscess
posit
case
practis
drainag
perform
patient
percutan
without
differ
group
clinic
improv
delay
patient
tubercul
abscess
patient
pyogen
abscess
vs
day
death
group
conclus
tubercul
psoa
abscess
present
younger
patient
lesser
underli
diseas
prolong
clinic
present
pyogen
abscess
tubercul
abscess
secondari
spondil
usual
bilater
involv
preval
microorgan
isol
wound
inpati
versu
outpati
spanish
teach
hospit
object
hidraden
suppurativa
hd
chronic
disord
character
dilat
sweat
gland
recurr
bacteri
infect
vitamin
e
administ
sever
patient
antioxid
attempt
reliev
tissu
function
probabl
alter
local
increas
oxid
statu
method
twenti
nine
patient
hd
male
femal
enrol
period
twelv
month
present
three
episod
bacteri
exacerb
least
two
year
detail
medic
histori
taken
upon
first
evalu
patient
examin
area
affect
diseas
ask
selfevalu
sever
condit
scale
repres
intact
skin
maximum
sever
patient
divid
three
group
treatment
n
control
b
n
vitamin
e
oral
mg
bid
c
n
vitamin
e
mg
tid
oral
patient
withhold
antimicrobi
regim
patient
followedup
threemonth
interv
ask
reevalu
condit
provid
detail
regard
frequenc
relaps
initi
treatment
result
mean
se
durat
diseas
year
involv
area
axilla
groin
involv
major
case
mean
interv
exacerb
initi
therapi
vitamin
e
day
initi
therapi
day
p
group
b
mean
se
time
interv
exacerb
initi
treatment
day
initi
treatment
day
group
c
respect
valu
day
day
mean
se
selfevalu
score
therapi
vitamin
e
patient
group
b
c
respect
respect
twelv
month
followup
latter
chang
constitut
signific
improv
p
conclus
vitamin
e
seem
improv
overal
clinic
condit
patient
hd
substanti
placebocontrol
studi
necessari
confirm
result
clonal
divers
toxin
gene
staphylococcu
aureu
caus
infect
clinic
ward
period
pollini
g
zanelli
sansoni
cresti
c
cellesi
gm
rossolini
siena
object
aureu
remain
one
lead
bacteri
pathogen
worldwid
repres
major
challeng
antimicrobi
chemotherapi
aim
studi
evalu
molecular
epidemiolog
aureu
infect
observ
infecti
diseas
ward
past
year
clinic
microbiolog
infect
volum
supplement
method
nonrepl
aureu
isol
collect
patient
staphylococc
infect
includ
foodborn
infect
osteomyel
skin
soft
tissu
infect
ssti
pneumonia
mening
bacteraemiaendocard
mostli
communityacquir
infecti
diseas
clinic
univers
siena
period
feb
march
isol
analys
antimicrobi
resist
clonal
divers
toxin
gene
seae
etad
tst
lukspv
lukfpv
suscept
test
perform
accord
nccl
guidelin
clonal
divers
determin
pfge
analysi
coagulas
coa
protein
spa
gene
polymorph
toxin
gene
analys
pcr
restrict
map
result
isol
methicillinsuscept
mssa
methicillinresist
mrsa
mecaposit
borderlin
genotyp
reveal
singl
mrsa
clone
remark
clonal
divers
among
mssa
isol
least
distinct
clonal
lineag
sever
clone
includ
mssa
mrsa
clone
detect
prolong
time
year
preval
clone
detect
period
exclus
associ
ssti
mostli
bullou
impetigo
toxin
gene
overal
detect
isol
frequent
sea
tst
eta
andor
etb
gene
six
isol
mssa
harbour
lukspv
lukfpv
gene
conclus
mrsa
rare
appear
sinc
signific
clonal
divers
observ
within
mssa
signific
relationship
observ
toxin
product
infect
eg
ssti
sever
group
streptococc
infect
romania
surveil
within
strepeuro
project
b
luca
straut
v
ungureanu
c
schalen
jasir
behalf
strepeuro
studi
group
object
last
year
sever
invas
streptococc
infect
often
afflict
otherwis
healthi
subject
yield
high
mortal
rate
increasingli
record
europ
area
main
object
investig
situat
romania
lack
earlier
data
field
method
strain
use
studi
clinic
isol
nine
region
romania
strain
mainli
blood
isol
steril
site
vitro
suscept
antibiot
test
disk
diffus
pdm
agar
follow
standard
instruct
ttype
perform
slide
agglutin
use
sera
sevapharma
pragu
spe
gene
detect
emm
sequenc
type
perform
accord
proviou
public
result
eighteen
month
case
report
preval
ttype
follow
type
fifteen
differ
emm
type
recognis
unusu
type
four
type
half
report
case
children
year
strain
harbour
spec
gene
harbour
spea
erythromycin
resist
uncommon
one
isol
wherea
overal
high
rate
tetracyclin
resist
found
conclus
first
report
sever
invas
streptococc
infect
sinc
surveil
previous
done
romania
popul
cover
eight
provinc
emm
type
distribut
might
concern
sinc
mani
unusu
type
previous
associ
sever
diseas
found
may
partli
relat
dissemin
new
type
popul
immun
classic
type
sinc
tetracyclin
use
treatment
streptococc
infect
level
tetracyclin
resist
among
clinic
isol
appear
compar
high
contrast
sever
european
countri
macrolid
resist
seem
common
among
invas
group
streptococci
romania
acknowledg
strepeuro
project
fund
european
commiss
sever
soft
tissu
infect
secondari
bacteraemia
due
communityacquir
mrsa
travel
return
congo
r
padmanabhan
r
shrestha
g
hall
gordon
l
saravolatz
cleveland
detroit
usa
object
commun
acquir
mrsa
increasingli
becom
global
problem
isol
possess
staphylococc
cassett
chromosom
scc
mec
type
iv
genom
differ
pattern
antibiot
suscept
hospit
acquir
strain
frequent
virul
caus
predominantli
skin
soft
tissu
infect
virtu
panton
valentin
leukocidin
pvl
toxin
gene
return
travel
spent
preced
four
week
congo
present
staphylococc
bacteraemia
larg
cutan
ulcer
right
lower
extrem
progress
extens
soft
tissu
necrosi
first
experienc
symptom
kinshasa
intern
airport
await
return
flight
unit
state
approxim
hour
prior
present
facil
method
mrsa
isol
blood
suscept
vancomycin
clindamycin
erythromycin
tetracyclin
trimethoprimsulfamethoxazol
gentamicin
puls
field
gel
electrophoresi
pfge
analysi
perform
use
patient
isol
along
anoth
strain
hospit
compar
strain
isol
midwestern
unit
state
pcr
amplif
gene
encod
pantonvalentin
leukocidin
pvl
perform
use
primer
describ
elsewher
result
pfge
demonstr
congo
strain
differ
midwestern
unit
state
strain
scc
mec
type
isol
reveal
strain
type
iv
pcr
analysi
detect
sequenc
specif
pvl
gene
conclus
differenti
diagnosi
ulcer
return
travel
larg
includ
bacteri
fungal
helminth
protozo
viral
arthropod
born
caus
mrsa
ad
list
widespread
occurr
camrsa
mani
part
world
would
support
find
organ
african
contin
knowledg
repres
first
camrsa
scc
type
iv
mec
gene
report
congo
tenyear
communityacquir
methicillinresist
staphylococcu
aureu
clone
denmark
object
determin
epidemiolog
denmark
pandem
european
camrsa
clone
respect
subtyp
dissemin
acquisit
type
infect
method
methicillin
resist
staphylococcu
aureu
mrsa
isol
denmark
refer
store
staphylococcu
laboratori
staten
serum
institut
n
isol
character
macrorestrict
smai
analysi
use
pfge
sccmec
type
dru
sequenc
type
antibiot
suscept
test
pcr
amplif
panton
valentin
leukocidin
gene
pvl
clinic
epidemiolog
inform
patient
obtain
discharg
summari
regist
result
mrsa
clone
account
total
number
mrsa
denmark
infect
due
primarili
commun
onset
therebi
account
commun
onset
mrsa
period
infect
skin
soft
tissu
infect
compar
antibiogram
streptomycin
kanamycin
tetracyclineand
fusid
acidresist
gentamicin
sensit
isol
store
aureu
bacteraemia
collect
trace
clone
back
one
five
isol
encount
pr
year
increas
isol
year
pfge
isol
exhibit
nine
differ
pattern
type
nine
type
isol
isol
subject
dru
type
earlier
enabl
separ
pfge
clone
subtyp
howev
possibl
isol
conclus
isol
caus
larg
proport
mrsa
infect
denmark
particular
among
infect
commun
onset
success
infect
clone
outsid
hospit
environ
may
part
due
small
sccmec
type
iv
abil
caus
skin
soft
tissu
infect
probabl
associ
express
pvl
dru
sequenc
type
could
subdivid
major
type
found
denmark
point
strict
clonal
clone
may
indic
well
adapt
pathogen
epidemiolog
manag
pressur
ulcer
acut
care
hospit
object
aim
studi
determin
pressur
ulcer
preval
acut
care
hospit
identifi
risk
factor
evalu
medic
non
medic
manag
pressur
ulcer
studi
microbiolog
contamin
pressur
ulcer
method
patient
standard
questionnair
complet
questionnair
includ
demograph
data
age
sex
previou
risk
factor
braden
scale
detect
pressur
ulcer
perform
skin
examin
patient
two
expert
skin
care
manag
ulcer
pressur
evalu
review
clinic
chart
patient
pressur
ulcer
pressur
ulcer
swab
inocul
select
media
data
enter
analys
epiinfo
cdc
atlanta
ga
result
total
patient
year
old
includ
ulcer
pressur
observ
patient
preval
heel
anckl
frequent
local
follow
sacrum
elbow
spinou
process
ischial
tuberos
pressur
ulcer
stage
stage
ii
stage
iii
stage
iv
eighti
percent
pressur
ulcer
acquir
within
hospit
use
univari
analysi
risk
factor
significantli
associ
pressur
ulcer
braden
cutoff
p
neurolog
disord
p
previou
ulcer
pressur
p
hospit
intens
care
unit
p
among
criteria
use
braden
scale
humid
activ
motil
nutrit
friction
shear
significantli
associ
ulcer
pressur
p
among
pressur
ulcer
diagnos
expert
skin
care
treat
treatment
consid
inappropri
mostli
stage
iii
accord
french
guidelin
microbiolog
result
show
ulcer
pressur
mostli
stage
iii
iv
colon
multipl
resist
bacteria
ie
methicillin
resist
staphylococcu
aureu
extend
spectrum
betalactamas
enterobacteriacea
conclus
prospect
preval
studi
led
better
awar
patient
risk
pressur
ulcer
surveil
also
contribut
better
knowledg
mobil
unit
geriatr
recent
creat
within
hospit
background
follow
surgeri
musculoskelet
infect
mi
posit
suction
drainag
cultur
sdc
consist
persist
sepsi
unfavor
evolut
major
case
object
studi
determin
effect
neg
sdc
obtain
subsequ
oper
repeat
oper
outcom
mi
method
one
hundr
patient
treat
surgic
mi
util
suction
drainag
hour
postop
appropri
antimicrobi
therapi
enrol
prospect
studi
surgic
treatment
consist
routin
practic
develop
treatment
mi
consist
drainag
purul
materi
prosthet
exchang
implant
remov
accumul
drainag
fluid
reservoir
cultur
sdc
consid
neg
bottl
result
neg
cultur
patient
place
one
three
possibl
mi
treatment
group
accord
sdc
result
identifi
first
surgic
procedur
follow
patient
neg
sdc
new
oper
perform
ii
patient
posit
sdc
new
oper
perform
sdc
neg
iii
patient
posit
sdc
new
oper
durat
antibiot
therapi
osteomyel
rang
week
other
mi
soft
tissu
infect
treat
day
result
group
similar
regard
gender
age
underli
condit
mi
bacteri
organ
surgeri
antibiot
therapi
major
patient
osteomyel
presenc
implant
final
review
cure
obtain
patient
group
patient
group
patient
group
conclus
neg
sdc
follow
mi
surgeri
strong
indic
eventu
outcom
infecti
process
microbi
aetiolog
osteomyel
foot
diabet
patient
relat
hospit
lowerextrem
amputationacut
infect
pt
recent
receiv
antibiot
therapi
predominantli
caus
aerob
gramposit
cocci
often
monomicrobi
infect
although
chronic
wound
tend
develop
polymicrobi
flora
object
know
microbi
etiolog
osteomyel
foot
diabet
pt
determin
best
choic
empir
antibiot
combin
method
diabet
pt
osteomyel
foot
admit
unit
includ
infect
document
intraop
sampl
osteomyel
histolopatholog
prouv
clinic
biolog
data
collect
result
diabet
pt
male
femal
median
age
year
includedth
comorbid
chronic
renal
failur
n
arteriopathi
n
obes
n
alcohol
n
immunodepress
n
clinic
data
fever
shock
local
sign
erythema
fistula
necrosi
foul
odor
median
rate
neutrophil
polynuclear
creactiv
protein
erythrocyt
sediment
respect
gl
mgl
mm
pt
polymicrobi
infectionth
intraop
sampl
n
yiel
major
gram
posit
cocci
mssa
n
mrsa
n
cn
n
streptococcu
sp
n
enterococcu
sp
n
follow
gram
neg
bacteria
pseudomona
sp
n
proteu
sp
n
morganella
sp
n
e
coli
n
klebsiella
sp
n
e
cloaca
n
citrobact
sp
n
serratia
sp
n
other
n
anaerob
n
pt
posit
blood
sampl
aureu
frequent
pathogen
isol
especi
monomicrobi
infect
infect
posit
blood
sampl
pseudomona
spp
seem
correl
chronic
renal
failur
immunodepress
clinic
data
significantli
associ
special
bacteria
except
necrosi
foul
odor
gram
neg
bacteria
anaerob
conclus
result
accord
clinic
studi
literatur
major
difficulti
treat
osteomyel
diabet
foot
well
document
infect
select
appropri
antibiot
treat
particularli
import
prolong
durat
therapi
requir
potenti
resist
pathogen
durat
hospitalis
length
stay
patient
hospitalis
complic
skin
skin
structur
infect
identifi
clinic
microbiolog
risk
factor
comparison
tigecyclin
vancomycinaztreonam
patient
polymicrobi
infect
gramneg
caus
pathogen
mostli
escherichia
coli
gramneg
caus
pathogen
preval
greatest
asia
conclus
analysi
show
signific
global
variat
csssi
subdiagnos
etiolog
comorbid
caus
pathogen
consist
find
sentri
antimicrobi
surveil
program
aureu
identifi
predomin
pathogen
csssi
especi
us
gramneg
pathogen
also
identifi
caus
substanti
proport
complic
skin
infect
find
may
offer
guidanc
select
effect
empir
therapi
especi
regard
newer
agent
expand
broadspectrum
activ
novel
approach
evalu
microbiolog
efficaci
tigecyclin
patient
complic
skin
skinstructur
infect
meagher
p
ambros
j
passarel
b
cirincion
babinchak
ej
ellisgross
buffalo
albani
collegevil
usa
object
tigecyclin
glycylcyclin
develop
treatment
patient
pt
seriou
infect
includ
complic
skin
skinstructur
infect
csssi
csssi
caus
mixtur
gramposit
neg
bacteria
staphylococcu
aureu
streptococci
predomin
pathogen
previou
analys
combin
pathogen
fail
identifi
exposurerespons
er
relationship
method
develop
creat
homogen
pt
popul
microbiolog
er
analysi
treatment
csssi
method
pt
csssi
clinic
trial
one
phase
two
phase
pharmacokinet
data
classifi
clinic
evalu
pool
analysi
pt
receiv
mg
load
dose
ld
mg
mg
mg
test
cure
visit
erad
persist
respons
evalu
indetermin
respons
exclud
non
pathogen
baselin
isol
exclud
five
homogen
pt
cohort
c
creat
base
baselin
pathogen
aureu
aureu
streptococci
gramposit
pathogen
polymicrobi
monomicrobi
infect
prospect
stepwis
procedur
combin
c
increas
sampl
size
use
logist
regress
use
evalu
steadyst
hr
area
concentrationtim
curv
auc
mic
ratio
aucmic
predict
respons
result
dataset
includ
pt
observ
n
n
could
evalu
due
small
sampl
size
analysi
began
pool
continu
aucmic
ratio
margin
signific
p
pt
like
success
respons
everi
oneunit
increas
aucmic
ad
includ
pathogen
mic
valu
mcgml
decreas
aucmic
ad
cure
lower
end
distribut
ad
signific
nois
analysi
ad
increas
sampl
size
decreas
abil
detect
relationship
conclus
analysi
pathogen
combin
could
identifi
er
relationship
polymicrobi
infect
gramneg
anaerob
pathogen
associ
high
mic
valu
ad
nois
analysi
decreas
predict
capabl
model
approach
creat
homogen
popul
base
two
key
pathogen
csssi
aureu
streptococci
critic
identifi
signific
er
relationship
exposurerespons
analysi
efficaci
tigecyclin
patient
complic
skin
skinstructur
infect
meagher
j
passarel
b
cirincion
van
wart
k
liolio
babinchak
ej
ellisgross
p
ambros
buffalo
collegevil
albani
usa
object
tigecyclin
first
glycylcyclin
reach
clinic
trial
develop
treatment
patient
pt
seriou
infect
includ
complic
skin
skinstructur
infect
csssi
pharmacokineticpharmacodynam
pkpd
relationship
includ
pt
covari
microbiolog
clinic
c
efficaci
evalu
pt
csssi
method
pt
csssi
clinic
trial
one
phase
two
phase
pk
data
classifi
c
evalu
pool
analysi
pt
infect
due
staphylococcu
aureu
andor
streptococci
predomin
pathogen
csssi
prospect
evalu
pt
receiv
mg
load
dose
ld
mg
mg
ld
mg
test
cure
visit
erad
persist
c
cure
failur
outcom
assess
indetermin
respons
exclud
steadyst
hr
area
concentrationtim
curv
auc
aucmic
ratio
evalu
predictor
respons
pt
covari
includ
age
weight
countri
baselin
pseudomona
aeruginosa
anaerob
comorbid
diabet
peripher
vascular
diseas
classif
regress
tree
cart
analys
determin
aucmic
breakpoint
bp
logist
regress
one
observationpt
perform
determin
predictor
efficaci
result
dataset
includ
pt
aureu
andor
streptococc
baselin
pathogen
mic
valu
rang
mcgml
clinic
cure
achiev
pt
pathogen
success
erad
median
aucmic
ratio
mg
dose
group
respect
covari
signific
predictor
efficaci
cart
identifi
signific
aucmic
bp
p
c
continu
aucmic
ratio
margin
signific
base
sampl
size
p
c
deem
inform
model
unit
increas
aucmic
within
observ
rang
pt
like
success
c
respons
like
success
respons
conclus
pt
aucmic
ratio
time
like
success
respons
median
auc
mic
ratio
dose
group
modelpredict
probabl
c
success
respect
like
import
treatment
option
csssi
introduct
vertebr
osteomyel
andor
sacroili
due
streptococcu
pneumonia
extrem
rare
although
one
common
pathogen
isol
blood
cultur
case
report
literatur
main
seri
vertebr
osteomyel
vo
spsi
repres
less
case
materi
method
report
case
spinal
infect
due
pneumonia
vo
si
psoa
abscess
seen
differ
acut
care
hospit
result
case
report
part
total
episod
pneumococc
bacteraemia
mean
age
patient
year
rang
men
alcohol
abus
immunosupress
smoke
common
comorbl
blood
cultur
posit
case
epidur
pu
vertebr
biopsi
also
posit
strain
suscept
penicillin
diagnos
made
mri
ct
scan
patient
reciv
betalactam
agent
mean
seven
week
monotherapi
cefotaxim
ampicillin
combin
vancomicingentamicin
case
one
case
need
surgeri
progress
psoa
abscess
foci
found
three
case
psoa
paravertebr
abscess
acromioclavicular
arthriti
conclus
spsi
rare
present
invas
pneumococc
diseas
underli
diseas
comnmon
territori
frequent
involv
infect
endocard
must
rule
cours
appear
benign
betalactam
antibiot
good
option
surgeri
occasion
indic
progress
diseas
despit
appropri
antimicrobi
therapi
lumbar
spine
spondyl
due
staphylococcu
schleiferi
follow
coronari
angioplasti
isol
pathogen
peripher
blood
cultur
karakolio
c
karagiannid
kallinikidi
f
markou
v
konto
g
tsinopoulo
serr
gr
old
man
present
acut
sever
lower
back
pain
week
subject
coronari
angioplasti
ischaem
heart
diseas
treat
nsaid
antibiot
without
improv
ct
scan
lumbar
spine
show
chang
vertebra
consist
spondyl
mri
imag
well
confirm
spondyl
also
reveal
presenc
left
paravertebr
abscess
admiss
hospit
low
grade
fever
document
clinic
examin
lower
limb
normal
staphylococcu
schleiferi
sensit
sever
antibiot
isol
set
blood
cultur
taken
arm
initi
ciprofloxacin
mg
bd
iv
administ
week
despit
continu
clinic
improv
mri
imag
week
commenc
antibiot
treatment
show
improv
radiolog
find
thu
levofloxacin
mg
bd
po
rifampicin
mg
bd
po
given
week
end
treatment
patient
symptomfre
resum
full
activ
mri
imag
show
consider
improv
multipl
blood
cultur
taken
arm
differ
time
point
help
isol
pathogen
caus
spondyl
avert
thu
need
difficult
intervent
sampl
focu
infect
diabet
use
topic
ocular
antibiot
populationbas
casecontrol
studi
object
conduct
populationbas
casecontrol
studi
examin
whether
patient
diabet
mellitu
increas
rel
risk
treat
topic
ocular
antibiot
compar
popul
control
method
incid
case
defin
individu
redeem
prescript
topic
ocular
antibiot
north
jutland
counti
denmark
ten
genderand
agematch
popul
control
per
case
select
use
uniqu
person
identifi
diabet
prior
topic
ocular
antibiot
prescript
determin
recordlinkag
counti
prescript
databas
hospit
discharg
registri
condit
logist
regress
estim
odd
ratio
or
ocular
antibiot
use
among
diabet
individu
popul
control
adjust
rang
comorbid
diseas
result
among
individu
treat
topic
ocular
antibiot
diabet
compar
among
control
subject
overal
adjust
use
ocular
antibiot
diabet
individu
confid
interv
ci
stratifi
analys
show
children
year
diabet
increas
rel
risk
ocular
antibiot
use
wherea
effect
diabet
risk
factor
low
individu
year
presenc
diseas
conclus
result
suggest
diabet
risk
factor
use
topic
ocular
antibiot
especi
younger
individu
object
determin
bacteri
speci
suscept
antibiot
infecti
conjunct
gener
practic
method
patient
suspect
infecti
conjunct
includ
gener
care
centr
netherland
eye
swab
taken
pathogen
found
bacteri
cultur
test
suscept
use
etest
chloramphenicol
fusid
acid
trimethoprim
ciprofloxacin
gentamicin
mic
accord
dutch
nation
criteria
result
affect
eye
cultur
posit
streptococcu
pneumonia
n
predomin
pathogen
follow
haemophilu
influenza
n
staphylococcu
aureu
n
chloramphenicol
ciprofloxacin
suscept
intermedi
suscept
rang
three
pathogen
wherea
case
antibiot
test
least
one
resist
rang
conclus
one
thirdth
patient
suspect
infecti
conjunctivi
gener
practic
bacteri
pathogen
found
although
prescript
antibiot
debat
basi
result
chloramphenicol
ciprofloxacin
seem
superior
fusid
acid
trimethoprim
gentamicin
investig
aetiolog
trachomalik
condit
rural
popul
guangxi
provinc
prc
p
cho
mv
boost
w
ng
hong
kong
hk
object
determin
presenc
trachoma
primari
school
children
zhuang
yiao
ethnic
minor
group
counti
guangxi
china
method
primari
school
children
examin
use
slit
lamp
sever
note
display
follicularpapillari
conjunct
suggest
trachoma
confirm
etiolog
condit
children
examin
followup
visit
subject
examin
slit
lamp
upper
lid
evert
applic
topic
anesthet
novesin
dacron
swab
pass
along
upper
tarsal
lengthwis
four
time
strict
asept
precaut
employ
prevent
crosscontamin
sampl
collect
swab
place
dnafre
tube
transport
hong
kong
test
use
roch
amplicor
kit
detect
chlamydia
trachomati
follow
instruct
twenti
children
display
signific
conjunctiv
sign
photograph
evert
upper
lid
taken
determin
visual
sign
correl
presenc
trachoma
confirm
pcr
result
sixtyf
primari
school
student
will
test
posit
trachoma
pcr
comparison
photograph
pcr
result
indic
children
show
sign
conjunct
posit
trachoma
addit
children
whose
eyelid
display
milder
form
conjunct
posit
pcr
obviou
corneal
involv
observ
children
conclus
confirm
hyperepidem
level
trachoma
found
among
ethnic
minor
children
counti
may
relat
poor
hygien
standard
scarciti
water
limeston
region
pcr
posit
children
show
sign
follicularpapillari
conjunct
may
indic
case
dormant
stage
also
possibl
failur
detect
organ
due
sampl
error
delay
pcr
analysi
nevertheless
high
level
infect
caus
concern
trachoma
remain
one
lead
caus
blind
investig
treatment
warrant
clinic
epidemiolog
consider
anthrax
constanta
counti
romania
rugina
im
dumitru
cn
rugina
e
dumea
e
basca
constanta
ro
introduct
anthrax
primarili
diseas
herbivor
human
becom
infect
come
contact
infect
anim
product
object
studi
case
human
anthrax
diagnos
last
twelv
year
characterist
epidemiolog
clinic
form
evolut
materi
method
retrospect
studi
period
twelv
year
perform
infecti
diseas
clinic
hospit
diagnosi
base
smear
cultur
vesicular
fluid
csf
result
period
fifteen
case
anthrax
human
identifi
repartit
case
accord
sex
group
reveal
high
predomin
male
case
case
diseas
preval
age
group
old
case
although
anthrax
observ
year
year
case
anthrax
occup
diseas
proveni
patient
rural
area
annual
incid
anthrax
character
low
valu
irregular
frequenc
diseas
case
case
case
accord
season
repartit
anthrax
preval
summer
month
case
frequent
clinic
form
anthrax
cutan
anthrax
case
one
patient
achiev
anthrax
mening
specif
treatment
penicillin
g
patient
cutan
anthrax
recoveri
complet
patient
anthrax
mening
die
conclus
constantza
counti
anthrax
remain
sporad
last
year
free
period
case
coutan
anthrax
regist
good
cooper
veterinari
physician
individu
awar
materi
key
prevent
anthrax
hemolyt
activ
strain
test
hemopept
activ
indirect
evid
virul
strain
phosphatas
enzym
lecithinas
strain
studi
ferment
glucos
sucros
glycerin
rhamnos
form
acid
without
ga
strain
grew
synthet
medium
although
growth
weak
ltyrosin
ltryptophan
lthreonin
lmethionin
ad
synthet
medium
pathogen
grow
typic
manner
two
anthrax
strain
moder
resist
rifampicin
mic
three
sensit
anthrax
strain
highli
sensit
tetracyclin
benzylpenicillin
gentamycin
oxacillin
conclus
regardless
sourc
isol
time
storag
anthrax
strain
isol
outbreak
virul
sporeform
capsuleform
cultur
studi
confirm
virul
form
b
anthraci
still
circul
kazakhstan
research
describ
abstract
made
possibl
part
support
provid
us
defens
threat
reduct
agenc
project
administ
us
crdf
import
laboratori
method
diagnos
anthrax
human
l
lukhnova
aikimbayev
mekamechenko
g
temiraliyeva
zakaryan
sagatova
almati
kaz
object
isol
anthrax
bacillu
use
bacteriolog
method
slow
frequent
mislead
literatur
suggest
anthrax
bacillu
isol
patient
infect
bacillu
anthraci
pathogen
quickli
perish
transform
atyp
form
number
bacilli
clinic
specimen
often
low
sensit
cultur
suggest
method
would
use
establish
diagnosi
anthrax
specif
serolog
method
would
benefici
diagnos
infect
bacillu
anthraci
method
conduct
studi
assess
variou
method
diagnosi
bacillu
anthraci
infect
patient
review
archiv
data
result
patholog
materi
patient
infect
bacillu
anthraci
southern
eastern
kazakhstan
oblast
result
inform
test
detect
anthrax
patient
delay
type
hypersensit
dth
dermatoallerg
test
anthraxin
eighti
one
per
cent
patient
sign
symptom
anthrax
gave
posit
reaction
anthraxin
ascoli
reaction
complet
scab
posit
patient
indirect
hemeagglutin
iha
test
posit
patient
clinicoepidemiolog
diagnosi
anthrax
confirm
cultur
case
serum
sampl
patient
diagnos
anthrax
eastern
kazakhstan
oblast
evalu
use
iha
high
titr
specif
antibodi
detect
patient
dermatolog
anthrax
lesion
anthrax
isol
conclus
data
suggest
anthraxin
dth
test
iha
good
method
establish
diagnosi
anthrax
cultur
anthrax
bacillu
least
effici
method
establish
diagnosi
result
laboratori
test
neg
inconclus
one
still
reli
clinicoepidemiolog
diagnosi
research
describ
abstract
made
possibl
part
support
provid
us
defens
threat
reduct
agenc
dtra
project
administ
us
civilian
research
develop
foundat
crdf
object
fluoroquinolon
bactericid
agent
frequent
use
treatment
respiratori
tract
infect
viridan
streptococci
vg
although
associ
diseas
gener
exist
part
normal
human
oral
flora
may
expos
antibiot
greater
frequenc
oppurtunist
pathogen
preliminari
data
suggest
vg
may
act
reservoir
fluoroquinolon
resist
spneumonia
horizont
transfer
compar
kill
kinet
moxifloxacin
mxf
levofloxacin
lev
vg
simul
saliva
concentr
method
eight
strain
vg
miti
parc
mutat
sorali
parc
mutat
challeng
mxf
lev
pharmacodynam
model
util
muellerhinton
broth
supplement
lyse
hors
blood
cultur
inocul
densiti
cfuml
incub
c
examin
viabl
growth
hr
exposur
antibiot
concentr
simul
salivari
level
salivari
concentr
mxf
mg
lev
mg
lgml
respect
protein
bind
mfx
lev
taken
adjust
salivari
level
mxf
lev
ugml
pcr
use
amplifi
parc
gyra
mutat
detect
dna
sequenc
result
mxf
lev
highli
bactericid
suscept
strain
vg
salivari
concentr
mfx
typic
erad
vg
hour
lev
hour
parc
mutant
mxf
lev
consist
bactericid
result
erad
hour
mxf
hour
lev
regrowth
observ
strain
smiti
parc
expos
lev
experi
mic
strain
lev
increas
fold
dna
sequenc
reveal
select
gyra
mutat
strain
regrowth
detect
orali
strain
conclus
mxf
lev
extrem
activ
suscept
vg
concentr
drug
found
saliva
howev
superior
kill
kinet
consist
observ
mxf
mxf
consist
erad
strain
parc
mutat
howev
regrowth
observ
occas
lev
suggest
mxf
may
less
like
drive
resist
among
vg
may
implic
due
abil
vg
exchang
genet
determin
pneumonia
moxifloxacin
ciprofloxacin
uptak
human
neutrophil
influenc
viabil
phagocytosi
oxid
burst
chemotaxi
berg
j
altricht
b
drewelow
rg
mundkowski
rostock
object
influenc
antibiot
immun
defenc
increas
interest
purpos
studi
set
cellular
model
correl
intracellular
concentr
fluorochinolon
moxifloxacin
ciprofloxacin
select
cell
function
earli
immun
respons
human
promyelot
cell
line
use
sepsi
treatment
extracorpor
immun
support
system
teraklin
gmbh
chosen
establish
model
second
stage
involv
nativ
human
polymorphonuclear
neutrophil
pmn
target
cell
method
promyelot
model
cell
line
differenti
toward
neutrophil
alltran
retino
acid
human
pmn
isol
use
dextran
sulfat
sediment
densiti
gradient
centrifug
cell
incub
antibiot
concentr
within
therapeut
rang
cmax
time
period
hour
extraand
intracellular
concentr
determin
hplcuv
viabil
cell
control
use
trypanblueexclus
assay
phagocytosi
oxid
burst
assess
combin
flow
cytometr
assay
stimul
cell
serumopsonis
fluoresceinisothiocyanateconjug
e
coli
presenc
dihydroethidium
indic
superoxid
product
twocompart
chamber
system
use
studi
influenc
either
fluorochinolon
chemotaxi
result
either
cell
type
moxifloxacin
accumul
rapidli
peak
concentr
within
min
wherea
intracellular
maximum
concentr
ciprofloxacin
achiev
h
accumul
rate
antibiot
insid
nativ
pmn
twice
high
differenti
eiss
cell
neither
moxifloxacin
ciprofloxacin
show
signific
influenc
viabil
immun
respons
paramet
phagocytosi
oxid
burst
nativ
pmn
chemotaxi
abil
reduc
minor
degreevi
phagocytosi
diffenti
eiss
cell
remain
unaffect
wherea
oxid
burst
appear
decreas
chemotact
actic
eiss
cell
could
stimul
conclus
signific
accumul
moxifloxacin
ciprofloxacin
determin
cell
type
howev
relev
influenc
viabil
phagocytosi
oxid
burst
chemotaxi
observ
henc
hint
found
suggest
restrict
use
moxifloxacin
ciprofloxacin
immunocompromis
patient
prospect
multicentr
vitro
studi
determin
resist
rate
compar
activ
moxifloxacin
vs
clinic
bacteri
isol
patient
respiratori
tract
infect
moxiaktiv
studi
dalhoff
g
korfmann
e
jacob
kiel
leverkusen
dresden
object
determin
preval
resist
current
clinic
isol
pneumonia
h
influenza
catarrhali
aureu
k
pneumonia
well
vitro
suscept
moxifloxacin
iv
antibiot
germani
method
isol
abovement
speci
cultur
standard
media
test
vitro
suscept
use
studi
centr
germani
valid
atcc
control
strain
includ
speci
drug
test
moxifloxacin
levofloxacin
amoxicillinclavulan
cefuroxim
clarithromycin
penicillin
g
latter
two
test
klebsiella
aureu
addit
test
oxacillin
resist
k
pneumonia
test
product
extend
spectrum
betalactamas
esbl
din
breakpoint
use
applic
result
overal
pathogen
hospitalis
patient
respiratori
tract
infect
analys
result
moxifloxacin
summar
tabl
pneumonia
isol
suscept
penicillin
g
clarithromycin
mgl
vitro
activ
levofloxacin
markedli
lower
moxifloxacin
h
influenza
show
almost
suscept
fluoroquinolon
clarithromycin
mgl
betalactamas
product
common
among
h
influenza
isol
germani
amoxicillinclavulan
show
far
higher
suscept
rate
penicillin
g
vs
due
high
rate
betalactamas
product
moraxella
isol
suscept
penicillin
g
compar
amoxicillinclavulan
moraxella
isol
fulli
suscept
fluoroquinolon
overal
klebsiella
isol
produc
esbl
interestingli
esbl
preval
eastern
germani
western
germani
esbl
produc
klebsiella
less
suscept
antibiot
cefotaxim
ceftazidim
nonesbl
produc
conclus
speci
test
fluoroquinolon
achiev
highest
overal
suscept
rate
compar
antibiot
penicillin
g
clarithromycin
ampicillinclavulan
cefuroxim
moxifloxacin
show
high
activ
current
respiratori
pathogen
germani
activ
fluoroquinolon
particular
gramposit
pathogen
object
drug
combin
becom
best
choic
treatment
seriou
infect
resist
microorgan
includ
p
aeruginosa
pa
test
ciprofloxacin
cip
doubl
tripl
combin
ceftazidim
caz
imipenem
imp
piperacillin
pip
amikacin
amk
mdr
clinic
isol
pa
method
mic
drug
alon
determin
broth
microdilut
techniqu
describ
nccl
doubl
tripl
combin
cip
drug
test
use
plate
timekil
assay
row
g
activ
moxifloxacin
pneumonia
sp
h
influenza
hi
catarrhali
mc
clinic
isol
collect
respiratori
tract
determin
mic
use
etest
compar
result
antimicrobi
agentsthes
result
also
compar
sp
versu
previou
studi
winter
period
interpret
criteria
r
accord
nccl
breakpoint
method
belgian
univers
nonunivers
medic
microbiolog
laboratori
particip
past
winter
period
multicentr
invitro
evalu
moxifloxacin
laboratori
includ
strain
sp
strain
hi
mc
total
number
evalu
strain
exclus
duplic
isol
test
condit
method
antibiot
suscept
test
perform
particip
centr
use
etest
antibiot
test
penicillin
ampicillin
amoxiclav
doxycyclin
clarithromycin
cefuroxim
ceftriaxon
ciprofloxacin
levofloxacin
moxifloxacinmedium
sp
mc
muellerhinton
agar
blood
hi
htm
agar
inoculum
direct
suspens
mc
farland
standardincub
hour
co
qualiti
control
perform
use
atcc
refer
strain
pneumonia
atcc
h
influenza
atcc
result
see
graph
conclus
followup
belgian
multicentr
studi
confirm
excel
invitro
potenc
moxifloxacin
clinic
isol
sp
hi
mc
demonstr
potent
fluoroquinolon
avail
belgium
treatment
lower
respiratori
tract
infect
accord
nccl
breakpoint
major
r
differ
sp
result
result
previou
studi
mean
use
new
fluoroquinolon
like
moxifloxacin
levofloxacin
led
date
increas
resist
sp
howev
repeat
followup
survey
continu
need
order
assess
activ
fluoroquinolon
monitor
ecolog
impact
recent
increas
fluoroquinolon
usag
respiratori
tract
infect
belgium
forthcom
year
object
object
sever
experi
evalu
vitro
activ
moxifloxacin
porphyromona
gingivali
pg
method
mic
moxifloxacin
strain
pg
determin
etest
ab
biodisk
solna
sweden
furthermor
spontan
mutat
rate
induct
resist
strain
mic
antibiot
determin
find
target
resist
fragment
gyra
gyrb
sequenc
final
efficaci
moxifloxacin
p
gingivali
atcc
consid
special
condit
effect
strain
biofilm
within
epitheli
cell
kb
cell
evalu
result
moxifloxacin
low
mic
valu
rang
lgml
subinhibitori
concentr
fluoroquinolon
induc
fast
mutat
spontan
mutat
rate
twofold
mic
eightfold
mic
often
mutant
exhibit
high
resist
mic
mgl
mutant
bore
phe
substitut
gyra
mic
elimin
pg
atcc
within
biofilm
h
mic
abl
kill
intracellular
p
gingivali
within
kb
cell
conclus
moxifloxacin
show
good
activ
plancton
p
gingivali
pg
within
biofilm
antibiot
higher
concentr
also
effici
intracellular
bacteria
rapid
develop
resist
observ
laboratori
moxifloxacin
might
altern
antibiot
treatment
p
gingivali
associ
periodont
nevertheless
clinic
studi
focu
improv
clinic
paramet
also
occurr
resist
strain
levofloxacin
activ
respiratori
isol
streptococcu
pneumonia
decreas
suscept
ciprofloxacin
spain
j
jl
n
c
r
behalf
spanish
surveil
group
respiratori
pathogen
object
test
activ
levofloxacin
recent
respiratori
isol
pneumonia
reduc
suscept
ciprofloxacin
mic
mgl
n
belong
nation
surveil
n
identifi
chromosom
mutat
isol
levofloxacin
mic
mgl
method
activ
levofloxacin
test
broth
microdilut
follow
nccl
recommend
genotyp
sequenci
qrdr
gyra
gyrb
parc
pare
done
strain
levofloxacin
mic
mgl
result
levofloxacin
mic
distribut
bold
given
tabl
whole
sampl
broken
ciprofloxacin
mic
categori
mutat
gyra
found
strain
gyrb
mutat
found
mutat
parc
occur
strain
final
mutat
pare
found
strain
chang
one
singl
parc
mutat
occur
strain
mgl
conclus
gemi
continu
highli
potent
fq
test
two
commonli
isol
gramneg
carti
pathogen
h
influenza
catarrhali
potenc
spectrum
consist
across
six
year
three
contin
norfloxacin
marker
decreas
suscept
fluoroquinolon
enterobacteria
use
vitek
system
l
pez
j
alcala
f
torr
ej
perea
pascual
sevil
e
object
detect
nalidix
acid
resist
acquir
import
enterobacteria
sinc
alreadi
resist
strain
develop
frequent
resist
fluorquinolon
suscept
strain
mani
clinic
laboratori
incorpor
vitek
system
benefit
routin
nalidix
test
includ
enterobacteria
card
aim
studi
use
norfloxacin
vitek
mic
valu
altern
marker
detect
nalidix
acid
resist
enterobacteria
strain
materi
method
total
isol
enterobacteriacea
analyz
routin
inocul
vitek
idgnb
card
load
vitek
system
recommend
manufactur
ninetysix
strain
higher
norfloxacin
vitek
mic
valu
mgl
still
within
suscept
rang
establish
nccl
breakpoint
strain
norfloxacin
vitek
mic
mgl
select
test
micrognalidix
aciddisk
nal
oxoid
accord
nccl
refer
result
norfloxacin
mgl
suscept
ciprofloxacin
phenotyp
repres
total
isol
load
vitek
system
studi
similar
preval
observ
previou
analysi
spain
select
group
one
highest
lowest
norfloxacin
vitek
mic
valu
includ
e
coli
isol
enterica
isol
respect
among
norfloxacin
vitek
mic
mgl
strain
isol
nal
resist
ciprofloxacin
suscept
agreement
norfloxacin
vitek
mic
mgl
nal
suscept
foun
strain
two
isol
one
e
cloaca
one
k
pneumonia
norfloxacin
vitek
mic
mgl
nal
isol
two
e
coli
one
p
mirabili
norfloxacin
vitek
mic
mgl
nalr
conclus
use
vitek
system
enterobacteria
consider
mic
norfloxacin
mgl
could
altern
marker
nalidix
acid
resist
decreas
suscept
fluoroquinolon
antibacteri
suscept
studi
object
p
aeruginosa
import
nosocomi
pathogen
caus
seriou
often
lethal
infect
immunocompromis
host
pathogen
intrins
resist
mani
antibiot
easili
develop
resist
toward
mani
current
avail
agent
natur
resist
attribut
low
permeabl
paeruginosa
outer
membran
varieti
antibiot
includ
glycopeptid
gli
sinc
gli
power
antibiot
gramposit
bacteria
resist
rare
develop
seem
interest
evalu
effect
combin
antimicrobi
agent
antibiot
might
disorgan
structur
outer
membran
allow
entranc
glicopeptid
gramneg
cell
order
verifi
hypothesi
ceftazidim
caz
test
associ
vancomycin
van
teicoplanin
tei
experi
carri
also
presenc
azithromycin
azi
normal
non
antipseudomon
agent
shown
interfer
virul
factor
method
bacteri
suspens
cfuml
seed
plate
contain
fix
concentr
gli
mgl
increas
dose
caz
survivor
count
hr
result
interpret
synerg
addit
indiffer
cfuml
reduct
found
drug
combin
comparison
drug
aloneth
experi
repeat
ad
azi
mgl
use
gli
concentr
rang
mgl
result
caz
combin
gli
react
synerg
case
addit
found
interact
indiffer
note
test
preliminari
result
test
perform
indic
addit
azi
increas
incid
synerg
addit
even
use
gli
concentr
mgl
conclus
caz
combin
gli
gave
addit
synergist
result
great
major
experi
simultan
combin
azi
caz
gli
alway
produc
addit
synergist
effect
p
aeruginosa
data
given
high
concentr
gli
employ
could
particular
interest
clinic
situat
drug
could
topic
administ
multicentr
correl
studi
vitek
refer
method
telithromycin
mupirocin
daptomycin
staphylococcu
spp
ke
aldridg
dizney
k
thomson
g
procop
new
orlean
omaha
cleveland
usa
object
clinic
studi
shown
appropri
antimicrobi
therapi
base
vitro
suscept
data
correl
better
patient
outcom
vitek
fulli
autom
suscept
test
methodolog
provid
rapid
h
result
varieti
aerob
facult
anaerob
gramposit
neg
pathogen
shown
correl
establish
refer
method
object
studi
correl
suscept
result
vitek
test
telithromycin
mupirocin
daptomycin
staphylococcu
spp
refer
methodolog
method
three
geograph
distinct
clinic
microbiolog
laboratori
particip
test
site
test
consecut
clinic
islat
blind
challeng
isol
staphylococci
sent
sitevitek
test
perform
accord
manufactur
recommend
challeng
isol
also
test
use
manual
prepar
inoculum
nccl
recommend
refer
agar
broth
microdilut
method
use
test
telithromycin
mupirocin
daptomycin
mic
result
collat
determin
per
cent
isol
suscept
vitro
efficaci
tigecyclin
test
communityacquir
respiratori
tract
infect
nosocomi
pneumonia
pathogen
conclus
among
r
subset
commonli
occur
pathogen
inhibit
mgl
tig
inhibit
mgl
current
nccl
breakpoint
tet
tig
highli
stabl
tetr
determin
includ
protect
ribosom
efflux
mechan
may
repres
superior
choic
among
parenter
agent
broadspectrum
coverag
includ
commonli
occurringand
problematicr
phenotyp
determin
minimum
inhibitori
mutant
prevent
concentr
telithromycin
clinic
isol
streptococcu
pneumonia
borso
c
hesj
l
blondeau
j
blondeau
saskatoon
object
telithromycin
tl
novel
ketolid
antimicrobi
agent
recent
approv
use
north
america
respiratori
tract
infect
sp
princip
pathogen
global
escal
penicillin
p
macrolid
resist
sp
compromis
use
betalactam
macrolid
compound
tl
report
activ
p
resist
sp
object
garenoxacin
grn
investig
desf
quinolon
enhanc
vitro
activ
gramposit
cocci
global
escal
antimicrobi
resist
amongst
respiratori
tract
pathogen
particularli
spha
highlight
import
quinolon
compound
treat
sp
infect
mutant
prevent
concentr
mpc
novel
vitro
measur
defin
drug
concentr
threshold
would
requir
organ
simultan
acquir
two
resist
mutat
growth
presenc
drug
measur
mic
mpc
grn
clinic
isol
sp
includ
multidrug
resist
strain
elev
mpc
levofloxacingrn
method
microbroth
dilut
accord
nccl
guidelin
follow
mic
test
use
toddhewitt
broth
twofold
concentr
drug
increment
mpc
test
billion
organ
appli
agar
plate
contain
grn
incub
co
screen
coloni
growth
hour
mpc
lowest
drug
concentr
complet
prevent
growth
select
organ
grn
mpc
valu
lgml
screen
amino
acid
substitut
quinolon
resist
determin
region
great
concern
nowaday
therapeut
altern
limit
fusid
acid
inhibit
protein
synthesi
side
effect
usual
welltoler
patient
oral
drug
fusid
acid
consid
altern
drug
treatment
infect
due
methicillin
suscept
resist
aureu
strain
evalu
synergi
glycopeptid
levofloxacin
betalactam
methicillinresist
staphylococcu
aureu
imi
vatp
lvx
piperacillintazobactam
ptz
vatp
consid
synergi
evalu
mean
checkerboard
assay
doubl
combin
tripl
combin
mrsa
strain
isol
respiratori
tract
infect
mean
time
kill
curv
strain
checkerboard
assay
synergi
defin
fraction
inhibitori
concentr
index
fici
addit
fici
indiffer
fici
antagon
fici
time
kill
studi
synergi
defin
log
decreas
bacteri
count
combin
respect
activ
singl
drug
moreov
mutat
rate
singl
combin
drug
antimicrobi
concentr
equal
resist
breakpoint
calcul
strain
result
synergi
addit
preval
effect
antagon
observ
checkerboard
assay
particular
lvx
vatp
ctx
tpva
gave
synergi
strain
respect
combin
lvx
va
cazcpmptz
lvx
tp
cazcpmptz
yield
synergi
addit
test
strain
combin
lvx
tp
caz
ptz
give
synergi
strain
time
kill
curv
evidenc
synergi
lvxctx
vatp
h
incub
synergist
tripl
combin
occur
frequent
lvx
tp
lvx
va
h
singl
antibiot
mutat
frequenc
rang
lvx
ctx
amk
imi
va
tp
test
doubl
tripl
combin
mutat
frequenc
fell
combin
conclus
studi
provid
vitro
evid
synergi
glycopeptid
fluoroquinolon
cephalosporin
betalactam
limit
occurr
mutat
mrsa
strain
respons
respiratori
infect
thu
underlin
potenti
role
therapi
infect
compar
activ
mic
mbc
daptomycin
quinupristindalfopristin
linezolid
vancomycin
teicoplanin
larg
worldwid
collect
visahvisa
engelhardt
karlsson
e
edl
p
ho
solna
object
worldwid
emerg
possibl
dissemin
vancomycin
va
resist
staphylococci
involv
vana
vr
visa
heterovisa
phenotyp
compris
formid
clinic
threat
comparison
vitro
activ
newer
gram
posit
agent
use
larger
worldwid
collect
visa
strain
becom
increasingli
import
individu
therapi
guidanc
epidemiolog
purpos
method
countri
collect
staphylococci
mrsa
mssa
visa
etest
macromethod
papauc
walsh
et
al
jcm
assess
mic
dp
qd
lz
va
tp
determin
use
nccl
broth
microdilut
bmd
etest
mbc
agent
subset
visa
nonvisa
strain
determin
use
etest
mbc
procedur
bmd
result
intermethod
agreement
n
antibiot
dilut
mic
mbc
result
continu
gradient
format
etest
allow
detect
subtl
upward
shift
mic
mbc
distribut
visa
well
detect
persist
coloni
mbc
assay
seen
less
bactericid
compound
conclus
mic
distribut
show
daptomycin
linezolid
maintain
potenc
larg
collect
visa
quinupristindalfopristin
glycopeptid
show
shift
toward
reduc
activ
mbc
result
show
daptomycin
superior
linezolid
bacteriostat
agent
potenti
use
newer
agent
visa
continu
assess
respect
static
cidal
activ
order
detect
subtl
shift
suscept
earli
possibl
perform
uniqu
etest
daptomycin
gradient
calcium
gradient
isosensitest
compar
nccl
broth
microdilut
mueller
hinton
object
daptomycin
dp
requir
physiolog
level
free
calcium
ion
ca
express
adequ
activ
suscept
test
method
significantli
influenc
ca
variat
agar
broth
nccl
broth
microdilut
bmd
use
final
physiolog
level
lgml
calcium
dp
test
etest
dp
uniqu
gradient
incorpor
constant
level
calcium
etest
dp
shown
equival
bmd
test
commerci
avail
mueller
hinton
mh
agar
sinc
isosensitest
iso
use
part
europ
inher
low
level
calcium
approxim
lgml
import
evalu
perform
etest
dp
iso
comparison
bmd
method
lab
studi
compar
etest
dp
iso
nccl
bmd
total
clinic
stock
strain
compris
clindamycin
cc
ciprofloxacin
c
tetracyclin
also
determin
whether
differ
antimicrobi
suscept
patter
among
differ
speci
vg
bovi
method
vg
bovi
isol
blood
identifi
speci
level
id
system
miti
anginosu
sangui
salivariu
mutan
mic
determin
agar
dilut
method
percentag
resist
determin
accord
nccl
criteria
streptococci
pneumonia
result
overal
streptococci
resist
least
one
antibiot
test
resist
suscept
speci
anginosu
salivariu
suscept
antibiot
test
mutan
strain
suscept
antibiot
test
resist
phenotyp
differ
speci
shown
tabl
conclus
expect
cc
resist
alway
associ
e
resist
overal
phenotyp
frequent
found
ecct
strain
present
bovi
anginosu
pattern
eccpt
second
common
phenotyp
frequent
sangui
miti
respect
miti
speci
show
number
phenotyp
heterogen
suscept
pattern
speci
vg
indic
need
accur
identif
vitro
antibacteri
activ
temocillin
extend
spectrum
betalactamas
enterobacteriacea
produc
clinic
isol
object
temocillin
methoxyderiv
ticarcillin
activ
enterobacteriacea
stabl
blactamas
includ
ampc
extend
spectrum
blactamas
esbl
howev
data
concern
activ
esbl
produc
strain
limit
aim
studi
describ
rang
minim
inhibitori
concentr
mic
temocillin
differ
speci
esbl
produc
enterobacteriacea
singl
tertiari
care
centr
belgium
method
esbl
produc
enterobacteriacea
e
aerogen
e
coli
e
cloaca
k
pneumonia
strain
patient
hospitalis
institut
period
januari
decemb
esbl
product
screen
doubledisk
test
confirm
oxoid
combin
disk
method
characteris
enzym
perform
multiplex
pcr
bla
tem
bla
shv
bla
ctxm
gene
famili
detect
dna
sequenc
andor
isoelectr
focus
mic
mgl
determin
agar
dilut
method
accord
nccl
guidelin
suscept
determin
accord
breakpoint
provid
fuch
et
al
suscept
mic
mgl
eur
j
clin
microbiol
result
isol
origin
screen
rectal
swab
urinari
tract
respiratori
tract
wound
blood
gastrointestin
tract
site
male
femal
patient
mean
age
rang
year
antimicrobi
activ
temocillin
esbl
produc
enterobacteriacea
summaris
tabl
conclus
studi
confirm
good
vitro
activ
temocillin
multiresist
esblproduc
clinic
isol
enterobacteriacea
activ
includ
enterobact
ampc
depress
mutant
strain
coproduc
multipl
esbl
data
suggest
temocillin
could
valuabl
drug
consid
treatment
infect
esblproduc
enterobacteriacea
vitro
activ
ertapenem
cefpodoximeresist
gramneg
bacilli
urin
introduct
resist
commonli
use
antibiot
urinari
tract
infect
uti
grow
concern
due
emerg
extendedspectrum
betalactamas
esbl
produc
bacteria
commun
report
differ
part
world
appear
dissemin
resist
bacteria
caus
seriou
concern
treatment
urinari
tract
infect
uti
object
ertapenem
latest
member
carbapenem
class
antimicrobi
aim
studi
assess
activ
ertapenem
collect
cefpodoximeresist
gramneg
bacilli
isol
urin
sampl
commun
hospitalbas
patient
materi
method
june
octob
laboratori
receiv
urin
sampl
gave
posit
cultur
hospitalis
patient
commun
gram
neg
bacilli
resist
cefpodoxim
mgl
ident
isol
confirm
use
api
api
biomerieux
franc
esbl
product
sought
use
mastdd
ident
resist
determin
carri
use
combin
pcr
nucleotid
sequenc
analysi
tech
differ
antibiot
order
evalu
altern
intrapartum
chemoprophylaxi
women
allerg
penicillin
colon
gb
strain
resist
macrolid
andor
lincosamid
character
mechan
resist
macrolid
lincosamid
evalu
clonal
relationship
strain
method
total
strain
collect
multicentr
studi
isol
newborn
diagnos
earlyonset
gb
diseas
strain
collect
vagina
rectum
pregnant
women
microdilut
method
use
studi
antimicrobi
suscept
disk
diffus
defin
macrolidelincosamid
resist
phenotyp
pcr
perform
determin
presenc
ermb
ermtr
mefa
resist
gene
evalu
clonal
relationship
pfge
total
dna
done
use
smai
result
strain
suscept
penicillin
ampicillin
vancomycin
quinupristindalfopristin
levofloxacin
teicoplanin
resist
erythromycin
azithromycin
josamycin
clindamycin
telithromycin
fosfomycin
among
macrolid
resist
strain
present
constitut
mlsb
phenotyp
cmlsb
induc
mlsb
phenotyp
imlsb
remain
phenotyp
three
strain
suscept
macrolid
resist
clindamycin
ermb
ermtr
mefa
gene
present
macrolid
resist
strain
two
strain
amplifi
none
studi
gene
strain
harbour
ermb
gene
show
constitut
phenotyp
strain
show
induc
phenotyp
harbour
ermtr
gene
telithromycin
resist
strain
present
cmlsb
phenotyp
poss
ermb
gene
one
ermtr
conclus
spain
high
rate
resist
macrolid
lincosamid
make
mandatori
perform
suscept
test
gb
strain
isol
pregnant
women
allerg
penicillin
region
ermb
methilas
main
caus
macrolid
resist
follow
ermtr
macrolid
eflux
pump
low
proport
wide
clonal
divers
among
resist
strain
macrolid
lincosamid
telithromycin
detect
ermx
determin
macrolid
resist
clinic
strain
corynebacterium
urealyticum
ortiz
ji
r
j
esteban
madrid
e
object
detect
presenc
ermx
macrolid
resist
gene
clinic
isol
c
urealyticum
method
c
urealyticum
strain
isol
clinic
sampl
n
hospit
strain
maintain
frozen
studi
evalu
macrolid
resist
perform
antibiot
suscept
test
perform
agar
dilut
assay
case
disc
diffus
assay
case
detect
ermx
gene
perform
use
primer
accord
protocol
describ
rosato
et
al
dna
extract
boil
suspens
bacteria
distil
water
amplif
product
analys
agaros
gel
electrophoresi
molecular
weight
amplicon
calcul
use
photocapt
softwar
biogen
usa
result
strain
resist
erythromycin
clindamycin
suscept
antimicrobi
detect
gen
ermx
case
resist
macrolideresist
strain
gave
neg
result
ermx
detect
suscept
strain
show
amplif
product
ermx
gene
detect
macrolideresist
corynebacterium
urealyticum
strain
howev
macrolideresist
strain
ermx
gene
detect
resist
determin
must
involv
macrolid
resist
among
corynebacterium
urealyticum
characteris
phenotyp
genotyp
macrolideresist
streptococcu
pyogen
object
resist
streptococcu
pyogen
macrolid
world
wide
problem
aim
present
studi
determin
preval
antibiot
resist
rate
erythromycin
em
resist
isol
korea
evalu
genet
mechan
phenotyp
distribut
clonal
relationship
method
total
em
resist
pyogen
clinic
specimen
studi
agar
dilut
method
determin
minim
inhibitori
concentr
mic
antimicrobi
agent
perform
resist
phenotyp
determin
tripledisc
test
resist
induct
experi
subinhibitori
concentr
erythromycin
lgml
genet
mechan
resist
determin
pcr
genet
related
also
investig
mean
emm
genotyp
random
amplifi
polymorph
dna
rapd
analysi
result
averag
em
resist
rate
crossresist
rate
clarithromycin
azithromycin
spiramycin
respect
common
resist
phenotyp
induc
ml
iml
follow
constitut
ml
cml
type
iml
isol
show
novel
imlsd
phenotyp
small
mm
inhibit
zone
around
three
disc
tripledisc
test
high
level
resist
clinamycin
spiramycin
erythromycin
induct
isol
cmlsa
imlsd
harbour
ermb
gene
imlsc
isol
harbour
erma
mefa
gene
respect
imlsd
isol
except
one
multidrug
resist
cmlsa
isol
genotyp
imlsd
isol
made
tight
cluster
phylogenet
tree
show
common
pattern
rapd
analysi
conclus
imlsd
common
macrolid
resist
phenotyp
korea
emm
gene
rapd
analysi
suggest
clonal
relationship
detect
induc
clindamycin
resist
cutan
staphylococci
clinic
isol
phenotyp
genotyp
method
isol
constitut
clindamycin
resist
aureu
coagulaseneg
staphylococci
mrsa
gene
present
clindamycin
suscept
isol
except
cn
among
isol
clindamycin
induc
resist
isol
possess
either
erma
ermc
cn
isol
possess
ermc
mrsa
one
cn
aureu
isol
neg
gene
test
isol
constitut
clindamycin
resist
amplifi
gene
test
among
aureu
isol
erma
gene
ermc
ermc
mrsa
gene
cn
isol
possess
ermc
possess
also
mrsa
gene
tabl
diskdiffus
test
detect
clindamycin
resist
strain
none
clindamycin
induc
resist
strain
detect
microscan
ermc
gen
preval
among
clindamycin
resist
cn
aureu
isol
ribosom
protein
mutat
bacillu
anthraci
associ
crossresist
macrolid
lincosamid
streptogramin
ketolid
antibiot
rob
chemoth
aim
studi
determin
ribosom
mutat
associ
resist
method
primer
design
use
amplifi
sequenc
riboprotein
gene
copi
rrna
gene
use
b
anthraci
str
ame
complet
genom
genbank
access
result
mic
mgl
two
signific
mutat
associ
resist
found
amino
acid
aa
insert
tandem
duplic
gene
posit
found
strain
quinupristindalfopristin
qd
mic
select
passag
qd
strain
crossresist
telithromycin
erythromycin
clarithromycin
clindamycin
mic
respect
amino
acid
insert
mgramgra
gene
also
posit
found
stern
strain
clarithromycin
mic
passag
clarithromycin
strain
crossresist
telithromycin
qd
erythromycin
clindamycin
mic
respect
conclus
tandem
duplic
found
import
mlsk
resist
separ
strain
b
anthraci
demonstr
locu
import
resist
develop
select
pressur
qd
clarithromycin
importantli
mutat
also
associ
crossresist
mlsk
antibiot
horizont
transfer
mlsb
resist
gene
erm
b
human
pathogen
clostridium
difficil
rumin
anaerob
butyrivibrio
fibrisolven
p
mastrantonio
f
barbanti
p
spigaglia
rome
object
aim
studi
investig
possibl
vitro
transfer
mlsb
resist
gene
erm
b
human
pathogen
clostridium
difficil
rumin
commens
butyrivibrio
fibrisolven
method
erm
b
posit
c
difficil
strain
use
filter
mate
donor
whereasth
b
fibrisolven
strain
tetracyclin
resist
b
fibrisolven
strain
rifampicin
resist
use
recipi
strain
cultur
broth
steril
rumen
anaerob
condit
filter
mate
perform
sheep
blood
agar
plate
supplement
hemin
vitamin
k
medium
supplement
erythromycin
mcgml
tetracyclin
mcgml
use
select
transconjug
mic
valu
assess
etest
erm
b
transfer
confirm
pcr
hybridis
assay
use
erm
b
probe
transconjug
genom
digest
pvuii
smai
pfge
result
transfer
averag
frequenc
mic
valu
erythromycin
mgl
donor
transconjug
intern
fragment
erm
b
gene
bp
amplifi
transconjug
specif
band
visualis
hybridis
assay
transconjug
genom
digest
pvuii
smai
retransf
erm
b
gene
b
fibrisolven
transconjug
c
difficil
erythromycin
suscept
strain
also
obtain
conclus
vitro
transfer
mlsb
resist
gene
erm
b
c
difficil
b
fibrisolven
viceversa
import
result
support
possibl
horizont
transfer
resist
gene
human
pathogen
bacteria
anim
commens
microorgan
could
occur
natur
condit
easili
expect
